<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Endometrial resection and ablation techniques for heavy menstrual bleeding - Bofill Rodriguez, M - 2019 | Cochrane Library</title> <meta content="Endometrial resection and ablation techniques for heavy menstrual bleeding - Bofill Rodriguez, M - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001501.pub5/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Endometrial resection and ablation techniques for heavy menstrual bleeding - Bofill Rodriguez, M - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001501.pub5/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD001501.pub5" name="dc.identifier" scheme="DOI"/> <meta content="Endometrial resection and ablation techniques for heavy menstrual bleeding" name="citation_title"/> <meta content="Magdalena Bofill Rodriguez" name="citation_author"/> <meta content="University of Auckland" name="citation_author_institution"/> <meta content="Anne Lethaby" name="citation_author"/> <meta content="University of Auckland" name="citation_author_institution"/> <meta content="a.lethaby@auckland.ac.nz" name="citation_author_email"/> <meta content="Mihaela Grigore" name="citation_author"/> <meta content="Grigore T. Popa University of Medicine and Pharmacy" name="citation_author_institution"/> <meta content="Julie Brown" name="citation_author"/> <meta content="Martha Hickey" name="citation_author"/> <meta content="The Royal Women's Hospital" name="citation_author_institution"/> <meta content="Cindy Farquhar" name="citation_author"/> <meta content="University of Auckland" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD001501.pub5" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/01/22" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001501.pub5/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001501.pub5/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001501.pub5/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Catheter Ablation; Electrodes; Endometrium [*surgery]; Hysterectomy; Laser Therapy; Menorrhagia [*surgery]; Operative Time; Patient Satisfaction; Postoperative Complications; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001501.pub5&amp;doi=10.1002/14651858.CD001501.pub5&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001501.pub5&amp;doi=10.1002/14651858.CD001501.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001501.pub5&amp;doi=10.1002/14651858.CD001501.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001501.pub5&amp;doi=10.1002/14651858.CD001501.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001501.pub5&amp;doi=10.1002/14651858.CD001501.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001501.pub5&amp;doi=10.1002/14651858.CD001501.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001501.pub5&amp;doi=10.1002/14651858.CD001501.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001501.pub5&amp;doi=10.1002/14651858.CD001501.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001501.pub5&amp;doi=10.1002/14651858.CD001501.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001501.pub5&amp;doi=10.1002/14651858.CD001501.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001501.pub5&amp;doi=10.1002/14651858.CD001501.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001501.pub5&amp;doi=10.1002/14651858.CD001501.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001501.pub5&amp;doi=10.1002/14651858.CD001501.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001501.pub5&amp;doi=10.1002/14651858.CD001501.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001501.pub5&amp;doi=10.1002/14651858.CD001501.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001501.pub5&amp;doi=10.1002/14651858.CD001501.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001501.pub5&amp;doi=10.1002/14651858.CD001501.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001501.pub5&amp;doi=10.1002/14651858.CD001501.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001501.pub5&amp;doi=10.1002/14651858.CD001501.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001501.pub5&amp;doi=10.1002/14651858.CD001501.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001501.pub5&amp;doi=10.1002/14651858.CD001501.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001501.pub5&amp;doi=10.1002/14651858.CD001501.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001501.pub5&amp;doi=10.1002/14651858.CD001501.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="mvgXlmVk";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD001501\x2epub5\x26doi\x3d10\x2e1002\x2f14651858\x2eCD001501\x2epub5\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001501\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001501\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANT","th","fr","ms","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD001501.pub5",title:"Endometrial resection and ablation techniques for heavy menstrual bleeding",firstPublishedDate:"Jan 22, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gynaecology and Fertility Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=mvgXlmVk&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001501.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001501.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD001501.pub5/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD001501.pub5/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001501.pub5%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD001501.PUB5" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD001501.pub5/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD001501.PUB5" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD001501.pub5/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD001501.pub5/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>8940 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD001501.pub5" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001501.pub5/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001501.pub5/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001501.pub5/full#CD001501-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001501.pub5/full#CD001501-sec-0323"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001501.pub5/full#CD001501-sec-0036"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001501.pub5/full#CD001501-sec-0037"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001501.pub5/full#CD001501-sec-0042"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001501.pub5/full#CD001501-sec-0043"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001501.pub5/full#CD001501-sec-0080"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001501.pub5/full#CD001501-sec-0313"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001501.pub5/appendices#CD001501-sec-0328"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/table_n/CD001501StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/table_n/CD001501StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001501.pub5/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001501.pub5/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001501.pub5/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001501.pub5/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001501.pub5/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD001501.pub5/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Endometrial resection and ablation techniques for heavy menstrual bleeding</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001501.pub5/information#CD001501-cr-0002">Magdalena Bofill Rodriguez</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001501.pub5/information#CD001501-cr-0003"><i class="icon corresponding-author fa fa-envelope"></i>Anne Lethaby</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001501.pub5/information#CD001501-cr-0004">Mihaela Grigore</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001501.pub5/information#CD001501-cr-0005">Julie Brown</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001501.pub5/information#CD001501-cr-0006">Martha Hickey</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001501.pub5/information#CD001501-cr-0007">Cindy Farquhar</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/information/en#CD001501-sec-0338">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 22 January 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD001501.pub5">https://doi.org/10.1002/14651858.CD001501.pub5</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD001501-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001501-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001501-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001501-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD001501-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD001501-abs-0002">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD001501-abs-0014">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD001501-abs-0001" lang="en"> <section id="CD001501-sec-0001"> <h3 class="title" id="CD001501-sec-0001">Background</h3> <p>Heavy menstrual bleeding (HMB) is a significant health problem in premenopausal women; it can reduce their quality of life and can cause social disruption and physical problems such as iron deficiency anaemia. First‐line treatment has traditionally consisted of medical therapy (hormonal and non‐hormonal), but this is not always successful in reducing menstrual bleeding to acceptable levels. Hysterectomy is a definitive treatment, but it is more costly and carries some risk. Endometrial ablation may be an alternative to hysterectomy that preserves the uterus. Many techniques have been developed to 'ablate' (remove) the lining of the endometrium. First‐generation techniques require visualisation of the uterus with a hysteroscope during the procedure; although it is safe, this procedure requires specific technical skills. Newer techniques for endometrial ablation (second‐ and third‐generation techniques) have been developed that are quicker than previous approaches because they do not require hysteroscopic visualisation during the procedure. </p> </section> <section id="CD001501-sec-0002"> <h3 class="title" id="CD001501-sec-0002">Objectives</h3> <p>To compare the efficacy, safety, and acceptability of endometrial destruction techniques to reduce heavy menstrual bleeding (HMB) in premenopausal women. </p> </section> <section id="CD001501-sec-0003"> <h3 class="title" id="CD001501-sec-0003">Search methods</h3> <p>We searched the Cochrane Gynaecology and Fertility Group Specialised Register of controlled trials, the Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library, MEDLINE, Embase, CINAHL, and PsycInfo (from inception to May 2018). We also searched trials registers, other sources of unpublished or grey literature, and reference lists of retrieved studies, and we made contact with experts in the field and with pharmaceutical companies that manufacture ablation devices. </p> </section> <section id="CD001501-sec-0004"> <h3 class="title" id="CD001501-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) comparing different endometrial ablation or resection techniques for women reporting HMB without known uterine pathology, other than fibroids outside the uterine cavity and smaller than 3 centimetres, were eligible. Outcomes included improvement in HMB and in quality of life, patient satisfaction, operative outcomes, complications, and the need for further surgery, including hysterectomy. </p> </section> <section id="CD001501-sec-0005"> <h3 class="title" id="CD001501-sec-0005">Data collection and analysis</h3> <p>Two review authors independently selected trials for inclusion, assessed trials for risk of bias, and extracted data. We contacted study authors for clarification of methods or for additional data. We assessed adverse events only if they were separately measured in the included trials. We undertook comparisons with individual techniques as well as an overall comparison of first‐ and second‐generation ablation methods. </p> </section> <section id="CD001501-sec-0006"> <h3 class="title" id="CD001501-sec-0006">Main results</h3> <p>We included in this update 28 studies (4287 women) with sample sizes ranging from 20 to 372. Most studies had low risk of bias for randomisation, attrition, and selective reporting. Less than half of these studies had adequate allocation concealment, and most were unblinded. Using GRADE, we determined that the quality of evidence ranged from moderate to very low. We downgraded evidence for risk of bias, imprecision, and inconsistency. </p> <p>Overall comparison of second‐generation versus first‐generation (i.e. gold standard hysteroscopic ablative) techniques revealed no evidence of differences in amenorrhoea at 1 year and 2 to 5 years' follow‐up (risk ratio (RR) 0.99, 95% confidence interval (CI) 0.78 to 1.27; 12 studies; 2145 women; I² = 77%; and RR 1.16, 95% CI 0.78 to 1.72; 672 women; 4 studies; I² = 80%; very low‐quality evidence) and showed subjective improvement at 1 year follow‐up based on a Pictorial Blood Assessment Chart (PBAC) (&lt; 75 or acceptable improvement) (RR 1.03, 95% CI 0.98 to 1.09; 5 studies; 1282 women; I² = 0%; and RR 1.12, 95% CI 0.97 to 1.28; 236 women; 1 study; low‐quality evidence). Study results showed no difference in patient satisfaction between second‐ and first‐generation techniques at 1 year follow‐up (RR 1.01, 95% CI 0.98 to 1.04; 11 studies; 1750 women; I² = 36%; low‐quality evidence) nor at 2 to 5 years' follow‐up (RR 1.02, 95% CI 0.93 to 1.13; 672 women; 4 studies; I² = 81%). </p> <p>Compared with first‐generation techniques, second‐generation endometrial ablation techniques were associated with shorter operating times (mean difference (MD) ‐13.52 minutes, 95% CI ‐16.90 to ‐10.13; 9 studies; 1822 women; low‐quality evidence) and more often were performed under local rather than general anaesthesia (RR 2.8, 95% CI 1.8 to 4.4; 6 studies; 1434 women; low‐quality evidence). </p> <p>We are uncertain whether perforation rates differed between second‐ and first‐generation techniques (RR 0.32, 95% CI 0.10 to 1.01; 1885 women; 8 studies; I² = 0%). </p> <p>Trials reported little or no difference between second‐ and first‐generation techniques in requirement for additional surgery (ablation or hysterectomy) at 1 year follow‐up (RR 0.72, 95% CI 0.41 to 1.26; 6 studies: 935 women; low‐quality evidence). At 5 years, results showed probably little or no difference between groups in the requirement for hysterectomy (RR 0.85, 95% CI 0.59 to 1.22; 4 studies; 758 women; moderate‐quality evidence). </p> </section> <section id="CD001501-sec-0007"> <h3 class="title" id="CD001501-sec-0007">Authors' conclusions</h3> <p>Approaches to endometrial ablation have evolved from first‐generation techniques to newer second‐ and third‐generation approaches. Current evidence suggests that compared to first‐generation techniques (endometrial laser ablation, transcervical resection of the endometrium, rollerball endometrial ablation), second‐generation approaches (thermal balloon endometrial ablation, microwave endometrial ablation, hydrothermal ablation, bipolar radiofrequency endometrial ablation, endometrial cryotherapy) are of equivalent efficacy for heavy menstrual bleeding, with comparable rates of amenorrhoea and improvement on the PBAC. Second‐generation techniques are associated with shorter operating times and are performed more often under local rather than general anaesthesia. It is uncertain whether perforation rates differed between second‐ and first‐generation techniques. Evidence was insufficient to show which second‐generation approaches were superior to others and to reveal the efficacy and safety of third‐generation approaches versus first‐ and second‐generation techniques. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD001501-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001501-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD001501-abs-0006">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD001501-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001501-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD001501-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD001501-abs-0011">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/th#CD001501-abs-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD001501-abs-0015">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD001501-abs-0007">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD001501-abs-0005" lang="en"> <h3>Are newer methods for destroying the lining of the uterus (endometrial ablation) more effective and safer compared to established methods? </h3> <p><b>Review question</b> </p> <p>This review compared the effectiveness, safety, acceptability, and complication rates of first‐, second‐ and third‐generation methods available to destroy the endometrium (lining of the uterus) for treatment of heavy menstrual bleeding (heavy periods) in premenopausal women. </p> <p><b>Background</b> </p> <p>Medication and hysterectomy (surgery to remove the womb) used to be the main treatment options for heavy menstrual bleeding. Both are still effective and safe options, but available new treatments focus on removing the lining of the womb (endometrium) from which the bleeding comes. These procedures involve either removing the endometrium (resection) or destroying it with thermal (heat) energy from a laser, electrical instruments, or other devices (ablation). These treatments can stop or reduce menstrual bleeding. </p> <p><b>Study characteristics</b> </p> <p>This review identified 28 randomised controlled trials undertaken in 4287 women. Most of the women knew which treatment they were receiving, which may have influenced their judgements about menstrual blood loss and satisfaction. Other aspects of study quality varied among trials. Evidence is current to May 2018. Nineteen of the 28 trials acknowledged that they received funding, supplies of equipment, or technical assistance from the pharmaceutical industry and from equipment manufacturers. </p> <p><b>Key results</b> </p> <p>Moderate‐ to very low‐quality evidence suggests that first‐ and second‐generation approaches were equally effective in the treatment of HMB. Newer (second‐generation) treatment approaches were safer in terms of rate of fluid overload, cervical lacerations, and haematometra, with similar rates of uterine perforation. The newer approaches (second‐generation ablation) were quicker and were more likely to be done under local (rather than general) anaesthesia compared with first‐generation approaches. Most women in both groups were satisfied with results of the procedure. Not enough evidence is available to show which second‐generation approaches are superior to others, and information about third‐generation approaches is not available for comparison. </p> <p><b>Quality of the evidence</b> </p> <p>Evidence ranged from moderate to very low quality. Few studies were blinded, data were limited, and heterogeneity was substantial for some outcomes, leading to downgrading of the quality of evidence. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD001501-sec-0323" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD001501-sec-0323"></div> <h3 class="title" id="CD001501-sec-0324">Implications for practice</h3> <section id="CD001501-sec-0324"> <p>Second‐generation techniques are safer, quicker, and equally effective when compared with first‐generation techniques for treatment of HMB; also, the potential for second‐generation methods to be performed under local anaesthesia offers a considerable advantage. </p> <p>Satisfaction rates and reduction in HMB are similar with both approaches.</p> <p>Second‐generation endometrial ablation should be considered for women with a normal uterus presenting with heavy menstrual bleeding, who are not planning a present or future pregnancy. </p> </section> <h3 class="title" id="CD001501-sec-0325">Implications for research</h3> <section id="CD001501-sec-0325"> <p>Future studies should focus on comparing different second‐generation approaches to clarify real advantages are associated with one method over the others; researchers should also compare third‐generation versus second‐generation approaches to assess which are better. </p> <p>Future research should use as inclusion criteria women’s reports of heavy menstrual bleeding, according to International Federation of Gynaecology and Obstetrics (FIGO) and National Institute for Health and Care Excellence (NICE) guidelines (<a href="./references#CD001501-bbs2-0074" title="MunroMG , CritchleyHO , FraserIS . The FIGO systems for nomenclature and classification of causes of abnormal uterine bleeding in the reproductive years: who needs them?. Americam Journal of Obstetrics &amp; Gynecology2012;207(4):259‐65. [DOI: 10.1016/j.ajog.2012.01.046] ">Munro 2012</a>; <a href="./references#CD001501-bbs2-0079" title="National Institute of Health and Care Excellence (NICE). Heavy menstrual bleeding. National Institute for Health and Care Excellence (2018) Heavy menstrual bleeding (NICE Guideline 88). Available at: https://www.nice.org.uk/guidance/conditions‐and‐diseases/gynaecological‐conditions/heavy‐menstrual‐bleeding [Accessed 22 May 2018]. [https://www.nice.org.uk/guidance/conditions‐and‐diseases/gynaecological‐conditions/heavy‐menstrual‐bleeding] ">NICE 2018</a>). One alternative involves using a questionnaire to evaluate the woman's menstrual bleeding such as "the menstrual bleeding questionnaire", which has been developed and validated to improve the assessment of women with self‐reported HMB in both clinical practice and research (<a href="./references#CD001501-bbs2-0071" title="MattesonK , ScottD , RakerC , ClarkM . The menstrual bleeding questionnaire: development and validation of a comprehensive patient‐reported outcome instrument for heavy menstrual bleeding. British Journal of Obstetrics and Gynaecology2015;122(5):681‐9. [DOI: 10.1111/1471‐0528.13273] ">Matteson 2015</a>). At this point, research shows no significant differences in bleeding outcomes between second‐generation techniques; therefore it will be important to evaluate the cost of different techniques for both women and the healthcare system. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD001501-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD001501-sec-0036"></div> <div class="table" id="CD001501-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Overall analyses: second‐generation endometrial ablation compared to first‐generation endometrial ablation for heavy menstrual bleeding</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Overall analyses: second‐generation endometrial ablation compared to first‐generation endometrial ablation for heavy menstrual bleeding</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Patient or population:</b> heavy menstrual bleeding<br/> <b>Setting:</b> clinic<br/> <b>Intervention:</b> overall analyses: second‐generation endometrial ablation<br/> <b>Comparison:</b> first‐generation endometrial ablation </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="2" rowspan="2" valign=""> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with first‐generation endometrial ablation</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with overall analyses: second‐generation endometrial ablation</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Bleeding</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Amenorrhoea at 1 year follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>394 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>390 per 1000<br/> (307 to 501) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.99<br/> (0.78 to 1.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2145<br/> (12 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>PBAC &lt; 75 or acceptable improvement at 12 months' follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>809 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>833 per 1000<br/> (793 to 882) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.03<br/> (0.98 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1282<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>d,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Amenorrhoea at 2 to 5 years' follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>484 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>561 per 1000<br/> (377 to 832) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.16<br/> (0.78 to 1.72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>672<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>b,f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>PBAC &lt; 75 or acceptable improvement at 5 years' follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>537 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>580 per 1000<br/> (467 to 720) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.08<br/> (0.87 to 1.34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>263<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>e,g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Satisfaction rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>At 1 year follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>898 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>907 per 1000<br/> (880 to 933) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.01<br/> (0.98 to 1.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1750<br/> (11 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>f,h</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>At 2 to 5 years' follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>868 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>886 per 1000<br/> (808 to 981) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.02<br/> (0.93 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>672<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>b,e,i</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Duration of operation (minutes)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean duration of operation (minutes) was 27</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 13.52 lower<br/> (16.9 lower to 10.13 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1822<br/> (9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>b,d,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Proportion given local anaesthesia (%)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>208 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>578 per 1000<br/> (366 to 915) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.78<br/> (1.76 to 4.40) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1434<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>b,d,j</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Complication rate ‐ perforation</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 per 1000<br/> (1 to 13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.32<br/> (0.10 to 1.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1885<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>e,k</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Requirement for additional surgery</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>At 1 year follow‐up (ablation or hysterectomy)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>66 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47 per 1000<br/> (27 to 83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.72<br/> (0.41 to 1.26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>935<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>f,l</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>At 2 to 5 years' follow‐up (hysterectomy)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>191 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>162 per 1000<br/> (113 to 233) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.85<br/> (0.59 to 1.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>758<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> CI: confidence interval; MD: mean difference; PBAC: Pictorial Blood Assessment Chart; RCT: randomised controlled trial; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup>Eight studies provided insufficient details for a judgement about allocation concealment; downgraded one level. </p> <p><sup>b</sup>Heterogeneity was high at I² &gt; 75%; downgraded two levels. </p> <p><sup>c</sup>The funnel plot suggested asymmetry; downgraded one level. </p> <p><sup>d</sup>Only two studies provided sufficient details for a judgement about allocation concealment; no blinding of participants/researchers or outcome assessors; downgraded one level. </p> <p><sup>e</sup>No blinding of participants/researchers or outcome assessors; downgraded one level. </p> <p><sup>f</sup>Three studies provided insufficient details for a judgement about allocation concealment; only one study provided adequate data on blinding of participants/researchers and outcome assessors; downgraded two levels. </p> <p><sup>g</sup>Evidence of imprecision based on one study with n &lt; 300; downgraded one level. </p> <p><sup>h</sup>Only one study provided adequate data on blinding of participants/researchers and outcome assessors; downgraded one level. </p> <p><sup>i</sup>Only one study provided sufficient details for a judgement about allocation concealment; downgraded one level. </p> <p><sup>j</sup>The confidence interval has a very wide range (1.76 to 4.40); downgraded one level. </p> <p><sup>k</sup>The number of events is very low and the confidence interval is wide; downgraded one level. </p> <p><sup>l</sup>The number of events is very low; downgraded one level. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD001501-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD001501-sec-0037"></div> <section id="CD001501-sec-0038"> <h3 class="title" id="CD001501-sec-0038">Description of the condition</h3> <p>Heavy menstrual bleeding (HMB), or menorrhagia, is a significant cause of ill health among women of reproductive age and can substantially impair their quality of life (<a href="./references#CD001501-bbs2-0079" title="National Institute of Health and Care Excellence (NICE). Heavy menstrual bleeding. National Institute for Health and Care Excellence (2018) Heavy menstrual bleeding (NICE Guideline 88). Available at: https://www.nice.org.uk/guidance/conditions‐and‐diseases/gynaecological‐conditions/heavy‐menstrual‐bleeding [Accessed 22 May 2018]. [https://www.nice.org.uk/guidance/conditions‐and‐diseases/gynaecological‐conditions/heavy‐menstrual‐bleeding] ">NICE 2018</a>). </p> <p>Heavy menstrual bleeding has been classically defined as blood loss greater than or equal to 80 mL per menstrual cycle (<a href="./references#CD001501-bbs2-0061" title="HallbergL , HogdahlAM , NilssonL , RyboG . Menstrual blood loss ‐ a population study. Acta Obstetricia et Gynecologica Scandinavian1966;45:320‐51. [PMID: 5922481] ">Hallberg 1966</a>). However, it is the woman's perception of her own menstrual loss that is the key determinant in her referral and subsequent treatment. According to the International Federation of Gynaecology and Obstetrics (FIGO), HMB is "an excessive menstrual blood loss that interferes with the woman's physical, emotional, social, and material quality of life, and can occur alone or in combination with other symptoms such as headache, fatigue, or dysmenorrhea" (<a href="./references#CD001501-bbs2-0074" title="MunroMG , CritchleyHO , FraserIS . The FIGO systems for nomenclature and classification of causes of abnormal uterine bleeding in the reproductive years: who needs them?. Americam Journal of Obstetrics &amp; Gynecology2012;207(4):259‐65. [DOI: 10.1016/j.ajog.2012.01.046] ">Munro 2012</a>). One in 20 women in the UK between 30 and 49 years of age consult their general practitioner (GP) each year with HMB (<a href="./references#CD001501-bbs2-0059" title="GrantC , GallierL , FaheyT , PearsonN , SarangiJ . Management of menorrhagia in primary care ‐ impact on referral and hysterectomy: data from the Somerset Morbidity Project. Journal of Epidemiology and Community Health2000;54:709‐13. [PMID: 10942454] ">Grant 2000</a>). According to a recent European survey, 27% of women over 18 years of age reported HMB in the previous 12‐month period (<a href="./references#CD001501-bbs2-0055" title="FraserI , MansourS , BreymannD , HoffmanC , MezzacasaC , PetragliaA . Prevalence of heavy menstrual bleeding and experiences of affected women in a European patient survey [Prevalence of heavy menstrual bleeding and experiences of affected women in a European patient survey]. International Journal of Gynaecology &amp; Obstetrics2015;128(3):196‐200. [DOI: 10.1016/j.ijgo.2014.09.027] ">Fraser 2015</a>). In New Zealand, for example, it is estimated that 1 in 50 GP consultations for women younger than 50 years are the result of HMB (<a href="./references#CD001501-bbs2-0080" title="Working Party on behalf of the National Health Committee of New Zealand. Guidelines for the management of heavy menstrual bleeding. Guidelines for the management of heavy menstrual bleeding in New Zealand. Available at file:///P:/Cochrane/various%20cochrane/guidelines‐management‐heavy‐menstrual‐bleeding%20NZ%201998.pdf accessed Nov 20171998. ">NZ HMB Guideline 1998</a>). In most cases, no pathology (abnormality) is found to explain the HMB (<a href="./references#CD001501-bbs2-0079" title="National Institute of Health and Care Excellence (NICE). Heavy menstrual bleeding. National Institute for Health and Care Excellence (2018) Heavy menstrual bleeding (NICE Guideline 88). Available at: https://www.nice.org.uk/guidance/conditions‐and‐diseases/gynaecological‐conditions/heavy‐menstrual‐bleeding [Accessed 22 May 2018]. [https://www.nice.org.uk/guidance/conditions‐and‐diseases/gynaecological‐conditions/heavy‐menstrual‐bleeding] ">NICE 2018</a>). Causes of HMB usually remain unknown, which limits the development of new non‐surgical therapies. </p> <p>Surgical treatment for HMB often follows failed or ineffective medical therapy, although it is also used as first‐line therapy. Hysterectomy has traditionally been regarded as the definitive surgical treatment for HMB, but in spite of a 100% success rate (complete cessation of menstruation) and high levels of satisfaction (<a href="./references#CD001501-bbs2-0073" title="MiddletonLJ , ChampaneriaR , DanielsJP , BhattacharyaS , CooperKG , HilkenNH , et al. for the International Heavy Menstrual Bleeding Individual Patient Data Meta‐analysis Collaborative Group. Hysterectomy, endometrial destruction, and levonorgestrel releasing intrauterine system (Mirena) for heavy menstrual bleeding: systematic review and meta‐analysis of data from individual patients. British Medical Journal2010;341:c3929. [DOI: 10.1136/bmj.c3929] ">Middleton 2010</a>), hysterectomy is a major surgical procedure with significant physical complications and social and economic costs. Almost half of the hysterectomies performed worldwide were carried out to treat women with HMB (<a href="./references#CD001501-bbs2-0069" title="MareshMJA , MetcalfeMA , McPhersonK , OvertonC , HallV , HargreavesJ . The VALUE national hysterectomy study: description of the patients and their surgery. British Journal of Obstetrics and Gynaecology2002;109:302‐12. [PMID: 11950186] ">Maresh 2002</a>). However, many women prefer less invasive surgical treatment, even when they are made aware that the success of that treatment cannot be assured (<a href="./references#CD001501-bbs2-0076" title="NageleF , RubingerT , MagosA . Why do women choose endometrial ablation rather than hysterectomy?. Fertility and Sterility1998;69(6):1063‐6. [PMID: 9627293] ">Nagele 1998</a>). A US review including 1169 women reported that 13.4% of those undergoing an endometrial ablation had a subsequent hysterectomy (mean follow‐up 39 months; standard deviation (SD) 19 months). The same study reported that the rate of hysterectomy was correlated with the age at which ablation was performed; in women younger than 36 at the time of ablation, the rate of hysterectomy was 21%, and among those 46 years of age or older at the time of ablation, the rate was 11% (<a href="./references#CD001501-bbs2-0088" title="ShavellV , DiamondM , SenterJ , KrugerM , JohnsA . Hysterectomy subsequent to endometrial ablation. Journal of Minimally Invasive Gynecology2012;19(4):459‐64. [DOI: https://doi.org/10.1016/j.jmig.2012.03.013] ">Shavell 2012</a>). A Scottish review of 14,078 women with endometrial ablation reported that 20% had a subsequent hysterectomy, and most of these procedures were performed within the first two years after ablation (<a href="./references#CD001501-bbs2-0045" title="CooperK , LeeAJ , ChienP , RajaEA , TimmarajuV , BhattacharyaS . Outcomes following hysterectomy or endometrial ablation for heavy menstrual bleeding: retrospective analysis of hospital episode statistics in Scotland. British Journal of Obstetrics and Gynaecology2011;118(10):1171‐9. [DOI: 10.1111/j.1471‐0528.2011.03011.x] ">Cooper 2011</a>). </p> </section> <section id="CD001501-sec-0039"> <h3 class="title" id="CD001501-sec-0039">Description of the intervention</h3> <p>Endometrial destruction techniques, which aim to destroy or remove endometrial tissue, have become increasingly popular as less invasive alternatives over the past two decades; as a result, the number of hysterectomies in the UK declined by 64% between 1995 and 2002 (<a href="./references#CD001501-bbs2-0085" title="ReidPC , MukriF . Trends in number of hysterectomies performed in England for menorrhagia: examination of health episode statistics, 1989 to 2002‐3. British Medical Journal2005;330:938‐9. [DOI: 10.1136/bmj.38376.505382.AE; PMCID: PMC556338 ] ">Reid 2005</a>). The first effective ablation of the endometrium under hysteroscopic vision for treatment of HMB was performed via laser photo‐vaporisation (<a href="./references#CD001501-bbs2-0058" title="GoldrathMH , FullerTA , SegalS . Laser photo‐vaporization of endometrium for the treatment of menorrhagia. American Journal of Obstetrics and Gynecology1981;140:14‐9. [PMID: 7223809] ">Goldrath 1981</a>). Rollerball ablation with simple and cheap electrosurgical equipment rather than expensive lasers was performed a few years later (<a href="./references#CD001501-bbs2-0067" title="LinBL , MiyamotoN , TomomatuM . The development of a new hysteroscopic resectoscope and its clinical applications on transcervical resection and endometrial ablation. Japanese Journal of Gynecologic and Obstetric Endoscopy1988;4:56‐9. ">Lin 1988</a>; <a href="./references#CD001501-bbs2-0091" title="VaincaillieTG . Electrocoagulation of the endometrium with the ball‐ended resectoscope. Obstetrics and Gynecology1989;74:425‐7. [PMID: 2761921] ">Vaincaillie 1989</a>). A method to excise rather than ablate the endometrium with an unmodified resectoscope (an instrument used for resection (excision)) was also developed and yielded good results (<a href="./references#CD001501-bbs2-0050" title="DeCherneyAH , PolanML . Hysteroscopic management of intrauterine lesions and intractable uterine bleeding. Obstetrics &amp; Gynecology1983;61:392‐7. [PMID: 6823383] ">DeCherney 1983</a>; <a href="./references#CD001501-bbs2-0051" title="DeCherneyAH , DiamondMP , LaveyG , PolanML . Endometrial ablation for intractable uterine bleeding: hysteroscopic resection. Obstetrics and Gynecology1987;70:668‐70. [PMID: 3627634] ">DeCherney 1987</a>). Transcervical resection of the endometrium (TCRE) is a technique that is often used in conjunction with rollerball ablation. These methods of ablation, also termed 'first‐generation methods', were the most commonly used and were widely regarded as the gold standard for endometrial ablation (<a href="./references#CD001501-bbs2-0046" title="CooperJM , EricksonML . Global endometrial technologies. Obstetrics and Gynecology Clinics of North America2000;27(2):385‐96. [PMID: 10857128] ">Cooper 2000</a>). All require direct visualisation by a hysteroscope (an instrument used to examine the uterine cavity), which may confer the additional advantage of diagnosis of polyps. Endometrial destruction techniques in use in the UK by 1995 included electrocautery ‐ either loop or rollerball (80%) ‐ laser (18%), and radiofrequency ‐ a procedure for which electromagnetic energy (2%) is used (<a href="./references#CD001501-bbs2-0084" title="RCOG Medical Audit Unit. Mistletoe Report for the Fifth Bulletin. Manchester: RCOG, 1995. ">RCOG 1995</a>). </p> <p>The expectation was that these first‐generation ablation methods would become an alternative to hysterectomy, but at least initially, the total number of operations for HMB increased (<a href="./references#CD001501-bbs2-0043" title="BridgmanSA , DunnKM . Has endometrial ablation replaced hysterectomy for the treatment of dysfunctional uterine bleeding? National figures. British Journal of Obstetrics and Gynaecology.2000;107:531‐4. [PMID: 10759274] ">Bridgman 2000</a>). More recent figures in the UK suggest that the rate of surgery for menorrhagia (based on data from 2004 to 2006) is 143 procedures per 100,000 premenopausal women (<a href="./references#CD001501-bbs2-0047" title="CromwellDA , MahmoodTA , TempletonA , van derMeulenJH . Surgery for menorrhagia within English regions: variation in rates of endometrial ablation and hysterectomy. British Journal of Obstetrics and Gynaecology2009;116:1373‐9. [DOI: 10.1111/j.1471‐0528.2009.02284.x] ">Cromwell 2009</a>), of which approximately 60% are endometrial ablations. In a long‐term follow‐up (up to 25 years) study in the UK, only 25% of women with endometrial resection or ablation underwent a subsequent hysterectomy, and 75% of these surgeries were performed during the first 5 years of follow‐up (<a href="./references#CD001501-bbs2-0065" title="KalampokasE , McRobbieS , PayneF , ParkinD . Long‐term incidence of hysterectomy following endometrial resection or endometrial ablation for heavy menstrual bleeding. International Journal of Gynaecology &amp; Obstetrics2017;139(1):61‐64. [DOI: 10.1002/ijgo.12259] ">Kalampokas 2017</a>), suggesting that endometrial ablation may have a role in limiting the number of hysterectomies. However, this may also reflect progression through menopause for many of these women. </p> <p>Drawbacks of these first‐generation ablation techniques include the expertise needed and patient morbidity. A prospective national audit of hysteroscopic endometrial ablation and resection (10,686 cases) in England and Wales between 1993 and 1994 assessed the incidence of complications and reported a total complication rate of 4.4% (<a href="./references#CD001501-bbs2-0081" title="OvertonC , HargreavesJ , MareshM . A national survey of the complications of endometrial destruction for menstrual disorders: the MISTLETOE study. British Journal of Obstetrics and Gynaecology1997;104(12):1351‐9. ">Overton 1997</a>). Complications are thought to be avoidable with good surgical technique and adequate training. However, hysteroscopic endometrial ablation requires an operating room environment, a surgeon with specific technical skills, and use of general or regional anaesthesia. </p> <p>Subsequently, second‐ and third‐generation non‐hysteroscopic techniques were developed; these are considered easier to perform and equally effective and safe (<a href="./references#CD001501-bbs2-0068" title="MadhuCK , NatteyJ , NaeemT . Second generation endometrial ablation techniques: an audit of clinical practice. Archives of Gynaecology and Obstetrics2009;280:599‐602. [DOI: 10.1007/s00404‐009‐0982‐7] ">Madhu 2009</a>), with lower complication rates,of around 1% for one second generation technique (bipolar) (<a href="./references#CD001501-bbs2-0002" title="AthanatosD , PadosG , VenetisC , StamatopoulosP , RoussoD , TsolakidisD , et al. Novasure impedance control system versus microwave endometrial ablation for the treatment of dysfunctional uterine bleeding: a double‐blind, randomized controlled trial. Clinical and Experimental Obstetrics &amp; Gynecology2015;42(3):347‐51. [PMID: 26152008] PadosG . Treatment of dysfunctional uterine bleeding with second generation ablation devices: microwaves (MEAA) vs Bipolar Impedance Control System (Novasure). http://clinicaltrials.gov/show/NCT01173965. ">Athanatos 2015</a>; <a href="./references#CD001501-bbs2-0016" title="LabergeP , Garza‐LealJ , FortinC , BasinskiC , ThielJ , LeylandN , et al. A prospective, randomized, multi‐center, controlled, international clinical study of the safety and efficacy of the Minerva endometrial ablation system: 6 and 12‐month follow‐up results. Journal of Minimally Invasive Gynecology. 2014. LabergeP , Garza‐LealJ , FortinC , GraingerD , JohnsDA , AdkinsRT , et al. A randomized controlled multicenter US Food and Drug Administration trial of the safety and efficacy of the Minerva Endometrial Ablation System: one‐year follow‐up results. Journal of Minimally Invasive Gynecology2017;24(1):124‐32. [DOI: 10.1016/j.jmig.2016.09.009] LabergeP , Garza‐LealJ , FortinC , ThielJ , JohnsD , GraingerD , et al. A randomized, controlled, multi‐center trial of the safety and efficacy of the Minerva Endometrial Ablation System: one‐year follow‐up results. Journal of Minimally Invasive Gynecology. 2016; Vol. 23:S1‐S252. ">Laberge 2016</a>). First‐generation ‐ commonly referred to as hysteroscopic ‐ techniques require hysteroscopic visualisation of the uterine cavity during the procedure. Examples in this group include endometrial laser ablation (ELA), transcervical resection of the endometrium (TCRE), and rollerball endometrial ablation. Second‐ and third‐generation approaches ‐ frequently referred to as non‐hysteroscopic techniques ‐ do not require direct visualisation of the uterine cavity during the procedure. Examples of second‐generation techniques include thermal balloon endometrial ablation (Cavaterm®, Thermachoice®), microwave endometrial ablation (MEA®, Microsulis®), hydrothermal ablation (Hydro ThermAblator®), bipolar radiofrequency endometrial ablation (Novasure®, Minerva®), and endometrial cryotherapy (Cerene®, Her Option®). An example of a third‐generation technique is Thermachoice III®. All of these second‐ and third‐generation techniques, with the exception of hydrothermal ablation and endometrial laser intrauterine thermal therapy, involve performing surgery without direct visualisation through a hysteroscope. They can be performed in outpatient settings and include cryoablation (<a href="./references#CD001501-bbs2-0083" title="PitroffR , MajiaS , MurrayA . Initial experience with transcervical cryoablation using saline as a uterine distension medium. Minimally Invasive Therapy1993;2:69‐73. [DOI: 10.3109/13645709309152670] ">Pitroff 1993</a>), hot saline solution irrigation (<a href="./references#CD001501-bbs2-0042" title="BaggishMS , ParaisoM , BrexnockEM , GriffeyS . A computer‐controlled, continuously circulating hot irrigating system for endometrial ablation. American Journal of Obstetrics and Gynecology1995;173:1842‐8. [PMID: 8610773] ">Baggish 1995</a>), diode laser hyperthermy (heating) (<a href="./references#CD001501-bbs2-0052" title="DonnezJ , PoletR , MathieuPE , KonwitzE , NisolleM , Casanas‐RouxF . Endometrial laser interstitial hyperthermy: a potential modality for endometrial ablation. Obstetrics and Gynecology1996;87:459‐64. [PMID: 8598976] ">Donnez 1996</a>), microwave ablation (<a href="./references#CD001501-bbs2-0087" title="SharpNC , CroninN , FeldbergI , EvansM , HodgsonD , EllisS . Microwaves for menorrhagia: a new fast technique for endometrial ablation. Lancet1995;346(8981):1003‐4. [PMID: 7475547] ">Sharp 1995</a>), a heated balloon system (<a href="./references#CD001501-bbs2-0090" title="SingerA , AlmanzaR , GutierrezA , HaberG , BolducL , NeuwirthR . Preliminary clinical experience with thermal balloon endometrial ablation method to treat menorrhagia. Obstetrics and Gynecology1994;83:732‐7. [PMID: 8164933] ">Singer 1994</a>), and photodynamic therapy (intrauterine light delivery) (<a href="./references#CD001501-bbs2-0054" title="FehrMK , MadsenSJ , SvaasandLO , TrombergBJ , EusebioJ , BernsMW , et al. Intrauterine light delivery for photodynamic therapy of the human endometrium. Human Reproduction1995;10:3067‐72. [PMID: 8747076] ">Fehr 1995</a>). Economic modelling suggests that second‐generation techniques may be more cost‐effective than first‐generation methods (<a href="./references#CD001501-bbs2-0056" title="GarsideR , SteinK , WyattK , RoundA , PriceA . The effectiveness and cost‐effectiveness of microwave and thermal balloon endometrial ablation for heavy menstrual bleeding: a systematic review and economic modelling. Health Technology Assessment2004; Vol. 8, issue 3:1‐155. [PMID: 14754561] ">Garside 2004</a>). Third‐generation approaches have replaced the latex for silicone on the balloon and involve active fluid circulation, which enables the total endometrial surface to receive equal heat distribution (<a href="./references#CD001501-bbs2-0030" title="CashC , Garza‐LealJ , DonovanA , GuidryC , RomanowskiC , PatelB . Clinical evaluation of long‐term safety and effectiveness of a third‐generation thermal uterine balloon therapy system for heavy menstrual bleeding. Journal of Minimally Invasive Gynecology2012;19(4):469‐76. ">Cash 2012</a>). </p> </section> <section id="CD001501-sec-0040"> <h3 class="title" id="CD001501-sec-0040">How the intervention might work</h3> <p>Endometrial destruction involves the removal of endometrial tissue. The endometrium can regenerate, and clinical improvement is predicated on removing the basal layer of the endometrium to prevent endometrial regrowth. The basal glands are believed to be the primary foci for endometrial regrowth. The endometrium can be removed under direct hysteroscopic view either by excision with an electrosurgical loop (one possible advantage of resection is that it yields a biopsy sample) or by ablation in which thermal energy of sufficient power is applied to its surface to produce necrosis (cell death) of the full thickness of the endometrium. </p> </section> <section id="CD001501-sec-0041"> <h3 class="title" id="CD001501-sec-0041">Why it is important to do this review</h3> <p>A wide range of techniques are available for ablating and destroying the endometrium to reduce HMB, and it is not clear which approaches offer the best options in terms of effectiveness and safety. The aim of this review is to assess the efficacy, safety, and acceptability of all methods, both by comparing individual techniques pairwise and by making overall comparisons between first‐ and second‐generation techniques. Other Cochrane reviews have compared endometrial ablation versus hysterectomy, and endometrial ablation versus medical therapies, for HMB (<a href="./references#CD001501-bbs2-0066" title="LethabyA , ShepperdS , CookeI . Endometrial resection and ablation versus hysterectomy for heavy menstrual bleeding (Cochrane Review). Cochrane Database of Systematic Reviews1999, Issue 2. [DOI: 10.1002/14651858.CD000329] ">Lethaby 2009</a>; <a href="./references#CD001501-bbs2-0070" title="MarjoribanksJ , LethabyA , FarquharC . Surgery versus medical therapy for heavy menstrual bleeding. Cochrane Database of Systematic Reviews2010, Issue 9. [DOI: 10.1002/14651858.CD003855.pub2] ">Marjoribanks 2010</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD001501-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD001501-sec-0042"></div> <p>To compare the effectiveness, safety, and acceptability of endometrial destruction techniques to reduce heavy menstrual bleeding (HMB) in premenopausal women. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD001501-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD001501-sec-0043"></div> <section id="CD001501-sec-0044"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD001501-sec-0045"> <h4 class="title">Types of studies</h4> <p>We sought to include all randomised controlled trials (RCTs) comparing techniques for ablation or resection of the endometrium for treatment of HMB. </p> </section> <section id="CD001501-sec-0046"> <h4 class="title">Types of participants</h4> <section id="CD001501-sec-0047"> <h5 class="title">Source of recruitment</h5> <p> <ul id="CD001501-list-0001"> <li> <p>Primary care, family planning, or specialist clinics</p> </li> </ul> </p> </section> <section id="CD001501-sec-0048"> <h5 class="title">Inclusion criteria</h5> <p> <ul id="CD001501-list-0002"> <li> <p>Women of reproductive years with regular heavy periods measured objectively or subjectively</p> </li> </ul> </p> </section> <section id="CD001501-sec-0049"> <h5 class="title">Exclusion criteria</h5> <p> <ul id="CD001501-list-0003"> <li> <p>Postmenopausal bleeding (longer than 1 year from the last period)</p> </li> <li> <p>Irregular menstruation and intermenstrual bleeding</p> </li> <li> <p>Pathological causes of HMB (e.g. uterine cancer)</p> </li> <li> <p>Iatrogenic causes of HMB (e.g. intrauterine coil devices)</p> </li> </ul> </p> </section> </section> <section id="CD001501-sec-0050"> <h4 class="title">Types of interventions</h4> <p>We included studies that compared endometrial resection and ablation techniques (TCRE, laser ablation, rollerball ablation, saline irrigation, microwave ablation, radiofrequency ablation, heated balloon, photodynamic therapy, cryoablation, and any other endometrial destruction techniques) against each other or grouped in the broad categories of first‐ or second‐generation techniques performed to reduce HMB. </p> </section> <section id="CD001501-sec-0051"> <h4 class="title">Types of outcome measures</h4> <p>Assessment of most of the following outcomes was related to duration of follow‐up after the initial surgical procedure. Given that the aim of endometrial resection and ablation therapies is to induce permanent resolution of heavy menstrual bleeding, long‐term follow up of these treatments is needed to enable informed decision‐making between surgical options. Thus, for the following outcomes, evaluation at different time points is considered important for assessing effects over time: 6 months, 12 months, 2 years, 2 to 5 years, and longer than 5 years. When trials measured outcomes at two different follow‐up times within categories (e.g. at 3 years and at 5 years), they recorded longer follow‐up time only within the category of 2 to 5 years. </p> <section id="CD001501-sec-0052"> <h5 class="title">Primary outcomes</h5> <section id="CD001501-sec-0053"> <h6 class="title">Menstrual bleeding</h6> <p> <ul id="CD001501-list-0004"> <li> <p>An objective measurement of menstrual blood loss (measured by the modified alkaline haematin method ‐ modified by <a href="./references#CD001501-bbs2-0077" title="NewtonJ , BarnardG , CollinsW . A rapid method for measuring menstrual blood loss using automatic extraction. Contraception1977;16:269‐82. [DOI: 10.1016/0010‐7824(77)90026‐9] ">Newton 1977</a> from the original technique of <a href="./references#CD001501-bbs2-0060" title="HallbergL , NilssonL . Determination of menstrual blood loss. Scandinavian Journal of Clinical and Laboratory Investigation1964;16:244‐8. [PMID: 14161862] ">Hallberg 1964</a>) </p> </li> <li> <p>A semi‐objective or subjective assessment of improvement in menstrual blood loss (measured by the Pictorial Blood Assessment Chart (PBAC) as in <a href="./references#CD001501-bbs2-0063" title="HighamJM , O'BrienPMS , ShawRW . Assessment of menstrual blood loss using a pictorial chart. British Journal of Obstetrics and Gynaecology1990;97:734‐9. [PMID: 2400752] ">Higham 1990</a>, or by women's perception of improvement) </p> </li> </ul> </p> <p><b>Rate of satisfaction</b> </p> <p> <ul id="CD001501-list-0005"> <li> <p>Assessment of satisfaction in terms of the outcome of the procedure (this outcome was moved from a secondary outcome to a primary outcome in the 2009 update) </p> </li> </ul> </p> </section> </section> <section id="CD001501-sec-0054"> <h5 class="title">Secondary outcomes</h5> <section id="CD001501-sec-0055"> <h6 class="title">Operative outcomes</h6> <p> <ul id="CD001501-list-0006"> <li> <p>Duration of surgery (in minutes)</p> </li> <li> <p>Operative difficulties (such as difficulty of surgery, technical complications, abandoning the procedure) </p> </li> <li> <p>Proportion given local rather than general anaesthesia</p> </li> </ul> </p> </section> <section id="CD001501-sec-0056"> <h6 class="title">Recovery</h6> <p> <ul id="CD001501-list-0007"> <li> <p>Length of hospital stay</p> </li> <li> <p>Time or ability to return to normal activities or work</p> </li> </ul> </p> </section> <section id="CD001501-sec-0057"> <h6 class="title">Quality of life</h6> <p> <ul id="CD001501-list-0008"> <li> <p>Women's perceived change in quality of life, when recorded in a reproducible and validated format </p> </li> <li> <p>Improvement in menstrual symptoms such as premenstrual syndrome (PMS) and dysmenorrhoea</p> </li> </ul> </p> </section> <section id="CD001501-sec-0058"> <h6 class="title">Adverse effects</h6> <p> <ul id="CD001501-list-0009"> <li> <p>Complication rate, frequency of specific adverse events both before and after discharge from hospital, divided into minor and major complications </p> <ul id="CD001501-list-0010"> <li> <p>Major complications</p> <ul id="CD001501-list-0011"> <li> <p>Perforation</p> </li> <li> <p>Endometritis</p> </li> <li> <p>Myometritis</p> </li> <li> <p>Cervical laceration/tear or stenosis</p> </li> <li> <p>Pelvic sepsis</p> </li> <li> <p>Pelvic abscess</p> </li> <li> <p>Pelvic inflammatory disease</p> </li> <li> <p>Haematometra</p> </li> <li> <p>Uterine tamponade</p> </li> <li> <p>Blood transfusion</p> </li> <li> <p>Glycine toxicity</p> </li> <li> <p>Fluid overload</p> </li> <li> <p>Fluid deficit</p> </li> <li> <p>Bowel obstruction</p> </li> <li> <p>Urinary incontinence</p> </li> </ul> </li> <li> <p>Minor complications</p> <ul id="CD001501-list-0012"> <li> <p>Skin rash and burning sensation</p> </li> <li> <p>Headache</p> </li> <li> <p>Nausea, vomiting, or severe pelvic pain</p> </li> <li> <p>Weakness or fatigue during the first 24 hours</p> </li> <li> <p>Backache during the first 24 hours</p> </li> <li> <p>Bradycardia</p> </li> <li> <p>Fever</p> </li> <li> <p>Chills</p> </li> <li> <p>Bloating</p> </li> <li> <p>Abdominal tenderness</p> </li> <li> <p>Dysuria</p> </li> <li> <p>Urinary tract infection (UTI)</p> </li> <li> <p>Hydrosalpinx</p> </li> <li> <p>Spotting during the first 24 hours</p> </li> <li> <p>Vaginal bleeding</p> </li> <li> <p>Abdominal cramping</p> </li> <li> <p>Infection (leucorrhoea)</p> </li> <li> <p>First‐degree burn</p> </li> </ul> </li> </ul> </li> <li> <p>Requirement for further surgery for menstrual symptoms (by duration of follow‐up)</p> </li> <li> <p>Mortality as a direct result of surgery</p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD001501-sec-0059"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD001501-sec-0060"> <h4 class="title">Electronic searches</h4> <p>The information specialist from the Cochrane Gynaecology and Fertility Group, Marian Showell, searched the following databases for the 2018 update. </p> <p> <ul id="CD001501-list-0013"> <li> <p>Cochrane Gynaecology and Fertility (CGFG) Specialised Register (PROCITE platform); searched 22 May 2018 (<a href="./appendices#CD001501-sec-0329">Appendix 1</a>). </p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL), Cochrane Register of Studies Online (CRSO) (Web platform); searched 22 May 2018 (<a href="./appendices#CD001501-sec-0330">Appendix 2</a>). </p> </li> <li> <p>MEDLINE (OVID platform); searched from 1946 to 22 May 2018 (<a href="./appendices#CD001501-sec-0331">Appendix 3</a>). </p> </li> <li> <p>Embase (OVID platform); searched from 1980 to 22 May 2018 (<a href="./appendices#CD001501-sec-0332">Appendix 4</a>). </p> </li> <li> <p>PsycINFO (OVID platform); searched from 1806 to 22 May 2018 (<a href="./appendices#CD001501-sec-0333">Appendix 5</a>). </p> </li> <li> <p>Cumulative Index to Nursing and Allied Health Literature (CINAHL) (EBSCO platform); searched from 1961 to 22 May 2018 (<a href="./appendices#CD001501-sec-0334">Appendix 6</a>). </p> </li> </ul> </p> <p>For the 2018 update, MB searched other electronic sources up to May 2018.</p> <p> <ul id="CD001501-list-0014"> <li> <p>Trial registries for ongoing and registered trials: ClinicalTrials.gov, a service of the US National Institutes of Health (<a href="http://www.clinicaltrials.gov" target="_blank">http://www.clinicaltrials.gov)</a>, and the World Health Organization International Trials Registry Platform search portal (<a href="http://www.who.int/trialsearch/Default.aspx" target="_blank">http://www.who.int/trialsearch/Default.aspx</a>). </p> </li> <li> <p>The Cochrane Library (<a href="http://www.cochrane.org/index.htm" target="_blank">http://www.cochrane.org/index.htm</a>) for Database of Abstracts of Reviews of Effects (DARE; reference lists from non‐Cochrane reviews on similar topics). </p> </li> <li> <p>OpenGrey for unpublished literature from Europe (<a href="http://www.opengrey.eu/" target="_blank">http://www.opengrey.eu/</a>). </p> </li> <li> <p>Latin American Caribbean Health Sciences Literature (LILACS) database: a source of trials from the Portuguese and Spanish‐speaking world (<a href="http://bvsalud.org/portal/?lang=en" target="_blank">http://bvsalud.org/portal/?lang=en</a> ‐ choose ‘LILACS’ in the ‘all sources’ dropdown box). </p> </li> <li> <p>PubMed and Google for recent trials that have not yet been indexed in the major databases.</p> </li> </ul> </p> </section> <section id="CD001501-sec-0061"> <h4 class="title">Searching other resources</h4> <p>We handsearched the reference lists of articles retrieved by the search.</p> <p>Some of the newer second‐generation techniques are undergoing development and rigorous testing. For previous updates, we contacted expert researchers in the field and companies that manufacture the newer devices to try to locate ongoing trials and unpublished data. We contacted two experts in the field to ask about ongoing research on endometrial ablation techniques: Dr. David Parkin (Aberdeen Royal Infirmary, UK) and Dr. Jed Hawe (South Cleveland Hospital, UK). We identified descriptions of several ongoing trials but we found insufficient details for review authors to initiate contact with study authors. </p> </section> </section> <section id="CD001501-sec-0062"> <h3 class="title" id="CD001501-sec-0062">Data collection and analysis</h3> <p>We conducted data collection and analysis in accordance with the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD001501-bbs2-0062" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011, 2011. [http://training.cochrane.org/handbook] ">Higgins 2011</a>). </p> <section id="CD001501-sec-0063"> <h4 class="title">Selection of studies</h4> <p>For the 2018 update, four review authors screened available abstracts (AL, MG, JB, MB). When the screened abstract presented a potentially eligible RCT, we obtained and inspected the full article to assess its relevance to this review based on the criteria for inclusion. We clarified uncertainty over eligibility through discussion between AL, MG, and JB or MB. We resolved disagreements as to study eligibility by consensus and found it was not necessary to involve another review author to arbitrate over selection. </p> </section> <section id="CD001501-sec-0064"> <h4 class="title">Data extraction and management</h4> <section id="CD001501-sec-0065"> <h5 class="title">Data extraction</h5> <p>Two of three review authors (MB, JB or MG) independently extracted study data using forms designed according to Cochrane guidelines. We collected the following details. </p> <section id="CD001501-sec-0066"> <h6 class="title">Trial characteristics</h6> <p> <ul id="CD001501-list-0015"> <li> <p>Method of randomisation</p> </li> <li> <p>Presence or absence of blinding to treatment allocation</p> </li> <li> <p>Quality of allocation concealment</p> </li> <li> <p>Numbers of women randomised, excluded, and lost to follow‐up</p> </li> <li> <p>Whether an intention‐to‐treat analysis was done</p> </li> <li> <p>Whether a power calculation was done</p> </li> <li> <p>Duration, timing, and location of the study</p> </li> <li> <p>Source of funding</p> </li> </ul> </p> </section> <section id="CD001501-sec-0067"> <h6 class="title">Characteristics of study participants</h6> <p> <ul id="CD001501-list-0016"> <li> <p>Age and any other recorded characteristics of women in the study</p> </li> <li> <p>Other inclusion criteria</p> </li> <li> <p>Exclusion criteria</p> </li> </ul> </p> </section> <section id="CD001501-sec-0068"> <h6 class="title">Interventions used</h6> <p> <ul id="CD001501-list-0017"> <li> <p>Type of endometrial destruction technique performed</p> </li> </ul> </p> </section> <section id="CD001501-sec-0069"> <h6 class="title">Outcomes</h6> <p> <ul id="CD001501-list-0018"> <li> <p>Methods used to measure menstrual blood loss</p> </li> <li> <p>Methods used to evaluate participant satisfaction, change in quality of life, and menstrual symptoms </p> </li> </ul> </p> </section> </section> </section> <section id="CD001501-sec-0070"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>For the 2018 update. three independent review authors (MG, MB, and JB) assessed the risk of bias of each study using the 'Risk of bias' tool developed by Cochrane (<a href="./references#CD001501-bbs2-0062" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011, 2011. [http://training.cochrane.org/handbook] ">Higgins 2011</a>). </p> <p>We assessed the following domains.</p> <p> <ul id="CD001501-list-0019"> <li> <p>Sequence generation (whether the allocation sequence was adequately generated, e.g. random numbers table, computer random numbers generator, coin tossing, throwing of dice). </p> </li> <li> <p>Allocation concealment (whether the allocation was adequately concealed, e.g. sequentially numbered containers of identical appearance, central allocation, sequentially numbered opaque and sealed envelopes). </p> </li> <li> <p>Blinding of participants, personnel, and outcome assessors (whether knowledge of the allocated intervention was adequately prevented during the study, e.g. by ensuring blinding of participants and key personnel; when there was no knowledge of blinding to the intervention, it was not likely to influence outcomes). </p> </li> <li> <p>Incomplete outcome data (whether incomplete outcome data were adequately addressed, e.g. missing data balanced in numbers across intervention groups, proportion of missing outcomes insufficient to affect estimates, reasons for missing data unlikely to be related to outcomes). </p> </li> <li> <p>Selective outcome reporting (whether reports of the study were free of suggestion of selective outcome reporting, e.g. previous publication of a study protocol, other evidence that the study contains all prespecified outcomes). </p> </li> <li> <p>Other sources of bias (whether the study was apparently free of other problems that could put it at high risk of bias, e.g. baseline imbalance, bias related to study design, early termination of study). </p> </li> </ul> </p> <p>We scored these domains as:</p> <p> <ul id="CD001501-list-0020"> <li> <p>criterion met (i.e. low risk of bias);</p> </li> <li> <p>unclear whether criterion met (i.e. uncertain risk of bias); or</p> </li> <li> <p>criterion not met (i.e. high risk of bias).</p> </li> </ul> </p> </section> <section id="CD001501-sec-0071"> <h4 class="title">Measures of treatment effect</h4> <p>Two review authors (MB, JB or MG) extracted data to enable calculation of risk ratios (RRs) for dichotomous data and mean differences (MDs) for continuous data, together with 95% confidence intervals (CIs). Some outcomes such as satisfaction with treatment were measured by ordinal data. We dichotomised these data to represent satisfaction with surgery (highly satisfied and satisfied combined) versus no satisfaction (doubtful or dissatisfied) by collapsing categories. We inspected continuous data for evidence of skew, when possible, according to guidance provided in the <i>Cochrane Handbook for Systematic Reviews of Interventions,</i> by calculating the observed mean minus the lowest (or highest) possible value divided by the standard deviation. </p> </section> <section id="CD001501-sec-0072"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis and randomisation was women in all studies. Researchers individually randomised participants to groups and collected and analysed a single measurement for each outcome from each participant. </p> </section> <section id="CD001501-sec-0073"> <h4 class="title">Dealing with missing data</h4> <p>We sought additional information on trial methods and trial results from the corresponding authors of some trials that appeared to meet eligibility criteria. We did this when aspects of methods were unclear or when data were provided in a form unsuitable for meta‐analysis. Authors of the following trials provided extra information: <a href="./references#CD001501-bbs2-0001" title="AbbottJ , HaweJ , HunterD , GarryR . A double‐blind randomized trial comparing the Cavaterm and the Novasure endometrial ablation systems for the treatment of dysfunctional uterine bleeding. Fertility and Sterility2003;80(1):203‐8. ">Abbott 2003</a>; <a href="./references#CD001501-bbs2-0002" title="AthanatosD , PadosG , VenetisC , StamatopoulosP , RoussoD , TsolakidisD , et al. Novasure impedance control system versus microwave endometrial ablation for the treatment of dysfunctional uterine bleeding: a double‐blind, randomized controlled trial. Clinical and Experimental Obstetrics &amp; Gynecology2015;42(3):347‐51. [PMID: 26152008] PadosG . Treatment of dysfunctional uterine bleeding with second generation ablation devices: microwaves (MEAA) vs Bipolar Impedance Control System (Novasure). http://clinicaltrials.gov/show/NCT01173965. ">Athanatos 2015</a>; <a href="./references#CD001501-bbs2-0016" title="LabergeP , Garza‐LealJ , FortinC , BasinskiC , ThielJ , LeylandN , et al. A prospective, randomized, multi‐center, controlled, international clinical study of the safety and efficacy of the Minerva endometrial ablation system: 6 and 12‐month follow‐up results. Journal of Minimally Invasive Gynecology. 2014. LabergeP , Garza‐LealJ , FortinC , GraingerD , JohnsDA , AdkinsRT , et al. A randomized controlled multicenter US Food and Drug Administration trial of the safety and efficacy of the Minerva Endometrial Ablation System: one‐year follow‐up results. Journal of Minimally Invasive Gynecology2017;24(1):124‐32. [DOI: 10.1016/j.jmig.2016.09.009] LabergeP , Garza‐LealJ , FortinC , ThielJ , JohnsD , GraingerD , et al. A randomized, controlled, multi‐center trial of the safety and efficacy of the Minerva Endometrial Ablation System: one‐year follow‐up results. Journal of Minimally Invasive Gynecology. 2016; Vol. 23:S1‐S252. ">Laberge 2016</a>. Gynecare (pharmaceutical company) provided funding for <a href="./references#CD001501-bbs2-0005" title="BoujidaVH , PhilipsenT , PelleJ , JoergensenJC . Five‐year follow‐up of endometrial ablation: endometrial coagulation versus endometrial resection. Obstetrics and Gynecology2002;99:988‐92. FurstSN , PhilipsenT , JoergensenJC . Ten‐year follow‐up of endometrial ablation. Acta Obstetricia et Gynecologica2007;86:334‐8. ">Boujida 2002,</a><a href="./references#CD001501-bbs2-0018" title="GraingerDA , TjadenDO , RowlandC , MeyerWR . Thermal balloon and rollerball ablation to treat menorrhagia: two‐year results of a multicenter, prospective, randomized clinical trial. Journal of the American Association of Gynecologic Laparoscopists2000;7(2):175‐9. LofferFD . Five year post‐procedure follow‐up of patients participating in a randomised trial of uterine balloon therapy vs rollerball ablation for the treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopy2001;8(1):48‐54. LofferFD . Three‐year comparison of thermal balloon and rollerball ablation in treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2001;8(1):48‐54. MeyerWR , WalshBW , GraingerDA , PeacockLM , LofferFD , SteegeJF . Thermal balloon and rollerball ablation to treat menorrhagia: a multicenter comparison. Obstetrics and Gynecology1998;92:98‐103. ">Meyer 1998,</a><a href="./references#CD001501-bbs2-0023" title="PerinoA , CastelliA , CucinellaG , BiondoA , PaneA , VeneziaR . A randomized comparison of endometrial laser intrauterine thermotherapy and hysteroscopic endometrial resection. Fertility and Sterility2004;82:731‐4. ">Perino 2004,</a> and <a href="./references#CD001501-bbs2-0027" title="vanZon‐RabelinkIAA , VleugelsMPH . Treating menorrhagia with endometrial ablation: rollerball electrocoagulation versus thermal ablation with the uterine balloon. Gynaecological Endoscopy Abstract from the 6th Annual Congress of the European Society for Gynaecological Endoscopy1997;6 Suppl 2:41. vanZon‐RabelinkIAA , VleugelsMPH , MerkusHMWM , deGraafR . Efficacy and satisfaction rate comparing endometrial ablation by rollerball electrocoagulation to uterine balloon thermal ablation in a randomised controlled trial. European Journal of Obstetrics, Gynecology, and Reproductive Biology2004;114(1):97‐103. vanZon‐RabelinkIAA , VleugelsMPH , MerkusHMWM , deGraafR . Endometrial ablation by rollerball electrocoagulation compared to uterine balloon thermal ablation. Technical and safety aspects. European Journal of Obstetrics, Gynecology, and Reproductive Biology2003;110:220‐3. ">van Zon‐Rabelink 2003</a>. One of the study authors provided additional information for <a href="./references#CD001501-bbs2-0021" title="BongersM , HermanM , PenninxJ , MolBW . Longterm follow‐up of a randomized controlled trial comparing NovaSure and hydrothermablation for dysfunctional uterine bleeding. Journal of Minimally Invasive Gynecology2011;18(6 Suppl 1):S34. PenninxJPM , HermanMC , MolBW , BongersMY . Five‐year follow‐up after comparing bipolar endometrial ablation with hydrothermablation for menorrhagia. Obstetrics and Gynecology2011;118:1287‐92. PenninxJPM , MolBW , EngelsR , vanRumsteMME , KleijnC , KoksCAM , et al. Bipolar radiofrequency endometrial ablation compared with hydrothermablation for dysfunctional uterine bleeding. Obstetrics and Gynecology2010;116:819‐26. ">Penninx 2010</a> for a previous update of this review. </p> </section> <section id="CD001501-sec-0074"> <h4 class="title">Assessment of heterogeneity</h4> <p>We analysed differences between studies in terms of methodological factors and variations between participants, interventions, and outcomes to determine whether it was appropriate to combine the studies in meta‐analysis. If studies were sufficiently homogeneous to consider pooling, we examined statistical heterogeneity between the results of different studies by inspecting scatter in data points on the graphs and the overlap in confidence intervals and, more formally, by checking the results of Chi² tests (with P &lt; 0.1 considered evidence of significant heterogeneity) and the I² statistic. The I² statistic is a measure of consistency between trials in a meta‐analysis (<a href="./references#CD001501-bbs2-0062" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011, 2011. [http://training.cochrane.org/handbook] ">Higgins 2011</a>). As a general rule, I² values up to 25% provide evidence of low heterogeneity, values from 25% to 50% moderate heterogeneity, and 75% or above substantial heterogeneity. </p> </section> <section id="CD001501-sec-0075"> <h4 class="title">Assessment of reporting biases</h4> <p>We undertook a comprehensive search, along with careful inspection of search results, to identify duplicates to reduce the risk of reporting bias. We also searched trial registers to ensure that all conducted trials were followed to locate publications. If we identified sufficient trials, we planned to investigate publication bias by preparing funnel plots of study results. </p> </section> <section id="CD001501-sec-0076"> <h4 class="title">Data synthesis</h4> <p>When we found evidence of skewed data in the measurement of outcomes (e.g. summary trial results expressed as median and range), we did not pool the data for these outcomes in the meta‐analysis but included them in table format. </p> <p>Before synthesis, we examined data for skew using the rough rule suggested in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD001501-bbs2-0062" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011, 2011. [http://training.cochrane.org/handbook] ">Higgins 2011</a>). In addition, we noted whether summary trial results were expressed as medians together with ranges, or if data were analysed via non‐parametric methods, or both, which is also suggestive of skew. When we found no evidence of major skew in the data and no evidence of clinical heterogeneity (from inspection of trial characteristics), we pooled the outcomes statistically in a meta‐analysis using RevMan software. When data could not be pooled because of skew, we included the outcome data in table format. </p> <p>We combined risk ratios (RRs) and 95% confidence intervals (CIs) for meta‐analysis using the Peto‐modified Mantel‐Haenszel method. For some dichotomous outcomes (e.g. the proportion of participants requiring further surgery), a higher proportion represented a negative consequence of that treatment, and for other outcomes (e.g. the proportion with improvement in menstrual blood loss), we considered a higher proportion as a benefit of treatment. This discrepancy in categorising of outcomes should be noted when summary graphs for the meta‐analysis are viewed for assessment of benefits as opposed to harms of treatment. Thus, for some dichotomous outcomes, treatment benefit is displayed as RRs and CIs to the left of the centre line, and for others, treatment benefit is displayed to the right of the centre line. We have clearly labelled the forest plot for each outcome for clarification. </p> <p>We combined mean differences (MDs) and 95% CIs for meta‐analysis using the inverse variance method. For all continuous outcomes in this review, a high value represents a negative consequence of treatment, for example, duration of surgery, amount of fluid deficit (difference between input and output fluid during surgery), and PBAC score for menstrual blood loss. Thus, in evaluation of the summary graphs, means and CIs to the left are considered a benefit of the experimental or comparative treatment. </p> <p>We used a fixed‐effect model to calculate summary effect measures. When we noted substantial statistical heterogeneity, we compared results from the fixed‐effect model against those from the random‐effects model to determine whether results were altered substantially by choice of model. A priori we expected that two of the outcomes ‐ duration of surgery and proportion ‐ would require local instead of general anaesthesia and would yield heterogeneous results regardless of comparison. For these comparisons, we used a random‐effects model. For all overall comparisons of first‐generation versus second‐generation methods, we used a random‐effects model because of expected clinical heterogeneity between trials. </p> </section> <section id="CD001501-sec-0077"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned subgroup analyses for different times of follow‐up after surgery, in particular, for rates of amenorrhoea, satisfaction, and the requirement for additional surgery. We collected these outcomes at 6 months; at 1, 2, and 2 to 5 years; and longer than 5 years after surgery. </p> </section> <section id="CD001501-sec-0078"> <h4 class="title">Sensitivity analysis</h4> <p>A priori we intended to perform sensitivity analysis to test the robustness of pooled results in the meta‐analysis based on: </p> <p> <ul id="CD001501-list-0021"> <li> <p>trials with good methods (evidence of adequate allocation concealment and intention‐to‐treat analysis) versus all included trials; </p> </li> <li> <p>trials with and without power calculations for sample size;</p> </li> <li> <p>trials with participants who had confirmed objective HMB loss (more than 80 mL per cycle) versus all included trials; and </p> </li> <li> <p>trials with participants who had initially failed medical treatment for HMB versus all included trials. </p> </li> </ul> </p> <p>For most comparisons, we identified an insufficient number of studies for inclusion to perform any of these sensitivity analyses. </p> <section id="CD001501-sec-0079"> <h5 class="title">Overall quality of the body of evidence</h5> <p>We generated a 'Summary of findings' table for the overall outcome of first‐generation versus second‐generation ablation techniques using GRADEpro software. We used the outcomes of bleeding and satisfaction up to 5 years' follow‐up, duration of operation, proportion given local anaesthesia, complication rate from perforation, and requirement for additional surgery at 12 months' and up to 5 years' follow‐up. This table evaluates the overall quality of the body of evidence for each of the main review outcomes using GRADE criteria (study limitations (i.e. risk of bias), consistency of effect, imprecision, indirectness, and publication bias). We have documented judgements about evidence quality (high, moderate, low, or very low) and have incorporated them into reporting of results for each outcome. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD001501-sec-0080" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD001501-sec-0080"></div> <section id="CD001501-sec-0081"> <h3 class="title">Description of studies</h3> <section id="CD001501-sec-0082"> <h4 class="title">Results of the search</h4> <p>2005 update: Review authors excluded one study that compared two types of balloon ablation ‐ Menotreat and Cavaterm. A total of 19 studies, some of which provided several different publications describing longer‐term follow‐up or different outcomes, met the inclusion criteria of the review for this update. </p> <p>2009 update: Two new trials (21 RCTs overall) were eligible for the 2009 update (<a href="./references#CD001501-bbs2-0006" title="BrunJ‐L , RaynalJ , BurletG , GalandB , QuereuxC , BernardP . Cavaterm thermal balloon endometrial ablation versus hysteroscopic endometrial resection to treat menorrhagia: the French, multicenter, randomized study. Journal of Minimally Invasive Gynecology2006;13:424‐30. ">Brun 2006</a>; <a href="./references#CD001501-bbs2-0019" title="OnogluA , TaskinO , InalM , SadikS , SimsekM , AkarM , et al. Comparison of the long‐term histopathologic and morphologic changes after endometrial rollerball ablation and resection: a prospective randomized trial. Journal of Minimally Invasive Gynecology2007;14:39‐42. ">Onoglu 2007</a>). Two studies provided additional follow‐up for previously included trials (<a href="./references#CD001501-bbs2-0004" title="BongersM , HermanM , JosienP , MolBW . Ten‐year follow‐up of a randomized controlled trial comparing NovaSure and Thermachoice in endometrial ablation for dysfunctional uterine bleeding. Journal of Minimally Invasive Gynecology2011;18(6 Suppl 1):S127. BongersMY , BourdrezP , HeintzPM , BrolmannHAM , MolBWJ . Bipolar radio frequency endometrial ablation compared with balloon endometrial ablation in dysfunctional uterine bleeding: impact on patients' health‐related quality of life. Fertility and Sterility2005;83(3):724‐34. BongersMY , BourdrezP , MolBWJ , HeintzAPM , BrolmannHAM . Randomised controlled trial of bipolar radio‐frequency endometrial ablation and balloon endometrial ablation. British Journal of Obstetrics and Gynaecology2004;111:1095‐102. HermanM , PenninxM , MolB , BongersM . Ten‐year follow‐up of a randomised controlled trial comparing bipolar endometrial ablation with balloon ablation for heavy menstrual bleeding. British Journal Obstetrics and Gynaecology2013;120:966‐970. [DOI: 10.1111/1471‐0528.12213] KleijnJH , EngelsR , BourdrezP , MolBWJ , BongersMY . Five‐year follow up of a randomised controlled trial comparing NovaSure and ThermaChoice endometrial ablation. British Journal of Obstetrics and Gynaecology2008;115:193‐8. ">Bongers 2004</a>; <a href="./references#CD001501-bbs2-0005" title="BoujidaVH , PhilipsenT , PelleJ , JoergensenJC . Five‐year follow‐up of endometrial ablation: endometrial coagulation versus endometrial resection. Obstetrics and Gynecology2002;99:988‐92. FurstSN , PhilipsenT , JoergensenJC . Ten‐year follow‐up of endometrial ablation. Acta Obstetricia et Gynecologica2007;86:334‐8. ">Boujida 2002</a>). </p> <p>2013 update: Review authors included in the 2013 update four new trials (25 RCTs overall), one of which provided two publications (<a href="./references#CD001501-bbs2-0007" title="ClarkTJ , SamuelN , MalickS , MiddletonLJ , DanielsJ , GuptaJK . Bipolar radiofrequency compared with thermal balloon endometrial ablation in the office. Obstetrics and Gynecology2011;117:109‐18. ">Clark 2011</a>; <a href="./references#CD001501-bbs2-0021" title="BongersM , HermanM , PenninxJ , MolBW . Longterm follow‐up of a randomized controlled trial comparing NovaSure and hydrothermablation for dysfunctional uterine bleeding. Journal of Minimally Invasive Gynecology2011;18(6 Suppl 1):S34. PenninxJPM , HermanMC , MolBW , BongersMY . Five‐year follow‐up after comparing bipolar endometrial ablation with hydrothermablation for menorrhagia. Obstetrics and Gynecology2011;118:1287‐92. PenninxJPM , MolBW , EngelsR , vanRumsteMME , KleijnC , KoksCAM , et al. Bipolar radiofrequency endometrial ablation compared with hydrothermablation for dysfunctional uterine bleeding. Obstetrics and Gynecology2010;116:819‐26. ">Penninx 2010</a>; <a href="./references#CD001501-bbs2-0025" title="SambrookA , EldersA , CooperK . Microwave endometrial ablation versus thermal balloon endometrial ablation (MEATBall): 5‐year follow up of a randomised controlled trial. British Journal of Obstetrics and Gynaecology2014;121:748‐54. [DOI: 10.1111/1471‐0528.12585] SambrookAM , CooperKG , CampbellMK , CookJA . Clinical outcomes from a randomised comparison of microwave endometrial ablation with thermal balloon endometrial ablation for the treatment of heavy menstrual bleeding. British Journal of Obstetrics and Gynaecology2009;116:1038‐45. ">Sambrook 2009</a>; <a href="./references#CD001501-bbs2-0026" title="ThabetSMA . New attempt using ablative curettage technique for managing benign premenopausal uterine bleeding. Obstetrics and Gynaecology Research2010;36(4):803‐9. ">Thabet 2010</a>). We have now excluded one study awaiting assessment since the 2009 update because it was not randomised (<a href="./references#CD001501-bbs2-0034" title="FengLM , GaoWL . Clinical analysis of abnormal uterine bleeding treatment with Thermablate EAS. Beijing da Xue Xue Bao2006;38(4):432‐5. ">Feng 2006</a>). </p> <p>2018 update: Review authors determined that five additional trials were eligible for inclusion in the 2018 update and obtained the full texts of these papers (when available) for closer inspection. Review authors included four new trials in the 2018 update (<a href="./references#CD001501-bbs2-0002" title="AthanatosD , PadosG , VenetisC , StamatopoulosP , RoussoD , TsolakidisD , et al. Novasure impedance control system versus microwave endometrial ablation for the treatment of dysfunctional uterine bleeding: a double‐blind, randomized controlled trial. Clinical and Experimental Obstetrics &amp; Gynecology2015;42(3):347‐51. [PMID: 26152008] PadosG . Treatment of dysfunctional uterine bleeding with second generation ablation devices: microwaves (MEAA) vs Bipolar Impedance Control System (Novasure). http://clinicaltrials.gov/show/NCT01173965. ">Athanatos 2015</a>: <a href="./references#CD001501-bbs2-0014" title="GhazizadehS , PanahiZ , GhanbariZ , Tarafdari MenshadiA , FarahmandianT , JavadianP . Comparative efficacy of NovaSure, the levonorgestrel‐releasing intrauterine system, and hysteroscopic endometrial resection in the treatment of menorrhagia: a randomized clinical trial. Journal of Gynecologic Surgery2014;30(4):215‐8. [DOI: 10.1089/gyn.2012.0041] ">Ghazizadeh 2014</a>; <a href="./references#CD001501-bbs2-0016" title="LabergeP , Garza‐LealJ , FortinC , BasinskiC , ThielJ , LeylandN , et al. A prospective, randomized, multi‐center, controlled, international clinical study of the safety and efficacy of the Minerva endometrial ablation system: 6 and 12‐month follow‐up results. Journal of Minimally Invasive Gynecology. 2014. LabergeP , Garza‐LealJ , FortinC , GraingerD , JohnsDA , AdkinsRT , et al. A randomized controlled multicenter US Food and Drug Administration trial of the safety and efficacy of the Minerva Endometrial Ablation System: one‐year follow‐up results. Journal of Minimally Invasive Gynecology2017;24(1):124‐32. [DOI: 10.1016/j.jmig.2016.09.009] LabergeP , Garza‐LealJ , FortinC , ThielJ , JohnsD , GraingerD , et al. A randomized, controlled, multi‐center trial of the safety and efficacy of the Minerva Endometrial Ablation System: one‐year follow‐up results. Journal of Minimally Invasive Gynecology. 2016; Vol. 23:S1‐S252. ">Laberge 2016</a>: <a href="./references#CD001501-bbs2-0022" title="PenninxJ , BongersM . Bipolar radiofrequency endometrial ablation versus thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. www.controlled‐trials.com/ISRCTN17974690. PenninxJ , HermanM , KruitwagenR , Ter HaarA , MolB , BongersM . Bipolar versus balloon endometrial ablation in the office: a randomized controlled trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;196:52‐6. [DOI: 10.1016/j.ejogrb.2015.10.010] PenninxJ , HermanM , MolB , KruitwagenR , BongersM . Bipolar radiofrequency endometrial ablation versus Thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. Journal of Minimally Invasive Gynecology2012;19(6):S21‐S22. [DOI: 10.1016/j.jmig.2012.08.076] PenninxJPM , HermanMC , MolBW , BongersMY . Bipolar radiofrequency endometrial ablation versus thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. Journal of Minimally Invasive Gynecology2012;19(6 Suppl 1):S21‐2. ">Penninx 2016</a>), and we categorised one study as awaiting classification (<a href="./references#CD001501-bbs2-0038" title="FengL , ZhangZ , YangQ , ChenQ . Preliminary results of a randomized controlled trial of the Cardea GEA System versus transcervical resection of the endometrium (TCRE) combined with roller‐ball ablation for the treatment of abnormal uterine bleeding. Journal of Minimally Invasive Gynecology2014;21:S139. ">Feng 2014</a>). We added new data for previously included studies (<a href="./references#CD001501-bbs2-0004" title="BongersM , HermanM , JosienP , MolBW . Ten‐year follow‐up of a randomized controlled trial comparing NovaSure and Thermachoice in endometrial ablation for dysfunctional uterine bleeding. Journal of Minimally Invasive Gynecology2011;18(6 Suppl 1):S127. BongersMY , BourdrezP , HeintzPM , BrolmannHAM , MolBWJ . Bipolar radio frequency endometrial ablation compared with balloon endometrial ablation in dysfunctional uterine bleeding: impact on patients' health‐related quality of life. Fertility and Sterility2005;83(3):724‐34. BongersMY , BourdrezP , MolBWJ , HeintzAPM , BrolmannHAM . Randomised controlled trial of bipolar radio‐frequency endometrial ablation and balloon endometrial ablation. British Journal of Obstetrics and Gynaecology2004;111:1095‐102. HermanM , PenninxM , MolB , BongersM . Ten‐year follow‐up of a randomised controlled trial comparing bipolar endometrial ablation with balloon ablation for heavy menstrual bleeding. British Journal Obstetrics and Gynaecology2013;120:966‐970. [DOI: 10.1111/1471‐0528.12213] KleijnJH , EngelsR , BourdrezP , MolBWJ , BongersMY . Five‐year follow up of a randomised controlled trial comparing NovaSure and ThermaChoice endometrial ablation. British Journal of Obstetrics and Gynaecology2008;115:193‐8. ">Bongers 2004</a>; <a href="./references#CD001501-bbs2-0021" title="BongersM , HermanM , PenninxJ , MolBW . Longterm follow‐up of a randomized controlled trial comparing NovaSure and hydrothermablation for dysfunctional uterine bleeding. Journal of Minimally Invasive Gynecology2011;18(6 Suppl 1):S34. PenninxJPM , HermanMC , MolBW , BongersMY . Five‐year follow‐up after comparing bipolar endometrial ablation with hydrothermablation for menorrhagia. Obstetrics and Gynecology2011;118:1287‐92. PenninxJPM , MolBW , EngelsR , vanRumsteMME , KleijnC , KoksCAM , et al. Bipolar radiofrequency endometrial ablation compared with hydrothermablation for dysfunctional uterine bleeding. Obstetrics and Gynecology2010;116:819‐26. ">Penninx 2010</a>). One study that was ongoing in the previous update did not start recruitment (<a href="./references#CD001501-bbs2-0032" title="CooperK . Blind versus visual endometrial ablation: a randomised controlled trial. http://www.controlled‐trials.com/mrct/trial/2292665/. [this trial did not take place due to lack of funding] ">Cooper 2012</a>); that study was stopped because of lack of funding and was moved to the excluded studies. We reviewed one trial that was previously included but excluded it at this update because it did not match our inclusion criteria (<a href="./references#CD001501-bbs2-0036" title="SoysalME , SoysalSK , VicdanK . Thermal balloon ablation in myoma‐induced menorrhagia under local anaesthesia. Gynecologic and Obstetric Investigation2001;51:128‐33. ">Soysal 2001</a>). </p> <p>Thus, a total of 28 trials (4287 women), with sample sizes ranging from 20 to 372, were eligible for this review. Full details of these studies can be found in the <a href="./references#CD001501-sec-0344" title="">Characteristics of included studies</a> table. We excluded a total of nine studies, and three are currently awaiting classification (see <a href="./references#CD001501-sec-0345" title="">Characteristics of excluded studies</a>). We identified one ongoing study (<a href="./references#CD001501-bbs2-0041" title="NazacA . Comparison of the efficiency of bipolar energy versus monopolar energy in endometrial ablation in women having menorrhagia. Clinicaltrials.govaccessed May 2018. [https://clinicaltrials.gov/ct2/show/NCT02642926] ">NCT02642926</a>). We have presented details of the screening and selection process in <a href="#CD001501-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD001501-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD001501-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD001501-sec-0083"> <h4 class="title">Included studies</h4> <section id="CD001501-sec-0084"> <h5 class="title">Study design and setting</h5> <p>All of the trials followed a parallel‐group design.</p> <p>Twenty of the trials were single‐centre studies, one each from Germany (<a href="./references#CD001501-bbs2-0024" title="RomerT . The treatment of recurrent menorrhagias ‐ Cavaterm‐balloon‐coagulation versus Rollerball‐endometrial ablation ‐ a prospective randomized comparative study [Die therapie rezidivierender Menorrhagien ‐ Cavaterm‐Ballon‐Koagulatioon versus Roller‐Ball‐Endometriumkoagulation ‐ eine prospektive randomisierte Vergleichsstudie]. Zentralblatt fur Gynakologie1998;120(10):511‐4. ">Romer 1998</a>), Australia (<a href="./references#CD001501-bbs2-0017" title="McClureN , MarnersM , HealyDL , HillDJ , LawrenceAS , WingfieldM , et al. A quantitative assessment of endometrial electrocautery in the management of menorrhagia and a comparative report of argon laser endometrial ablation. Gynaecological Endoscopy1992;1:199‐202. ">McClure 1992</a>), Egypt (<a href="./references#CD001501-bbs2-0026" title="ThabetSMA . New attempt using ablative curettage technique for managing benign premenopausal uterine bleeding. Obstetrics and Gynaecology Research2010;36(4):803‐9. ">Thabet 2010</a>), Denmark (<a href="./references#CD001501-bbs2-0005" title="BoujidaVH , PhilipsenT , PelleJ , JoergensenJC . Five‐year follow‐up of endometrial ablation: endometrial coagulation versus endometrial resection. Obstetrics and Gynecology2002;99:988‐92. FurstSN , PhilipsenT , JoergensenJC . Ten‐year follow‐up of endometrial ablation. Acta Obstetricia et Gynecologica2007;86:334‐8. ">Boujida 2002</a>), Greece (<a href="./references#CD001501-bbs2-0002" title="AthanatosD , PadosG , VenetisC , StamatopoulosP , RoussoD , TsolakidisD , et al. Novasure impedance control system versus microwave endometrial ablation for the treatment of dysfunctional uterine bleeding: a double‐blind, randomized controlled trial. Clinical and Experimental Obstetrics &amp; Gynecology2015;42(3):347‐51. [PMID: 26152008] PadosG . Treatment of dysfunctional uterine bleeding with second generation ablation devices: microwaves (MEAA) vs Bipolar Impedance Control System (Novasure). http://clinicaltrials.gov/show/NCT01173965. ">Athanatos 2015</a>), Turkey (<a href="./references#CD001501-bbs2-0019" title="OnogluA , TaskinO , InalM , SadikS , SimsekM , AkarM , et al. Comparison of the long‐term histopathologic and morphologic changes after endometrial rollerball ablation and resection: a prospective randomized trial. Journal of Minimally Invasive Gynecology2007;14:39‐42. ">Onoglu 2007</a>), and Iran (<a href="./references#CD001501-bbs2-0014" title="GhazizadehS , PanahiZ , GhanbariZ , Tarafdari MenshadiA , FarahmandianT , JavadianP . Comparative efficacy of NovaSure, the levonorgestrel‐releasing intrauterine system, and hysteroscopic endometrial resection in the treatment of menorrhagia: a randomized clinical trial. Journal of Gynecologic Surgery2014;30(4):215‐8. [DOI: 10.1089/gyn.2012.0041] ">Ghazizadeh 2014</a>); four from the Netherlands (<a href="./references#CD001501-bbs2-0004" title="BongersM , HermanM , JosienP , MolBW . Ten‐year follow‐up of a randomized controlled trial comparing NovaSure and Thermachoice in endometrial ablation for dysfunctional uterine bleeding. Journal of Minimally Invasive Gynecology2011;18(6 Suppl 1):S127. BongersMY , BourdrezP , HeintzPM , BrolmannHAM , MolBWJ . Bipolar radio frequency endometrial ablation compared with balloon endometrial ablation in dysfunctional uterine bleeding: impact on patients' health‐related quality of life. Fertility and Sterility2005;83(3):724‐34. BongersMY , BourdrezP , MolBWJ , HeintzAPM , BrolmannHAM . Randomised controlled trial of bipolar radio‐frequency endometrial ablation and balloon endometrial ablation. British Journal of Obstetrics and Gynaecology2004;111:1095‐102. HermanM , PenninxM , MolB , BongersM . Ten‐year follow‐up of a randomised controlled trial comparing bipolar endometrial ablation with balloon ablation for heavy menstrual bleeding. British Journal Obstetrics and Gynaecology2013;120:966‐970. [DOI: 10.1111/1471‐0528.12213] KleijnJH , EngelsR , BourdrezP , MolBWJ , BongersMY . Five‐year follow up of a randomised controlled trial comparing NovaSure and ThermaChoice endometrial ablation. British Journal of Obstetrics and Gynaecology2008;115:193‐8. ">Bongers 2004</a>; <a href="./references#CD001501-bbs2-0021" title="BongersM , HermanM , PenninxJ , MolBW . Longterm follow‐up of a randomized controlled trial comparing NovaSure and hydrothermablation for dysfunctional uterine bleeding. Journal of Minimally Invasive Gynecology2011;18(6 Suppl 1):S34. PenninxJPM , HermanMC , MolBW , BongersMY . Five‐year follow‐up after comparing bipolar endometrial ablation with hydrothermablation for menorrhagia. Obstetrics and Gynecology2011;118:1287‐92. PenninxJPM , MolBW , EngelsR , vanRumsteMME , KleijnC , KoksCAM , et al. Bipolar radiofrequency endometrial ablation compared with hydrothermablation for dysfunctional uterine bleeding. Obstetrics and Gynecology2010;116:819‐26. ">Penninx 2010</a>; <a href="./references#CD001501-bbs2-0022" title="PenninxJ , BongersM . Bipolar radiofrequency endometrial ablation versus thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. www.controlled‐trials.com/ISRCTN17974690. PenninxJ , HermanM , KruitwagenR , Ter HaarA , MolB , BongersM . Bipolar versus balloon endometrial ablation in the office: a randomized controlled trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;196:52‐6. [DOI: 10.1016/j.ejogrb.2015.10.010] PenninxJ , HermanM , MolB , KruitwagenR , BongersM . Bipolar radiofrequency endometrial ablation versus Thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. Journal of Minimally Invasive Gynecology2012;19(6):S21‐S22. [DOI: 10.1016/j.jmig.2012.08.076] PenninxJPM , HermanMC , MolBW , BongersMY . Bipolar radiofrequency endometrial ablation versus thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. Journal of Minimally Invasive Gynecology2012;19(6 Suppl 1):S21‐2. ">Penninx 2016</a>; <a href="./references#CD001501-bbs2-0027" title="vanZon‐RabelinkIAA , VleugelsMPH . Treating menorrhagia with endometrial ablation: rollerball electrocoagulation versus thermal ablation with the uterine balloon. Gynaecological Endoscopy Abstract from the 6th Annual Congress of the European Society for Gynaecological Endoscopy1997;6 Suppl 2:41. vanZon‐RabelinkIAA , VleugelsMPH , MerkusHMWM , deGraafR . Efficacy and satisfaction rate comparing endometrial ablation by rollerball electrocoagulation to uterine balloon thermal ablation in a randomised controlled trial. European Journal of Obstetrics, Gynecology, and Reproductive Biology2004;114(1):97‐103. vanZon‐RabelinkIAA , VleugelsMPH , MerkusHMWM , deGraafR . Endometrial ablation by rollerball electrocoagulation compared to uterine balloon thermal ablation. Technical and safety aspects. European Journal of Obstetrics, Gynecology, and Reproductive Biology2003;110:220‐3. ">van Zon‐Rabelink 2003</a>); three from Italy (<a href="./references#CD001501-bbs2-0020" title="PellicanoM , GuidaM , AcunzoG , CirilloD , BifulcoG , NappiC . Hysteroscopic transcervical endometrial resection versus thermal destruction for menorrhagia: a prospective randomized trial on satisfaction rate. American Journal of Obstetrics and Gynecology2002;187:545‐50. ">Pellicano 2002</a>; <a href="./references#CD001501-bbs2-0023" title="PerinoA , CastelliA , CucinellaG , BiondoA , PaneA , VeneziaR . A randomized comparison of endometrial laser intrauterine thermotherapy and hysteroscopic endometrial resection. Fertility and Sterility2004;82:731‐4. ">Perino 2004</a>: <a href="./references#CD001501-bbs2-0028" title="VercelliniP , OldaniS , YaylayanL , ZainaB , DeGiorgiO , CrosignaniPG . Randomised comparison of vaporising electrode and cutting loop for endometrial ablation. Obstetrics and Gynecology1999;94:521‐7. ">Vercellini 1999</a>); and six from the UK (<a href="./references#CD001501-bbs2-0001" title="AbbottJ , HaweJ , HunterD , GarryR . A double‐blind randomized trial comparing the Cavaterm and the Novasure endometrial ablation systems for the treatment of dysfunctional uterine bleeding. Fertility and Sterility2003;80(1):203‐8. ">Abbott 2003</a>; <a href="./references#CD001501-bbs2-0003" title="BhattacharyaS , CameronIM , ParkinDE , AbramovichDR , MollisonJ , PinionSB , et al. A pragmatic randomised comparison of transcervical resection of the endometrium with endometrial laser ablation for the treatment of menorrhagia. British Journal of Obstetrics and Gynaecology1997;104:601‐7. ">Bhattacharya 1997</a>; <a href="./references#CD001501-bbs2-0007" title="ClarkTJ , SamuelN , MalickS , MiddletonLJ , DanielsJ , GuptaJK . Bipolar radiofrequency compared with thermal balloon endometrial ablation in the office. Obstetrics and Gynecology2011;117:109‐18. ">Clark 2011</a>; <a href="./references#CD001501-bbs2-0008" title="BainC , CooperKG , ParkinDE . Microwave endometrial ablation versus endometrial resection: a randomized controlled trial. Obstetrics and Gynecology2002;99:983‐7. CooperKG , BainC , LawrieL , ParkinDE . A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium: follow up at a minimum of five years. British Journal of Obstetrics and Gynaecology2005;112:470‐5. CooperKG , BainC , ParkinDE . Comparison of microwave endometrial ablation and transcervical resection of the endometrium for treatment of heavy menstrual loss: a randomised trial. Lancet1999;354:1859‐63. SambrookAM , BainC , ParkinDE , CooperKG . A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium: follow up at a minimum of 10 years. British Journal of Obstetrics and Gynaecology2009;116:1033‐7. ">Cooper 1999</a>; <a href="./references#CD001501-bbs2-0015" title="HaweJ , AbbottJ , HunterD , PhillipsG , GarryR . A randomised controlled trial comparing the Cavaterm endometrial ablation system with the Nd:YAG laser for the treatment of dysfunctional uterine bleeding. British Journal of Obstetrics and Gynaecology2003;110:350‐7. ">Hawe 2003</a>; <a href="./references#CD001501-bbs2-0025" title="SambrookA , EldersA , CooperK . Microwave endometrial ablation versus thermal balloon endometrial ablation (MEATBall): 5‐year follow up of a randomised controlled trial. British Journal of Obstetrics and Gynaecology2014;121:748‐54. [DOI: 10.1111/1471‐0528.12585] SambrookAM , CooperKG , CampbellMK , CookJA . Clinical outcomes from a randomised comparison of microwave endometrial ablation with thermal balloon endometrial ablation for the treatment of heavy menstrual bleeding. British Journal of Obstetrics and Gynaecology2009;116:1038‐45. ">Sambrook 2009</a>). We identified eight multi‐centre trials, two based in Canada, USA, and Mexico (<a href="./references#CD001501-bbs2-0009" title="CooperJ , GimpelsonR , LabergeP , GalenD , Garza‐LealJG , ScottJ , et al. A randomized, multicenter trial of safety and efficacy of the NovaSure system in the treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2002;9(4):418‐28. ">Cooper 2002;</a><a href="./references#CD001501-bbs2-0016" title="LabergeP , Garza‐LealJ , FortinC , BasinskiC , ThielJ , LeylandN , et al. A prospective, randomized, multi‐center, controlled, international clinical study of the safety and efficacy of the Minerva endometrial ablation system: 6 and 12‐month follow‐up results. Journal of Minimally Invasive Gynecology. 2014. LabergeP , Garza‐LealJ , FortinC , GraingerD , JohnsDA , AdkinsRT , et al. A randomized controlled multicenter US Food and Drug Administration trial of the safety and efficacy of the Minerva Endometrial Ablation System: one‐year follow‐up results. Journal of Minimally Invasive Gynecology2017;24(1):124‐32. [DOI: 10.1016/j.jmig.2016.09.009] LabergeP , Garza‐LealJ , FortinC , ThielJ , JohnsD , GraingerD , et al. A randomized, controlled, multi‐center trial of the safety and efficacy of the Minerva Endometrial Ablation System: one‐year follow‐up results. Journal of Minimally Invasive Gynecology. 2016; Vol. 23:S1‐S252. ">Laberge 2016</a>); one in USA‐Canada and UK (<a href="./references#CD001501-bbs2-0010" title="CooperJM , AndersonTL , FortinCA , JackSA , PlentlMB . Microwave endometrial ablation vs rollerball electroablation for menorrhagia: a multicenter randomized trial. Journal of the American Association of Gynecologic Laparoscopists2004;11(3):394‐403. ">Cooper 2004</a>); one in USA‐Australia (<a href="./references#CD001501-bbs2-0011" title="CorsonSL , BrillAI , BrooksPG , CooperJM , IndmanPD , LiuJH , et al. Interim results of the American Vesta trial of endometrial ablation. Journal of the American Association of Gynecologic Laparoscopists1999;6(1):45‐9. CorsonSL , BrillAI , BrooksPG , CooperJM , IndmanPD , LiuJH , et al. One‐year results of the Vesta system for endometrial ablation. Journal of the American Association of Gynecologic Laparoscopists2000;7(4):489‐97. ">Corson 2000</a>), one in USA‐Canada (<a href="./references#CD001501-bbs2-0018" title="GraingerDA , TjadenDO , RowlandC , MeyerWR . Thermal balloon and rollerball ablation to treat menorrhagia: two‐year results of a multicenter, prospective, randomized clinical trial. Journal of the American Association of Gynecologic Laparoscopists2000;7(2):175‐9. LofferFD . Five year post‐procedure follow‐up of patients participating in a randomised trial of uterine balloon therapy vs rollerball ablation for the treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopy2001;8(1):48‐54. LofferFD . Three‐year comparison of thermal balloon and rollerball ablation in treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2001;8(1):48‐54. MeyerWR , WalshBW , GraingerDA , PeacockLM , LofferFD , SteegeJF . Thermal balloon and rollerball ablation to treat menorrhagia: a multicenter comparison. Obstetrics and Gynecology1998;92:98‐103. ">Meyer 1998</a>), and two in the USA (<a href="./references#CD001501-bbs2-0012" title="CorsonSL . A multicenter evaluation of endometrial ablation by hydrothermablator and rollerball for treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2001;8(3):359‐67. GoldrathMH . Evaluation of hydrothermablator and rollerball endometrial ablation for menorrhagia 3 years after treatment. Journal of the American Association of Gynecologic Laparoscopists2003;10(4):505‐11. LofferF . A clinical comparison of hydrothermablation (HTA) and rollerball for endometrial ablation to treat menorrhagia: a randomized multicenter clinical trial. XVI FIGO World Congress of Obstetrics &amp; Gynecology. 2000; Vol. Abstract Book 2:95. ">Corson 2001</a>; <a href="./references#CD001501-bbs2-0013" title="DulebaAJ , HeppardMC , SoderstromRM , TownsendDE . A randomized study comparing endometrial cryoablation and rollerball electroablation for treatment of dysfunctional uterine bleeding. Journal of the American Association of Gynecologic Laparoscopists2003;10(1):17‐26. TownsendDE , DulebaAJ , WilkesMM , et al. Durability of treatment effects after cryoablation versus rollerball electroablation for abnormal uterine bleeding: two‐year results of a multicenter randomized trial. American Journal of Obstetrics and Gynecology2003;188:699‐701. ">Duleba 2003</a>), and with three having additional centres in Canada, UK, or Australia; one multi‐centre trial had six centres, all based in France (<a href="./references#CD001501-bbs2-0006" title="BrunJ‐L , RaynalJ , BurletG , GalandB , QuereuxC , BernardP . Cavaterm thermal balloon endometrial ablation versus hysteroscopic endometrial resection to treat menorrhagia: the French, multicenter, randomized study. Journal of Minimally Invasive Gynecology2006;13:424‐30. ">Brun 2006</a>). </p> <p>Few of these studies used strict intention‐to‐treat (ITT) analyses or specified methods to deal with missing data. Twelve trials did not report an ITT analysis. Seven claimed that ITT analysis was performed but over time a percentage of participants were lost to follow‐up, so the claim of ITT was misleading. However, ITT analysis was usually performed in these studies when researchers assessed outcomes such as complication rates. Four trials performed true ITT analyses, and one had no reported dropouts. One other trial did not report ITT analysis and replaced dropouts with new cases. </p> <p>Seventeen trials reported their recruiting time frame. One was recruited between 1989 and 1991 (<a href="./references#CD001501-bbs2-0017" title="McClureN , MarnersM , HealyDL , HillDJ , LawrenceAS , WingfieldM , et al. A quantitative assessment of endometrial electrocautery in the management of menorrhagia and a comparative report of argon laser endometrial ablation. Gynaecological Endoscopy1992;1:199‐202. ">McClure 1992</a>), 12 between 1995 and 2002 (<a href="./references#CD001501-bbs2-0001" title="AbbottJ , HaweJ , HunterD , GarryR . A double‐blind randomized trial comparing the Cavaterm and the Novasure endometrial ablation systems for the treatment of dysfunctional uterine bleeding. Fertility and Sterility2003;80(1):203‐8. ">Abbott 2003</a>; <a href="./references#CD001501-bbs2-0004" title="BongersM , HermanM , JosienP , MolBW . Ten‐year follow‐up of a randomized controlled trial comparing NovaSure and Thermachoice in endometrial ablation for dysfunctional uterine bleeding. Journal of Minimally Invasive Gynecology2011;18(6 Suppl 1):S127. BongersMY , BourdrezP , HeintzPM , BrolmannHAM , MolBWJ . Bipolar radio frequency endometrial ablation compared with balloon endometrial ablation in dysfunctional uterine bleeding: impact on patients' health‐related quality of life. Fertility and Sterility2005;83(3):724‐34. BongersMY , BourdrezP , MolBWJ , HeintzAPM , BrolmannHAM . Randomised controlled trial of bipolar radio‐frequency endometrial ablation and balloon endometrial ablation. British Journal of Obstetrics and Gynaecology2004;111:1095‐102. HermanM , PenninxM , MolB , BongersM . Ten‐year follow‐up of a randomised controlled trial comparing bipolar endometrial ablation with balloon ablation for heavy menstrual bleeding. British Journal Obstetrics and Gynaecology2013;120:966‐970. [DOI: 10.1111/1471‐0528.12213] KleijnJH , EngelsR , BourdrezP , MolBWJ , BongersMY . Five‐year follow up of a randomised controlled trial comparing NovaSure and ThermaChoice endometrial ablation. British Journal of Obstetrics and Gynaecology2008;115:193‐8. ">Bongers 2004</a>; <a href="./references#CD001501-bbs2-0006" title="BrunJ‐L , RaynalJ , BurletG , GalandB , QuereuxC , BernardP . Cavaterm thermal balloon endometrial ablation versus hysteroscopic endometrial resection to treat menorrhagia: the French, multicenter, randomized study. Journal of Minimally Invasive Gynecology2006;13:424‐30. ">Brun 2006</a>; <a href="./references#CD001501-bbs2-0008" title="BainC , CooperKG , ParkinDE . Microwave endometrial ablation versus endometrial resection: a randomized controlled trial. Obstetrics and Gynecology2002;99:983‐7. CooperKG , BainC , LawrieL , ParkinDE . A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium: follow up at a minimum of five years. British Journal of Obstetrics and Gynaecology2005;112:470‐5. CooperKG , BainC , ParkinDE . Comparison of microwave endometrial ablation and transcervical resection of the endometrium for treatment of heavy menstrual loss: a randomised trial. Lancet1999;354:1859‐63. SambrookAM , BainC , ParkinDE , CooperKG . A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium: follow up at a minimum of 10 years. British Journal of Obstetrics and Gynaecology2009;116:1033‐7. ">Cooper 1999</a>; <a href="./references#CD001501-bbs2-0010" title="CooperJM , AndersonTL , FortinCA , JackSA , PlentlMB . Microwave endometrial ablation vs rollerball electroablation for menorrhagia: a multicenter randomized trial. Journal of the American Association of Gynecologic Laparoscopists2004;11(3):394‐403. ">Cooper 2004</a>; <a href="./references#CD001501-bbs2-0011" title="CorsonSL , BrillAI , BrooksPG , CooperJM , IndmanPD , LiuJH , et al. Interim results of the American Vesta trial of endometrial ablation. Journal of the American Association of Gynecologic Laparoscopists1999;6(1):45‐9. CorsonSL , BrillAI , BrooksPG , CooperJM , IndmanPD , LiuJH , et al. One‐year results of the Vesta system for endometrial ablation. Journal of the American Association of Gynecologic Laparoscopists2000;7(4):489‐97. ">Corson 2000</a>; <a href="./references#CD001501-bbs2-0015" title="HaweJ , AbbottJ , HunterD , PhillipsG , GarryR . A randomised controlled trial comparing the Cavaterm endometrial ablation system with the Nd:YAG laser for the treatment of dysfunctional uterine bleeding. British Journal of Obstetrics and Gynaecology2003;110:350‐7. ">Hawe 2003</a>; <a href="./references#CD001501-bbs2-0018" title="GraingerDA , TjadenDO , RowlandC , MeyerWR . Thermal balloon and rollerball ablation to treat menorrhagia: two‐year results of a multicenter, prospective, randomized clinical trial. Journal of the American Association of Gynecologic Laparoscopists2000;7(2):175‐9. LofferFD . Five year post‐procedure follow‐up of patients participating in a randomised trial of uterine balloon therapy vs rollerball ablation for the treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopy2001;8(1):48‐54. LofferFD . Three‐year comparison of thermal balloon and rollerball ablation in treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2001;8(1):48‐54. MeyerWR , WalshBW , GraingerDA , PeacockLM , LofferFD , SteegeJF . Thermal balloon and rollerball ablation to treat menorrhagia: a multicenter comparison. Obstetrics and Gynecology1998;92:98‐103. ">Meyer 1998</a>; <a href="./references#CD001501-bbs2-0020" title="PellicanoM , GuidaM , AcunzoG , CirilloD , BifulcoG , NappiC . Hysteroscopic transcervical endometrial resection versus thermal destruction for menorrhagia: a prospective randomized trial on satisfaction rate. American Journal of Obstetrics and Gynecology2002;187:545‐50. ">Pellicano 2002</a>; <a href="./references#CD001501-bbs2-0023" title="PerinoA , CastelliA , CucinellaG , BiondoA , PaneA , VeneziaR . A randomized comparison of endometrial laser intrauterine thermotherapy and hysteroscopic endometrial resection. Fertility and Sterility2004;82:731‐4. ">Perino 2004</a>; <a href="./references#CD001501-bbs2-0026" title="ThabetSMA . New attempt using ablative curettage technique for managing benign premenopausal uterine bleeding. Obstetrics and Gynaecology Research2010;36(4):803‐9. ">Thabet 2010</a>; <a href="./references#CD001501-bbs2-0028" title="VercelliniP , OldaniS , YaylayanL , ZainaB , DeGiorgiO , CrosignaniPG . Randomised comparison of vaporising electrode and cutting loop for endometrial ablation. Obstetrics and Gynecology1999;94:521‐7. ">Vercellini 1999</a>), and four between 2004 and 2010 (<a href="./references#CD001501-bbs2-0002" title="AthanatosD , PadosG , VenetisC , StamatopoulosP , RoussoD , TsolakidisD , et al. Novasure impedance control system versus microwave endometrial ablation for the treatment of dysfunctional uterine bleeding: a double‐blind, randomized controlled trial. Clinical and Experimental Obstetrics &amp; Gynecology2015;42(3):347‐51. [PMID: 26152008] PadosG . Treatment of dysfunctional uterine bleeding with second generation ablation devices: microwaves (MEAA) vs Bipolar Impedance Control System (Novasure). http://clinicaltrials.gov/show/NCT01173965. ">Athanatos 2015</a>; <a href="./references#CD001501-bbs2-0007" title="ClarkTJ , SamuelN , MalickS , MiddletonLJ , DanielsJ , GuptaJK . Bipolar radiofrequency compared with thermal balloon endometrial ablation in the office. Obstetrics and Gynecology2011;117:109‐18. ">Clark 2011</a>; <a href="./references#CD001501-bbs2-0021" title="BongersM , HermanM , PenninxJ , MolBW . Longterm follow‐up of a randomized controlled trial comparing NovaSure and hydrothermablation for dysfunctional uterine bleeding. Journal of Minimally Invasive Gynecology2011;18(6 Suppl 1):S34. PenninxJPM , HermanMC , MolBW , BongersMY . Five‐year follow‐up after comparing bipolar endometrial ablation with hydrothermablation for menorrhagia. Obstetrics and Gynecology2011;118:1287‐92. PenninxJPM , MolBW , EngelsR , vanRumsteMME , KleijnC , KoksCAM , et al. Bipolar radiofrequency endometrial ablation compared with hydrothermablation for dysfunctional uterine bleeding. Obstetrics and Gynecology2010;116:819‐26. ">Penninx 2010</a>; <a href="./references#CD001501-bbs2-0025" title="SambrookA , EldersA , CooperK . Microwave endometrial ablation versus thermal balloon endometrial ablation (MEATBall): 5‐year follow up of a randomised controlled trial. British Journal of Obstetrics and Gynaecology2014;121:748‐54. [DOI: 10.1111/1471‐0528.12585] SambrookAM , CooperKG , CampbellMK , CookJA . Clinical outcomes from a randomised comparison of microwave endometrial ablation with thermal balloon endometrial ablation for the treatment of heavy menstrual bleeding. British Journal of Obstetrics and Gynaecology2009;116:1038‐45. ">Sambrook 2009</a>). </p> </section> <section id="CD001501-sec-0085"> <h5 class="title">Participants</h5> <p>The 28 included studies included 4287 premenopausal participants, most within the age range 30 to 50 years. All of these studies recruited women from secondary or tertiary referral centres or clinics who described HMB. </p> <p>The presence of fibroids was an exclusion criterion in 15 studies. All trials required that the uterine cavity be normal in size with no uterine pathology, except one (<a href="./references#CD001501-bbs2-0016" title="LabergeP , Garza‐LealJ , FortinC , BasinskiC , ThielJ , LeylandN , et al. A prospective, randomized, multi‐center, controlled, international clinical study of the safety and efficacy of the Minerva endometrial ablation system: 6 and 12‐month follow‐up results. Journal of Minimally Invasive Gynecology. 2014. LabergeP , Garza‐LealJ , FortinC , GraingerD , JohnsDA , AdkinsRT , et al. A randomized controlled multicenter US Food and Drug Administration trial of the safety and efficacy of the Minerva Endometrial Ablation System: one‐year follow‐up results. Journal of Minimally Invasive Gynecology2017;24(1):124‐32. [DOI: 10.1016/j.jmig.2016.09.009] LabergeP , Garza‐LealJ , FortinC , ThielJ , JohnsD , GraingerD , et al. A randomized, controlled, multi‐center trial of the safety and efficacy of the Minerva Endometrial Ablation System: one‐year follow‐up results. Journal of Minimally Invasive Gynecology. 2016; Vol. 23:S1‐S252. ">Laberge 2016</a>), which excluded polyps larger than 2 cm. One trial excluded only submucous fibroids (<a href="./references#CD001501-bbs2-0006" title="BrunJ‐L , RaynalJ , BurletG , GalandB , QuereuxC , BernardP . Cavaterm thermal balloon endometrial ablation versus hysteroscopic endometrial resection to treat menorrhagia: the French, multicenter, randomized study. Journal of Minimally Invasive Gynecology2006;13:424‐30. ">Brun 2006</a>), and another excluded both submucous fibroids and fibroids outside the the uterine cavity and greater than 3 cm (<a href="./references#CD001501-bbs2-0007" title="ClarkTJ , SamuelN , MalickS , MiddletonLJ , DanielsJ , GuptaJK . Bipolar radiofrequency compared with thermal balloon endometrial ablation in the office. Obstetrics and Gynecology2011;117:109‐18. ">Clark 2011</a>). One trial screened 637 women with self‐assessed HMB, but after applying exclusion criteria, enrolled and randomised less than half (n = 276) (<a href="./references#CD001501-bbs2-0011" title="CorsonSL , BrillAI , BrooksPG , CooperJM , IndmanPD , LiuJH , et al. Interim results of the American Vesta trial of endometrial ablation. Journal of the American Association of Gynecologic Laparoscopists1999;6(1):45‐9. CorsonSL , BrillAI , BrooksPG , CooperJM , IndmanPD , LiuJH , et al. One‐year results of the Vesta system for endometrial ablation. Journal of the American Association of Gynecologic Laparoscopists2000;7(4):489‐97. ">Corson 2000</a>). Almost half of the excluded women had uterine pathology in the form of fibroids or polyps. </p> <p>Eighteen studies required women to have completed their families (<a href="./references#CD001501-bbs2-0001" title="AbbottJ , HaweJ , HunterD , GarryR . A double‐blind randomized trial comparing the Cavaterm and the Novasure endometrial ablation systems for the treatment of dysfunctional uterine bleeding. Fertility and Sterility2003;80(1):203‐8. ">Abbott 2003</a>; <a href="./references#CD001501-bbs2-0002" title="AthanatosD , PadosG , VenetisC , StamatopoulosP , RoussoD , TsolakidisD , et al. Novasure impedance control system versus microwave endometrial ablation for the treatment of dysfunctional uterine bleeding: a double‐blind, randomized controlled trial. Clinical and Experimental Obstetrics &amp; Gynecology2015;42(3):347‐51. [PMID: 26152008] PadosG . Treatment of dysfunctional uterine bleeding with second generation ablation devices: microwaves (MEAA) vs Bipolar Impedance Control System (Novasure). http://clinicaltrials.gov/show/NCT01173965. ">Athanatos 2015</a>; <a href="./references#CD001501-bbs2-0004" title="BongersM , HermanM , JosienP , MolBW . Ten‐year follow‐up of a randomized controlled trial comparing NovaSure and Thermachoice in endometrial ablation for dysfunctional uterine bleeding. Journal of Minimally Invasive Gynecology2011;18(6 Suppl 1):S127. BongersMY , BourdrezP , HeintzPM , BrolmannHAM , MolBWJ . Bipolar radio frequency endometrial ablation compared with balloon endometrial ablation in dysfunctional uterine bleeding: impact on patients' health‐related quality of life. Fertility and Sterility2005;83(3):724‐34. BongersMY , BourdrezP , MolBWJ , HeintzAPM , BrolmannHAM . Randomised controlled trial of bipolar radio‐frequency endometrial ablation and balloon endometrial ablation. British Journal of Obstetrics and Gynaecology2004;111:1095‐102. HermanM , PenninxM , MolB , BongersM . Ten‐year follow‐up of a randomised controlled trial comparing bipolar endometrial ablation with balloon ablation for heavy menstrual bleeding. British Journal Obstetrics and Gynaecology2013;120:966‐970. [DOI: 10.1111/1471‐0528.12213] KleijnJH , EngelsR , BourdrezP , MolBWJ , BongersMY . Five‐year follow up of a randomised controlled trial comparing NovaSure and ThermaChoice endometrial ablation. British Journal of Obstetrics and Gynaecology2008;115:193‐8. ">Bongers 2004</a>; <a href="./references#CD001501-bbs2-0005" title="BoujidaVH , PhilipsenT , PelleJ , JoergensenJC . Five‐year follow‐up of endometrial ablation: endometrial coagulation versus endometrial resection. Obstetrics and Gynecology2002;99:988‐92. FurstSN , PhilipsenT , JoergensenJC . Ten‐year follow‐up of endometrial ablation. Acta Obstetricia et Gynecologica2007;86:334‐8. ">Boujida 2002</a>; <a href="./references#CD001501-bbs2-0006" title="BrunJ‐L , RaynalJ , BurletG , GalandB , QuereuxC , BernardP . Cavaterm thermal balloon endometrial ablation versus hysteroscopic endometrial resection to treat menorrhagia: the French, multicenter, randomized study. Journal of Minimally Invasive Gynecology2006;13:424‐30. ">Brun 2006</a>; <a href="./references#CD001501-bbs2-0008" title="BainC , CooperKG , ParkinDE . Microwave endometrial ablation versus endometrial resection: a randomized controlled trial. Obstetrics and Gynecology2002;99:983‐7. CooperKG , BainC , LawrieL , ParkinDE . A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium: follow up at a minimum of five years. British Journal of Obstetrics and Gynaecology2005;112:470‐5. CooperKG , BainC , ParkinDE . Comparison of microwave endometrial ablation and transcervical resection of the endometrium for treatment of heavy menstrual loss: a randomised trial. Lancet1999;354:1859‐63. SambrookAM , BainC , ParkinDE , CooperKG . A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium: follow up at a minimum of 10 years. British Journal of Obstetrics and Gynaecology2009;116:1033‐7. ">Cooper 1999</a>; <a href="./references#CD001501-bbs2-0009" title="CooperJ , GimpelsonR , LabergeP , GalenD , Garza‐LealJG , ScottJ , et al. A randomized, multicenter trial of safety and efficacy of the NovaSure system in the treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2002;9(4):418‐28. ">Cooper 2002</a>; <a href="./references#CD001501-bbs2-0010" title="CooperJM , AndersonTL , FortinCA , JackSA , PlentlMB . Microwave endometrial ablation vs rollerball electroablation for menorrhagia: a multicenter randomized trial. Journal of the American Association of Gynecologic Laparoscopists2004;11(3):394‐403. ">Cooper 2004</a>; <a href="./references#CD001501-bbs2-0011" title="CorsonSL , BrillAI , BrooksPG , CooperJM , IndmanPD , LiuJH , et al. Interim results of the American Vesta trial of endometrial ablation. Journal of the American Association of Gynecologic Laparoscopists1999;6(1):45‐9. CorsonSL , BrillAI , BrooksPG , CooperJM , IndmanPD , LiuJH , et al. One‐year results of the Vesta system for endometrial ablation. Journal of the American Association of Gynecologic Laparoscopists2000;7(4):489‐97. ">Corson 2000</a>; <a href="./references#CD001501-bbs2-0012" title="CorsonSL . A multicenter evaluation of endometrial ablation by hydrothermablator and rollerball for treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2001;8(3):359‐67. GoldrathMH . Evaluation of hydrothermablator and rollerball endometrial ablation for menorrhagia 3 years after treatment. Journal of the American Association of Gynecologic Laparoscopists2003;10(4):505‐11. LofferF . A clinical comparison of hydrothermablation (HTA) and rollerball for endometrial ablation to treat menorrhagia: a randomized multicenter clinical trial. XVI FIGO World Congress of Obstetrics &amp; Gynecology. 2000; Vol. Abstract Book 2:95. ">Corson 2001</a>; <a href="./references#CD001501-bbs2-0013" title="DulebaAJ , HeppardMC , SoderstromRM , TownsendDE . A randomized study comparing endometrial cryoablation and rollerball electroablation for treatment of dysfunctional uterine bleeding. Journal of the American Association of Gynecologic Laparoscopists2003;10(1):17‐26. TownsendDE , DulebaAJ , WilkesMM , et al. Durability of treatment effects after cryoablation versus rollerball electroablation for abnormal uterine bleeding: two‐year results of a multicenter randomized trial. American Journal of Obstetrics and Gynecology2003;188:699‐701. ">Duleba 2003</a>; <a href="./references#CD001501-bbs2-0015" title="HaweJ , AbbottJ , HunterD , PhillipsG , GarryR . A randomised controlled trial comparing the Cavaterm endometrial ablation system with the Nd:YAG laser for the treatment of dysfunctional uterine bleeding. British Journal of Obstetrics and Gynaecology2003;110:350‐7. ">Hawe 2003</a>; <a href="./references#CD001501-bbs2-0016" title="LabergeP , Garza‐LealJ , FortinC , BasinskiC , ThielJ , LeylandN , et al. A prospective, randomized, multi‐center, controlled, international clinical study of the safety and efficacy of the Minerva endometrial ablation system: 6 and 12‐month follow‐up results. Journal of Minimally Invasive Gynecology. 2014. LabergeP , Garza‐LealJ , FortinC , GraingerD , JohnsDA , AdkinsRT , et al. A randomized controlled multicenter US Food and Drug Administration trial of the safety and efficacy of the Minerva Endometrial Ablation System: one‐year follow‐up results. Journal of Minimally Invasive Gynecology2017;24(1):124‐32. [DOI: 10.1016/j.jmig.2016.09.009] LabergeP , Garza‐LealJ , FortinC , ThielJ , JohnsD , GraingerD , et al. A randomized, controlled, multi‐center trial of the safety and efficacy of the Minerva Endometrial Ablation System: one‐year follow‐up results. Journal of Minimally Invasive Gynecology. 2016; Vol. 23:S1‐S252. ">Laberge 2016</a>; <a href="./references#CD001501-bbs2-0018" title="GraingerDA , TjadenDO , RowlandC , MeyerWR . Thermal balloon and rollerball ablation to treat menorrhagia: two‐year results of a multicenter, prospective, randomized clinical trial. Journal of the American Association of Gynecologic Laparoscopists2000;7(2):175‐9. LofferFD . Five year post‐procedure follow‐up of patients participating in a randomised trial of uterine balloon therapy vs rollerball ablation for the treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopy2001;8(1):48‐54. LofferFD . Three‐year comparison of thermal balloon and rollerball ablation in treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2001;8(1):48‐54. MeyerWR , WalshBW , GraingerDA , PeacockLM , LofferFD , SteegeJF . Thermal balloon and rollerball ablation to treat menorrhagia: a multicenter comparison. Obstetrics and Gynecology1998;92:98‐103. ">Meyer 1998</a>; <a href="./references#CD001501-bbs2-0021" title="BongersM , HermanM , PenninxJ , MolBW . Longterm follow‐up of a randomized controlled trial comparing NovaSure and hydrothermablation for dysfunctional uterine bleeding. Journal of Minimally Invasive Gynecology2011;18(6 Suppl 1):S34. PenninxJPM , HermanMC , MolBW , BongersMY . Five‐year follow‐up after comparing bipolar endometrial ablation with hydrothermablation for menorrhagia. Obstetrics and Gynecology2011;118:1287‐92. PenninxJPM , MolBW , EngelsR , vanRumsteMME , KleijnC , KoksCAM , et al. Bipolar radiofrequency endometrial ablation compared with hydrothermablation for dysfunctional uterine bleeding. Obstetrics and Gynecology2010;116:819‐26. ">Penninx 2010</a>; <a href="./references#CD001501-bbs2-0022" title="PenninxJ , BongersM . Bipolar radiofrequency endometrial ablation versus thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. www.controlled‐trials.com/ISRCTN17974690. PenninxJ , HermanM , KruitwagenR , Ter HaarA , MolB , BongersM . Bipolar versus balloon endometrial ablation in the office: a randomized controlled trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;196:52‐6. [DOI: 10.1016/j.ejogrb.2015.10.010] PenninxJ , HermanM , MolB , KruitwagenR , BongersM . Bipolar radiofrequency endometrial ablation versus Thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. Journal of Minimally Invasive Gynecology2012;19(6):S21‐S22. [DOI: 10.1016/j.jmig.2012.08.076] PenninxJPM , HermanMC , MolBW , BongersMY . Bipolar radiofrequency endometrial ablation versus thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. Journal of Minimally Invasive Gynecology2012;19(6 Suppl 1):S21‐2. ">Penninx 2016</a>; <a href="./references#CD001501-bbs2-0025" title="SambrookA , EldersA , CooperK . Microwave endometrial ablation versus thermal balloon endometrial ablation (MEATBall): 5‐year follow up of a randomised controlled trial. British Journal of Obstetrics and Gynaecology2014;121:748‐54. [DOI: 10.1111/1471‐0528.12585] SambrookAM , CooperKG , CampbellMK , CookJA . Clinical outcomes from a randomised comparison of microwave endometrial ablation with thermal balloon endometrial ablation for the treatment of heavy menstrual bleeding. British Journal of Obstetrics and Gynaecology2009;116:1038‐45. ">Sambrook 2009</a>; <a href="./references#CD001501-bbs2-0028" title="VercelliniP , OldaniS , YaylayanL , ZainaB , DeGiorgiO , CrosignaniPG . Randomised comparison of vaporising electrode and cutting loop for endometrial ablation. Obstetrics and Gynecology1999;94:521‐7. ">Vercellini 1999</a>), and 14 studies included women who previously had not tolerated or had received ineffective medical therapy for their heavy bleeding (<a href="./references#CD001501-bbs2-0002" title="AthanatosD , PadosG , VenetisC , StamatopoulosP , RoussoD , TsolakidisD , et al. Novasure impedance control system versus microwave endometrial ablation for the treatment of dysfunctional uterine bleeding: a double‐blind, randomized controlled trial. Clinical and Experimental Obstetrics &amp; Gynecology2015;42(3):347‐51. [PMID: 26152008] PadosG . Treatment of dysfunctional uterine bleeding with second generation ablation devices: microwaves (MEAA) vs Bipolar Impedance Control System (Novasure). http://clinicaltrials.gov/show/NCT01173965. ">Athanatos 2015</a>; <a href="./references#CD001501-bbs2-0006" title="BrunJ‐L , RaynalJ , BurletG , GalandB , QuereuxC , BernardP . Cavaterm thermal balloon endometrial ablation versus hysteroscopic endometrial resection to treat menorrhagia: the French, multicenter, randomized study. Journal of Minimally Invasive Gynecology2006;13:424‐30. ">Brun 2006</a>; <a href="./references#CD001501-bbs2-0007" title="ClarkTJ , SamuelN , MalickS , MiddletonLJ , DanielsJ , GuptaJK . Bipolar radiofrequency compared with thermal balloon endometrial ablation in the office. Obstetrics and Gynecology2011;117:109‐18. ">Clark 2011</a>; <a href="./references#CD001501-bbs2-0009" title="CooperJ , GimpelsonR , LabergeP , GalenD , Garza‐LealJG , ScottJ , et al. A randomized, multicenter trial of safety and efficacy of the NovaSure system in the treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2002;9(4):418‐28. ">Cooper 2002</a>; <a href="./references#CD001501-bbs2-0010" title="CooperJM , AndersonTL , FortinCA , JackSA , PlentlMB . Microwave endometrial ablation vs rollerball electroablation for menorrhagia: a multicenter randomized trial. Journal of the American Association of Gynecologic Laparoscopists2004;11(3):394‐403. ">Cooper 2004</a>; <a href="./references#CD001501-bbs2-0011" title="CorsonSL , BrillAI , BrooksPG , CooperJM , IndmanPD , LiuJH , et al. Interim results of the American Vesta trial of endometrial ablation. Journal of the American Association of Gynecologic Laparoscopists1999;6(1):45‐9. CorsonSL , BrillAI , BrooksPG , CooperJM , IndmanPD , LiuJH , et al. One‐year results of the Vesta system for endometrial ablation. Journal of the American Association of Gynecologic Laparoscopists2000;7(4):489‐97. ">Corson 2000</a>; <a href="./references#CD001501-bbs2-0012" title="CorsonSL . A multicenter evaluation of endometrial ablation by hydrothermablator and rollerball for treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2001;8(3):359‐67. GoldrathMH . Evaluation of hydrothermablator and rollerball endometrial ablation for menorrhagia 3 years after treatment. Journal of the American Association of Gynecologic Laparoscopists2003;10(4):505‐11. LofferF . A clinical comparison of hydrothermablation (HTA) and rollerball for endometrial ablation to treat menorrhagia: a randomized multicenter clinical trial. XVI FIGO World Congress of Obstetrics &amp; Gynecology. 2000; Vol. Abstract Book 2:95. ">Corson 2001</a>; <a href="./references#CD001501-bbs2-0013" title="DulebaAJ , HeppardMC , SoderstromRM , TownsendDE . A randomized study comparing endometrial cryoablation and rollerball electroablation for treatment of dysfunctional uterine bleeding. Journal of the American Association of Gynecologic Laparoscopists2003;10(1):17‐26. TownsendDE , DulebaAJ , WilkesMM , et al. Durability of treatment effects after cryoablation versus rollerball electroablation for abnormal uterine bleeding: two‐year results of a multicenter randomized trial. American Journal of Obstetrics and Gynecology2003;188:699‐701. ">Duleba 2003</a>; <a href="./references#CD001501-bbs2-0014" title="GhazizadehS , PanahiZ , GhanbariZ , Tarafdari MenshadiA , FarahmandianT , JavadianP . Comparative efficacy of NovaSure, the levonorgestrel‐releasing intrauterine system, and hysteroscopic endometrial resection in the treatment of menorrhagia: a randomized clinical trial. Journal of Gynecologic Surgery2014;30(4):215‐8. [DOI: 10.1089/gyn.2012.0041] ">Ghazizadeh 2014</a>; <a href="./references#CD001501-bbs2-0018" title="GraingerDA , TjadenDO , RowlandC , MeyerWR . Thermal balloon and rollerball ablation to treat menorrhagia: two‐year results of a multicenter, prospective, randomized clinical trial. Journal of the American Association of Gynecologic Laparoscopists2000;7(2):175‐9. LofferFD . Five year post‐procedure follow‐up of patients participating in a randomised trial of uterine balloon therapy vs rollerball ablation for the treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopy2001;8(1):48‐54. LofferFD . Three‐year comparison of thermal balloon and rollerball ablation in treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2001;8(1):48‐54. MeyerWR , WalshBW , GraingerDA , PeacockLM , LofferFD , SteegeJF . Thermal balloon and rollerball ablation to treat menorrhagia: a multicenter comparison. Obstetrics and Gynecology1998;92:98‐103. ">Meyer 1998</a>; <a href="./references#CD001501-bbs2-0020" title="PellicanoM , GuidaM , AcunzoG , CirilloD , BifulcoG , NappiC . Hysteroscopic transcervical endometrial resection versus thermal destruction for menorrhagia: a prospective randomized trial on satisfaction rate. American Journal of Obstetrics and Gynecology2002;187:545‐50. ">Pellicano 2002</a>; <a href="./references#CD001501-bbs2-0023" title="PerinoA , CastelliA , CucinellaG , BiondoA , PaneA , VeneziaR . A randomized comparison of endometrial laser intrauterine thermotherapy and hysteroscopic endometrial resection. Fertility and Sterility2004;82:731‐4. ">Perino 2004</a>; <a href="./references#CD001501-bbs2-0024" title="RomerT . The treatment of recurrent menorrhagias ‐ Cavaterm‐balloon‐coagulation versus Rollerball‐endometrial ablation ‐ a prospective randomized comparative study [Die therapie rezidivierender Menorrhagien ‐ Cavaterm‐Ballon‐Koagulatioon versus Roller‐Ball‐Endometriumkoagulation ‐ eine prospektive randomisierte Vergleichsstudie]. Zentralblatt fur Gynakologie1998;120(10):511‐4. ">Romer 1998</a>; <a href="./references#CD001501-bbs2-0027" title="vanZon‐RabelinkIAA , VleugelsMPH . Treating menorrhagia with endometrial ablation: rollerball electrocoagulation versus thermal ablation with the uterine balloon. Gynaecological Endoscopy Abstract from the 6th Annual Congress of the European Society for Gynaecological Endoscopy1997;6 Suppl 2:41. vanZon‐RabelinkIAA , VleugelsMPH , MerkusHMWM , deGraafR . Efficacy and satisfaction rate comparing endometrial ablation by rollerball electrocoagulation to uterine balloon thermal ablation in a randomised controlled trial. European Journal of Obstetrics, Gynecology, and Reproductive Biology2004;114(1):97‐103. vanZon‐RabelinkIAA , VleugelsMPH , MerkusHMWM , deGraafR . Endometrial ablation by rollerball electrocoagulation compared to uterine balloon thermal ablation. Technical and safety aspects. European Journal of Obstetrics, Gynecology, and Reproductive Biology2003;110:220‐3. ">van Zon‐Rabelink 2003</a>). Fourteen studies objectively confirmed the women's report of excessive bleeding by requiring them to record their blood loss (<a href="./references#CD001501-bbs2-0001" title="AbbottJ , HaweJ , HunterD , GarryR . A double‐blind randomized trial comparing the Cavaterm and the Novasure endometrial ablation systems for the treatment of dysfunctional uterine bleeding. Fertility and Sterility2003;80(1):203‐8. ">Abbott 2003</a>; <a href="./references#CD001501-bbs2-0002" title="AthanatosD , PadosG , VenetisC , StamatopoulosP , RoussoD , TsolakidisD , et al. Novasure impedance control system versus microwave endometrial ablation for the treatment of dysfunctional uterine bleeding: a double‐blind, randomized controlled trial. Clinical and Experimental Obstetrics &amp; Gynecology2015;42(3):347‐51. [PMID: 26152008] PadosG . Treatment of dysfunctional uterine bleeding with second generation ablation devices: microwaves (MEAA) vs Bipolar Impedance Control System (Novasure). http://clinicaltrials.gov/show/NCT01173965. ">Athanatos 2015</a>; <a href="./references#CD001501-bbs2-0004" title="BongersM , HermanM , JosienP , MolBW . Ten‐year follow‐up of a randomized controlled trial comparing NovaSure and Thermachoice in endometrial ablation for dysfunctional uterine bleeding. Journal of Minimally Invasive Gynecology2011;18(6 Suppl 1):S127. BongersMY , BourdrezP , HeintzPM , BrolmannHAM , MolBWJ . Bipolar radio frequency endometrial ablation compared with balloon endometrial ablation in dysfunctional uterine bleeding: impact on patients' health‐related quality of life. Fertility and Sterility2005;83(3):724‐34. BongersMY , BourdrezP , MolBWJ , HeintzAPM , BrolmannHAM . Randomised controlled trial of bipolar radio‐frequency endometrial ablation and balloon endometrial ablation. British Journal of Obstetrics and Gynaecology2004;111:1095‐102. HermanM , PenninxM , MolB , BongersM . Ten‐year follow‐up of a randomised controlled trial comparing bipolar endometrial ablation with balloon ablation for heavy menstrual bleeding. British Journal Obstetrics and Gynaecology2013;120:966‐970. [DOI: 10.1111/1471‐0528.12213] KleijnJH , EngelsR , BourdrezP , MolBWJ , BongersMY . Five‐year follow up of a randomised controlled trial comparing NovaSure and ThermaChoice endometrial ablation. British Journal of Obstetrics and Gynaecology2008;115:193‐8. ">Bongers 2004</a>; <a href="./references#CD001501-bbs2-0006" title="BrunJ‐L , RaynalJ , BurletG , GalandB , QuereuxC , BernardP . Cavaterm thermal balloon endometrial ablation versus hysteroscopic endometrial resection to treat menorrhagia: the French, multicenter, randomized study. Journal of Minimally Invasive Gynecology2006;13:424‐30. ">Brun 2006</a>; <a href="./references#CD001501-bbs2-0009" title="CooperJ , GimpelsonR , LabergeP , GalenD , Garza‐LealJG , ScottJ , et al. A randomized, multicenter trial of safety and efficacy of the NovaSure system in the treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2002;9(4):418‐28. ">Cooper 2002</a>; <a href="./references#CD001501-bbs2-0010" title="CooperJM , AndersonTL , FortinCA , JackSA , PlentlMB . Microwave endometrial ablation vs rollerball electroablation for menorrhagia: a multicenter randomized trial. Journal of the American Association of Gynecologic Laparoscopists2004;11(3):394‐403. ">Cooper 2004</a>; <a href="./references#CD001501-bbs2-0011" title="CorsonSL , BrillAI , BrooksPG , CooperJM , IndmanPD , LiuJH , et al. Interim results of the American Vesta trial of endometrial ablation. Journal of the American Association of Gynecologic Laparoscopists1999;6(1):45‐9. CorsonSL , BrillAI , BrooksPG , CooperJM , IndmanPD , LiuJH , et al. One‐year results of the Vesta system for endometrial ablation. Journal of the American Association of Gynecologic Laparoscopists2000;7(4):489‐97. ">Corson 2000</a>; <a href="./references#CD001501-bbs2-0013" title="DulebaAJ , HeppardMC , SoderstromRM , TownsendDE . A randomized study comparing endometrial cryoablation and rollerball electroablation for treatment of dysfunctional uterine bleeding. Journal of the American Association of Gynecologic Laparoscopists2003;10(1):17‐26. TownsendDE , DulebaAJ , WilkesMM , et al. Durability of treatment effects after cryoablation versus rollerball electroablation for abnormal uterine bleeding: two‐year results of a multicenter randomized trial. American Journal of Obstetrics and Gynecology2003;188:699‐701. ">Duleba 2003</a>; <a href="./references#CD001501-bbs2-0015" title="HaweJ , AbbottJ , HunterD , PhillipsG , GarryR . A randomised controlled trial comparing the Cavaterm endometrial ablation system with the Nd:YAG laser for the treatment of dysfunctional uterine bleeding. British Journal of Obstetrics and Gynaecology2003;110:350‐7. ">Hawe 2003</a>; <a href="./references#CD001501-bbs2-0017" title="McClureN , MarnersM , HealyDL , HillDJ , LawrenceAS , WingfieldM , et al. A quantitative assessment of endometrial electrocautery in the management of menorrhagia and a comparative report of argon laser endometrial ablation. Gynaecological Endoscopy1992;1:199‐202. ">McClure 1992</a>; <a href="./references#CD001501-bbs2-0018" title="GraingerDA , TjadenDO , RowlandC , MeyerWR . Thermal balloon and rollerball ablation to treat menorrhagia: two‐year results of a multicenter, prospective, randomized clinical trial. Journal of the American Association of Gynecologic Laparoscopists2000;7(2):175‐9. LofferFD . Five year post‐procedure follow‐up of patients participating in a randomised trial of uterine balloon therapy vs rollerball ablation for the treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopy2001;8(1):48‐54. LofferFD . Three‐year comparison of thermal balloon and rollerball ablation in treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2001;8(1):48‐54. MeyerWR , WalshBW , GraingerDA , PeacockLM , LofferFD , SteegeJF . Thermal balloon and rollerball ablation to treat menorrhagia: a multicenter comparison. Obstetrics and Gynecology1998;92:98‐103. ">Meyer 1998</a>; <a href="./references#CD001501-bbs2-0021" title="BongersM , HermanM , PenninxJ , MolBW . Longterm follow‐up of a randomized controlled trial comparing NovaSure and hydrothermablation for dysfunctional uterine bleeding. Journal of Minimally Invasive Gynecology2011;18(6 Suppl 1):S34. PenninxJPM , HermanMC , MolBW , BongersMY . Five‐year follow‐up after comparing bipolar endometrial ablation with hydrothermablation for menorrhagia. Obstetrics and Gynecology2011;118:1287‐92. PenninxJPM , MolBW , EngelsR , vanRumsteMME , KleijnC , KoksCAM , et al. Bipolar radiofrequency endometrial ablation compared with hydrothermablation for dysfunctional uterine bleeding. Obstetrics and Gynecology2010;116:819‐26. ">Penninx 2010</a>; <a href="./references#CD001501-bbs2-0022" title="PenninxJ , BongersM . Bipolar radiofrequency endometrial ablation versus thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. www.controlled‐trials.com/ISRCTN17974690. PenninxJ , HermanM , KruitwagenR , Ter HaarA , MolB , BongersM . Bipolar versus balloon endometrial ablation in the office: a randomized controlled trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;196:52‐6. [DOI: 10.1016/j.ejogrb.2015.10.010] PenninxJ , HermanM , MolB , KruitwagenR , BongersM . Bipolar radiofrequency endometrial ablation versus Thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. Journal of Minimally Invasive Gynecology2012;19(6):S21‐S22. [DOI: 10.1016/j.jmig.2012.08.076] PenninxJPM , HermanMC , MolBW , BongersMY . Bipolar radiofrequency endometrial ablation versus thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. Journal of Minimally Invasive Gynecology2012;19(6 Suppl 1):S21‐2. ">Penninx 2016</a>; <a href="./references#CD001501-bbs2-0027" title="vanZon‐RabelinkIAA , VleugelsMPH . Treating menorrhagia with endometrial ablation: rollerball electrocoagulation versus thermal ablation with the uterine balloon. Gynaecological Endoscopy Abstract from the 6th Annual Congress of the European Society for Gynaecological Endoscopy1997;6 Suppl 2:41. vanZon‐RabelinkIAA , VleugelsMPH , MerkusHMWM , deGraafR . Efficacy and satisfaction rate comparing endometrial ablation by rollerball electrocoagulation to uterine balloon thermal ablation in a randomised controlled trial. European Journal of Obstetrics, Gynecology, and Reproductive Biology2004;114(1):97‐103. vanZon‐RabelinkIAA , VleugelsMPH , MerkusHMWM , deGraafR . Endometrial ablation by rollerball electrocoagulation compared to uterine balloon thermal ablation. Technical and safety aspects. European Journal of Obstetrics, Gynecology, and Reproductive Biology2003;110:220‐3. ">van Zon‐Rabelink 2003</a>; <a href="./references#CD001501-bbs2-0028" title="VercelliniP , OldaniS , YaylayanL , ZainaB , DeGiorgiO , CrosignaniPG . Randomised comparison of vaporising electrode and cutting loop for endometrial ablation. Obstetrics and Gynecology1999;94:521‐7. ">Vercellini 1999</a>). This occurred before surgery and before trial entry. Nine studies required women to have PBAC measurements of 150 or greater before entry (<a href="./references#CD001501-bbs2-0001" title="AbbottJ , HaweJ , HunterD , GarryR . A double‐blind randomized trial comparing the Cavaterm and the Novasure endometrial ablation systems for the treatment of dysfunctional uterine bleeding. Fertility and Sterility2003;80(1):203‐8. ">Abbott 2003</a>; <a href="./references#CD001501-bbs2-0002" title="AthanatosD , PadosG , VenetisC , StamatopoulosP , RoussoD , TsolakidisD , et al. Novasure impedance control system versus microwave endometrial ablation for the treatment of dysfunctional uterine bleeding: a double‐blind, randomized controlled trial. Clinical and Experimental Obstetrics &amp; Gynecology2015;42(3):347‐51. [PMID: 26152008] PadosG . Treatment of dysfunctional uterine bleeding with second generation ablation devices: microwaves (MEAA) vs Bipolar Impedance Control System (Novasure). http://clinicaltrials.gov/show/NCT01173965. ">Athanatos 2015</a>; <a href="./references#CD001501-bbs2-0004" title="BongersM , HermanM , JosienP , MolBW . Ten‐year follow‐up of a randomized controlled trial comparing NovaSure and Thermachoice in endometrial ablation for dysfunctional uterine bleeding. Journal of Minimally Invasive Gynecology2011;18(6 Suppl 1):S127. BongersMY , BourdrezP , HeintzPM , BrolmannHAM , MolBWJ . Bipolar radio frequency endometrial ablation compared with balloon endometrial ablation in dysfunctional uterine bleeding: impact on patients' health‐related quality of life. Fertility and Sterility2005;83(3):724‐34. BongersMY , BourdrezP , MolBWJ , HeintzAPM , BrolmannHAM . Randomised controlled trial of bipolar radio‐frequency endometrial ablation and balloon endometrial ablation. British Journal of Obstetrics and Gynaecology2004;111:1095‐102. HermanM , PenninxM , MolB , BongersM . Ten‐year follow‐up of a randomised controlled trial comparing bipolar endometrial ablation with balloon ablation for heavy menstrual bleeding. British Journal Obstetrics and Gynaecology2013;120:966‐970. [DOI: 10.1111/1471‐0528.12213] KleijnJH , EngelsR , BourdrezP , MolBWJ , BongersMY . Five‐year follow up of a randomised controlled trial comparing NovaSure and ThermaChoice endometrial ablation. British Journal of Obstetrics and Gynaecology2008;115:193‐8. ">Bongers 2004</a>; <a href="./references#CD001501-bbs2-0009" title="CooperJ , GimpelsonR , LabergeP , GalenD , Garza‐LealJG , ScottJ , et al. A randomized, multicenter trial of safety and efficacy of the NovaSure system in the treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2002;9(4):418‐28. ">Cooper 2002</a>; <a href="./references#CD001501-bbs2-0011" title="CorsonSL , BrillAI , BrooksPG , CooperJM , IndmanPD , LiuJH , et al. Interim results of the American Vesta trial of endometrial ablation. Journal of the American Association of Gynecologic Laparoscopists1999;6(1):45‐9. CorsonSL , BrillAI , BrooksPG , CooperJM , IndmanPD , LiuJH , et al. One‐year results of the Vesta system for endometrial ablation. Journal of the American Association of Gynecologic Laparoscopists2000;7(4):489‐97. ">Corson 2000</a>; <a href="./references#CD001501-bbs2-0013" title="DulebaAJ , HeppardMC , SoderstromRM , TownsendDE . A randomized study comparing endometrial cryoablation and rollerball electroablation for treatment of dysfunctional uterine bleeding. Journal of the American Association of Gynecologic Laparoscopists2003;10(1):17‐26. TownsendDE , DulebaAJ , WilkesMM , et al. Durability of treatment effects after cryoablation versus rollerball electroablation for abnormal uterine bleeding: two‐year results of a multicenter randomized trial. American Journal of Obstetrics and Gynecology2003;188:699‐701. ">Duleba 2003</a>; <a href="./references#CD001501-bbs2-0018" title="GraingerDA , TjadenDO , RowlandC , MeyerWR . Thermal balloon and rollerball ablation to treat menorrhagia: two‐year results of a multicenter, prospective, randomized clinical trial. Journal of the American Association of Gynecologic Laparoscopists2000;7(2):175‐9. LofferFD . Five year post‐procedure follow‐up of patients participating in a randomised trial of uterine balloon therapy vs rollerball ablation for the treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopy2001;8(1):48‐54. LofferFD . Three‐year comparison of thermal balloon and rollerball ablation in treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2001;8(1):48‐54. MeyerWR , WalshBW , GraingerDA , PeacockLM , LofferFD , SteegeJF . Thermal balloon and rollerball ablation to treat menorrhagia: a multicenter comparison. Obstetrics and Gynecology1998;92:98‐103. ">Meyer 1998</a>; <a href="./references#CD001501-bbs2-0021" title="BongersM , HermanM , PenninxJ , MolBW . Longterm follow‐up of a randomized controlled trial comparing NovaSure and hydrothermablation for dysfunctional uterine bleeding. Journal of Minimally Invasive Gynecology2011;18(6 Suppl 1):S34. PenninxJPM , HermanMC , MolBW , BongersMY . Five‐year follow‐up after comparing bipolar endometrial ablation with hydrothermablation for menorrhagia. Obstetrics and Gynecology2011;118:1287‐92. PenninxJPM , MolBW , EngelsR , vanRumsteMME , KleijnC , KoksCAM , et al. Bipolar radiofrequency endometrial ablation compared with hydrothermablation for dysfunctional uterine bleeding. Obstetrics and Gynecology2010;116:819‐26. ">Penninx 2010</a>; <a href="./references#CD001501-bbs2-0022" title="PenninxJ , BongersM . Bipolar radiofrequency endometrial ablation versus thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. www.controlled‐trials.com/ISRCTN17974690. PenninxJ , HermanM , KruitwagenR , Ter HaarA , MolB , BongersM . Bipolar versus balloon endometrial ablation in the office: a randomized controlled trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;196:52‐6. [DOI: 10.1016/j.ejogrb.2015.10.010] PenninxJ , HermanM , MolB , KruitwagenR , BongersM . Bipolar radiofrequency endometrial ablation versus Thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. Journal of Minimally Invasive Gynecology2012;19(6):S21‐S22. [DOI: 10.1016/j.jmig.2012.08.076] PenninxJPM , HermanMC , MolBW , BongersMY . Bipolar radiofrequency endometrial ablation versus thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. Journal of Minimally Invasive Gynecology2012;19(6 Suppl 1):S21‐2. ">Penninx 2016</a>), three required women to have PBAC measurements of 100 or greater before entry (<a href="./references#CD001501-bbs2-0006" title="BrunJ‐L , RaynalJ , BurletG , GalandB , QuereuxC , BernardP . Cavaterm thermal balloon endometrial ablation versus hysteroscopic endometrial resection to treat menorrhagia: the French, multicenter, randomized study. Journal of Minimally Invasive Gynecology2006;13:424‐30. ">Brun 2006</a>; <a href="./references#CD001501-bbs2-0015" title="HaweJ , AbbottJ , HunterD , PhillipsG , GarryR . A randomised controlled trial comparing the Cavaterm endometrial ablation system with the Nd:YAG laser for the treatment of dysfunctional uterine bleeding. British Journal of Obstetrics and Gynaecology2003;110:350‐7. ">Hawe 2003</a>; <a href="./references#CD001501-bbs2-0028" title="VercelliniP , OldaniS , YaylayanL , ZainaB , DeGiorgiO , CrosignaniPG . Randomised comparison of vaporising electrode and cutting loop for endometrial ablation. Obstetrics and Gynecology1999;94:521‐7. ">Vercellini 1999</a>), and two required a blood loss score greater than 185 (<a href="./references#CD001501-bbs2-0010" title="CooperJM , AndersonTL , FortinCA , JackSA , PlentlMB . Microwave endometrial ablation vs rollerball electroablation for menorrhagia: a multicenter randomized trial. Journal of the American Association of Gynecologic Laparoscopists2004;11(3):394‐403. ">Cooper 2004</a>; <a href="./references#CD001501-bbs2-0027" title="vanZon‐RabelinkIAA , VleugelsMPH . Treating menorrhagia with endometrial ablation: rollerball electrocoagulation versus thermal ablation with the uterine balloon. Gynaecological Endoscopy Abstract from the 6th Annual Congress of the European Society for Gynaecological Endoscopy1997;6 Suppl 2:41. vanZon‐RabelinkIAA , VleugelsMPH , MerkusHMWM , deGraafR . Efficacy and satisfaction rate comparing endometrial ablation by rollerball electrocoagulation to uterine balloon thermal ablation in a randomised controlled trial. European Journal of Obstetrics, Gynecology, and Reproductive Biology2004;114(1):97‐103. vanZon‐RabelinkIAA , VleugelsMPH , MerkusHMWM , deGraafR . Endometrial ablation by rollerball electrocoagulation compared to uterine balloon thermal ablation. Technical and safety aspects. European Journal of Obstetrics, Gynecology, and Reproductive Biology2003;110:220‐3. ">van Zon‐Rabelink 2003</a>). Two studies used the alkaline haematin method (<a href="./references#CD001501-bbs2-0060" title="HallbergL , NilssonL . Determination of menstrual blood loss. Scandinavian Journal of Clinical and Laboratory Investigation1964;16:244‐8. [PMID: 14161862] ">Hallberg 1964</a>): one included women if their blood loss exceeded 70 mL per cycle (<a href="./references#CD001501-bbs2-0017" title="McClureN , MarnersM , HealyDL , HillDJ , LawrenceAS , WingfieldM , et al. A quantitative assessment of endometrial electrocautery in the management of menorrhagia and a comparative report of argon laser endometrial ablation. Gynaecological Endoscopy1992;1:199‐202. ">McClure 1992</a>), and the other used more than 160 mL per cycle as an inclusion criterion (<a href="./references#CD001501-bbs2-0016" title="LabergeP , Garza‐LealJ , FortinC , BasinskiC , ThielJ , LeylandN , et al. A prospective, randomized, multi‐center, controlled, international clinical study of the safety and efficacy of the Minerva endometrial ablation system: 6 and 12‐month follow‐up results. Journal of Minimally Invasive Gynecology. 2014. LabergeP , Garza‐LealJ , FortinC , GraingerD , JohnsDA , AdkinsRT , et al. A randomized controlled multicenter US Food and Drug Administration trial of the safety and efficacy of the Minerva Endometrial Ablation System: one‐year follow‐up results. Journal of Minimally Invasive Gynecology2017;24(1):124‐32. [DOI: 10.1016/j.jmig.2016.09.009] LabergeP , Garza‐LealJ , FortinC , ThielJ , JohnsD , GraingerD , et al. A randomized, controlled, multi‐center trial of the safety and efficacy of the Minerva Endometrial Ablation System: one‐year follow‐up results. Journal of Minimally Invasive Gynecology. 2016; Vol. 23:S1‐S252. ">Laberge 2016</a>). All but one study reported comparable demographic characteristics between comparison groups at baseline (<a href="./references#CD001501-bbs2-0006" title="BrunJ‐L , RaynalJ , BurletG , GalandB , QuereuxC , BernardP . Cavaterm thermal balloon endometrial ablation versus hysteroscopic endometrial resection to treat menorrhagia: the French, multicenter, randomized study. Journal of Minimally Invasive Gynecology2006;13:424‐30. ">Brun 2006</a>). In <a href="./references#CD001501-bbs2-0006" title="BrunJ‐L , RaynalJ , BurletG , GalandB , QuereuxC , BernardP . Cavaterm thermal balloon endometrial ablation versus hysteroscopic endometrial resection to treat menorrhagia: the French, multicenter, randomized study. Journal of Minimally Invasive Gynecology2006;13:424‐30. ">Brun 2006</a>, women undergoing balloon ablation had significantly heavier blood loss than those undergoing TCRE at baseline (menstrual blood loss chart 400 vs 266; P = 0.002). </p> </section> <section id="CD001501-sec-0086"> <h5 class="title">Interventions</h5> <p>Most of the included studies reported some kind of pretreatment before surgery (particularly first‐generation techniques). In 13 trials, participants had been given preoperative gonadotropin‐releasing hormone (GnRH) analogues to prepare and thin the endometrium before surgery (<a href="./references#CD001501-bbs2-0002" title="AthanatosD , PadosG , VenetisC , StamatopoulosP , RoussoD , TsolakidisD , et al. Novasure impedance control system versus microwave endometrial ablation for the treatment of dysfunctional uterine bleeding: a double‐blind, randomized controlled trial. Clinical and Experimental Obstetrics &amp; Gynecology2015;42(3):347‐51. [PMID: 26152008] PadosG . Treatment of dysfunctional uterine bleeding with second generation ablation devices: microwaves (MEAA) vs Bipolar Impedance Control System (Novasure). http://clinicaltrials.gov/show/NCT01173965. ">Athanatos 2015</a>; <a href="./references#CD001501-bbs2-0003" title="BhattacharyaS , CameronIM , ParkinDE , AbramovichDR , MollisonJ , PinionSB , et al. A pragmatic randomised comparison of transcervical resection of the endometrium with endometrial laser ablation for the treatment of menorrhagia. British Journal of Obstetrics and Gynaecology1997;104:601‐7. ">Bhattacharya 1997</a>; <a href="./references#CD001501-bbs2-0008" title="BainC , CooperKG , ParkinDE . Microwave endometrial ablation versus endometrial resection: a randomized controlled trial. Obstetrics and Gynecology2002;99:983‐7. CooperKG , BainC , LawrieL , ParkinDE . A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium: follow up at a minimum of five years. British Journal of Obstetrics and Gynaecology2005;112:470‐5. CooperKG , BainC , ParkinDE . Comparison of microwave endometrial ablation and transcervical resection of the endometrium for treatment of heavy menstrual loss: a randomised trial. Lancet1999;354:1859‐63. SambrookAM , BainC , ParkinDE , CooperKG . A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium: follow up at a minimum of 10 years. British Journal of Obstetrics and Gynaecology2009;116:1033‐7. ">Cooper 1999</a>; <a href="./references#CD001501-bbs2-0010" title="CooperJM , AndersonTL , FortinCA , JackSA , PlentlMB . Microwave endometrial ablation vs rollerball electroablation for menorrhagia: a multicenter randomized trial. Journal of the American Association of Gynecologic Laparoscopists2004;11(3):394‐403. ">Cooper 2004</a>; <a href="./references#CD001501-bbs2-0012" title="CorsonSL . A multicenter evaluation of endometrial ablation by hydrothermablator and rollerball for treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2001;8(3):359‐67. GoldrathMH . Evaluation of hydrothermablator and rollerball endometrial ablation for menorrhagia 3 years after treatment. Journal of the American Association of Gynecologic Laparoscopists2003;10(4):505‐11. LofferF . A clinical comparison of hydrothermablation (HTA) and rollerball for endometrial ablation to treat menorrhagia: a randomized multicenter clinical trial. XVI FIGO World Congress of Obstetrics &amp; Gynecology. 2000; Vol. Abstract Book 2:95. ">Corson 2001</a>; <a href="./references#CD001501-bbs2-0013" title="DulebaAJ , HeppardMC , SoderstromRM , TownsendDE . A randomized study comparing endometrial cryoablation and rollerball electroablation for treatment of dysfunctional uterine bleeding. Journal of the American Association of Gynecologic Laparoscopists2003;10(1):17‐26. TownsendDE , DulebaAJ , WilkesMM , et al. Durability of treatment effects after cryoablation versus rollerball electroablation for abnormal uterine bleeding: two‐year results of a multicenter randomized trial. American Journal of Obstetrics and Gynecology2003;188:699‐701. ">Duleba 2003</a>; <a href="./references#CD001501-bbs2-0015" title="HaweJ , AbbottJ , HunterD , PhillipsG , GarryR . A randomised controlled trial comparing the Cavaterm endometrial ablation system with the Nd:YAG laser for the treatment of dysfunctional uterine bleeding. British Journal of Obstetrics and Gynaecology2003;110:350‐7. ">Hawe 2003</a>; <a href="./references#CD001501-bbs2-0019" title="OnogluA , TaskinO , InalM , SadikS , SimsekM , AkarM , et al. Comparison of the long‐term histopathologic and morphologic changes after endometrial rollerball ablation and resection: a prospective randomized trial. Journal of Minimally Invasive Gynecology2007;14:39‐42. ">Onoglu 2007</a>; <a href="./references#CD001501-bbs2-0020" title="PellicanoM , GuidaM , AcunzoG , CirilloD , BifulcoG , NappiC . Hysteroscopic transcervical endometrial resection versus thermal destruction for menorrhagia: a prospective randomized trial on satisfaction rate. American Journal of Obstetrics and Gynecology2002;187:545‐50. ">Pellicano 2002</a>; <a href="./references#CD001501-bbs2-0023" title="PerinoA , CastelliA , CucinellaG , BiondoA , PaneA , VeneziaR . A randomized comparison of endometrial laser intrauterine thermotherapy and hysteroscopic endometrial resection. Fertility and Sterility2004;82:731‐4. ">Perino 2004</a>; <a href="./references#CD001501-bbs2-0024" title="RomerT . The treatment of recurrent menorrhagias ‐ Cavaterm‐balloon‐coagulation versus Rollerball‐endometrial ablation ‐ a prospective randomized comparative study [Die therapie rezidivierender Menorrhagien ‐ Cavaterm‐Ballon‐Koagulatioon versus Roller‐Ball‐Endometriumkoagulation ‐ eine prospektive randomisierte Vergleichsstudie]. Zentralblatt fur Gynakologie1998;120(10):511‐4. ">Romer 1998</a>; <a href="./references#CD001501-bbs2-0027" title="vanZon‐RabelinkIAA , VleugelsMPH . Treating menorrhagia with endometrial ablation: rollerball electrocoagulation versus thermal ablation with the uterine balloon. Gynaecological Endoscopy Abstract from the 6th Annual Congress of the European Society for Gynaecological Endoscopy1997;6 Suppl 2:41. vanZon‐RabelinkIAA , VleugelsMPH , MerkusHMWM , deGraafR . Efficacy and satisfaction rate comparing endometrial ablation by rollerball electrocoagulation to uterine balloon thermal ablation in a randomised controlled trial. European Journal of Obstetrics, Gynecology, and Reproductive Biology2004;114(1):97‐103. vanZon‐RabelinkIAA , VleugelsMPH , MerkusHMWM , deGraafR . Endometrial ablation by rollerball electrocoagulation compared to uterine balloon thermal ablation. Technical and safety aspects. European Journal of Obstetrics, Gynecology, and Reproductive Biology2003;110:220‐3. ">van Zon‐Rabelink 2003</a>; <a href="./references#CD001501-bbs2-0028" title="VercelliniP , OldaniS , YaylayanL , ZainaB , DeGiorgiO , CrosignaniPG . Randomised comparison of vaporising electrode and cutting loop for endometrial ablation. Obstetrics and Gynecology1999;94:521‐7. ">Vercellini 1999</a>), although one of these studies provided pretreatment only to the TCRE group ‐ not to the balloon group (<a href="./references#CD001501-bbs2-0020" title="PellicanoM , GuidaM , AcunzoG , CirilloD , BifulcoG , NappiC . Hysteroscopic transcervical endometrial resection versus thermal destruction for menorrhagia: a prospective randomized trial on satisfaction rate. American Journal of Obstetrics and Gynecology2002;187:545‐50. ">Pellicano 2002</a>). Studies also provided preoperative treatment with progestogens for 3 months (<a href="./references#CD001501-bbs2-0017" title="McClureN , MarnersM , HealyDL , HillDJ , LawrenceAS , WingfieldM , et al. A quantitative assessment of endometrial electrocautery in the management of menorrhagia and a comparative report of argon laser endometrial ablation. Gynaecological Endoscopy1992;1:199‐202. ">McClure 1992</a>), and for 2 weeks (<a href="./references#CD001501-bbs2-0025" title="SambrookA , EldersA , CooperK . Microwave endometrial ablation versus thermal balloon endometrial ablation (MEATBall): 5‐year follow up of a randomised controlled trial. British Journal of Obstetrics and Gynaecology2014;121:748‐54. [DOI: 10.1111/1471‐0528.12585] SambrookAM , CooperKG , CampbellMK , CookJA . Clinical outcomes from a randomised comparison of microwave endometrial ablation with thermal balloon endometrial ablation for the treatment of heavy menstrual bleeding. British Journal of Obstetrics and Gynaecology2009;116:1038‐45. ">Sambrook 2009</a>). One study required 2 weeks of oral contraceptive therapy before surgery to ensure that women were scheduled at a similar time in their cycle (<a href="./references#CD001501-bbs2-0011" title="CorsonSL , BrillAI , BrooksPG , CooperJM , IndmanPD , LiuJH , et al. Interim results of the American Vesta trial of endometrial ablation. Journal of the American Association of Gynecologic Laparoscopists1999;6(1):45‐9. CorsonSL , BrillAI , BrooksPG , CooperJM , IndmanPD , LiuJH , et al. One‐year results of the Vesta system for endometrial ablation. Journal of the American Association of Gynecologic Laparoscopists2000;7(4):489‐97. ">Corson 2000</a>). Another study performed a loop resection of the endometrium before ablation only for the roller ball group ‐ not for the bipolar group (<a href="./references#CD001501-bbs2-0016" title="LabergeP , Garza‐LealJ , FortinC , BasinskiC , ThielJ , LeylandN , et al. A prospective, randomized, multi‐center, controlled, international clinical study of the safety and efficacy of the Minerva endometrial ablation system: 6 and 12‐month follow‐up results. Journal of Minimally Invasive Gynecology. 2014. LabergeP , Garza‐LealJ , FortinC , GraingerD , JohnsDA , AdkinsRT , et al. A randomized controlled multicenter US Food and Drug Administration trial of the safety and efficacy of the Minerva Endometrial Ablation System: one‐year follow‐up results. Journal of Minimally Invasive Gynecology2017;24(1):124‐32. [DOI: 10.1016/j.jmig.2016.09.009] LabergeP , Garza‐LealJ , FortinC , ThielJ , JohnsD , GraingerD , et al. A randomized, controlled, multi‐center trial of the safety and efficacy of the Minerva Endometrial Ablation System: one‐year follow‐up results. Journal of Minimally Invasive Gynecology. 2016; Vol. 23:S1‐S252. ">Laberge 2016</a>). Three other trials used non‐steroidal anti‐inflammatory drugs (NSAIDs) to prevent uterine cramping (<a href="./references#CD001501-bbs2-0007" title="ClarkTJ , SamuelN , MalickS , MiddletonLJ , DanielsJ , GuptaJK . Bipolar radiofrequency compared with thermal balloon endometrial ablation in the office. Obstetrics and Gynecology2011;117:109‐18. ">Clark 2011</a>; <a href="./references#CD001501-bbs2-0018" title="GraingerDA , TjadenDO , RowlandC , MeyerWR . Thermal balloon and rollerball ablation to treat menorrhagia: two‐year results of a multicenter, prospective, randomized clinical trial. Journal of the American Association of Gynecologic Laparoscopists2000;7(2):175‐9. LofferFD . Five year post‐procedure follow‐up of patients participating in a randomised trial of uterine balloon therapy vs rollerball ablation for the treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopy2001;8(1):48‐54. LofferFD . Three‐year comparison of thermal balloon and rollerball ablation in treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2001;8(1):48‐54. MeyerWR , WalshBW , GraingerDA , PeacockLM , LofferFD , SteegeJF . Thermal balloon and rollerball ablation to treat menorrhagia: a multicenter comparison. Obstetrics and Gynecology1998;92:98‐103. ">Meyer 1998</a>; <a href="./references#CD001501-bbs2-0022" title="PenninxJ , BongersM . Bipolar radiofrequency endometrial ablation versus thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. www.controlled‐trials.com/ISRCTN17974690. PenninxJ , HermanM , KruitwagenR , Ter HaarA , MolB , BongersM . Bipolar versus balloon endometrial ablation in the office: a randomized controlled trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;196:52‐6. [DOI: 10.1016/j.ejogrb.2015.10.010] PenninxJ , HermanM , MolB , KruitwagenR , BongersM . Bipolar radiofrequency endometrial ablation versus Thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. Journal of Minimally Invasive Gynecology2012;19(6):S21‐S22. [DOI: 10.1016/j.jmig.2012.08.076] PenninxJPM , HermanMC , MolBW , BongersMY . Bipolar radiofrequency endometrial ablation versus thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. Journal of Minimally Invasive Gynecology2012;19(6 Suppl 1):S21‐2. ">Penninx 2016</a>). The remaining nine trials provided no preoperative therapy (<a href="./references#CD001501-bbs2-0001" title="AbbottJ , HaweJ , HunterD , GarryR . A double‐blind randomized trial comparing the Cavaterm and the Novasure endometrial ablation systems for the treatment of dysfunctional uterine bleeding. Fertility and Sterility2003;80(1):203‐8. ">Abbott 2003</a>; <a href="./references#CD001501-bbs2-0004" title="BongersM , HermanM , JosienP , MolBW . Ten‐year follow‐up of a randomized controlled trial comparing NovaSure and Thermachoice in endometrial ablation for dysfunctional uterine bleeding. Journal of Minimally Invasive Gynecology2011;18(6 Suppl 1):S127. BongersMY , BourdrezP , HeintzPM , BrolmannHAM , MolBWJ . Bipolar radio frequency endometrial ablation compared with balloon endometrial ablation in dysfunctional uterine bleeding: impact on patients' health‐related quality of life. Fertility and Sterility2005;83(3):724‐34. BongersMY , BourdrezP , MolBWJ , HeintzAPM , BrolmannHAM . Randomised controlled trial of bipolar radio‐frequency endometrial ablation and balloon endometrial ablation. British Journal of Obstetrics and Gynaecology2004;111:1095‐102. HermanM , PenninxM , MolB , BongersM . Ten‐year follow‐up of a randomised controlled trial comparing bipolar endometrial ablation with balloon ablation for heavy menstrual bleeding. British Journal Obstetrics and Gynaecology2013;120:966‐970. [DOI: 10.1111/1471‐0528.12213] KleijnJH , EngelsR , BourdrezP , MolBWJ , BongersMY . Five‐year follow up of a randomised controlled trial comparing NovaSure and ThermaChoice endometrial ablation. British Journal of Obstetrics and Gynaecology2008;115:193‐8. ">Bongers 2004</a>; <a href="./references#CD001501-bbs2-0005" title="BoujidaVH , PhilipsenT , PelleJ , JoergensenJC . Five‐year follow‐up of endometrial ablation: endometrial coagulation versus endometrial resection. Obstetrics and Gynecology2002;99:988‐92. FurstSN , PhilipsenT , JoergensenJC . Ten‐year follow‐up of endometrial ablation. Acta Obstetricia et Gynecologica2007;86:334‐8. ">Boujida 2002</a>; <a href="./references#CD001501-bbs2-0006" title="BrunJ‐L , RaynalJ , BurletG , GalandB , QuereuxC , BernardP . Cavaterm thermal balloon endometrial ablation versus hysteroscopic endometrial resection to treat menorrhagia: the French, multicenter, randomized study. Journal of Minimally Invasive Gynecology2006;13:424‐30. ">Brun 2006</a>; <a href="./references#CD001501-bbs2-0009" title="CooperJ , GimpelsonR , LabergeP , GalenD , Garza‐LealJG , ScottJ , et al. A randomized, multicenter trial of safety and efficacy of the NovaSure system in the treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2002;9(4):418‐28. ">Cooper 2002</a>; <a href="./references#CD001501-bbs2-0014" title="GhazizadehS , PanahiZ , GhanbariZ , Tarafdari MenshadiA , FarahmandianT , JavadianP . Comparative efficacy of NovaSure, the levonorgestrel‐releasing intrauterine system, and hysteroscopic endometrial resection in the treatment of menorrhagia: a randomized clinical trial. Journal of Gynecologic Surgery2014;30(4):215‐8. [DOI: 10.1089/gyn.2012.0041] ">Ghazizadeh 2014</a>; <a href="./references#CD001501-bbs2-0018" title="GraingerDA , TjadenDO , RowlandC , MeyerWR . Thermal balloon and rollerball ablation to treat menorrhagia: two‐year results of a multicenter, prospective, randomized clinical trial. Journal of the American Association of Gynecologic Laparoscopists2000;7(2):175‐9. LofferFD . Five year post‐procedure follow‐up of patients participating in a randomised trial of uterine balloon therapy vs rollerball ablation for the treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopy2001;8(1):48‐54. LofferFD . Three‐year comparison of thermal balloon and rollerball ablation in treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2001;8(1):48‐54. MeyerWR , WalshBW , GraingerDA , PeacockLM , LofferFD , SteegeJF . Thermal balloon and rollerball ablation to treat menorrhagia: a multicenter comparison. Obstetrics and Gynecology1998;92:98‐103. ">Meyer 1998</a>; <a href="./references#CD001501-bbs2-0021" title="BongersM , HermanM , PenninxJ , MolBW . Longterm follow‐up of a randomized controlled trial comparing NovaSure and hydrothermablation for dysfunctional uterine bleeding. Journal of Minimally Invasive Gynecology2011;18(6 Suppl 1):S34. PenninxJPM , HermanMC , MolBW , BongersMY . Five‐year follow‐up after comparing bipolar endometrial ablation with hydrothermablation for menorrhagia. Obstetrics and Gynecology2011;118:1287‐92. PenninxJPM , MolBW , EngelsR , vanRumsteMME , KleijnC , KoksCAM , et al. Bipolar radiofrequency endometrial ablation compared with hydrothermablation for dysfunctional uterine bleeding. Obstetrics and Gynecology2010;116:819‐26. ">Penninx 2010</a>; <a href="./references#CD001501-bbs2-0026" title="ThabetSMA . New attempt using ablative curettage technique for managing benign premenopausal uterine bleeding. Obstetrics and Gynaecology Research2010;36(4):803‐9. ">Thabet 2010</a>). </p> <p>Five trials compared first‐generation ablation methods.</p> <p> <ul id="CD001501-list-0022"> <li> <p>Two compared laser ablation versus TCRE (one using an argon laser, the other a neodymium yttrium aluminium garnet (Nd:YAG) laser) (<a href="./references#CD001501-bbs2-0003" title="BhattacharyaS , CameronIM , ParkinDE , AbramovichDR , MollisonJ , PinionSB , et al. A pragmatic randomised comparison of transcervical resection of the endometrium with endometrial laser ablation for the treatment of menorrhagia. British Journal of Obstetrics and Gynaecology1997;104:601‐7. ">Bhattacharya 1997;</a><a href="./references#CD001501-bbs2-0017" title="McClureN , MarnersM , HealyDL , HillDJ , LawrenceAS , WingfieldM , et al. A quantitative assessment of endometrial electrocautery in the management of menorrhagia and a comparative report of argon laser endometrial ablation. Gynaecological Endoscopy1992;1:199‐202. ">McClure 1992</a>). </p> </li> <li> <p>One compared a vaporising electrode procedure versus TCRE (<a href="./references#CD001501-bbs2-0028" title="VercelliniP , OldaniS , YaylayanL , ZainaB , DeGiorgiO , CrosignaniPG . Randomised comparison of vaporising electrode and cutting loop for endometrial ablation. Obstetrics and Gynecology1999;94:521‐7. ">Vercellini 1999</a>). </p> </li> <li> <p>Two compared rollerball versus TCRE (<a href="./references#CD001501-bbs2-0005" title="BoujidaVH , PhilipsenT , PelleJ , JoergensenJC . Five‐year follow‐up of endometrial ablation: endometrial coagulation versus endometrial resection. Obstetrics and Gynecology2002;99:988‐92. FurstSN , PhilipsenT , JoergensenJC . Ten‐year follow‐up of endometrial ablation. Acta Obstetricia et Gynecologica2007;86:334‐8. ">Boujida 2002</a>; <a href="./references#CD001501-bbs2-0019" title="OnogluA , TaskinO , InalM , SadikS , SimsekM , AkarM , et al. Comparison of the long‐term histopathologic and morphologic changes after endometrial rollerball ablation and resection: a prospective randomized trial. Journal of Minimally Invasive Gynecology2007;14:39‐42. ">Onoglu 2007</a>). </p> </li> </ul> </p> <p>All TCRE comparison groups also underwent rollerball ablation to treat the uterine cornua (a horn‐like area within the uterus) and fundus (body of the uterus). It was claimed that the vaporising electrode (unlike rollerball) could be used to treat submucous fibroids. </p> <p>Fifteen trials compared second‐generation methods versus first‐generation methods.</p> <p> <ul id="CD001501-list-0023"> <li> <p>Three compared balloon ablation (three with Thermachoice, one with Cavaterm) versus rollerball (<a href="./references#CD001501-bbs2-0018" title="GraingerDA , TjadenDO , RowlandC , MeyerWR . Thermal balloon and rollerball ablation to treat menorrhagia: two‐year results of a multicenter, prospective, randomized clinical trial. Journal of the American Association of Gynecologic Laparoscopists2000;7(2):175‐9. LofferFD . Five year post‐procedure follow‐up of patients participating in a randomised trial of uterine balloon therapy vs rollerball ablation for the treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopy2001;8(1):48‐54. LofferFD . Three‐year comparison of thermal balloon and rollerball ablation in treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2001;8(1):48‐54. MeyerWR , WalshBW , GraingerDA , PeacockLM , LofferFD , SteegeJF . Thermal balloon and rollerball ablation to treat menorrhagia: a multicenter comparison. Obstetrics and Gynecology1998;92:98‐103. ">Meyer 1998</a>; <a href="./references#CD001501-bbs2-0024" title="RomerT . The treatment of recurrent menorrhagias ‐ Cavaterm‐balloon‐coagulation versus Rollerball‐endometrial ablation ‐ a prospective randomized comparative study [Die therapie rezidivierender Menorrhagien ‐ Cavaterm‐Ballon‐Koagulatioon versus Roller‐Ball‐Endometriumkoagulation ‐ eine prospektive randomisierte Vergleichsstudie]. Zentralblatt fur Gynakologie1998;120(10):511‐4. ">Romer 1998</a>; <a href="./references#CD001501-bbs2-0027" title="vanZon‐RabelinkIAA , VleugelsMPH . Treating menorrhagia with endometrial ablation: rollerball electrocoagulation versus thermal ablation with the uterine balloon. Gynaecological Endoscopy Abstract from the 6th Annual Congress of the European Society for Gynaecological Endoscopy1997;6 Suppl 2:41. vanZon‐RabelinkIAA , VleugelsMPH , MerkusHMWM , deGraafR . Efficacy and satisfaction rate comparing endometrial ablation by rollerball electrocoagulation to uterine balloon thermal ablation in a randomised controlled trial. European Journal of Obstetrics, Gynecology, and Reproductive Biology2004;114(1):97‐103. vanZon‐RabelinkIAA , VleugelsMPH , MerkusHMWM , deGraafR . Endometrial ablation by rollerball electrocoagulation compared to uterine balloon thermal ablation. Technical and safety aspects. European Journal of Obstetrics, Gynecology, and Reproductive Biology2003;110:220‐3. ">van Zon‐Rabelink 2003</a>). </p> </li> <li> <p>One compared the Vesta system versus rollerball (<a href="./references#CD001501-bbs2-0011" title="CorsonSL , BrillAI , BrooksPG , CooperJM , IndmanPD , LiuJH , et al. Interim results of the American Vesta trial of endometrial ablation. Journal of the American Association of Gynecologic Laparoscopists1999;6(1):45‐9. CorsonSL , BrillAI , BrooksPG , CooperJM , IndmanPD , LiuJH , et al. One‐year results of the Vesta system for endometrial ablation. Journal of the American Association of Gynecologic Laparoscopists2000;7(4):489‐97. ">Corson 2000</a>). </p> </li> <li> <p>Two compared microwave ablation versus TCRE and rollerball (<a href="./references#CD001501-bbs2-0008" title="BainC , CooperKG , ParkinDE . Microwave endometrial ablation versus endometrial resection: a randomized controlled trial. Obstetrics and Gynecology2002;99:983‐7. CooperKG , BainC , LawrieL , ParkinDE . A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium: follow up at a minimum of five years. British Journal of Obstetrics and Gynaecology2005;112:470‐5. CooperKG , BainC , ParkinDE . Comparison of microwave endometrial ablation and transcervical resection of the endometrium for treatment of heavy menstrual loss: a randomised trial. Lancet1999;354:1859‐63. SambrookAM , BainC , ParkinDE , CooperKG . A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium: follow up at a minimum of 10 years. British Journal of Obstetrics and Gynaecology2009;116:1033‐7. ">Cooper 1999</a>; <a href="./references#CD001501-bbs2-0010" title="CooperJM , AndersonTL , FortinCA , JackSA , PlentlMB . Microwave endometrial ablation vs rollerball electroablation for menorrhagia: a multicenter randomized trial. Journal of the American Association of Gynecologic Laparoscopists2004;11(3):394‐403. ">Cooper 2004</a>). </p> </li> <li> <p>One compared heated saline (Hydro ThermAblator) versus rollerball (<a href="./references#CD001501-bbs2-0012" title="CorsonSL . A multicenter evaluation of endometrial ablation by hydrothermablator and rollerball for treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2001;8(3):359‐67. GoldrathMH . Evaluation of hydrothermablator and rollerball endometrial ablation for menorrhagia 3 years after treatment. Journal of the American Association of Gynecologic Laparoscopists2003;10(4):505‐11. LofferF . A clinical comparison of hydrothermablation (HTA) and rollerball for endometrial ablation to treat menorrhagia: a randomized multicenter clinical trial. XVI FIGO World Congress of Obstetrics &amp; Gynecology. 2000; Vol. Abstract Book 2:95. ">Corson 2001</a>). </p> </li> <li> <p>One compared cryoablation versus rollerball (<a href="./references#CD001501-bbs2-0013" title="DulebaAJ , HeppardMC , SoderstromRM , TownsendDE . A randomized study comparing endometrial cryoablation and rollerball electroablation for treatment of dysfunctional uterine bleeding. Journal of the American Association of Gynecologic Laparoscopists2003;10(1):17‐26. TownsendDE , DulebaAJ , WilkesMM , et al. Durability of treatment effects after cryoablation versus rollerball electroablation for abnormal uterine bleeding: two‐year results of a multicenter randomized trial. American Journal of Obstetrics and Gynecology2003;188:699‐701. ">Duleba 2003</a>). </p> </li> <li> <p>One compared laser versus TCRE (<a href="./references#CD001501-bbs2-0023" title="PerinoA , CastelliA , CucinellaG , BiondoA , PaneA , VeneziaR . A randomized comparison of endometrial laser intrauterine thermotherapy and hysteroscopic endometrial resection. Fertility and Sterility2004;82:731‐4. ">Perino 2004</a>). </p> </li> <li> <p>Two compared electrode ablation versus TCRE plus rollerball (<a href="./references#CD001501-bbs2-0011" title="CorsonSL , BrillAI , BrooksPG , CooperJM , IndmanPD , LiuJH , et al. Interim results of the American Vesta trial of endometrial ablation. Journal of the American Association of Gynecologic Laparoscopists1999;6(1):45‐9. CorsonSL , BrillAI , BrooksPG , CooperJM , IndmanPD , LiuJH , et al. One‐year results of the Vesta system for endometrial ablation. Journal of the American Association of Gynecologic Laparoscopists2000;7(4):489‐97. ">Corson 2000</a>; <a href="./references#CD001501-bbs2-0009" title="CooperJ , GimpelsonR , LabergeP , GalenD , Garza‐LealJG , ScottJ , et al. A randomized, multicenter trial of safety and efficacy of the NovaSure system in the treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2002;9(4):418‐28. ">Cooper 2002</a>). </p> </li> <li> <p>One compared balloon (Cavaterm) versus laser (Nd:YAG) (<a href="./references#CD001501-bbs2-0015" title="HaweJ , AbbottJ , HunterD , PhillipsG , GarryR . A randomised controlled trial comparing the Cavaterm endometrial ablation system with the Nd:YAG laser for the treatment of dysfunctional uterine bleeding. British Journal of Obstetrics and Gynaecology2003;110:350‐7. ">Hawe 2003</a>). </p> </li> <li> <p>Two compared balloon (Cavaterm) versus TCRE plus rollerball (<a href="./references#CD001501-bbs2-0006" title="BrunJ‐L , RaynalJ , BurletG , GalandB , QuereuxC , BernardP . Cavaterm thermal balloon endometrial ablation versus hysteroscopic endometrial resection to treat menorrhagia: the French, multicenter, randomized study. Journal of Minimally Invasive Gynecology2006;13:424‐30. ">Brun 2006</a>; <a href="./references#CD001501-bbs2-0020" title="PellicanoM , GuidaM , AcunzoG , CirilloD , BifulcoG , NappiC . Hysteroscopic transcervical endometrial resection versus thermal destruction for menorrhagia: a prospective randomized trial on satisfaction rate. American Journal of Obstetrics and Gynecology2002;187:545‐50. ">Pellicano 2002</a>). </p> </li> <li> <p>One compared bipolar (Minerva) versus rollerball (<a href="./references#CD001501-bbs2-0016" title="LabergeP , Garza‐LealJ , FortinC , BasinskiC , ThielJ , LeylandN , et al. A prospective, randomized, multi‐center, controlled, international clinical study of the safety and efficacy of the Minerva endometrial ablation system: 6 and 12‐month follow‐up results. Journal of Minimally Invasive Gynecology. 2014. LabergeP , Garza‐LealJ , FortinC , GraingerD , JohnsDA , AdkinsRT , et al. A randomized controlled multicenter US Food and Drug Administration trial of the safety and efficacy of the Minerva Endometrial Ablation System: one‐year follow‐up results. Journal of Minimally Invasive Gynecology2017;24(1):124‐32. [DOI: 10.1016/j.jmig.2016.09.009] LabergeP , Garza‐LealJ , FortinC , ThielJ , JohnsD , GraingerD , et al. A randomized, controlled, multi‐center trial of the safety and efficacy of the Minerva Endometrial Ablation System: one‐year follow‐up results. Journal of Minimally Invasive Gynecology. 2016; Vol. 23:S1‐S252. ">Laberge 2016</a>). </p> </li> </ul> </p> <p>Seven trials compared second‐generation techniques.</p> <p> <ul id="CD001501-list-0024"> <li> <p>Four compared bipolar electrode ablation (Novasure) versus balloon (<a href="./references#CD001501-bbs2-0001" title="AbbottJ , HaweJ , HunterD , GarryR . A double‐blind randomized trial comparing the Cavaterm and the Novasure endometrial ablation systems for the treatment of dysfunctional uterine bleeding. Fertility and Sterility2003;80(1):203‐8. ">Abbott 2003;</a><a href="./references#CD001501-bbs2-0004" title="BongersM , HermanM , JosienP , MolBW . Ten‐year follow‐up of a randomized controlled trial comparing NovaSure and Thermachoice in endometrial ablation for dysfunctional uterine bleeding. Journal of Minimally Invasive Gynecology2011;18(6 Suppl 1):S127. BongersMY , BourdrezP , HeintzPM , BrolmannHAM , MolBWJ . Bipolar radio frequency endometrial ablation compared with balloon endometrial ablation in dysfunctional uterine bleeding: impact on patients' health‐related quality of life. Fertility and Sterility2005;83(3):724‐34. BongersMY , BourdrezP , MolBWJ , HeintzAPM , BrolmannHAM . Randomised controlled trial of bipolar radio‐frequency endometrial ablation and balloon endometrial ablation. British Journal of Obstetrics and Gynaecology2004;111:1095‐102. HermanM , PenninxM , MolB , BongersM . Ten‐year follow‐up of a randomised controlled trial comparing bipolar endometrial ablation with balloon ablation for heavy menstrual bleeding. British Journal Obstetrics and Gynaecology2013;120:966‐970. [DOI: 10.1111/1471‐0528.12213] KleijnJH , EngelsR , BourdrezP , MolBWJ , BongersMY . Five‐year follow up of a randomised controlled trial comparing NovaSure and ThermaChoice endometrial ablation. British Journal of Obstetrics and Gynaecology2008;115:193‐8. ">Bongers 2004;</a><a href="./references#CD001501-bbs2-0007" title="ClarkTJ , SamuelN , MalickS , MiddletonLJ , DanielsJ , GuptaJK . Bipolar radiofrequency compared with thermal balloon endometrial ablation in the office. Obstetrics and Gynecology2011;117:109‐18. ">Clark 2011;</a><a href="./references#CD001501-bbs2-0022" title="PenninxJ , BongersM . Bipolar radiofrequency endometrial ablation versus thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. www.controlled‐trials.com/ISRCTN17974690. PenninxJ , HermanM , KruitwagenR , Ter HaarA , MolB , BongersM . Bipolar versus balloon endometrial ablation in the office: a randomized controlled trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;196:52‐6. [DOI: 10.1016/j.ejogrb.2015.10.010] PenninxJ , HermanM , MolB , KruitwagenR , BongersM . Bipolar radiofrequency endometrial ablation versus Thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. Journal of Minimally Invasive Gynecology2012;19(6):S21‐S22. [DOI: 10.1016/j.jmig.2012.08.076] PenninxJPM , HermanMC , MolBW , BongersMY . Bipolar radiofrequency endometrial ablation versus thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. Journal of Minimally Invasive Gynecology2012;19(6 Suppl 1):S21‐2. ">Penninx 2016</a>). </p> </li> <li> <p>One compared bipolar radiofrequency versus hydrothermal ablation (<a href="./references#CD001501-bbs2-0021" title="BongersM , HermanM , PenninxJ , MolBW . Longterm follow‐up of a randomized controlled trial comparing NovaSure and hydrothermablation for dysfunctional uterine bleeding. Journal of Minimally Invasive Gynecology2011;18(6 Suppl 1):S34. PenninxJPM , HermanMC , MolBW , BongersMY . Five‐year follow‐up after comparing bipolar endometrial ablation with hydrothermablation for menorrhagia. Obstetrics and Gynecology2011;118:1287‐92. PenninxJPM , MolBW , EngelsR , vanRumsteMME , KleijnC , KoksCAM , et al. Bipolar radiofrequency endometrial ablation compared with hydrothermablation for dysfunctional uterine bleeding. Obstetrics and Gynecology2010;116:819‐26. ">Penninx 2010</a>). </p> </li> <li> <p>One compared bipolar electrode ablation (Novasure) versus microwave (<a href="./references#CD001501-bbs2-0002" title="AthanatosD , PadosG , VenetisC , StamatopoulosP , RoussoD , TsolakidisD , et al. Novasure impedance control system versus microwave endometrial ablation for the treatment of dysfunctional uterine bleeding: a double‐blind, randomized controlled trial. Clinical and Experimental Obstetrics &amp; Gynecology2015;42(3):347‐51. [PMID: 26152008] PadosG . Treatment of dysfunctional uterine bleeding with second generation ablation devices: microwaves (MEAA) vs Bipolar Impedance Control System (Novasure). http://clinicaltrials.gov/show/NCT01173965. ">Athanatos 2015</a>). </p> </li> <li> <p>One compared microwave versus balloon ablation (<a href="./references#CD001501-bbs2-0025" title="SambrookA , EldersA , CooperK . Microwave endometrial ablation versus thermal balloon endometrial ablation (MEATBall): 5‐year follow up of a randomised controlled trial. British Journal of Obstetrics and Gynaecology2014;121:748‐54. [DOI: 10.1111/1471‐0528.12585] SambrookAM , CooperKG , CampbellMK , CookJA . Clinical outcomes from a randomised comparison of microwave endometrial ablation with thermal balloon endometrial ablation for the treatment of heavy menstrual bleeding. British Journal of Obstetrics and Gynaecology2009;116:1038‐45. ">Sambrook 2009</a>). </p> </li> </ul> </p> <p>All first‐generation techniques (laser, rollerball, vaporising electrode, and transcervical resection), which use the hysteroscope, were then combined and compared with all second‐generation techniques (balloon, microwave, Vesta system, cryoablation, thermal laser, bipolar electrode ablation, and hydrothermal ablation), which are blind techniques. An additional trial compared overcurettage versus ablative curettage (<a href="./references#CD001501-bbs2-0026" title="ThabetSMA . New attempt using ablative curettage technique for managing benign premenopausal uterine bleeding. Obstetrics and Gynaecology Research2010;36(4):803‐9. ">Thabet 2010</a>). </p> </section> <section id="CD001501-sec-0087"> <h5 class="title">Outcomes</h5> <section id="CD001501-sec-0088"> <h6 class="title">Bleeding</h6> <p>Researchers measured bleeding as an outcome in 25 of the 28 trials (<a href="./references#CD001501-bbs2-0001" title="AbbottJ , HaweJ , HunterD , GarryR . A double‐blind randomized trial comparing the Cavaterm and the Novasure endometrial ablation systems for the treatment of dysfunctional uterine bleeding. Fertility and Sterility2003;80(1):203‐8. ">Abbott 2003</a>; <a href="./references#CD001501-bbs2-0002" title="AthanatosD , PadosG , VenetisC , StamatopoulosP , RoussoD , TsolakidisD , et al. Novasure impedance control system versus microwave endometrial ablation for the treatment of dysfunctional uterine bleeding: a double‐blind, randomized controlled trial. Clinical and Experimental Obstetrics &amp; Gynecology2015;42(3):347‐51. [PMID: 26152008] PadosG . Treatment of dysfunctional uterine bleeding with second generation ablation devices: microwaves (MEAA) vs Bipolar Impedance Control System (Novasure). http://clinicaltrials.gov/show/NCT01173965. ">Athanatos 2015</a>; <a href="./references#CD001501-bbs2-0003" title="BhattacharyaS , CameronIM , ParkinDE , AbramovichDR , MollisonJ , PinionSB , et al. A pragmatic randomised comparison of transcervical resection of the endometrium with endometrial laser ablation for the treatment of menorrhagia. British Journal of Obstetrics and Gynaecology1997;104:601‐7. ">Bhattacharya 1997</a>; <a href="./references#CD001501-bbs2-0004" title="BongersM , HermanM , JosienP , MolBW . Ten‐year follow‐up of a randomized controlled trial comparing NovaSure and Thermachoice in endometrial ablation for dysfunctional uterine bleeding. Journal of Minimally Invasive Gynecology2011;18(6 Suppl 1):S127. BongersMY , BourdrezP , HeintzPM , BrolmannHAM , MolBWJ . Bipolar radio frequency endometrial ablation compared with balloon endometrial ablation in dysfunctional uterine bleeding: impact on patients' health‐related quality of life. Fertility and Sterility2005;83(3):724‐34. BongersMY , BourdrezP , MolBWJ , HeintzAPM , BrolmannHAM . Randomised controlled trial of bipolar radio‐frequency endometrial ablation and balloon endometrial ablation. British Journal of Obstetrics and Gynaecology2004;111:1095‐102. HermanM , PenninxM , MolB , BongersM . Ten‐year follow‐up of a randomised controlled trial comparing bipolar endometrial ablation with balloon ablation for heavy menstrual bleeding. British Journal Obstetrics and Gynaecology2013;120:966‐970. [DOI: 10.1111/1471‐0528.12213] KleijnJH , EngelsR , BourdrezP , MolBWJ , BongersMY . Five‐year follow up of a randomised controlled trial comparing NovaSure and ThermaChoice endometrial ablation. British Journal of Obstetrics and Gynaecology2008;115:193‐8. ">Bongers 2004</a>; <a href="./references#CD001501-bbs2-0006" title="BrunJ‐L , RaynalJ , BurletG , GalandB , QuereuxC , BernardP . Cavaterm thermal balloon endometrial ablation versus hysteroscopic endometrial resection to treat menorrhagia: the French, multicenter, randomized study. Journal of Minimally Invasive Gynecology2006;13:424‐30. ">Brun 2006</a>; <a href="./references#CD001501-bbs2-0007" title="ClarkTJ , SamuelN , MalickS , MiddletonLJ , DanielsJ , GuptaJK . Bipolar radiofrequency compared with thermal balloon endometrial ablation in the office. Obstetrics and Gynecology2011;117:109‐18. ">Clark 2011</a>; <a href="./references#CD001501-bbs2-0008" title="BainC , CooperKG , ParkinDE . Microwave endometrial ablation versus endometrial resection: a randomized controlled trial. Obstetrics and Gynecology2002;99:983‐7. CooperKG , BainC , LawrieL , ParkinDE . A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium: follow up at a minimum of five years. British Journal of Obstetrics and Gynaecology2005;112:470‐5. CooperKG , BainC , ParkinDE . Comparison of microwave endometrial ablation and transcervical resection of the endometrium for treatment of heavy menstrual loss: a randomised trial. Lancet1999;354:1859‐63. SambrookAM , BainC , ParkinDE , CooperKG . A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium: follow up at a minimum of 10 years. British Journal of Obstetrics and Gynaecology2009;116:1033‐7. ">Cooper 1999</a>; <a href="./references#CD001501-bbs2-0009" title="CooperJ , GimpelsonR , LabergeP , GalenD , Garza‐LealJG , ScottJ , et al. A randomized, multicenter trial of safety and efficacy of the NovaSure system in the treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2002;9(4):418‐28. ">Cooper 2002</a>; <a href="./references#CD001501-bbs2-0010" title="CooperJM , AndersonTL , FortinCA , JackSA , PlentlMB . Microwave endometrial ablation vs rollerball electroablation for menorrhagia: a multicenter randomized trial. Journal of the American Association of Gynecologic Laparoscopists2004;11(3):394‐403. ">Cooper 2004</a>; <a href="./references#CD001501-bbs2-0011" title="CorsonSL , BrillAI , BrooksPG , CooperJM , IndmanPD , LiuJH , et al. Interim results of the American Vesta trial of endometrial ablation. Journal of the American Association of Gynecologic Laparoscopists1999;6(1):45‐9. CorsonSL , BrillAI , BrooksPG , CooperJM , IndmanPD , LiuJH , et al. One‐year results of the Vesta system for endometrial ablation. Journal of the American Association of Gynecologic Laparoscopists2000;7(4):489‐97. ">Corson 2000</a>; <a href="./references#CD001501-bbs2-0012" title="CorsonSL . A multicenter evaluation of endometrial ablation by hydrothermablator and rollerball for treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2001;8(3):359‐67. GoldrathMH . Evaluation of hydrothermablator and rollerball endometrial ablation for menorrhagia 3 years after treatment. Journal of the American Association of Gynecologic Laparoscopists2003;10(4):505‐11. LofferF . A clinical comparison of hydrothermablation (HTA) and rollerball for endometrial ablation to treat menorrhagia: a randomized multicenter clinical trial. XVI FIGO World Congress of Obstetrics &amp; Gynecology. 2000; Vol. Abstract Book 2:95. ">Corson 2001</a>; <a href="./references#CD001501-bbs2-0013" title="DulebaAJ , HeppardMC , SoderstromRM , TownsendDE . A randomized study comparing endometrial cryoablation and rollerball electroablation for treatment of dysfunctional uterine bleeding. Journal of the American Association of Gynecologic Laparoscopists2003;10(1):17‐26. TownsendDE , DulebaAJ , WilkesMM , et al. Durability of treatment effects after cryoablation versus rollerball electroablation for abnormal uterine bleeding: two‐year results of a multicenter randomized trial. American Journal of Obstetrics and Gynecology2003;188:699‐701. ">Duleba 2003</a>; <a href="./references#CD001501-bbs2-0014" title="GhazizadehS , PanahiZ , GhanbariZ , Tarafdari MenshadiA , FarahmandianT , JavadianP . Comparative efficacy of NovaSure, the levonorgestrel‐releasing intrauterine system, and hysteroscopic endometrial resection in the treatment of menorrhagia: a randomized clinical trial. Journal of Gynecologic Surgery2014;30(4):215‐8. [DOI: 10.1089/gyn.2012.0041] ">Ghazizadeh 2014</a>; <a href="./references#CD001501-bbs2-0015" title="HaweJ , AbbottJ , HunterD , PhillipsG , GarryR . A randomised controlled trial comparing the Cavaterm endometrial ablation system with the Nd:YAG laser for the treatment of dysfunctional uterine bleeding. British Journal of Obstetrics and Gynaecology2003;110:350‐7. ">Hawe 2003</a>; <a href="./references#CD001501-bbs2-0016" title="LabergeP , Garza‐LealJ , FortinC , BasinskiC , ThielJ , LeylandN , et al. A prospective, randomized, multi‐center, controlled, international clinical study of the safety and efficacy of the Minerva endometrial ablation system: 6 and 12‐month follow‐up results. Journal of Minimally Invasive Gynecology. 2014. LabergeP , Garza‐LealJ , FortinC , GraingerD , JohnsDA , AdkinsRT , et al. A randomized controlled multicenter US Food and Drug Administration trial of the safety and efficacy of the Minerva Endometrial Ablation System: one‐year follow‐up results. Journal of Minimally Invasive Gynecology2017;24(1):124‐32. [DOI: 10.1016/j.jmig.2016.09.009] LabergeP , Garza‐LealJ , FortinC , ThielJ , JohnsD , GraingerD , et al. A randomized, controlled, multi‐center trial of the safety and efficacy of the Minerva Endometrial Ablation System: one‐year follow‐up results. Journal of Minimally Invasive Gynecology. 2016; Vol. 23:S1‐S252. ">Laberge 2016</a>; <a href="./references#CD001501-bbs2-0017" title="McClureN , MarnersM , HealyDL , HillDJ , LawrenceAS , WingfieldM , et al. A quantitative assessment of endometrial electrocautery in the management of menorrhagia and a comparative report of argon laser endometrial ablation. Gynaecological Endoscopy1992;1:199‐202. ">McClure 1992</a>; <a href="./references#CD001501-bbs2-0018" title="GraingerDA , TjadenDO , RowlandC , MeyerWR . Thermal balloon and rollerball ablation to treat menorrhagia: two‐year results of a multicenter, prospective, randomized clinical trial. Journal of the American Association of Gynecologic Laparoscopists2000;7(2):175‐9. LofferFD . Five year post‐procedure follow‐up of patients participating in a randomised trial of uterine balloon therapy vs rollerball ablation for the treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopy2001;8(1):48‐54. LofferFD . Three‐year comparison of thermal balloon and rollerball ablation in treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2001;8(1):48‐54. MeyerWR , WalshBW , GraingerDA , PeacockLM , LofferFD , SteegeJF . Thermal balloon and rollerball ablation to treat menorrhagia: a multicenter comparison. Obstetrics and Gynecology1998;92:98‐103. ">Meyer 1998</a>; <a href="./references#CD001501-bbs2-0021" title="BongersM , HermanM , PenninxJ , MolBW . Longterm follow‐up of a randomized controlled trial comparing NovaSure and hydrothermablation for dysfunctional uterine bleeding. Journal of Minimally Invasive Gynecology2011;18(6 Suppl 1):S34. PenninxJPM , HermanMC , MolBW , BongersMY . Five‐year follow‐up after comparing bipolar endometrial ablation with hydrothermablation for menorrhagia. Obstetrics and Gynecology2011;118:1287‐92. PenninxJPM , MolBW , EngelsR , vanRumsteMME , KleijnC , KoksCAM , et al. Bipolar radiofrequency endometrial ablation compared with hydrothermablation for dysfunctional uterine bleeding. Obstetrics and Gynecology2010;116:819‐26. ">Penninx 2010</a>; <a href="./references#CD001501-bbs2-0022" title="PenninxJ , BongersM . Bipolar radiofrequency endometrial ablation versus thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. www.controlled‐trials.com/ISRCTN17974690. PenninxJ , HermanM , KruitwagenR , Ter HaarA , MolB , BongersM . Bipolar versus balloon endometrial ablation in the office: a randomized controlled trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;196:52‐6. [DOI: 10.1016/j.ejogrb.2015.10.010] PenninxJ , HermanM , MolB , KruitwagenR , BongersM . Bipolar radiofrequency endometrial ablation versus Thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. Journal of Minimally Invasive Gynecology2012;19(6):S21‐S22. [DOI: 10.1016/j.jmig.2012.08.076] PenninxJPM , HermanMC , MolBW , BongersMY . Bipolar radiofrequency endometrial ablation versus thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. Journal of Minimally Invasive Gynecology2012;19(6 Suppl 1):S21‐2. ">Penninx 2016</a>; <a href="./references#CD001501-bbs2-0023" title="PerinoA , CastelliA , CucinellaG , BiondoA , PaneA , VeneziaR . A randomized comparison of endometrial laser intrauterine thermotherapy and hysteroscopic endometrial resection. Fertility and Sterility2004;82:731‐4. ">Perino 2004</a>; <a href="./references#CD001501-bbs2-0024" title="RomerT . The treatment of recurrent menorrhagias ‐ Cavaterm‐balloon‐coagulation versus Rollerball‐endometrial ablation ‐ a prospective randomized comparative study [Die therapie rezidivierender Menorrhagien ‐ Cavaterm‐Ballon‐Koagulatioon versus Roller‐Ball‐Endometriumkoagulation ‐ eine prospektive randomisierte Vergleichsstudie]. Zentralblatt fur Gynakologie1998;120(10):511‐4. ">Romer 1998</a>; <a href="./references#CD001501-bbs2-0025" title="SambrookA , EldersA , CooperK . Microwave endometrial ablation versus thermal balloon endometrial ablation (MEATBall): 5‐year follow up of a randomised controlled trial. British Journal of Obstetrics and Gynaecology2014;121:748‐54. [DOI: 10.1111/1471‐0528.12585] SambrookAM , CooperKG , CampbellMK , CookJA . Clinical outcomes from a randomised comparison of microwave endometrial ablation with thermal balloon endometrial ablation for the treatment of heavy menstrual bleeding. British Journal of Obstetrics and Gynaecology2009;116:1038‐45. ">Sambrook 2009</a>; <a href="./references#CD001501-bbs2-0026" title="ThabetSMA . New attempt using ablative curettage technique for managing benign premenopausal uterine bleeding. Obstetrics and Gynaecology Research2010;36(4):803‐9. ">Thabet 2010</a>; <a href="./references#CD001501-bbs2-0027" title="vanZon‐RabelinkIAA , VleugelsMPH . Treating menorrhagia with endometrial ablation: rollerball electrocoagulation versus thermal ablation with the uterine balloon. Gynaecological Endoscopy Abstract from the 6th Annual Congress of the European Society for Gynaecological Endoscopy1997;6 Suppl 2:41. vanZon‐RabelinkIAA , VleugelsMPH , MerkusHMWM , deGraafR . Efficacy and satisfaction rate comparing endometrial ablation by rollerball electrocoagulation to uterine balloon thermal ablation in a randomised controlled trial. European Journal of Obstetrics, Gynecology, and Reproductive Biology2004;114(1):97‐103. vanZon‐RabelinkIAA , VleugelsMPH , MerkusHMWM , deGraafR . Endometrial ablation by rollerball electrocoagulation compared to uterine balloon thermal ablation. Technical and safety aspects. European Journal of Obstetrics, Gynecology, and Reproductive Biology2003;110:220‐3. ">van Zon‐Rabelink 2003</a>; <a href="./references#CD001501-bbs2-0028" title="VercelliniP , OldaniS , YaylayanL , ZainaB , DeGiorgiO , CrosignaniPG . Randomised comparison of vaporising electrode and cutting loop for endometrial ablation. Obstetrics and Gynecology1999;94:521‐7. ">Vercellini 1999</a>). The most common way to describe bleeding was to report amenorrhoea. Twenty‐two trials reported amenorrhoea (<a href="./references#CD001501-bbs2-0001" title="AbbottJ , HaweJ , HunterD , GarryR . A double‐blind randomized trial comparing the Cavaterm and the Novasure endometrial ablation systems for the treatment of dysfunctional uterine bleeding. Fertility and Sterility2003;80(1):203‐8. ">Abbott 2003</a>; <a href="./references#CD001501-bbs2-0002" title="AthanatosD , PadosG , VenetisC , StamatopoulosP , RoussoD , TsolakidisD , et al. Novasure impedance control system versus microwave endometrial ablation for the treatment of dysfunctional uterine bleeding: a double‐blind, randomized controlled trial. Clinical and Experimental Obstetrics &amp; Gynecology2015;42(3):347‐51. [PMID: 26152008] PadosG . Treatment of dysfunctional uterine bleeding with second generation ablation devices: microwaves (MEAA) vs Bipolar Impedance Control System (Novasure). http://clinicaltrials.gov/show/NCT01173965. ">Athanatos 2015</a>; <a href="./references#CD001501-bbs2-0003" title="BhattacharyaS , CameronIM , ParkinDE , AbramovichDR , MollisonJ , PinionSB , et al. A pragmatic randomised comparison of transcervical resection of the endometrium with endometrial laser ablation for the treatment of menorrhagia. British Journal of Obstetrics and Gynaecology1997;104:601‐7. ">Bhattacharya 1997</a>; <a href="./references#CD001501-bbs2-0004" title="BongersM , HermanM , JosienP , MolBW . Ten‐year follow‐up of a randomized controlled trial comparing NovaSure and Thermachoice in endometrial ablation for dysfunctional uterine bleeding. Journal of Minimally Invasive Gynecology2011;18(6 Suppl 1):S127. BongersMY , BourdrezP , HeintzPM , BrolmannHAM , MolBWJ . Bipolar radio frequency endometrial ablation compared with balloon endometrial ablation in dysfunctional uterine bleeding: impact on patients' health‐related quality of life. Fertility and Sterility2005;83(3):724‐34. BongersMY , BourdrezP , MolBWJ , HeintzAPM , BrolmannHAM . Randomised controlled trial of bipolar radio‐frequency endometrial ablation and balloon endometrial ablation. British Journal of Obstetrics and Gynaecology2004;111:1095‐102. HermanM , PenninxM , MolB , BongersM . Ten‐year follow‐up of a randomised controlled trial comparing bipolar endometrial ablation with balloon ablation for heavy menstrual bleeding. British Journal Obstetrics and Gynaecology2013;120:966‐970. [DOI: 10.1111/1471‐0528.12213] KleijnJH , EngelsR , BourdrezP , MolBWJ , BongersMY . Five‐year follow up of a randomised controlled trial comparing NovaSure and ThermaChoice endometrial ablation. British Journal of Obstetrics and Gynaecology2008;115:193‐8. ">Bongers 2004</a>; <a href="./references#CD001501-bbs2-0006" title="BrunJ‐L , RaynalJ , BurletG , GalandB , QuereuxC , BernardP . Cavaterm thermal balloon endometrial ablation versus hysteroscopic endometrial resection to treat menorrhagia: the French, multicenter, randomized study. Journal of Minimally Invasive Gynecology2006;13:424‐30. ">Brun 2006</a>; <a href="./references#CD001501-bbs2-0007" title="ClarkTJ , SamuelN , MalickS , MiddletonLJ , DanielsJ , GuptaJK . Bipolar radiofrequency compared with thermal balloon endometrial ablation in the office. Obstetrics and Gynecology2011;117:109‐18. ">Clark 2011</a>; <a href="./references#CD001501-bbs2-0008" title="BainC , CooperKG , ParkinDE . Microwave endometrial ablation versus endometrial resection: a randomized controlled trial. Obstetrics and Gynecology2002;99:983‐7. CooperKG , BainC , LawrieL , ParkinDE . A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium: follow up at a minimum of five years. British Journal of Obstetrics and Gynaecology2005;112:470‐5. CooperKG , BainC , ParkinDE . Comparison of microwave endometrial ablation and transcervical resection of the endometrium for treatment of heavy menstrual loss: a randomised trial. Lancet1999;354:1859‐63. SambrookAM , BainC , ParkinDE , CooperKG . A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium: follow up at a minimum of 10 years. British Journal of Obstetrics and Gynaecology2009;116:1033‐7. ">Cooper 1999</a>; <a href="./references#CD001501-bbs2-0009" title="CooperJ , GimpelsonR , LabergeP , GalenD , Garza‐LealJG , ScottJ , et al. A randomized, multicenter trial of safety and efficacy of the NovaSure system in the treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2002;9(4):418‐28. ">Cooper 2002</a>; <a href="./references#CD001501-bbs2-0010" title="CooperJM , AndersonTL , FortinCA , JackSA , PlentlMB . Microwave endometrial ablation vs rollerball electroablation for menorrhagia: a multicenter randomized trial. Journal of the American Association of Gynecologic Laparoscopists2004;11(3):394‐403. ">Cooper 2004</a>; <a href="./references#CD001501-bbs2-0011" title="CorsonSL , BrillAI , BrooksPG , CooperJM , IndmanPD , LiuJH , et al. Interim results of the American Vesta trial of endometrial ablation. Journal of the American Association of Gynecologic Laparoscopists1999;6(1):45‐9. CorsonSL , BrillAI , BrooksPG , CooperJM , IndmanPD , LiuJH , et al. One‐year results of the Vesta system for endometrial ablation. Journal of the American Association of Gynecologic Laparoscopists2000;7(4):489‐97. ">Corson 2000</a>; <a href="./references#CD001501-bbs2-0013" title="DulebaAJ , HeppardMC , SoderstromRM , TownsendDE . A randomized study comparing endometrial cryoablation and rollerball electroablation for treatment of dysfunctional uterine bleeding. Journal of the American Association of Gynecologic Laparoscopists2003;10(1):17‐26. TownsendDE , DulebaAJ , WilkesMM , et al. Durability of treatment effects after cryoablation versus rollerball electroablation for abnormal uterine bleeding: two‐year results of a multicenter randomized trial. American Journal of Obstetrics and Gynecology2003;188:699‐701. ">Duleba 2003</a>; <a href="./references#CD001501-bbs2-0015" title="HaweJ , AbbottJ , HunterD , PhillipsG , GarryR . A randomised controlled trial comparing the Cavaterm endometrial ablation system with the Nd:YAG laser for the treatment of dysfunctional uterine bleeding. British Journal of Obstetrics and Gynaecology2003;110:350‐7. ">Hawe 2003</a>; <a href="./references#CD001501-bbs2-0016" title="LabergeP , Garza‐LealJ , FortinC , BasinskiC , ThielJ , LeylandN , et al. A prospective, randomized, multi‐center, controlled, international clinical study of the safety and efficacy of the Minerva endometrial ablation system: 6 and 12‐month follow‐up results. Journal of Minimally Invasive Gynecology. 2014. LabergeP , Garza‐LealJ , FortinC , GraingerD , JohnsDA , AdkinsRT , et al. A randomized controlled multicenter US Food and Drug Administration trial of the safety and efficacy of the Minerva Endometrial Ablation System: one‐year follow‐up results. Journal of Minimally Invasive Gynecology2017;24(1):124‐32. [DOI: 10.1016/j.jmig.2016.09.009] LabergeP , Garza‐LealJ , FortinC , ThielJ , JohnsD , GraingerD , et al. A randomized, controlled, multi‐center trial of the safety and efficacy of the Minerva Endometrial Ablation System: one‐year follow‐up results. Journal of Minimally Invasive Gynecology. 2016; Vol. 23:S1‐S252. ">Laberge 2016</a>; <a href="./references#CD001501-bbs2-0017" title="McClureN , MarnersM , HealyDL , HillDJ , LawrenceAS , WingfieldM , et al. A quantitative assessment of endometrial electrocautery in the management of menorrhagia and a comparative report of argon laser endometrial ablation. Gynaecological Endoscopy1992;1:199‐202. ">McClure 1992</a>; <a href="./references#CD001501-bbs2-0018" title="GraingerDA , TjadenDO , RowlandC , MeyerWR . Thermal balloon and rollerball ablation to treat menorrhagia: two‐year results of a multicenter, prospective, randomized clinical trial. Journal of the American Association of Gynecologic Laparoscopists2000;7(2):175‐9. LofferFD . Five year post‐procedure follow‐up of patients participating in a randomised trial of uterine balloon therapy vs rollerball ablation for the treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopy2001;8(1):48‐54. LofferFD . Three‐year comparison of thermal balloon and rollerball ablation in treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2001;8(1):48‐54. MeyerWR , WalshBW , GraingerDA , PeacockLM , LofferFD , SteegeJF . Thermal balloon and rollerball ablation to treat menorrhagia: a multicenter comparison. Obstetrics and Gynecology1998;92:98‐103. ">Meyer 1998</a>; <a href="./references#CD001501-bbs2-0021" title="BongersM , HermanM , PenninxJ , MolBW . Longterm follow‐up of a randomized controlled trial comparing NovaSure and hydrothermablation for dysfunctional uterine bleeding. Journal of Minimally Invasive Gynecology2011;18(6 Suppl 1):S34. PenninxJPM , HermanMC , MolBW , BongersMY . Five‐year follow‐up after comparing bipolar endometrial ablation with hydrothermablation for menorrhagia. Obstetrics and Gynecology2011;118:1287‐92. PenninxJPM , MolBW , EngelsR , vanRumsteMME , KleijnC , KoksCAM , et al. Bipolar radiofrequency endometrial ablation compared with hydrothermablation for dysfunctional uterine bleeding. Obstetrics and Gynecology2010;116:819‐26. ">Penninx 2010</a>; <a href="./references#CD001501-bbs2-0022" title="PenninxJ , BongersM . Bipolar radiofrequency endometrial ablation versus thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. www.controlled‐trials.com/ISRCTN17974690. PenninxJ , HermanM , KruitwagenR , Ter HaarA , MolB , BongersM . Bipolar versus balloon endometrial ablation in the office: a randomized controlled trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;196:52‐6. [DOI: 10.1016/j.ejogrb.2015.10.010] PenninxJ , HermanM , MolB , KruitwagenR , BongersM . Bipolar radiofrequency endometrial ablation versus Thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. Journal of Minimally Invasive Gynecology2012;19(6):S21‐S22. [DOI: 10.1016/j.jmig.2012.08.076] PenninxJPM , HermanMC , MolBW , BongersMY . Bipolar radiofrequency endometrial ablation versus thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. Journal of Minimally Invasive Gynecology2012;19(6 Suppl 1):S21‐2. ">Penninx 2016</a>; <a href="./references#CD001501-bbs2-0023" title="PerinoA , CastelliA , CucinellaG , BiondoA , PaneA , VeneziaR . A randomized comparison of endometrial laser intrauterine thermotherapy and hysteroscopic endometrial resection. Fertility and Sterility2004;82:731‐4. ">Perino 2004</a>; <a href="./references#CD001501-bbs2-0024" title="RomerT . The treatment of recurrent menorrhagias ‐ Cavaterm‐balloon‐coagulation versus Rollerball‐endometrial ablation ‐ a prospective randomized comparative study [Die therapie rezidivierender Menorrhagien ‐ Cavaterm‐Ballon‐Koagulatioon versus Roller‐Ball‐Endometriumkoagulation ‐ eine prospektive randomisierte Vergleichsstudie]. Zentralblatt fur Gynakologie1998;120(10):511‐4. ">Romer 1998</a>; <a href="./references#CD001501-bbs2-0025" title="SambrookA , EldersA , CooperK . Microwave endometrial ablation versus thermal balloon endometrial ablation (MEATBall): 5‐year follow up of a randomised controlled trial. British Journal of Obstetrics and Gynaecology2014;121:748‐54. [DOI: 10.1111/1471‐0528.12585] SambrookAM , CooperKG , CampbellMK , CookJA . Clinical outcomes from a randomised comparison of microwave endometrial ablation with thermal balloon endometrial ablation for the treatment of heavy menstrual bleeding. British Journal of Obstetrics and Gynaecology2009;116:1038‐45. ">Sambrook 2009</a>; <a href="./references#CD001501-bbs2-0026" title="ThabetSMA . New attempt using ablative curettage technique for managing benign premenopausal uterine bleeding. Obstetrics and Gynaecology Research2010;36(4):803‐9. ">Thabet 2010</a>; <a href="./references#CD001501-bbs2-0028" title="VercelliniP , OldaniS , YaylayanL , ZainaB , DeGiorgiO , CrosignaniPG . Randomised comparison of vaporising electrode and cutting loop for endometrial ablation. Obstetrics and Gynecology1999;94:521‐7. ">Vercellini 1999</a>). One reported PBAC &lt; 100 (<a href="./references#CD001501-bbs2-0012" title="CorsonSL . A multicenter evaluation of endometrial ablation by hydrothermablator and rollerball for treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2001;8(3):359‐67. GoldrathMH . Evaluation of hydrothermablator and rollerball endometrial ablation for menorrhagia 3 years after treatment. Journal of the American Association of Gynecologic Laparoscopists2003;10(4):505‐11. LofferF . A clinical comparison of hydrothermablation (HTA) and rollerball for endometrial ablation to treat menorrhagia: a randomized multicenter clinical trial. XVI FIGO World Congress of Obstetrics &amp; Gynecology. 2000; Vol. Abstract Book 2:95. ">Corson 2001</a>), and five reported PBAC &lt; 75 (<a href="./references#CD001501-bbs2-0008" title="BainC , CooperKG , ParkinDE . Microwave endometrial ablation versus endometrial resection: a randomized controlled trial. Obstetrics and Gynecology2002;99:983‐7. CooperKG , BainC , LawrieL , ParkinDE . A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium: follow up at a minimum of five years. British Journal of Obstetrics and Gynaecology2005;112:470‐5. CooperKG , BainC , ParkinDE . Comparison of microwave endometrial ablation and transcervical resection of the endometrium for treatment of heavy menstrual loss: a randomised trial. Lancet1999;354:1859‐63. SambrookAM , BainC , ParkinDE , CooperKG . A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium: follow up at a minimum of 10 years. British Journal of Obstetrics and Gynaecology2009;116:1033‐7. ">Cooper 1999</a>; <a href="./references#CD001501-bbs2-0009" title="CooperJ , GimpelsonR , LabergeP , GalenD , Garza‐LealJG , ScottJ , et al. A randomized, multicenter trial of safety and efficacy of the NovaSure system in the treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2002;9(4):418‐28. ">Cooper 2002</a>; <a href="./references#CD001501-bbs2-0010" title="CooperJM , AndersonTL , FortinCA , JackSA , PlentlMB . Microwave endometrial ablation vs rollerball electroablation for menorrhagia: a multicenter randomized trial. Journal of the American Association of Gynecologic Laparoscopists2004;11(3):394‐403. ">Cooper 2004</a>; <a href="./references#CD001501-bbs2-0011" title="CorsonSL , BrillAI , BrooksPG , CooperJM , IndmanPD , LiuJH , et al. Interim results of the American Vesta trial of endometrial ablation. Journal of the American Association of Gynecologic Laparoscopists1999;6(1):45‐9. CorsonSL , BrillAI , BrooksPG , CooperJM , IndmanPD , LiuJH , et al. One‐year results of the Vesta system for endometrial ablation. Journal of the American Association of Gynecologic Laparoscopists2000;7(4):489‐97. ">Corson 2000</a>; <a href="./references#CD001501-bbs2-0012" title="CorsonSL . A multicenter evaluation of endometrial ablation by hydrothermablator and rollerball for treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2001;8(3):359‐67. GoldrathMH . Evaluation of hydrothermablator and rollerball endometrial ablation for menorrhagia 3 years after treatment. Journal of the American Association of Gynecologic Laparoscopists2003;10(4):505‐11. LofferF . A clinical comparison of hydrothermablation (HTA) and rollerball for endometrial ablation to treat menorrhagia: a randomized multicenter clinical trial. XVI FIGO World Congress of Obstetrics &amp; Gynecology. 2000; Vol. Abstract Book 2:95. ">Corson 2001</a>). </p> </section> <section id="CD001501-sec-0089"> <h6 class="title">Rate of satisfaction</h6> <p>Investigators in 19 of the 28 trials reported the rate of satisfaction with the procedure (<a href="./references#CD001501-bbs2-0001" title="AbbottJ , HaweJ , HunterD , GarryR . A double‐blind randomized trial comparing the Cavaterm and the Novasure endometrial ablation systems for the treatment of dysfunctional uterine bleeding. Fertility and Sterility2003;80(1):203‐8. ">Abbott 2003</a>; <a href="./references#CD001501-bbs2-0002" title="AthanatosD , PadosG , VenetisC , StamatopoulosP , RoussoD , TsolakidisD , et al. Novasure impedance control system versus microwave endometrial ablation for the treatment of dysfunctional uterine bleeding: a double‐blind, randomized controlled trial. Clinical and Experimental Obstetrics &amp; Gynecology2015;42(3):347‐51. [PMID: 26152008] PadosG . Treatment of dysfunctional uterine bleeding with second generation ablation devices: microwaves (MEAA) vs Bipolar Impedance Control System (Novasure). http://clinicaltrials.gov/show/NCT01173965. ">Athanatos 2015</a>; <a href="./references#CD001501-bbs2-0003" title="BhattacharyaS , CameronIM , ParkinDE , AbramovichDR , MollisonJ , PinionSB , et al. A pragmatic randomised comparison of transcervical resection of the endometrium with endometrial laser ablation for the treatment of menorrhagia. British Journal of Obstetrics and Gynaecology1997;104:601‐7. ">Bhattacharya 1997</a>; <a href="./references#CD001501-bbs2-0004" title="BongersM , HermanM , JosienP , MolBW . Ten‐year follow‐up of a randomized controlled trial comparing NovaSure and Thermachoice in endometrial ablation for dysfunctional uterine bleeding. Journal of Minimally Invasive Gynecology2011;18(6 Suppl 1):S127. BongersMY , BourdrezP , HeintzPM , BrolmannHAM , MolBWJ . Bipolar radio frequency endometrial ablation compared with balloon endometrial ablation in dysfunctional uterine bleeding: impact on patients' health‐related quality of life. Fertility and Sterility2005;83(3):724‐34. BongersMY , BourdrezP , MolBWJ , HeintzAPM , BrolmannHAM . Randomised controlled trial of bipolar radio‐frequency endometrial ablation and balloon endometrial ablation. British Journal of Obstetrics and Gynaecology2004;111:1095‐102. HermanM , PenninxM , MolB , BongersM . Ten‐year follow‐up of a randomised controlled trial comparing bipolar endometrial ablation with balloon ablation for heavy menstrual bleeding. British Journal Obstetrics and Gynaecology2013;120:966‐970. [DOI: 10.1111/1471‐0528.12213] KleijnJH , EngelsR , BourdrezP , MolBWJ , BongersMY . Five‐year follow up of a randomised controlled trial comparing NovaSure and ThermaChoice endometrial ablation. British Journal of Obstetrics and Gynaecology2008;115:193‐8. ">Bongers 2004</a>; <a href="./references#CD001501-bbs2-0006" title="BrunJ‐L , RaynalJ , BurletG , GalandB , QuereuxC , BernardP . Cavaterm thermal balloon endometrial ablation versus hysteroscopic endometrial resection to treat menorrhagia: the French, multicenter, randomized study. Journal of Minimally Invasive Gynecology2006;13:424‐30. ">Brun 2006</a>; <a href="./references#CD001501-bbs2-0007" title="ClarkTJ , SamuelN , MalickS , MiddletonLJ , DanielsJ , GuptaJK . Bipolar radiofrequency compared with thermal balloon endometrial ablation in the office. Obstetrics and Gynecology2011;117:109‐18. ">Clark 2011</a>; <a href="./references#CD001501-bbs2-0008" title="BainC , CooperKG , ParkinDE . Microwave endometrial ablation versus endometrial resection: a randomized controlled trial. Obstetrics and Gynecology2002;99:983‐7. CooperKG , BainC , LawrieL , ParkinDE . A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium: follow up at a minimum of five years. British Journal of Obstetrics and Gynaecology2005;112:470‐5. CooperKG , BainC , ParkinDE . Comparison of microwave endometrial ablation and transcervical resection of the endometrium for treatment of heavy menstrual loss: a randomised trial. Lancet1999;354:1859‐63. SambrookAM , BainC , ParkinDE , CooperKG . A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium: follow up at a minimum of 10 years. British Journal of Obstetrics and Gynaecology2009;116:1033‐7. ">Cooper 1999</a>; <a href="./references#CD001501-bbs2-0009" title="CooperJ , GimpelsonR , LabergeP , GalenD , Garza‐LealJG , ScottJ , et al. A randomized, multicenter trial of safety and efficacy of the NovaSure system in the treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2002;9(4):418‐28. ">Cooper 2002</a>; <a href="./references#CD001501-bbs2-0010" title="CooperJM , AndersonTL , FortinCA , JackSA , PlentlMB . Microwave endometrial ablation vs rollerball electroablation for menorrhagia: a multicenter randomized trial. Journal of the American Association of Gynecologic Laparoscopists2004;11(3):394‐403. ">Cooper 2004</a>; <a href="./references#CD001501-bbs2-0013" title="DulebaAJ , HeppardMC , SoderstromRM , TownsendDE . A randomized study comparing endometrial cryoablation and rollerball electroablation for treatment of dysfunctional uterine bleeding. Journal of the American Association of Gynecologic Laparoscopists2003;10(1):17‐26. TownsendDE , DulebaAJ , WilkesMM , et al. Durability of treatment effects after cryoablation versus rollerball electroablation for abnormal uterine bleeding: two‐year results of a multicenter randomized trial. American Journal of Obstetrics and Gynecology2003;188:699‐701. ">Duleba 2003</a>; <a href="./references#CD001501-bbs2-0015" title="HaweJ , AbbottJ , HunterD , PhillipsG , GarryR . A randomised controlled trial comparing the Cavaterm endometrial ablation system with the Nd:YAG laser for the treatment of dysfunctional uterine bleeding. British Journal of Obstetrics and Gynaecology2003;110:350‐7. ">Hawe 2003</a>; <a href="./references#CD001501-bbs2-0018" title="GraingerDA , TjadenDO , RowlandC , MeyerWR . Thermal balloon and rollerball ablation to treat menorrhagia: two‐year results of a multicenter, prospective, randomized clinical trial. Journal of the American Association of Gynecologic Laparoscopists2000;7(2):175‐9. LofferFD . Five year post‐procedure follow‐up of patients participating in a randomised trial of uterine balloon therapy vs rollerball ablation for the treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopy2001;8(1):48‐54. LofferFD . Three‐year comparison of thermal balloon and rollerball ablation in treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2001;8(1):48‐54. MeyerWR , WalshBW , GraingerDA , PeacockLM , LofferFD , SteegeJF . Thermal balloon and rollerball ablation to treat menorrhagia: a multicenter comparison. Obstetrics and Gynecology1998;92:98‐103. ">Meyer 1998</a>; <a href="./references#CD001501-bbs2-0016" title="LabergeP , Garza‐LealJ , FortinC , BasinskiC , ThielJ , LeylandN , et al. A prospective, randomized, multi‐center, controlled, international clinical study of the safety and efficacy of the Minerva endometrial ablation system: 6 and 12‐month follow‐up results. Journal of Minimally Invasive Gynecology. 2014. LabergeP , Garza‐LealJ , FortinC , GraingerD , JohnsDA , AdkinsRT , et al. A randomized controlled multicenter US Food and Drug Administration trial of the safety and efficacy of the Minerva Endometrial Ablation System: one‐year follow‐up results. Journal of Minimally Invasive Gynecology2017;24(1):124‐32. [DOI: 10.1016/j.jmig.2016.09.009] LabergeP , Garza‐LealJ , FortinC , ThielJ , JohnsD , GraingerD , et al. A randomized, controlled, multi‐center trial of the safety and efficacy of the Minerva Endometrial Ablation System: one‐year follow‐up results. Journal of Minimally Invasive Gynecology. 2016; Vol. 23:S1‐S252. ">Laberge 2016</a>; <a href="./references#CD001501-bbs2-0020" title="PellicanoM , GuidaM , AcunzoG , CirilloD , BifulcoG , NappiC . Hysteroscopic transcervical endometrial resection versus thermal destruction for menorrhagia: a prospective randomized trial on satisfaction rate. American Journal of Obstetrics and Gynecology2002;187:545‐50. ">Pellicano 2002</a>; <a href="./references#CD001501-bbs2-0021" title="BongersM , HermanM , PenninxJ , MolBW . Longterm follow‐up of a randomized controlled trial comparing NovaSure and hydrothermablation for dysfunctional uterine bleeding. Journal of Minimally Invasive Gynecology2011;18(6 Suppl 1):S34. PenninxJPM , HermanMC , MolBW , BongersMY . Five‐year follow‐up after comparing bipolar endometrial ablation with hydrothermablation for menorrhagia. Obstetrics and Gynecology2011;118:1287‐92. PenninxJPM , MolBW , EngelsR , vanRumsteMME , KleijnC , KoksCAM , et al. Bipolar radiofrequency endometrial ablation compared with hydrothermablation for dysfunctional uterine bleeding. Obstetrics and Gynecology2010;116:819‐26. ">Penninx 2010</a>; <a href="./references#CD001501-bbs2-0022" title="PenninxJ , BongersM . Bipolar radiofrequency endometrial ablation versus thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. www.controlled‐trials.com/ISRCTN17974690. PenninxJ , HermanM , KruitwagenR , Ter HaarA , MolB , BongersM . Bipolar versus balloon endometrial ablation in the office: a randomized controlled trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;196:52‐6. [DOI: 10.1016/j.ejogrb.2015.10.010] PenninxJ , HermanM , MolB , KruitwagenR , BongersM . Bipolar radiofrequency endometrial ablation versus Thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. Journal of Minimally Invasive Gynecology2012;19(6):S21‐S22. [DOI: 10.1016/j.jmig.2012.08.076] PenninxJPM , HermanMC , MolBW , BongersMY . Bipolar radiofrequency endometrial ablation versus thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. Journal of Minimally Invasive Gynecology2012;19(6 Suppl 1):S21‐2. ">Penninx 2016</a>; <a href="./references#CD001501-bbs2-0023" title="PerinoA , CastelliA , CucinellaG , BiondoA , PaneA , VeneziaR . A randomized comparison of endometrial laser intrauterine thermotherapy and hysteroscopic endometrial resection. Fertility and Sterility2004;82:731‐4. ">Perino 2004</a>; <a href="./references#CD001501-bbs2-0024" title="RomerT . The treatment of recurrent menorrhagias ‐ Cavaterm‐balloon‐coagulation versus Rollerball‐endometrial ablation ‐ a prospective randomized comparative study [Die therapie rezidivierender Menorrhagien ‐ Cavaterm‐Ballon‐Koagulatioon versus Roller‐Ball‐Endometriumkoagulation ‐ eine prospektive randomisierte Vergleichsstudie]. Zentralblatt fur Gynakologie1998;120(10):511‐4. ">Romer 1998</a>; <a href="./references#CD001501-bbs2-0025" title="SambrookA , EldersA , CooperK . Microwave endometrial ablation versus thermal balloon endometrial ablation (MEATBall): 5‐year follow up of a randomised controlled trial. British Journal of Obstetrics and Gynaecology2014;121:748‐54. [DOI: 10.1111/1471‐0528.12585] SambrookAM , CooperKG , CampbellMK , CookJA . Clinical outcomes from a randomised comparison of microwave endometrial ablation with thermal balloon endometrial ablation for the treatment of heavy menstrual bleeding. British Journal of Obstetrics and Gynaecology2009;116:1038‐45. ">Sambrook 2009</a>). </p> </section> <section id="CD001501-sec-0090"> <h6 class="title">Operative outcomes</h6> <p>A total of 19 trials compared the duration of surgery (in minutes) (<a href="./references#CD001501-bbs2-0001" title="AbbottJ , HaweJ , HunterD , GarryR . A double‐blind randomized trial comparing the Cavaterm and the Novasure endometrial ablation systems for the treatment of dysfunctional uterine bleeding. Fertility and Sterility2003;80(1):203‐8. ">Abbott 2003</a>; <a href="./references#CD001501-bbs2-0003" title="BhattacharyaS , CameronIM , ParkinDE , AbramovichDR , MollisonJ , PinionSB , et al. A pragmatic randomised comparison of transcervical resection of the endometrium with endometrial laser ablation for the treatment of menorrhagia. British Journal of Obstetrics and Gynaecology1997;104:601‐7. ">Bhattacharya 1997</a>; <a href="./references#CD001501-bbs2-0004" title="BongersM , HermanM , JosienP , MolBW . Ten‐year follow‐up of a randomized controlled trial comparing NovaSure and Thermachoice in endometrial ablation for dysfunctional uterine bleeding. Journal of Minimally Invasive Gynecology2011;18(6 Suppl 1):S127. BongersMY , BourdrezP , HeintzPM , BrolmannHAM , MolBWJ . Bipolar radio frequency endometrial ablation compared with balloon endometrial ablation in dysfunctional uterine bleeding: impact on patients' health‐related quality of life. Fertility and Sterility2005;83(3):724‐34. BongersMY , BourdrezP , MolBWJ , HeintzAPM , BrolmannHAM . Randomised controlled trial of bipolar radio‐frequency endometrial ablation and balloon endometrial ablation. British Journal of Obstetrics and Gynaecology2004;111:1095‐102. HermanM , PenninxM , MolB , BongersM . Ten‐year follow‐up of a randomised controlled trial comparing bipolar endometrial ablation with balloon ablation for heavy menstrual bleeding. British Journal Obstetrics and Gynaecology2013;120:966‐970. [DOI: 10.1111/1471‐0528.12213] KleijnJH , EngelsR , BourdrezP , MolBWJ , BongersMY . Five‐year follow up of a randomised controlled trial comparing NovaSure and ThermaChoice endometrial ablation. British Journal of Obstetrics and Gynaecology2008;115:193‐8. ">Bongers 2004</a>; <a href="./references#CD001501-bbs2-0006" title="BrunJ‐L , RaynalJ , BurletG , GalandB , QuereuxC , BernardP . Cavaterm thermal balloon endometrial ablation versus hysteroscopic endometrial resection to treat menorrhagia: the French, multicenter, randomized study. Journal of Minimally Invasive Gynecology2006;13:424‐30. ">Brun 2006</a>; <a href="./references#CD001501-bbs2-0007" title="ClarkTJ , SamuelN , MalickS , MiddletonLJ , DanielsJ , GuptaJK . Bipolar radiofrequency compared with thermal balloon endometrial ablation in the office. Obstetrics and Gynecology2011;117:109‐18. ">Clark 2011</a>; <a href="./references#CD001501-bbs2-0008" title="BainC , CooperKG , ParkinDE . Microwave endometrial ablation versus endometrial resection: a randomized controlled trial. Obstetrics and Gynecology2002;99:983‐7. CooperKG , BainC , LawrieL , ParkinDE . A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium: follow up at a minimum of five years. British Journal of Obstetrics and Gynaecology2005;112:470‐5. CooperKG , BainC , ParkinDE . Comparison of microwave endometrial ablation and transcervical resection of the endometrium for treatment of heavy menstrual loss: a randomised trial. Lancet1999;354:1859‐63. SambrookAM , BainC , ParkinDE , CooperKG . A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium: follow up at a minimum of 10 years. British Journal of Obstetrics and Gynaecology2009;116:1033‐7. ">Cooper 1999</a>; <a href="./references#CD001501-bbs2-0009" title="CooperJ , GimpelsonR , LabergeP , GalenD , Garza‐LealJG , ScottJ , et al. A randomized, multicenter trial of safety and efficacy of the NovaSure system in the treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2002;9(4):418‐28. ">Cooper 2002</a>; <a href="./references#CD001501-bbs2-0011" title="CorsonSL , BrillAI , BrooksPG , CooperJM , IndmanPD , LiuJH , et al. Interim results of the American Vesta trial of endometrial ablation. Journal of the American Association of Gynecologic Laparoscopists1999;6(1):45‐9. CorsonSL , BrillAI , BrooksPG , CooperJM , IndmanPD , LiuJH , et al. One‐year results of the Vesta system for endometrial ablation. Journal of the American Association of Gynecologic Laparoscopists2000;7(4):489‐97. ">Corson 2000</a>; <a href="./references#CD001501-bbs2-0016" title="LabergeP , Garza‐LealJ , FortinC , BasinskiC , ThielJ , LeylandN , et al. A prospective, randomized, multi‐center, controlled, international clinical study of the safety and efficacy of the Minerva endometrial ablation system: 6 and 12‐month follow‐up results. Journal of Minimally Invasive Gynecology. 2014. LabergeP , Garza‐LealJ , FortinC , GraingerD , JohnsDA , AdkinsRT , et al. A randomized controlled multicenter US Food and Drug Administration trial of the safety and efficacy of the Minerva Endometrial Ablation System: one‐year follow‐up results. Journal of Minimally Invasive Gynecology2017;24(1):124‐32. [DOI: 10.1016/j.jmig.2016.09.009] LabergeP , Garza‐LealJ , FortinC , ThielJ , JohnsD , GraingerD , et al. A randomized, controlled, multi‐center trial of the safety and efficacy of the Minerva Endometrial Ablation System: one‐year follow‐up results. Journal of Minimally Invasive Gynecology. 2016; Vol. 23:S1‐S252. ">Laberge 2016</a>; <a href="./references#CD001501-bbs2-0017" title="McClureN , MarnersM , HealyDL , HillDJ , LawrenceAS , WingfieldM , et al. A quantitative assessment of endometrial electrocautery in the management of menorrhagia and a comparative report of argon laser endometrial ablation. Gynaecological Endoscopy1992;1:199‐202. ">McClure 1992</a>; <a href="./references#CD001501-bbs2-0018" title="GraingerDA , TjadenDO , RowlandC , MeyerWR . Thermal balloon and rollerball ablation to treat menorrhagia: two‐year results of a multicenter, prospective, randomized clinical trial. Journal of the American Association of Gynecologic Laparoscopists2000;7(2):175‐9. LofferFD . Five year post‐procedure follow‐up of patients participating in a randomised trial of uterine balloon therapy vs rollerball ablation for the treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopy2001;8(1):48‐54. LofferFD . Three‐year comparison of thermal balloon and rollerball ablation in treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2001;8(1):48‐54. MeyerWR , WalshBW , GraingerDA , PeacockLM , LofferFD , SteegeJF . Thermal balloon and rollerball ablation to treat menorrhagia: a multicenter comparison. Obstetrics and Gynecology1998;92:98‐103. ">Meyer 1998</a>; <a href="./references#CD001501-bbs2-0019" title="OnogluA , TaskinO , InalM , SadikS , SimsekM , AkarM , et al. Comparison of the long‐term histopathologic and morphologic changes after endometrial rollerball ablation and resection: a prospective randomized trial. Journal of Minimally Invasive Gynecology2007;14:39‐42. ">Onoglu 2007</a>; <a href="./references#CD001501-bbs2-0020" title="PellicanoM , GuidaM , AcunzoG , CirilloD , BifulcoG , NappiC . Hysteroscopic transcervical endometrial resection versus thermal destruction for menorrhagia: a prospective randomized trial on satisfaction rate. American Journal of Obstetrics and Gynecology2002;187:545‐50. ">Pellicano 2002</a>; <a href="./references#CD001501-bbs2-0021" title="BongersM , HermanM , PenninxJ , MolBW . Longterm follow‐up of a randomized controlled trial comparing NovaSure and hydrothermablation for dysfunctional uterine bleeding. Journal of Minimally Invasive Gynecology2011;18(6 Suppl 1):S34. PenninxJPM , HermanMC , MolBW , BongersMY . Five‐year follow‐up after comparing bipolar endometrial ablation with hydrothermablation for menorrhagia. Obstetrics and Gynecology2011;118:1287‐92. PenninxJPM , MolBW , EngelsR , vanRumsteMME , KleijnC , KoksCAM , et al. Bipolar radiofrequency endometrial ablation compared with hydrothermablation for dysfunctional uterine bleeding. Obstetrics and Gynecology2010;116:819‐26. ">Penninx 2010</a>; <a href="./references#CD001501-bbs2-0022" title="PenninxJ , BongersM . Bipolar radiofrequency endometrial ablation versus thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. www.controlled‐trials.com/ISRCTN17974690. PenninxJ , HermanM , KruitwagenR , Ter HaarA , MolB , BongersM . Bipolar versus balloon endometrial ablation in the office: a randomized controlled trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;196:52‐6. [DOI: 10.1016/j.ejogrb.2015.10.010] PenninxJ , HermanM , MolB , KruitwagenR , BongersM . Bipolar radiofrequency endometrial ablation versus Thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. Journal of Minimally Invasive Gynecology2012;19(6):S21‐S22. [DOI: 10.1016/j.jmig.2012.08.076] PenninxJPM , HermanMC , MolBW , BongersMY . Bipolar radiofrequency endometrial ablation versus thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. Journal of Minimally Invasive Gynecology2012;19(6 Suppl 1):S21‐2. ">Penninx 2016</a>; <a href="./references#CD001501-bbs2-0023" title="PerinoA , CastelliA , CucinellaG , BiondoA , PaneA , VeneziaR . A randomized comparison of endometrial laser intrauterine thermotherapy and hysteroscopic endometrial resection. Fertility and Sterility2004;82:731‐4. ">Perino 2004</a>; <a href="./references#CD001501-bbs2-0025" title="SambrookA , EldersA , CooperK . Microwave endometrial ablation versus thermal balloon endometrial ablation (MEATBall): 5‐year follow up of a randomised controlled trial. British Journal of Obstetrics and Gynaecology2014;121:748‐54. [DOI: 10.1111/1471‐0528.12585] SambrookAM , CooperKG , CampbellMK , CookJA . Clinical outcomes from a randomised comparison of microwave endometrial ablation with thermal balloon endometrial ablation for the treatment of heavy menstrual bleeding. British Journal of Obstetrics and Gynaecology2009;116:1038‐45. ">Sambrook 2009</a>; <a href="./references#CD001501-bbs2-0027" title="vanZon‐RabelinkIAA , VleugelsMPH . Treating menorrhagia with endometrial ablation: rollerball electrocoagulation versus thermal ablation with the uterine balloon. Gynaecological Endoscopy Abstract from the 6th Annual Congress of the European Society for Gynaecological Endoscopy1997;6 Suppl 2:41. vanZon‐RabelinkIAA , VleugelsMPH , MerkusHMWM , deGraafR . Efficacy and satisfaction rate comparing endometrial ablation by rollerball electrocoagulation to uterine balloon thermal ablation in a randomised controlled trial. European Journal of Obstetrics, Gynecology, and Reproductive Biology2004;114(1):97‐103. vanZon‐RabelinkIAA , VleugelsMPH , MerkusHMWM , deGraafR . Endometrial ablation by rollerball electrocoagulation compared to uterine balloon thermal ablation. Technical and safety aspects. European Journal of Obstetrics, Gynecology, and Reproductive Biology2003;110:220‐3. ">van Zon‐Rabelink 2003</a>; <a href="./references#CD001501-bbs2-0028" title="VercelliniP , OldaniS , YaylayanL , ZainaB , DeGiorgiO , CrosignaniPG . Randomised comparison of vaporising electrode and cutting loop for endometrial ablation. Obstetrics and Gynecology1999;94:521‐7. ">Vercellini 1999</a>). Twelve trials reported operative difficulties such as difficulty of surgery, technical complications, and abandoning the procedure (<a href="./references#CD001501-bbs2-0001" title="AbbottJ , HaweJ , HunterD , GarryR . A double‐blind randomized trial comparing the Cavaterm and the Novasure endometrial ablation systems for the treatment of dysfunctional uterine bleeding. Fertility and Sterility2003;80(1):203‐8. ">Abbott 2003</a>; <a href="./references#CD001501-bbs2-0003" title="BhattacharyaS , CameronIM , ParkinDE , AbramovichDR , MollisonJ , PinionSB , et al. A pragmatic randomised comparison of transcervical resection of the endometrium with endometrial laser ablation for the treatment of menorrhagia. British Journal of Obstetrics and Gynaecology1997;104:601‐7. ">Bhattacharya 1997</a>; <a href="./references#CD001501-bbs2-0005" title="BoujidaVH , PhilipsenT , PelleJ , JoergensenJC . Five‐year follow‐up of endometrial ablation: endometrial coagulation versus endometrial resection. Obstetrics and Gynecology2002;99:988‐92. FurstSN , PhilipsenT , JoergensenJC . Ten‐year follow‐up of endometrial ablation. Acta Obstetricia et Gynecologica2007;86:334‐8. ">Boujida 2002</a>; <a href="./references#CD001501-bbs2-0006" title="BrunJ‐L , RaynalJ , BurletG , GalandB , QuereuxC , BernardP . Cavaterm thermal balloon endometrial ablation versus hysteroscopic endometrial resection to treat menorrhagia: the French, multicenter, randomized study. Journal of Minimally Invasive Gynecology2006;13:424‐30. ">Brun 2006</a>; <a href="./references#CD001501-bbs2-0008" title="BainC , CooperKG , ParkinDE . Microwave endometrial ablation versus endometrial resection: a randomized controlled trial. Obstetrics and Gynecology2002;99:983‐7. CooperKG , BainC , LawrieL , ParkinDE . A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium: follow up at a minimum of five years. British Journal of Obstetrics and Gynaecology2005;112:470‐5. CooperKG , BainC , ParkinDE . Comparison of microwave endometrial ablation and transcervical resection of the endometrium for treatment of heavy menstrual loss: a randomised trial. Lancet1999;354:1859‐63. SambrookAM , BainC , ParkinDE , CooperKG . A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium: follow up at a minimum of 10 years. British Journal of Obstetrics and Gynaecology2009;116:1033‐7. ">Cooper 1999</a>; <a href="./references#CD001501-bbs2-0011" title="CorsonSL , BrillAI , BrooksPG , CooperJM , IndmanPD , LiuJH , et al. Interim results of the American Vesta trial of endometrial ablation. Journal of the American Association of Gynecologic Laparoscopists1999;6(1):45‐9. CorsonSL , BrillAI , BrooksPG , CooperJM , IndmanPD , LiuJH , et al. One‐year results of the Vesta system for endometrial ablation. Journal of the American Association of Gynecologic Laparoscopists2000;7(4):489‐97. ">Corson 2000</a>; <a href="./references#CD001501-bbs2-0015" title="HaweJ , AbbottJ , HunterD , PhillipsG , GarryR . A randomised controlled trial comparing the Cavaterm endometrial ablation system with the Nd:YAG laser for the treatment of dysfunctional uterine bleeding. British Journal of Obstetrics and Gynaecology2003;110:350‐7. ">Hawe 2003</a>; <a href="./references#CD001501-bbs2-0020" title="PellicanoM , GuidaM , AcunzoG , CirilloD , BifulcoG , NappiC . Hysteroscopic transcervical endometrial resection versus thermal destruction for menorrhagia: a prospective randomized trial on satisfaction rate. American Journal of Obstetrics and Gynecology2002;187:545‐50. ">Pellicano 2002</a>; <a href="./references#CD001501-bbs2-0023" title="PerinoA , CastelliA , CucinellaG , BiondoA , PaneA , VeneziaR . A randomized comparison of endometrial laser intrauterine thermotherapy and hysteroscopic endometrial resection. Fertility and Sterility2004;82:731‐4. ">Perino 2004</a>; <a href="./references#CD001501-bbs2-0025" title="SambrookA , EldersA , CooperK . Microwave endometrial ablation versus thermal balloon endometrial ablation (MEATBall): 5‐year follow up of a randomised controlled trial. British Journal of Obstetrics and Gynaecology2014;121:748‐54. [DOI: 10.1111/1471‐0528.12585] SambrookAM , CooperKG , CampbellMK , CookJA . Clinical outcomes from a randomised comparison of microwave endometrial ablation with thermal balloon endometrial ablation for the treatment of heavy menstrual bleeding. British Journal of Obstetrics and Gynaecology2009;116:1038‐45. ">Sambrook 2009</a>; <a href="./references#CD001501-bbs2-0027" title="vanZon‐RabelinkIAA , VleugelsMPH . Treating menorrhagia with endometrial ablation: rollerball electrocoagulation versus thermal ablation with the uterine balloon. Gynaecological Endoscopy Abstract from the 6th Annual Congress of the European Society for Gynaecological Endoscopy1997;6 Suppl 2:41. vanZon‐RabelinkIAA , VleugelsMPH , MerkusHMWM , deGraafR . Efficacy and satisfaction rate comparing endometrial ablation by rollerball electrocoagulation to uterine balloon thermal ablation in a randomised controlled trial. European Journal of Obstetrics, Gynecology, and Reproductive Biology2004;114(1):97‐103. vanZon‐RabelinkIAA , VleugelsMPH , MerkusHMWM , deGraafR . Endometrial ablation by rollerball electrocoagulation compared to uterine balloon thermal ablation. Technical and safety aspects. European Journal of Obstetrics, Gynecology, and Reproductive Biology2003;110:220‐3. ">van Zon‐Rabelink 2003</a>; <a href="./references#CD001501-bbs2-0028" title="VercelliniP , OldaniS , YaylayanL , ZainaB , DeGiorgiO , CrosignaniPG . Randomised comparison of vaporising electrode and cutting loop for endometrial ablation. Obstetrics and Gynecology1999;94:521‐7. ">Vercellini 1999</a>). Only six trials compared the proportion given local rather than general anaesthesia (<a href="./references#CD001501-bbs2-0009" title="CooperJ , GimpelsonR , LabergeP , GalenD , Garza‐LealJG , ScottJ , et al. A randomized, multicenter trial of safety and efficacy of the NovaSure system in the treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2002;9(4):418‐28. ">Cooper 2002</a>; <a href="./references#CD001501-bbs2-0010" title="CooperJM , AndersonTL , FortinCA , JackSA , PlentlMB . Microwave endometrial ablation vs rollerball electroablation for menorrhagia: a multicenter randomized trial. Journal of the American Association of Gynecologic Laparoscopists2004;11(3):394‐403. ">Cooper 2004</a>; <a href="./references#CD001501-bbs2-0011" title="CorsonSL , BrillAI , BrooksPG , CooperJM , IndmanPD , LiuJH , et al. Interim results of the American Vesta trial of endometrial ablation. Journal of the American Association of Gynecologic Laparoscopists1999;6(1):45‐9. CorsonSL , BrillAI , BrooksPG , CooperJM , IndmanPD , LiuJH , et al. One‐year results of the Vesta system for endometrial ablation. Journal of the American Association of Gynecologic Laparoscopists2000;7(4):489‐97. ">Corson 2000</a>; <a href="./references#CD001501-bbs2-0012" title="CorsonSL . A multicenter evaluation of endometrial ablation by hydrothermablator and rollerball for treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2001;8(3):359‐67. GoldrathMH . Evaluation of hydrothermablator and rollerball endometrial ablation for menorrhagia 3 years after treatment. Journal of the American Association of Gynecologic Laparoscopists2003;10(4):505‐11. LofferF . A clinical comparison of hydrothermablation (HTA) and rollerball for endometrial ablation to treat menorrhagia: a randomized multicenter clinical trial. XVI FIGO World Congress of Obstetrics &amp; Gynecology. 2000; Vol. Abstract Book 2:95. ">Corson 2001</a>; <a href="./references#CD001501-bbs2-0013" title="DulebaAJ , HeppardMC , SoderstromRM , TownsendDE . A randomized study comparing endometrial cryoablation and rollerball electroablation for treatment of dysfunctional uterine bleeding. Journal of the American Association of Gynecologic Laparoscopists2003;10(1):17‐26. TownsendDE , DulebaAJ , WilkesMM , et al. Durability of treatment effects after cryoablation versus rollerball electroablation for abnormal uterine bleeding: two‐year results of a multicenter randomized trial. American Journal of Obstetrics and Gynecology2003;188:699‐701. ">Duleba 2003</a>; <a href="./references#CD001501-bbs2-0025" title="SambrookA , EldersA , CooperK . Microwave endometrial ablation versus thermal balloon endometrial ablation (MEATBall): 5‐year follow up of a randomised controlled trial. British Journal of Obstetrics and Gynaecology2014;121:748‐54. [DOI: 10.1111/1471‐0528.12585] SambrookAM , CooperKG , CampbellMK , CookJA . Clinical outcomes from a randomised comparison of microwave endometrial ablation with thermal balloon endometrial ablation for the treatment of heavy menstrual bleeding. British Journal of Obstetrics and Gynaecology2009;116:1038‐45. ">Sambrook 2009</a>). Six trials reported length of hospital stay and time or ability to return to normal activities or work (<a href="./references#CD001501-bbs2-0006" title="BrunJ‐L , RaynalJ , BurletG , GalandB , QuereuxC , BernardP . Cavaterm thermal balloon endometrial ablation versus hysteroscopic endometrial resection to treat menorrhagia: the French, multicenter, randomized study. Journal of Minimally Invasive Gynecology2006;13:424‐30. ">Brun 2006</a>; <a href="./references#CD001501-bbs2-0007" title="ClarkTJ , SamuelN , MalickS , MiddletonLJ , DanielsJ , GuptaJK . Bipolar radiofrequency compared with thermal balloon endometrial ablation in the office. Obstetrics and Gynecology2011;117:109‐18. ">Clark 2011</a>; <a href="./references#CD001501-bbs2-0008" title="BainC , CooperKG , ParkinDE . Microwave endometrial ablation versus endometrial resection: a randomized controlled trial. Obstetrics and Gynecology2002;99:983‐7. CooperKG , BainC , LawrieL , ParkinDE . A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium: follow up at a minimum of five years. British Journal of Obstetrics and Gynaecology2005;112:470‐5. CooperKG , BainC , ParkinDE . Comparison of microwave endometrial ablation and transcervical resection of the endometrium for treatment of heavy menstrual loss: a randomised trial. Lancet1999;354:1859‐63. SambrookAM , BainC , ParkinDE , CooperKG . A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium: follow up at a minimum of 10 years. British Journal of Obstetrics and Gynaecology2009;116:1033‐7. ">Cooper 1999</a>; <a href="./references#CD001501-bbs2-0020" title="PellicanoM , GuidaM , AcunzoG , CirilloD , BifulcoG , NappiC . Hysteroscopic transcervical endometrial resection versus thermal destruction for menorrhagia: a prospective randomized trial on satisfaction rate. American Journal of Obstetrics and Gynecology2002;187:545‐50. ">Pellicano 2002</a>; <a href="./references#CD001501-bbs2-0025" title="SambrookA , EldersA , CooperK . Microwave endometrial ablation versus thermal balloon endometrial ablation (MEATBall): 5‐year follow up of a randomised controlled trial. British Journal of Obstetrics and Gynaecology2014;121:748‐54. [DOI: 10.1111/1471‐0528.12585] SambrookAM , CooperKG , CampbellMK , CookJA . Clinical outcomes from a randomised comparison of microwave endometrial ablation with thermal balloon endometrial ablation for the treatment of heavy menstrual bleeding. British Journal of Obstetrics and Gynaecology2009;116:1038‐45. ">Sambrook 2009</a>; <a href="./references#CD001501-bbs2-0026" title="ThabetSMA . New attempt using ablative curettage technique for managing benign premenopausal uterine bleeding. Obstetrics and Gynaecology Research2010;36(4):803‐9. ">Thabet 2010</a>). </p> </section> <section id="CD001501-sec-0091"> <h6 class="title">Quality of life</h6> <p>Six trials recorded women's perceived change in quality of life in a reproducible and validated format (<a href="./references#CD001501-bbs2-0001" title="AbbottJ , HaweJ , HunterD , GarryR . A double‐blind randomized trial comparing the Cavaterm and the Novasure endometrial ablation systems for the treatment of dysfunctional uterine bleeding. Fertility and Sterility2003;80(1):203‐8. ">Abbott 2003</a>; <a href="./references#CD001501-bbs2-0004" title="BongersM , HermanM , JosienP , MolBW . Ten‐year follow‐up of a randomized controlled trial comparing NovaSure and Thermachoice in endometrial ablation for dysfunctional uterine bleeding. Journal of Minimally Invasive Gynecology2011;18(6 Suppl 1):S127. BongersMY , BourdrezP , HeintzPM , BrolmannHAM , MolBWJ . Bipolar radio frequency endometrial ablation compared with balloon endometrial ablation in dysfunctional uterine bleeding: impact on patients' health‐related quality of life. Fertility and Sterility2005;83(3):724‐34. BongersMY , BourdrezP , MolBWJ , HeintzAPM , BrolmannHAM . Randomised controlled trial of bipolar radio‐frequency endometrial ablation and balloon endometrial ablation. British Journal of Obstetrics and Gynaecology2004;111:1095‐102. HermanM , PenninxM , MolB , BongersM . Ten‐year follow‐up of a randomised controlled trial comparing bipolar endometrial ablation with balloon ablation for heavy menstrual bleeding. British Journal Obstetrics and Gynaecology2013;120:966‐970. [DOI: 10.1111/1471‐0528.12213] KleijnJH , EngelsR , BourdrezP , MolBWJ , BongersMY . Five‐year follow up of a randomised controlled trial comparing NovaSure and ThermaChoice endometrial ablation. British Journal of Obstetrics and Gynaecology2008;115:193‐8. ">Bongers 2004</a>; <a href="./references#CD001501-bbs2-0007" title="ClarkTJ , SamuelN , MalickS , MiddletonLJ , DanielsJ , GuptaJK . Bipolar radiofrequency compared with thermal balloon endometrial ablation in the office. Obstetrics and Gynecology2011;117:109‐18. ">Clark 2011</a>; <a href="./references#CD001501-bbs2-0008" title="BainC , CooperKG , ParkinDE . Microwave endometrial ablation versus endometrial resection: a randomized controlled trial. Obstetrics and Gynecology2002;99:983‐7. CooperKG , BainC , LawrieL , ParkinDE . A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium: follow up at a minimum of five years. British Journal of Obstetrics and Gynaecology2005;112:470‐5. CooperKG , BainC , ParkinDE . Comparison of microwave endometrial ablation and transcervical resection of the endometrium for treatment of heavy menstrual loss: a randomised trial. Lancet1999;354:1859‐63. SambrookAM , BainC , ParkinDE , CooperKG . A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium: follow up at a minimum of 10 years. British Journal of Obstetrics and Gynaecology2009;116:1033‐7. ">Cooper 1999</a>; <a href="./references#CD001501-bbs2-0015" title="HaweJ , AbbottJ , HunterD , PhillipsG , GarryR . A randomised controlled trial comparing the Cavaterm endometrial ablation system with the Nd:YAG laser for the treatment of dysfunctional uterine bleeding. British Journal of Obstetrics and Gynaecology2003;110:350‐7. ">Hawe 2003</a>; <a href="./references#CD001501-bbs2-0025" title="SambrookA , EldersA , CooperK . Microwave endometrial ablation versus thermal balloon endometrial ablation (MEATBall): 5‐year follow up of a randomised controlled trial. British Journal of Obstetrics and Gynaecology2014;121:748‐54. [DOI: 10.1111/1471‐0528.12585] SambrookAM , CooperKG , CampbellMK , CookJA . Clinical outcomes from a randomised comparison of microwave endometrial ablation with thermal balloon endometrial ablation for the treatment of heavy menstrual bleeding. British Journal of Obstetrics and Gynaecology2009;116:1038‐45. ">Sambrook 2009</a>). </p> </section> <section id="CD001501-sec-0092"> <h6 class="title">Improvement in other menstrual symptoms</h6> <p>Five trials reported on improvement in premenstrual syndrome (PMS) (<a href="./references#CD001501-bbs2-0001" title="AbbottJ , HaweJ , HunterD , GarryR . A double‐blind randomized trial comparing the Cavaterm and the Novasure endometrial ablation systems for the treatment of dysfunctional uterine bleeding. Fertility and Sterility2003;80(1):203‐8. ">Abbott 2003</a>; <a href="./references#CD001501-bbs2-0008" title="BainC , CooperKG , ParkinDE . Microwave endometrial ablation versus endometrial resection: a randomized controlled trial. Obstetrics and Gynecology2002;99:983‐7. CooperKG , BainC , LawrieL , ParkinDE . A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium: follow up at a minimum of five years. British Journal of Obstetrics and Gynaecology2005;112:470‐5. CooperKG , BainC , ParkinDE . Comparison of microwave endometrial ablation and transcervical resection of the endometrium for treatment of heavy menstrual loss: a randomised trial. Lancet1999;354:1859‐63. SambrookAM , BainC , ParkinDE , CooperKG . A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium: follow up at a minimum of 10 years. British Journal of Obstetrics and Gynaecology2009;116:1033‐7. ">Cooper 1999</a>; <a href="./references#CD001501-bbs2-0015" title="HaweJ , AbbottJ , HunterD , PhillipsG , GarryR . A randomised controlled trial comparing the Cavaterm endometrial ablation system with the Nd:YAG laser for the treatment of dysfunctional uterine bleeding. British Journal of Obstetrics and Gynaecology2003;110:350‐7. ">Hawe 2003</a>; <a href="./references#CD001501-bbs2-0016" title="LabergeP , Garza‐LealJ , FortinC , BasinskiC , ThielJ , LeylandN , et al. A prospective, randomized, multi‐center, controlled, international clinical study of the safety and efficacy of the Minerva endometrial ablation system: 6 and 12‐month follow‐up results. Journal of Minimally Invasive Gynecology. 2014. LabergeP , Garza‐LealJ , FortinC , GraingerD , JohnsDA , AdkinsRT , et al. A randomized controlled multicenter US Food and Drug Administration trial of the safety and efficacy of the Minerva Endometrial Ablation System: one‐year follow‐up results. Journal of Minimally Invasive Gynecology2017;24(1):124‐32. [DOI: 10.1016/j.jmig.2016.09.009] LabergeP , Garza‐LealJ , FortinC , ThielJ , JohnsD , GraingerD , et al. A randomized, controlled, multi‐center trial of the safety and efficacy of the Minerva Endometrial Ablation System: one‐year follow‐up results. Journal of Minimally Invasive Gynecology. 2016; Vol. 23:S1‐S252. ">Laberge 2016</a>; <a href="./references#CD001501-bbs2-0018" title="GraingerDA , TjadenDO , RowlandC , MeyerWR . Thermal balloon and rollerball ablation to treat menorrhagia: two‐year results of a multicenter, prospective, randomized clinical trial. Journal of the American Association of Gynecologic Laparoscopists2000;7(2):175‐9. LofferFD . Five year post‐procedure follow‐up of patients participating in a randomised trial of uterine balloon therapy vs rollerball ablation for the treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopy2001;8(1):48‐54. LofferFD . Three‐year comparison of thermal balloon and rollerball ablation in treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2001;8(1):48‐54. MeyerWR , WalshBW , GraingerDA , PeacockLM , LofferFD , SteegeJF . Thermal balloon and rollerball ablation to treat menorrhagia: a multicenter comparison. Obstetrics and Gynecology1998;92:98‐103. ">Meyer 1998</a>), and nine reported on improvement in dysmenorrhoea (<a href="./references#CD001501-bbs2-0001" title="AbbottJ , HaweJ , HunterD , GarryR . A double‐blind randomized trial comparing the Cavaterm and the Novasure endometrial ablation systems for the treatment of dysfunctional uterine bleeding. Fertility and Sterility2003;80(1):203‐8. ">Abbott 2003</a>; <a href="./references#CD001501-bbs2-0002" title="AthanatosD , PadosG , VenetisC , StamatopoulosP , RoussoD , TsolakidisD , et al. Novasure impedance control system versus microwave endometrial ablation for the treatment of dysfunctional uterine bleeding: a double‐blind, randomized controlled trial. Clinical and Experimental Obstetrics &amp; Gynecology2015;42(3):347‐51. [PMID: 26152008] PadosG . Treatment of dysfunctional uterine bleeding with second generation ablation devices: microwaves (MEAA) vs Bipolar Impedance Control System (Novasure). http://clinicaltrials.gov/show/NCT01173965. ">Athanatos 2015</a>; <a href="./references#CD001501-bbs2-0003" title="BhattacharyaS , CameronIM , ParkinDE , AbramovichDR , MollisonJ , PinionSB , et al. A pragmatic randomised comparison of transcervical resection of the endometrium with endometrial laser ablation for the treatment of menorrhagia. British Journal of Obstetrics and Gynaecology1997;104:601‐7. ">Bhattacharya 1997</a>; <a href="./references#CD001501-bbs2-0008" title="BainC , CooperKG , ParkinDE . Microwave endometrial ablation versus endometrial resection: a randomized controlled trial. Obstetrics and Gynecology2002;99:983‐7. CooperKG , BainC , LawrieL , ParkinDE . A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium: follow up at a minimum of five years. British Journal of Obstetrics and Gynaecology2005;112:470‐5. CooperKG , BainC , ParkinDE . Comparison of microwave endometrial ablation and transcervical resection of the endometrium for treatment of heavy menstrual loss: a randomised trial. Lancet1999;354:1859‐63. SambrookAM , BainC , ParkinDE , CooperKG . A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium: follow up at a minimum of 10 years. British Journal of Obstetrics and Gynaecology2009;116:1033‐7. ">Cooper 1999</a>; <a href="./references#CD001501-bbs2-0010" title="CooperJM , AndersonTL , FortinCA , JackSA , PlentlMB . Microwave endometrial ablation vs rollerball electroablation for menorrhagia: a multicenter randomized trial. Journal of the American Association of Gynecologic Laparoscopists2004;11(3):394‐403. ">Cooper 2004</a>; <a href="./references#CD001501-bbs2-0015" title="HaweJ , AbbottJ , HunterD , PhillipsG , GarryR . A randomised controlled trial comparing the Cavaterm endometrial ablation system with the Nd:YAG laser for the treatment of dysfunctional uterine bleeding. British Journal of Obstetrics and Gynaecology2003;110:350‐7. ">Hawe 2003</a>; <a href="./references#CD001501-bbs2-0016" title="LabergeP , Garza‐LealJ , FortinC , BasinskiC , ThielJ , LeylandN , et al. A prospective, randomized, multi‐center, controlled, international clinical study of the safety and efficacy of the Minerva endometrial ablation system: 6 and 12‐month follow‐up results. Journal of Minimally Invasive Gynecology. 2014. LabergeP , Garza‐LealJ , FortinC , GraingerD , JohnsDA , AdkinsRT , et al. A randomized controlled multicenter US Food and Drug Administration trial of the safety and efficacy of the Minerva Endometrial Ablation System: one‐year follow‐up results. Journal of Minimally Invasive Gynecology2017;24(1):124‐32. [DOI: 10.1016/j.jmig.2016.09.009] LabergeP , Garza‐LealJ , FortinC , ThielJ , JohnsD , GraingerD , et al. A randomized, controlled, multi‐center trial of the safety and efficacy of the Minerva Endometrial Ablation System: one‐year follow‐up results. Journal of Minimally Invasive Gynecology. 2016; Vol. 23:S1‐S252. ">Laberge 2016</a>; <a href="./references#CD001501-bbs2-0018" title="GraingerDA , TjadenDO , RowlandC , MeyerWR . Thermal balloon and rollerball ablation to treat menorrhagia: two‐year results of a multicenter, prospective, randomized clinical trial. Journal of the American Association of Gynecologic Laparoscopists2000;7(2):175‐9. LofferFD . Five year post‐procedure follow‐up of patients participating in a randomised trial of uterine balloon therapy vs rollerball ablation for the treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopy2001;8(1):48‐54. LofferFD . Three‐year comparison of thermal balloon and rollerball ablation in treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2001;8(1):48‐54. MeyerWR , WalshBW , GraingerDA , PeacockLM , LofferFD , SteegeJF . Thermal balloon and rollerball ablation to treat menorrhagia: a multicenter comparison. Obstetrics and Gynecology1998;92:98‐103. ">Meyer 1998</a>; <a href="./references#CD001501-bbs2-0021" title="BongersM , HermanM , PenninxJ , MolBW . Longterm follow‐up of a randomized controlled trial comparing NovaSure and hydrothermablation for dysfunctional uterine bleeding. Journal of Minimally Invasive Gynecology2011;18(6 Suppl 1):S34. PenninxJPM , HermanMC , MolBW , BongersMY . Five‐year follow‐up after comparing bipolar endometrial ablation with hydrothermablation for menorrhagia. Obstetrics and Gynecology2011;118:1287‐92. PenninxJPM , MolBW , EngelsR , vanRumsteMME , KleijnC , KoksCAM , et al. Bipolar radiofrequency endometrial ablation compared with hydrothermablation for dysfunctional uterine bleeding. Obstetrics and Gynecology2010;116:819‐26. ">Penninx 2010</a>). </p> </section> <section id="CD001501-sec-0093"> <h6 class="title">Complication rate</h6> <p>Fourteen trials reported the frequency of specific adverse events both before and after discharge from the hospital (<a href="./references#CD001501-bbs2-0002" title="AthanatosD , PadosG , VenetisC , StamatopoulosP , RoussoD , TsolakidisD , et al. Novasure impedance control system versus microwave endometrial ablation for the treatment of dysfunctional uterine bleeding: a double‐blind, randomized controlled trial. Clinical and Experimental Obstetrics &amp; Gynecology2015;42(3):347‐51. [PMID: 26152008] PadosG . Treatment of dysfunctional uterine bleeding with second generation ablation devices: microwaves (MEAA) vs Bipolar Impedance Control System (Novasure). http://clinicaltrials.gov/show/NCT01173965. ">Athanatos 2015</a>; <a href="./references#CD001501-bbs2-0003" title="BhattacharyaS , CameronIM , ParkinDE , AbramovichDR , MollisonJ , PinionSB , et al. A pragmatic randomised comparison of transcervical resection of the endometrium with endometrial laser ablation for the treatment of menorrhagia. British Journal of Obstetrics and Gynaecology1997;104:601‐7. ">Bhattacharya 1997</a>; <a href="./references#CD001501-bbs2-0007" title="ClarkTJ , SamuelN , MalickS , MiddletonLJ , DanielsJ , GuptaJK . Bipolar radiofrequency compared with thermal balloon endometrial ablation in the office. Obstetrics and Gynecology2011;117:109‐18. ">Clark 2011</a>; <a href="./references#CD001501-bbs2-0008" title="BainC , CooperKG , ParkinDE . Microwave endometrial ablation versus endometrial resection: a randomized controlled trial. Obstetrics and Gynecology2002;99:983‐7. CooperKG , BainC , LawrieL , ParkinDE . A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium: follow up at a minimum of five years. British Journal of Obstetrics and Gynaecology2005;112:470‐5. CooperKG , BainC , ParkinDE . Comparison of microwave endometrial ablation and transcervical resection of the endometrium for treatment of heavy menstrual loss: a randomised trial. Lancet1999;354:1859‐63. SambrookAM , BainC , ParkinDE , CooperKG . A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium: follow up at a minimum of 10 years. British Journal of Obstetrics and Gynaecology2009;116:1033‐7. ">Cooper 1999</a>; <a href="./references#CD001501-bbs2-0009" title="CooperJ , GimpelsonR , LabergeP , GalenD , Garza‐LealJG , ScottJ , et al. A randomized, multicenter trial of safety and efficacy of the NovaSure system in the treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2002;9(4):418‐28. ">Cooper 2002</a>; <a href="./references#CD001501-bbs2-0010" title="CooperJM , AndersonTL , FortinCA , JackSA , PlentlMB . Microwave endometrial ablation vs rollerball electroablation for menorrhagia: a multicenter randomized trial. Journal of the American Association of Gynecologic Laparoscopists2004;11(3):394‐403. ">Cooper 2004</a>; <a href="./references#CD001501-bbs2-0011" title="CorsonSL , BrillAI , BrooksPG , CooperJM , IndmanPD , LiuJH , et al. Interim results of the American Vesta trial of endometrial ablation. Journal of the American Association of Gynecologic Laparoscopists1999;6(1):45‐9. CorsonSL , BrillAI , BrooksPG , CooperJM , IndmanPD , LiuJH , et al. One‐year results of the Vesta system for endometrial ablation. Journal of the American Association of Gynecologic Laparoscopists2000;7(4):489‐97. ">Corson 2000</a>; <a href="./references#CD001501-bbs2-0012" title="CorsonSL . A multicenter evaluation of endometrial ablation by hydrothermablator and rollerball for treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2001;8(3):359‐67. GoldrathMH . Evaluation of hydrothermablator and rollerball endometrial ablation for menorrhagia 3 years after treatment. Journal of the American Association of Gynecologic Laparoscopists2003;10(4):505‐11. LofferF . A clinical comparison of hydrothermablation (HTA) and rollerball for endometrial ablation to treat menorrhagia: a randomized multicenter clinical trial. XVI FIGO World Congress of Obstetrics &amp; Gynecology. 2000; Vol. Abstract Book 2:95. ">Corson 2001</a>; <a href="./references#CD001501-bbs2-0016" title="LabergeP , Garza‐LealJ , FortinC , BasinskiC , ThielJ , LeylandN , et al. A prospective, randomized, multi‐center, controlled, international clinical study of the safety and efficacy of the Minerva endometrial ablation system: 6 and 12‐month follow‐up results. Journal of Minimally Invasive Gynecology. 2014. LabergeP , Garza‐LealJ , FortinC , GraingerD , JohnsDA , AdkinsRT , et al. A randomized controlled multicenter US Food and Drug Administration trial of the safety and efficacy of the Minerva Endometrial Ablation System: one‐year follow‐up results. Journal of Minimally Invasive Gynecology2017;24(1):124‐32. [DOI: 10.1016/j.jmig.2016.09.009] LabergeP , Garza‐LealJ , FortinC , ThielJ , JohnsD , GraingerD , et al. A randomized, controlled, multi‐center trial of the safety and efficacy of the Minerva Endometrial Ablation System: one‐year follow‐up results. Journal of Minimally Invasive Gynecology. 2016; Vol. 23:S1‐S252. ">Laberge 2016</a>; <a href="./references#CD001501-bbs2-0018" title="GraingerDA , TjadenDO , RowlandC , MeyerWR . Thermal balloon and rollerball ablation to treat menorrhagia: two‐year results of a multicenter, prospective, randomized clinical trial. Journal of the American Association of Gynecologic Laparoscopists2000;7(2):175‐9. LofferFD . Five year post‐procedure follow‐up of patients participating in a randomised trial of uterine balloon therapy vs rollerball ablation for the treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopy2001;8(1):48‐54. LofferFD . Three‐year comparison of thermal balloon and rollerball ablation in treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2001;8(1):48‐54. MeyerWR , WalshBW , GraingerDA , PeacockLM , LofferFD , SteegeJF . Thermal balloon and rollerball ablation to treat menorrhagia: a multicenter comparison. Obstetrics and Gynecology1998;92:98‐103. ">Meyer 1998</a>; <a href="./references#CD001501-bbs2-0020" title="PellicanoM , GuidaM , AcunzoG , CirilloD , BifulcoG , NappiC . Hysteroscopic transcervical endometrial resection versus thermal destruction for menorrhagia: a prospective randomized trial on satisfaction rate. American Journal of Obstetrics and Gynecology2002;187:545‐50. ">Pellicano 2002</a>; <a href="./references#CD001501-bbs2-0021" title="BongersM , HermanM , PenninxJ , MolBW . Longterm follow‐up of a randomized controlled trial comparing NovaSure and hydrothermablation for dysfunctional uterine bleeding. Journal of Minimally Invasive Gynecology2011;18(6 Suppl 1):S34. PenninxJPM , HermanMC , MolBW , BongersMY . Five‐year follow‐up after comparing bipolar endometrial ablation with hydrothermablation for menorrhagia. Obstetrics and Gynecology2011;118:1287‐92. PenninxJPM , MolBW , EngelsR , vanRumsteMME , KleijnC , KoksCAM , et al. Bipolar radiofrequency endometrial ablation compared with hydrothermablation for dysfunctional uterine bleeding. Obstetrics and Gynecology2010;116:819‐26. ">Penninx 2010</a>; <a href="./references#CD001501-bbs2-0026" title="ThabetSMA . New attempt using ablative curettage technique for managing benign premenopausal uterine bleeding. Obstetrics and Gynaecology Research2010;36(4):803‐9. ">Thabet 2010</a>; <a href="./references#CD001501-bbs2-0027" title="vanZon‐RabelinkIAA , VleugelsMPH . Treating menorrhagia with endometrial ablation: rollerball electrocoagulation versus thermal ablation with the uterine balloon. Gynaecological Endoscopy Abstract from the 6th Annual Congress of the European Society for Gynaecological Endoscopy1997;6 Suppl 2:41. vanZon‐RabelinkIAA , VleugelsMPH , MerkusHMWM , deGraafR . Efficacy and satisfaction rate comparing endometrial ablation by rollerball electrocoagulation to uterine balloon thermal ablation in a randomised controlled trial. European Journal of Obstetrics, Gynecology, and Reproductive Biology2004;114(1):97‐103. vanZon‐RabelinkIAA , VleugelsMPH , MerkusHMWM , deGraafR . Endometrial ablation by rollerball electrocoagulation compared to uterine balloon thermal ablation. Technical and safety aspects. European Journal of Obstetrics, Gynecology, and Reproductive Biology2003;110:220‐3. ">van Zon‐Rabelink 2003</a>). </p> <p>We have divided complications into major and minor complications.</p> <section id="CD001501-sec-0094"> <p><b>Major complications</b></p> <p> <ul id="CD001501-list-0025"> <li> <p>Perforation</p> </li> <li> <p>Endometritis</p> </li> <li> <p>Myometritis</p> </li> <li> <p>Cervical laceration/tear or stenosis</p> </li> <li> <p>Pelvic sepsis</p> </li> <li> <p>Pelvic abscess</p> </li> <li> <p>Pelvic inflammatory disease</p> </li> <li> <p>Haematometra</p> </li> <li> <p>Uterine tamponade</p> </li> <li> <p>Blood transfusion</p> </li> <li> <p>Glycine toxicity</p> </li> <li> <p>Fluid overload</p> </li> <li> <p>Fluid deficit</p> </li> <li> <p>Bowel obstruction</p> </li> <li> <p>Urinary incontinence</p> </li> </ul> </p> </section> <section id="CD001501-sec-0095"> <p><b>Minor complications</b></p> <p> <ul id="CD001501-list-0026"> <li> <p>Skin rash and burning sensation</p> </li> <li> <p>Headache</p> </li> <li> <p>Nausea, vomiting or severe pelvic pain</p> </li> <li> <p>Weakness or fatigue during the first 24 hours</p> </li> <li> <p>Backache during the first 24 hours</p> </li> <li> <p>Bradycardia</p> </li> <li> <p>Fever</p> </li> <li> <p>Chills</p> </li> <li> <p>Bloating</p> </li> <li> <p>Abdominal tenderness</p> </li> <li> <p>Dysuria</p> </li> <li> <p>Urinary tract infection (UTI)</p> </li> <li> <p>Hydrosalpinx</p> </li> <li> <p>Spotting during the first 24 hours</p> </li> <li> <p>Vaginal bleeding</p> </li> <li> <p>Abdominal cramping</p> </li> <li> <p>Infection (leucorrhoea)</p> </li> <li> <p>First‐degree burn</p> </li> </ul> </p> </section> </section> <section id="CD001501-sec-0096"> <h6 class="title">Requirement for further surgery</h6> <p>A total of 23 trials reported on the requirement for further surgery (<a href="./references#CD001501-bbs2-0001" title="AbbottJ , HaweJ , HunterD , GarryR . A double‐blind randomized trial comparing the Cavaterm and the Novasure endometrial ablation systems for the treatment of dysfunctional uterine bleeding. Fertility and Sterility2003;80(1):203‐8. ">Abbott 2003</a>; <a href="./references#CD001501-bbs2-0002" title="AthanatosD , PadosG , VenetisC , StamatopoulosP , RoussoD , TsolakidisD , et al. Novasure impedance control system versus microwave endometrial ablation for the treatment of dysfunctional uterine bleeding: a double‐blind, randomized controlled trial. Clinical and Experimental Obstetrics &amp; Gynecology2015;42(3):347‐51. [PMID: 26152008] PadosG . Treatment of dysfunctional uterine bleeding with second generation ablation devices: microwaves (MEAA) vs Bipolar Impedance Control System (Novasure). http://clinicaltrials.gov/show/NCT01173965. ">Athanatos 2015</a>; <a href="./references#CD001501-bbs2-0003" title="BhattacharyaS , CameronIM , ParkinDE , AbramovichDR , MollisonJ , PinionSB , et al. A pragmatic randomised comparison of transcervical resection of the endometrium with endometrial laser ablation for the treatment of menorrhagia. British Journal of Obstetrics and Gynaecology1997;104:601‐7. ">Bhattacharya 1997</a>; <a href="./references#CD001501-bbs2-0004" title="BongersM , HermanM , JosienP , MolBW . Ten‐year follow‐up of a randomized controlled trial comparing NovaSure and Thermachoice in endometrial ablation for dysfunctional uterine bleeding. Journal of Minimally Invasive Gynecology2011;18(6 Suppl 1):S127. BongersMY , BourdrezP , HeintzPM , BrolmannHAM , MolBWJ . Bipolar radio frequency endometrial ablation compared with balloon endometrial ablation in dysfunctional uterine bleeding: impact on patients' health‐related quality of life. Fertility and Sterility2005;83(3):724‐34. BongersMY , BourdrezP , MolBWJ , HeintzAPM , BrolmannHAM . Randomised controlled trial of bipolar radio‐frequency endometrial ablation and balloon endometrial ablation. British Journal of Obstetrics and Gynaecology2004;111:1095‐102. HermanM , PenninxM , MolB , BongersM . Ten‐year follow‐up of a randomised controlled trial comparing bipolar endometrial ablation with balloon ablation for heavy menstrual bleeding. British Journal Obstetrics and Gynaecology2013;120:966‐970. [DOI: 10.1111/1471‐0528.12213] KleijnJH , EngelsR , BourdrezP , MolBWJ , BongersMY . Five‐year follow up of a randomised controlled trial comparing NovaSure and ThermaChoice endometrial ablation. British Journal of Obstetrics and Gynaecology2008;115:193‐8. ">Bongers 2004</a>; <a href="./references#CD001501-bbs2-0005" title="BoujidaVH , PhilipsenT , PelleJ , JoergensenJC . Five‐year follow‐up of endometrial ablation: endometrial coagulation versus endometrial resection. Obstetrics and Gynecology2002;99:988‐92. FurstSN , PhilipsenT , JoergensenJC . Ten‐year follow‐up of endometrial ablation. Acta Obstetricia et Gynecologica2007;86:334‐8. ">Boujida 2002</a>; <a href="./references#CD001501-bbs2-0006" title="BrunJ‐L , RaynalJ , BurletG , GalandB , QuereuxC , BernardP . Cavaterm thermal balloon endometrial ablation versus hysteroscopic endometrial resection to treat menorrhagia: the French, multicenter, randomized study. Journal of Minimally Invasive Gynecology2006;13:424‐30. ">Brun 2006</a>; <a href="./references#CD001501-bbs2-0007" title="ClarkTJ , SamuelN , MalickS , MiddletonLJ , DanielsJ , GuptaJK . Bipolar radiofrequency compared with thermal balloon endometrial ablation in the office. Obstetrics and Gynecology2011;117:109‐18. ">Clark 2011</a>; <a href="./references#CD001501-bbs2-0008" title="BainC , CooperKG , ParkinDE . Microwave endometrial ablation versus endometrial resection: a randomized controlled trial. Obstetrics and Gynecology2002;99:983‐7. CooperKG , BainC , LawrieL , ParkinDE . A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium: follow up at a minimum of five years. British Journal of Obstetrics and Gynaecology2005;112:470‐5. CooperKG , BainC , ParkinDE . Comparison of microwave endometrial ablation and transcervical resection of the endometrium for treatment of heavy menstrual loss: a randomised trial. Lancet1999;354:1859‐63. SambrookAM , BainC , ParkinDE , CooperKG . A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium: follow up at a minimum of 10 years. British Journal of Obstetrics and Gynaecology2009;116:1033‐7. ">Cooper 1999</a>; <a href="./references#CD001501-bbs2-0010" title="CooperJM , AndersonTL , FortinCA , JackSA , PlentlMB . Microwave endometrial ablation vs rollerball electroablation for menorrhagia: a multicenter randomized trial. Journal of the American Association of Gynecologic Laparoscopists2004;11(3):394‐403. ">Cooper 2004</a>; <a href="./references#CD001501-bbs2-0011" title="CorsonSL , BrillAI , BrooksPG , CooperJM , IndmanPD , LiuJH , et al. Interim results of the American Vesta trial of endometrial ablation. Journal of the American Association of Gynecologic Laparoscopists1999;6(1):45‐9. CorsonSL , BrillAI , BrooksPG , CooperJM , IndmanPD , LiuJH , et al. One‐year results of the Vesta system for endometrial ablation. Journal of the American Association of Gynecologic Laparoscopists2000;7(4):489‐97. ">Corson 2000</a>; <a href="./references#CD001501-bbs2-0012" title="CorsonSL . A multicenter evaluation of endometrial ablation by hydrothermablator and rollerball for treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2001;8(3):359‐67. GoldrathMH . Evaluation of hydrothermablator and rollerball endometrial ablation for menorrhagia 3 years after treatment. Journal of the American Association of Gynecologic Laparoscopists2003;10(4):505‐11. LofferF . A clinical comparison of hydrothermablation (HTA) and rollerball for endometrial ablation to treat menorrhagia: a randomized multicenter clinical trial. XVI FIGO World Congress of Obstetrics &amp; Gynecology. 2000; Vol. Abstract Book 2:95. ">Corson 2001</a>; <a href="./references#CD001501-bbs2-0013" title="DulebaAJ , HeppardMC , SoderstromRM , TownsendDE . A randomized study comparing endometrial cryoablation and rollerball electroablation for treatment of dysfunctional uterine bleeding. Journal of the American Association of Gynecologic Laparoscopists2003;10(1):17‐26. TownsendDE , DulebaAJ , WilkesMM , et al. Durability of treatment effects after cryoablation versus rollerball electroablation for abnormal uterine bleeding: two‐year results of a multicenter randomized trial. American Journal of Obstetrics and Gynecology2003;188:699‐701. ">Duleba 2003</a>; <a href="./references#CD001501-bbs2-0015" title="HaweJ , AbbottJ , HunterD , PhillipsG , GarryR . A randomised controlled trial comparing the Cavaterm endometrial ablation system with the Nd:YAG laser for the treatment of dysfunctional uterine bleeding. British Journal of Obstetrics and Gynaecology2003;110:350‐7. ">Hawe 2003</a>; <a href="./references#CD001501-bbs2-0016" title="LabergeP , Garza‐LealJ , FortinC , BasinskiC , ThielJ , LeylandN , et al. A prospective, randomized, multi‐center, controlled, international clinical study of the safety and efficacy of the Minerva endometrial ablation system: 6 and 12‐month follow‐up results. Journal of Minimally Invasive Gynecology. 2014. LabergeP , Garza‐LealJ , FortinC , GraingerD , JohnsDA , AdkinsRT , et al. A randomized controlled multicenter US Food and Drug Administration trial of the safety and efficacy of the Minerva Endometrial Ablation System: one‐year follow‐up results. Journal of Minimally Invasive Gynecology2017;24(1):124‐32. [DOI: 10.1016/j.jmig.2016.09.009] LabergeP , Garza‐LealJ , FortinC , ThielJ , JohnsD , GraingerD , et al. A randomized, controlled, multi‐center trial of the safety and efficacy of the Minerva Endometrial Ablation System: one‐year follow‐up results. Journal of Minimally Invasive Gynecology. 2016; Vol. 23:S1‐S252. ">Laberge 2016</a>; <a href="./references#CD001501-bbs2-0017" title="McClureN , MarnersM , HealyDL , HillDJ , LawrenceAS , WingfieldM , et al. A quantitative assessment of endometrial electrocautery in the management of menorrhagia and a comparative report of argon laser endometrial ablation. Gynaecological Endoscopy1992;1:199‐202. ">McClure 1992</a>; <a href="./references#CD001501-bbs2-0018" title="GraingerDA , TjadenDO , RowlandC , MeyerWR . Thermal balloon and rollerball ablation to treat menorrhagia: two‐year results of a multicenter, prospective, randomized clinical trial. Journal of the American Association of Gynecologic Laparoscopists2000;7(2):175‐9. LofferFD . Five year post‐procedure follow‐up of patients participating in a randomised trial of uterine balloon therapy vs rollerball ablation for the treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopy2001;8(1):48‐54. LofferFD . Three‐year comparison of thermal balloon and rollerball ablation in treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2001;8(1):48‐54. MeyerWR , WalshBW , GraingerDA , PeacockLM , LofferFD , SteegeJF . Thermal balloon and rollerball ablation to treat menorrhagia: a multicenter comparison. Obstetrics and Gynecology1998;92:98‐103. ">Meyer 1998</a>; <a href="./references#CD001501-bbs2-0020" title="PellicanoM , GuidaM , AcunzoG , CirilloD , BifulcoG , NappiC . Hysteroscopic transcervical endometrial resection versus thermal destruction for menorrhagia: a prospective randomized trial on satisfaction rate. American Journal of Obstetrics and Gynecology2002;187:545‐50. ">Pellicano 2002</a>; <a href="./references#CD001501-bbs2-0021" title="BongersM , HermanM , PenninxJ , MolBW . Longterm follow‐up of a randomized controlled trial comparing NovaSure and hydrothermablation for dysfunctional uterine bleeding. Journal of Minimally Invasive Gynecology2011;18(6 Suppl 1):S34. PenninxJPM , HermanMC , MolBW , BongersMY . Five‐year follow‐up after comparing bipolar endometrial ablation with hydrothermablation for menorrhagia. Obstetrics and Gynecology2011;118:1287‐92. PenninxJPM , MolBW , EngelsR , vanRumsteMME , KleijnC , KoksCAM , et al. Bipolar radiofrequency endometrial ablation compared with hydrothermablation for dysfunctional uterine bleeding. Obstetrics and Gynecology2010;116:819‐26. ">Penninx 2010</a>; <a href="./references#CD001501-bbs2-0022" title="PenninxJ , BongersM . Bipolar radiofrequency endometrial ablation versus thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. www.controlled‐trials.com/ISRCTN17974690. PenninxJ , HermanM , KruitwagenR , Ter HaarA , MolB , BongersM . Bipolar versus balloon endometrial ablation in the office: a randomized controlled trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;196:52‐6. [DOI: 10.1016/j.ejogrb.2015.10.010] PenninxJ , HermanM , MolB , KruitwagenR , BongersM . Bipolar radiofrequency endometrial ablation versus Thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. Journal of Minimally Invasive Gynecology2012;19(6):S21‐S22. [DOI: 10.1016/j.jmig.2012.08.076] PenninxJPM , HermanMC , MolBW , BongersMY . Bipolar radiofrequency endometrial ablation versus thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. Journal of Minimally Invasive Gynecology2012;19(6 Suppl 1):S21‐2. ">Penninx 2016</a>; <a href="./references#CD001501-bbs2-0023" title="PerinoA , CastelliA , CucinellaG , BiondoA , PaneA , VeneziaR . A randomized comparison of endometrial laser intrauterine thermotherapy and hysteroscopic endometrial resection. Fertility and Sterility2004;82:731‐4. ">Perino 2004</a>; <a href="./references#CD001501-bbs2-0025" title="SambrookA , EldersA , CooperK . Microwave endometrial ablation versus thermal balloon endometrial ablation (MEATBall): 5‐year follow up of a randomised controlled trial. British Journal of Obstetrics and Gynaecology2014;121:748‐54. [DOI: 10.1111/1471‐0528.12585] SambrookAM , CooperKG , CampbellMK , CookJA . Clinical outcomes from a randomised comparison of microwave endometrial ablation with thermal balloon endometrial ablation for the treatment of heavy menstrual bleeding. British Journal of Obstetrics and Gynaecology2009;116:1038‐45. ">Sambrook 2009</a>; <a href="./references#CD001501-bbs2-0026" title="ThabetSMA . New attempt using ablative curettage technique for managing benign premenopausal uterine bleeding. Obstetrics and Gynaecology Research2010;36(4):803‐9. ">Thabet 2010</a>; <a href="./references#CD001501-bbs2-0027" title="vanZon‐RabelinkIAA , VleugelsMPH . Treating menorrhagia with endometrial ablation: rollerball electrocoagulation versus thermal ablation with the uterine balloon. Gynaecological Endoscopy Abstract from the 6th Annual Congress of the European Society for Gynaecological Endoscopy1997;6 Suppl 2:41. vanZon‐RabelinkIAA , VleugelsMPH , MerkusHMWM , deGraafR . Efficacy and satisfaction rate comparing endometrial ablation by rollerball electrocoagulation to uterine balloon thermal ablation in a randomised controlled trial. European Journal of Obstetrics, Gynecology, and Reproductive Biology2004;114(1):97‐103. vanZon‐RabelinkIAA , VleugelsMPH , MerkusHMWM , deGraafR . Endometrial ablation by rollerball electrocoagulation compared to uterine balloon thermal ablation. Technical and safety aspects. European Journal of Obstetrics, Gynecology, and Reproductive Biology2003;110:220‐3. ">van Zon‐Rabelink 2003</a>). </p> <p>Sixteen trials reported on the requirement for further endometrial ablation or hysterectomy (<a href="./references#CD001501-bbs2-0001" title="AbbottJ , HaweJ , HunterD , GarryR . A double‐blind randomized trial comparing the Cavaterm and the Novasure endometrial ablation systems for the treatment of dysfunctional uterine bleeding. Fertility and Sterility2003;80(1):203‐8. ">Abbott 2003</a>; <a href="./references#CD001501-bbs2-0003" title="BhattacharyaS , CameronIM , ParkinDE , AbramovichDR , MollisonJ , PinionSB , et al. A pragmatic randomised comparison of transcervical resection of the endometrium with endometrial laser ablation for the treatment of menorrhagia. British Journal of Obstetrics and Gynaecology1997;104:601‐7. ">Bhattacharya 1997</a>; <a href="./references#CD001501-bbs2-0005" title="BoujidaVH , PhilipsenT , PelleJ , JoergensenJC . Five‐year follow‐up of endometrial ablation: endometrial coagulation versus endometrial resection. Obstetrics and Gynecology2002;99:988‐92. FurstSN , PhilipsenT , JoergensenJC . Ten‐year follow‐up of endometrial ablation. Acta Obstetricia et Gynecologica2007;86:334‐8. ">Boujida 2002</a>; <a href="./references#CD001501-bbs2-0006" title="BrunJ‐L , RaynalJ , BurletG , GalandB , QuereuxC , BernardP . Cavaterm thermal balloon endometrial ablation versus hysteroscopic endometrial resection to treat menorrhagia: the French, multicenter, randomized study. Journal of Minimally Invasive Gynecology2006;13:424‐30. ">Brun 2006</a>; <a href="./references#CD001501-bbs2-0007" title="ClarkTJ , SamuelN , MalickS , MiddletonLJ , DanielsJ , GuptaJK . Bipolar radiofrequency compared with thermal balloon endometrial ablation in the office. Obstetrics and Gynecology2011;117:109‐18. ">Clark 2011</a>; <a href="./references#CD001501-bbs2-0008" title="BainC , CooperKG , ParkinDE . Microwave endometrial ablation versus endometrial resection: a randomized controlled trial. Obstetrics and Gynecology2002;99:983‐7. CooperKG , BainC , LawrieL , ParkinDE . A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium: follow up at a minimum of five years. British Journal of Obstetrics and Gynaecology2005;112:470‐5. CooperKG , BainC , ParkinDE . Comparison of microwave endometrial ablation and transcervical resection of the endometrium for treatment of heavy menstrual loss: a randomised trial. Lancet1999;354:1859‐63. SambrookAM , BainC , ParkinDE , CooperKG . A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium: follow up at a minimum of 10 years. British Journal of Obstetrics and Gynaecology2009;116:1033‐7. ">Cooper 1999</a>; <a href="./references#CD001501-bbs2-0010" title="CooperJM , AndersonTL , FortinCA , JackSA , PlentlMB . Microwave endometrial ablation vs rollerball electroablation for menorrhagia: a multicenter randomized trial. Journal of the American Association of Gynecologic Laparoscopists2004;11(3):394‐403. ">Cooper 2004</a>; <a href="./references#CD001501-bbs2-0012" title="CorsonSL . A multicenter evaluation of endometrial ablation by hydrothermablator and rollerball for treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2001;8(3):359‐67. GoldrathMH . Evaluation of hydrothermablator and rollerball endometrial ablation for menorrhagia 3 years after treatment. Journal of the American Association of Gynecologic Laparoscopists2003;10(4):505‐11. LofferF . A clinical comparison of hydrothermablation (HTA) and rollerball for endometrial ablation to treat menorrhagia: a randomized multicenter clinical trial. XVI FIGO World Congress of Obstetrics &amp; Gynecology. 2000; Vol. Abstract Book 2:95. ">Corson 2001</a>; <a href="./references#CD001501-bbs2-0013" title="DulebaAJ , HeppardMC , SoderstromRM , TownsendDE . A randomized study comparing endometrial cryoablation and rollerball electroablation for treatment of dysfunctional uterine bleeding. Journal of the American Association of Gynecologic Laparoscopists2003;10(1):17‐26. TownsendDE , DulebaAJ , WilkesMM , et al. Durability of treatment effects after cryoablation versus rollerball electroablation for abnormal uterine bleeding: two‐year results of a multicenter randomized trial. American Journal of Obstetrics and Gynecology2003;188:699‐701. ">Duleba 2003</a>; <a href="./references#CD001501-bbs2-0015" title="HaweJ , AbbottJ , HunterD , PhillipsG , GarryR . A randomised controlled trial comparing the Cavaterm endometrial ablation system with the Nd:YAG laser for the treatment of dysfunctional uterine bleeding. British Journal of Obstetrics and Gynaecology2003;110:350‐7. ">Hawe 2003</a>; <a href="./references#CD001501-bbs2-0017" title="McClureN , MarnersM , HealyDL , HillDJ , LawrenceAS , WingfieldM , et al. A quantitative assessment of endometrial electrocautery in the management of menorrhagia and a comparative report of argon laser endometrial ablation. Gynaecological Endoscopy1992;1:199‐202. ">McClure 1992</a>; <a href="./references#CD001501-bbs2-0018" title="GraingerDA , TjadenDO , RowlandC , MeyerWR . Thermal balloon and rollerball ablation to treat menorrhagia: two‐year results of a multicenter, prospective, randomized clinical trial. Journal of the American Association of Gynecologic Laparoscopists2000;7(2):175‐9. LofferFD . Five year post‐procedure follow‐up of patients participating in a randomised trial of uterine balloon therapy vs rollerball ablation for the treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopy2001;8(1):48‐54. LofferFD . Three‐year comparison of thermal balloon and rollerball ablation in treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2001;8(1):48‐54. MeyerWR , WalshBW , GraingerDA , PeacockLM , LofferFD , SteegeJF . Thermal balloon and rollerball ablation to treat menorrhagia: a multicenter comparison. Obstetrics and Gynecology1998;92:98‐103. ">Meyer 1998</a>; <a href="./references#CD001501-bbs2-0020" title="PellicanoM , GuidaM , AcunzoG , CirilloD , BifulcoG , NappiC . Hysteroscopic transcervical endometrial resection versus thermal destruction for menorrhagia: a prospective randomized trial on satisfaction rate. American Journal of Obstetrics and Gynecology2002;187:545‐50. ">Pellicano 2002</a>; <a href="./references#CD001501-bbs2-0021" title="BongersM , HermanM , PenninxJ , MolBW . Longterm follow‐up of a randomized controlled trial comparing NovaSure and hydrothermablation for dysfunctional uterine bleeding. Journal of Minimally Invasive Gynecology2011;18(6 Suppl 1):S34. PenninxJPM , HermanMC , MolBW , BongersMY . Five‐year follow‐up after comparing bipolar endometrial ablation with hydrothermablation for menorrhagia. Obstetrics and Gynecology2011;118:1287‐92. PenninxJPM , MolBW , EngelsR , vanRumsteMME , KleijnC , KoksCAM , et al. Bipolar radiofrequency endometrial ablation compared with hydrothermablation for dysfunctional uterine bleeding. Obstetrics and Gynecology2010;116:819‐26. ">Penninx 2010</a>; <a href="./references#CD001501-bbs2-0022" title="PenninxJ , BongersM . Bipolar radiofrequency endometrial ablation versus thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. www.controlled‐trials.com/ISRCTN17974690. PenninxJ , HermanM , KruitwagenR , Ter HaarA , MolB , BongersM . Bipolar versus balloon endometrial ablation in the office: a randomized controlled trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;196:52‐6. [DOI: 10.1016/j.ejogrb.2015.10.010] PenninxJ , HermanM , MolB , KruitwagenR , BongersM . Bipolar radiofrequency endometrial ablation versus Thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. Journal of Minimally Invasive Gynecology2012;19(6):S21‐S22. [DOI: 10.1016/j.jmig.2012.08.076] PenninxJPM , HermanMC , MolBW , BongersMY . Bipolar radiofrequency endometrial ablation versus thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. Journal of Minimally Invasive Gynecology2012;19(6 Suppl 1):S21‐2. ">Penninx 2016</a>; <a href="./references#CD001501-bbs2-0027" title="vanZon‐RabelinkIAA , VleugelsMPH . Treating menorrhagia with endometrial ablation: rollerball electrocoagulation versus thermal ablation with the uterine balloon. Gynaecological Endoscopy Abstract from the 6th Annual Congress of the European Society for Gynaecological Endoscopy1997;6 Suppl 2:41. vanZon‐RabelinkIAA , VleugelsMPH , MerkusHMWM , deGraafR . Efficacy and satisfaction rate comparing endometrial ablation by rollerball electrocoagulation to uterine balloon thermal ablation in a randomised controlled trial. European Journal of Obstetrics, Gynecology, and Reproductive Biology2004;114(1):97‐103. vanZon‐RabelinkIAA , VleugelsMPH , MerkusHMWM , deGraafR . Endometrial ablation by rollerball electrocoagulation compared to uterine balloon thermal ablation. Technical and safety aspects. European Journal of Obstetrics, Gynecology, and Reproductive Biology2003;110:220‐3. ">van Zon‐Rabelink 2003</a>). </p> <p>Nineteen trials reported on the requirement for further hysterectomy (<a href="./references#CD001501-bbs2-0002" title="AthanatosD , PadosG , VenetisC , StamatopoulosP , RoussoD , TsolakidisD , et al. Novasure impedance control system versus microwave endometrial ablation for the treatment of dysfunctional uterine bleeding: a double‐blind, randomized controlled trial. Clinical and Experimental Obstetrics &amp; Gynecology2015;42(3):347‐51. [PMID: 26152008] PadosG . Treatment of dysfunctional uterine bleeding with second generation ablation devices: microwaves (MEAA) vs Bipolar Impedance Control System (Novasure). http://clinicaltrials.gov/show/NCT01173965. ">Athanatos 2015</a>; <a href="./references#CD001501-bbs2-0004" title="BongersM , HermanM , JosienP , MolBW . Ten‐year follow‐up of a randomized controlled trial comparing NovaSure and Thermachoice in endometrial ablation for dysfunctional uterine bleeding. Journal of Minimally Invasive Gynecology2011;18(6 Suppl 1):S127. BongersMY , BourdrezP , HeintzPM , BrolmannHAM , MolBWJ . Bipolar radio frequency endometrial ablation compared with balloon endometrial ablation in dysfunctional uterine bleeding: impact on patients' health‐related quality of life. Fertility and Sterility2005;83(3):724‐34. BongersMY , BourdrezP , MolBWJ , HeintzAPM , BrolmannHAM . Randomised controlled trial of bipolar radio‐frequency endometrial ablation and balloon endometrial ablation. British Journal of Obstetrics and Gynaecology2004;111:1095‐102. HermanM , PenninxM , MolB , BongersM . Ten‐year follow‐up of a randomised controlled trial comparing bipolar endometrial ablation with balloon ablation for heavy menstrual bleeding. British Journal Obstetrics and Gynaecology2013;120:966‐970. [DOI: 10.1111/1471‐0528.12213] KleijnJH , EngelsR , BourdrezP , MolBWJ , BongersMY . Five‐year follow up of a randomised controlled trial comparing NovaSure and ThermaChoice endometrial ablation. British Journal of Obstetrics and Gynaecology2008;115:193‐8. ">Bongers 2004</a>; <a href="./references#CD001501-bbs2-0005" title="BoujidaVH , PhilipsenT , PelleJ , JoergensenJC . Five‐year follow‐up of endometrial ablation: endometrial coagulation versus endometrial resection. Obstetrics and Gynecology2002;99:988‐92. FurstSN , PhilipsenT , JoergensenJC . Ten‐year follow‐up of endometrial ablation. Acta Obstetricia et Gynecologica2007;86:334‐8. ">Boujida 2002</a>; <a href="./references#CD001501-bbs2-0006" title="BrunJ‐L , RaynalJ , BurletG , GalandB , QuereuxC , BernardP . Cavaterm thermal balloon endometrial ablation versus hysteroscopic endometrial resection to treat menorrhagia: the French, multicenter, randomized study. Journal of Minimally Invasive Gynecology2006;13:424‐30. ">Brun 2006</a>; <a href="./references#CD001501-bbs2-0007" title="ClarkTJ , SamuelN , MalickS , MiddletonLJ , DanielsJ , GuptaJK . Bipolar radiofrequency compared with thermal balloon endometrial ablation in the office. Obstetrics and Gynecology2011;117:109‐18. ">Clark 2011</a>; <a href="./references#CD001501-bbs2-0008" title="BainC , CooperKG , ParkinDE . Microwave endometrial ablation versus endometrial resection: a randomized controlled trial. Obstetrics and Gynecology2002;99:983‐7. CooperKG , BainC , LawrieL , ParkinDE . A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium: follow up at a minimum of five years. British Journal of Obstetrics and Gynaecology2005;112:470‐5. CooperKG , BainC , ParkinDE . Comparison of microwave endometrial ablation and transcervical resection of the endometrium for treatment of heavy menstrual loss: a randomised trial. Lancet1999;354:1859‐63. SambrookAM , BainC , ParkinDE , CooperKG . A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium: follow up at a minimum of 10 years. British Journal of Obstetrics and Gynaecology2009;116:1033‐7. ">Cooper 1999</a>; <a href="./references#CD001501-bbs2-0010" title="CooperJM , AndersonTL , FortinCA , JackSA , PlentlMB . Microwave endometrial ablation vs rollerball electroablation for menorrhagia: a multicenter randomized trial. Journal of the American Association of Gynecologic Laparoscopists2004;11(3):394‐403. ">Cooper 2004</a>; <a href="./references#CD001501-bbs2-0011" title="CorsonSL , BrillAI , BrooksPG , CooperJM , IndmanPD , LiuJH , et al. Interim results of the American Vesta trial of endometrial ablation. Journal of the American Association of Gynecologic Laparoscopists1999;6(1):45‐9. CorsonSL , BrillAI , BrooksPG , CooperJM , IndmanPD , LiuJH , et al. One‐year results of the Vesta system for endometrial ablation. Journal of the American Association of Gynecologic Laparoscopists2000;7(4):489‐97. ">Corson 2000</a>; <a href="./references#CD001501-bbs2-0012" title="CorsonSL . A multicenter evaluation of endometrial ablation by hydrothermablator and rollerball for treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2001;8(3):359‐67. GoldrathMH . Evaluation of hydrothermablator and rollerball endometrial ablation for menorrhagia 3 years after treatment. Journal of the American Association of Gynecologic Laparoscopists2003;10(4):505‐11. LofferF . A clinical comparison of hydrothermablation (HTA) and rollerball for endometrial ablation to treat menorrhagia: a randomized multicenter clinical trial. XVI FIGO World Congress of Obstetrics &amp; Gynecology. 2000; Vol. Abstract Book 2:95. ">Corson 2001</a>; <a href="./references#CD001501-bbs2-0013" title="DulebaAJ , HeppardMC , SoderstromRM , TownsendDE . A randomized study comparing endometrial cryoablation and rollerball electroablation for treatment of dysfunctional uterine bleeding. Journal of the American Association of Gynecologic Laparoscopists2003;10(1):17‐26. TownsendDE , DulebaAJ , WilkesMM , et al. Durability of treatment effects after cryoablation versus rollerball electroablation for abnormal uterine bleeding: two‐year results of a multicenter randomized trial. American Journal of Obstetrics and Gynecology2003;188:699‐701. ">Duleba 2003</a>; <a href="./references#CD001501-bbs2-0016" title="LabergeP , Garza‐LealJ , FortinC , BasinskiC , ThielJ , LeylandN , et al. A prospective, randomized, multi‐center, controlled, international clinical study of the safety and efficacy of the Minerva endometrial ablation system: 6 and 12‐month follow‐up results. Journal of Minimally Invasive Gynecology. 2014. LabergeP , Garza‐LealJ , FortinC , GraingerD , JohnsDA , AdkinsRT , et al. A randomized controlled multicenter US Food and Drug Administration trial of the safety and efficacy of the Minerva Endometrial Ablation System: one‐year follow‐up results. Journal of Minimally Invasive Gynecology2017;24(1):124‐32. [DOI: 10.1016/j.jmig.2016.09.009] LabergeP , Garza‐LealJ , FortinC , ThielJ , JohnsD , GraingerD , et al. A randomized, controlled, multi‐center trial of the safety and efficacy of the Minerva Endometrial Ablation System: one‐year follow‐up results. Journal of Minimally Invasive Gynecology. 2016; Vol. 23:S1‐S252. ">Laberge 2016</a>; <a href="./references#CD001501-bbs2-0018" title="GraingerDA , TjadenDO , RowlandC , MeyerWR . Thermal balloon and rollerball ablation to treat menorrhagia: two‐year results of a multicenter, prospective, randomized clinical trial. Journal of the American Association of Gynecologic Laparoscopists2000;7(2):175‐9. LofferFD . Five year post‐procedure follow‐up of patients participating in a randomised trial of uterine balloon therapy vs rollerball ablation for the treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopy2001;8(1):48‐54. LofferFD . Three‐year comparison of thermal balloon and rollerball ablation in treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2001;8(1):48‐54. MeyerWR , WalshBW , GraingerDA , PeacockLM , LofferFD , SteegeJF . Thermal balloon and rollerball ablation to treat menorrhagia: a multicenter comparison. Obstetrics and Gynecology1998;92:98‐103. ">Meyer 1998</a>; <a href="./references#CD001501-bbs2-0020" title="PellicanoM , GuidaM , AcunzoG , CirilloD , BifulcoG , NappiC . Hysteroscopic transcervical endometrial resection versus thermal destruction for menorrhagia: a prospective randomized trial on satisfaction rate. American Journal of Obstetrics and Gynecology2002;187:545‐50. ">Pellicano 2002</a>; <a href="./references#CD001501-bbs2-0021" title="BongersM , HermanM , PenninxJ , MolBW . Longterm follow‐up of a randomized controlled trial comparing NovaSure and hydrothermablation for dysfunctional uterine bleeding. Journal of Minimally Invasive Gynecology2011;18(6 Suppl 1):S34. PenninxJPM , HermanMC , MolBW , BongersMY . Five‐year follow‐up after comparing bipolar endometrial ablation with hydrothermablation for menorrhagia. Obstetrics and Gynecology2011;118:1287‐92. PenninxJPM , MolBW , EngelsR , vanRumsteMME , KleijnC , KoksCAM , et al. Bipolar radiofrequency endometrial ablation compared with hydrothermablation for dysfunctional uterine bleeding. Obstetrics and Gynecology2010;116:819‐26. ">Penninx 2010</a>; <a href="./references#CD001501-bbs2-0022" title="PenninxJ , BongersM . Bipolar radiofrequency endometrial ablation versus thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. www.controlled‐trials.com/ISRCTN17974690. PenninxJ , HermanM , KruitwagenR , Ter HaarA , MolB , BongersM . Bipolar versus balloon endometrial ablation in the office: a randomized controlled trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;196:52‐6. [DOI: 10.1016/j.ejogrb.2015.10.010] PenninxJ , HermanM , MolB , KruitwagenR , BongersM . Bipolar radiofrequency endometrial ablation versus Thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. Journal of Minimally Invasive Gynecology2012;19(6):S21‐S22. [DOI: 10.1016/j.jmig.2012.08.076] PenninxJPM , HermanMC , MolBW , BongersMY . Bipolar radiofrequency endometrial ablation versus thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. Journal of Minimally Invasive Gynecology2012;19(6 Suppl 1):S21‐2. ">Penninx 2016</a>; <a href="./references#CD001501-bbs2-0023" title="PerinoA , CastelliA , CucinellaG , BiondoA , PaneA , VeneziaR . A randomized comparison of endometrial laser intrauterine thermotherapy and hysteroscopic endometrial resection. Fertility and Sterility2004;82:731‐4. ">Perino 2004</a>; <a href="./references#CD001501-bbs2-0025" title="SambrookA , EldersA , CooperK . Microwave endometrial ablation versus thermal balloon endometrial ablation (MEATBall): 5‐year follow up of a randomised controlled trial. British Journal of Obstetrics and Gynaecology2014;121:748‐54. [DOI: 10.1111/1471‐0528.12585] SambrookAM , CooperKG , CampbellMK , CookJA . Clinical outcomes from a randomised comparison of microwave endometrial ablation with thermal balloon endometrial ablation for the treatment of heavy menstrual bleeding. British Journal of Obstetrics and Gynaecology2009;116:1038‐45. ">Sambrook 2009</a>; <a href="./references#CD001501-bbs2-0026" title="ThabetSMA . New attempt using ablative curettage technique for managing benign premenopausal uterine bleeding. Obstetrics and Gynaecology Research2010;36(4):803‐9. ">Thabet 2010</a>; <a href="./references#CD001501-bbs2-0027" title="vanZon‐RabelinkIAA , VleugelsMPH . Treating menorrhagia with endometrial ablation: rollerball electrocoagulation versus thermal ablation with the uterine balloon. Gynaecological Endoscopy Abstract from the 6th Annual Congress of the European Society for Gynaecological Endoscopy1997;6 Suppl 2:41. vanZon‐RabelinkIAA , VleugelsMPH , MerkusHMWM , deGraafR . Efficacy and satisfaction rate comparing endometrial ablation by rollerball electrocoagulation to uterine balloon thermal ablation in a randomised controlled trial. European Journal of Obstetrics, Gynecology, and Reproductive Biology2004;114(1):97‐103. vanZon‐RabelinkIAA , VleugelsMPH , MerkusHMWM , deGraafR . Endometrial ablation by rollerball electrocoagulation compared to uterine balloon thermal ablation. Technical and safety aspects. European Journal of Obstetrics, Gynecology, and Reproductive Biology2003;110:220‐3. ">van Zon‐Rabelink 2003</a>). </p> </section> <section id="CD001501-sec-0097"> <h6 class="title">Mortality as a direct result of surgery</h6> <p>No trials reported mortality as a result of surgery.</p> </section> </section> <section id="CD001501-sec-0098"> <h5 class="title">Follow‐up</h5> <p>Eight trials followed up on women at 12 months (<a href="./references#CD001501-bbs2-0010" title="CooperJM , AndersonTL , FortinCA , JackSA , PlentlMB . Microwave endometrial ablation vs rollerball electroablation for menorrhagia: a multicenter randomized trial. Journal of the American Association of Gynecologic Laparoscopists2004;11(3):394‐403. ">Cooper 2004</a>; <a href="./references#CD001501-bbs2-0012" title="CorsonSL . A multicenter evaluation of endometrial ablation by hydrothermablator and rollerball for treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2001;8(3):359‐67. GoldrathMH . Evaluation of hydrothermablator and rollerball endometrial ablation for menorrhagia 3 years after treatment. Journal of the American Association of Gynecologic Laparoscopists2003;10(4):505‐11. LofferF . A clinical comparison of hydrothermablation (HTA) and rollerball for endometrial ablation to treat menorrhagia: a randomized multicenter clinical trial. XVI FIGO World Congress of Obstetrics &amp; Gynecology. 2000; Vol. Abstract Book 2:95. ">Corson 2001</a>; <a href="./references#CD001501-bbs2-0013" title="DulebaAJ , HeppardMC , SoderstromRM , TownsendDE . A randomized study comparing endometrial cryoablation and rollerball electroablation for treatment of dysfunctional uterine bleeding. Journal of the American Association of Gynecologic Laparoscopists2003;10(1):17‐26. TownsendDE , DulebaAJ , WilkesMM , et al. Durability of treatment effects after cryoablation versus rollerball electroablation for abnormal uterine bleeding: two‐year results of a multicenter randomized trial. American Journal of Obstetrics and Gynecology2003;188:699‐701. ">Duleba 2003</a>; <a href="./references#CD001501-bbs2-0016" title="LabergeP , Garza‐LealJ , FortinC , BasinskiC , ThielJ , LeylandN , et al. A prospective, randomized, multi‐center, controlled, international clinical study of the safety and efficacy of the Minerva endometrial ablation system: 6 and 12‐month follow‐up results. Journal of Minimally Invasive Gynecology. 2014. LabergeP , Garza‐LealJ , FortinC , GraingerD , JohnsDA , AdkinsRT , et al. A randomized controlled multicenter US Food and Drug Administration trial of the safety and efficacy of the Minerva Endometrial Ablation System: one‐year follow‐up results. Journal of Minimally Invasive Gynecology2017;24(1):124‐32. [DOI: 10.1016/j.jmig.2016.09.009] LabergeP , Garza‐LealJ , FortinC , ThielJ , JohnsD , GraingerD , et al. A randomized, controlled, multi‐center trial of the safety and efficacy of the Minerva Endometrial Ablation System: one‐year follow‐up results. Journal of Minimally Invasive Gynecology. 2016; Vol. 23:S1‐S252. ">Laberge 2016</a>; <a href="./references#CD001501-bbs2-0018" title="GraingerDA , TjadenDO , RowlandC , MeyerWR . Thermal balloon and rollerball ablation to treat menorrhagia: two‐year results of a multicenter, prospective, randomized clinical trial. Journal of the American Association of Gynecologic Laparoscopists2000;7(2):175‐9. LofferFD . Five year post‐procedure follow‐up of patients participating in a randomised trial of uterine balloon therapy vs rollerball ablation for the treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopy2001;8(1):48‐54. LofferFD . Three‐year comparison of thermal balloon and rollerball ablation in treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2001;8(1):48‐54. MeyerWR , WalshBW , GraingerDA , PeacockLM , LofferFD , SteegeJF . Thermal balloon and rollerball ablation to treat menorrhagia: a multicenter comparison. Obstetrics and Gynecology1998;92:98‐103. ">Meyer 1998</a>; <a href="./references#CD001501-bbs2-0022" title="PenninxJ , BongersM . Bipolar radiofrequency endometrial ablation versus thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. www.controlled‐trials.com/ISRCTN17974690. PenninxJ , HermanM , KruitwagenR , Ter HaarA , MolB , BongersM . Bipolar versus balloon endometrial ablation in the office: a randomized controlled trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;196:52‐6. [DOI: 10.1016/j.ejogrb.2015.10.010] PenninxJ , HermanM , MolB , KruitwagenR , BongersM . Bipolar radiofrequency endometrial ablation versus Thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. Journal of Minimally Invasive Gynecology2012;19(6):S21‐S22. [DOI: 10.1016/j.jmig.2012.08.076] PenninxJPM , HermanMC , MolBW , BongersMY . Bipolar radiofrequency endometrial ablation versus thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. Journal of Minimally Invasive Gynecology2012;19(6 Suppl 1):S21‐2. ">Penninx 2016</a>; <a href="./references#CD001501-bbs2-0023" title="PerinoA , CastelliA , CucinellaG , BiondoA , PaneA , VeneziaR . A randomized comparison of endometrial laser intrauterine thermotherapy and hysteroscopic endometrial resection. Fertility and Sterility2004;82:731‐4. ">Perino 2004</a>; <a href="./references#CD001501-bbs2-0028" title="VercelliniP , OldaniS , YaylayanL , ZainaB , DeGiorgiO , CrosignaniPG . Randomised comparison of vaporising electrode and cutting loop for endometrial ablation. Obstetrics and Gynecology1999;94:521‐7. ">Vercellini 1999</a>). Seven trials followed up on women at 3 and/or 6 months and at 12 months (<a href="./references#CD001501-bbs2-0001" title="AbbottJ , HaweJ , HunterD , GarryR . A double‐blind randomized trial comparing the Cavaterm and the Novasure endometrial ablation systems for the treatment of dysfunctional uterine bleeding. Fertility and Sterility2003;80(1):203‐8. ">Abbott 2003</a>; <a href="./references#CD001501-bbs2-0002" title="AthanatosD , PadosG , VenetisC , StamatopoulosP , RoussoD , TsolakidisD , et al. Novasure impedance control system versus microwave endometrial ablation for the treatment of dysfunctional uterine bleeding: a double‐blind, randomized controlled trial. Clinical and Experimental Obstetrics &amp; Gynecology2015;42(3):347‐51. [PMID: 26152008] PadosG . Treatment of dysfunctional uterine bleeding with second generation ablation devices: microwaves (MEAA) vs Bipolar Impedance Control System (Novasure). http://clinicaltrials.gov/show/NCT01173965. ">Athanatos 2015</a>; <a href="./references#CD001501-bbs2-0006" title="BrunJ‐L , RaynalJ , BurletG , GalandB , QuereuxC , BernardP . Cavaterm thermal balloon endometrial ablation versus hysteroscopic endometrial resection to treat menorrhagia: the French, multicenter, randomized study. Journal of Minimally Invasive Gynecology2006;13:424‐30. ">Brun 2006</a>; <a href="./references#CD001501-bbs2-0007" title="ClarkTJ , SamuelN , MalickS , MiddletonLJ , DanielsJ , GuptaJK . Bipolar radiofrequency compared with thermal balloon endometrial ablation in the office. Obstetrics and Gynecology2011;117:109‐18. ">Clark 2011</a>; <a href="./references#CD001501-bbs2-0009" title="CooperJ , GimpelsonR , LabergeP , GalenD , Garza‐LealJG , ScottJ , et al. A randomized, multicenter trial of safety and efficacy of the NovaSure system in the treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2002;9(4):418‐28. ">Cooper 2002</a>; <a href="./references#CD001501-bbs2-0011" title="CorsonSL , BrillAI , BrooksPG , CooperJM , IndmanPD , LiuJH , et al. Interim results of the American Vesta trial of endometrial ablation. Journal of the American Association of Gynecologic Laparoscopists1999;6(1):45‐9. CorsonSL , BrillAI , BrooksPG , CooperJM , IndmanPD , LiuJH , et al. One‐year results of the Vesta system for endometrial ablation. Journal of the American Association of Gynecologic Laparoscopists2000;7(4):489‐97. ">Corson 2000</a>; <a href="./references#CD001501-bbs2-0015" title="HaweJ , AbbottJ , HunterD , PhillipsG , GarryR . A randomised controlled trial comparing the Cavaterm endometrial ablation system with the Nd:YAG laser for the treatment of dysfunctional uterine bleeding. British Journal of Obstetrics and Gynaecology2003;110:350‐7. ">Hawe 2003</a>). One trial provided 6 months' follow‐up (<a href="./references#CD001501-bbs2-0017" title="McClureN , MarnersM , HealyDL , HillDJ , LawrenceAS , WingfieldM , et al. A quantitative assessment of endometrial electrocautery in the management of menorrhagia and a comparative report of argon laser endometrial ablation. Gynaecological Endoscopy1992;1:199‐202. ">McClure 1992</a>), and another provided 9 and 15 months' follow‐up (<a href="./references#CD001501-bbs2-0024" title="RomerT . The treatment of recurrent menorrhagias ‐ Cavaterm‐balloon‐coagulation versus Rollerball‐endometrial ablation ‐ a prospective randomized comparative study [Die therapie rezidivierender Menorrhagien ‐ Cavaterm‐Ballon‐Koagulatioon versus Roller‐Ball‐Endometriumkoagulation ‐ eine prospektive randomisierte Vergleichsstudie]. Zentralblatt fur Gynakologie1998;120(10):511‐4. ">Romer 1998</a>). </p> <p>One trial reported 3, 12, and 24 months' follow‐up (<a href="./references#CD001501-bbs2-0020" title="PellicanoM , GuidaM , AcunzoG , CirilloD , BifulcoG , NappiC . Hysteroscopic transcervical endometrial resection versus thermal destruction for menorrhagia: a prospective randomized trial on satisfaction rate. American Journal of Obstetrics and Gynecology2002;187:545‐50. ">Pellicano 2002</a>). Two provided follow‐up at different times and up to 5 years (<a href="./references#CD001501-bbs2-0021" title="BongersM , HermanM , PenninxJ , MolBW . Longterm follow‐up of a randomized controlled trial comparing NovaSure and hydrothermablation for dysfunctional uterine bleeding. Journal of Minimally Invasive Gynecology2011;18(6 Suppl 1):S34. PenninxJPM , HermanMC , MolBW , BongersMY . Five‐year follow‐up after comparing bipolar endometrial ablation with hydrothermablation for menorrhagia. Obstetrics and Gynecology2011;118:1287‐92. PenninxJPM , MolBW , EngelsR , vanRumsteMME , KleijnC , KoksCAM , et al. Bipolar radiofrequency endometrial ablation compared with hydrothermablation for dysfunctional uterine bleeding. Obstetrics and Gynecology2010;116:819‐26. ">Penninx 2010</a>; <a href="./references#CD001501-bbs2-0025" title="SambrookA , EldersA , CooperK . Microwave endometrial ablation versus thermal balloon endometrial ablation (MEATBall): 5‐year follow up of a randomised controlled trial. British Journal of Obstetrics and Gynaecology2014;121:748‐54. [DOI: 10.1111/1471‐0528.12585] SambrookAM , CooperKG , CampbellMK , CookJA . Clinical outcomes from a randomised comparison of microwave endometrial ablation with thermal balloon endometrial ablation for the treatment of heavy menstrual bleeding. British Journal of Obstetrics and Gynaecology2009;116:1038‐45. ">Sambrook 2009</a>). Three trials followed up at different times and up to 10 years (<a href="./references#CD001501-bbs2-0004" title="BongersM , HermanM , JosienP , MolBW . Ten‐year follow‐up of a randomized controlled trial comparing NovaSure and Thermachoice in endometrial ablation for dysfunctional uterine bleeding. Journal of Minimally Invasive Gynecology2011;18(6 Suppl 1):S127. BongersMY , BourdrezP , HeintzPM , BrolmannHAM , MolBWJ . Bipolar radio frequency endometrial ablation compared with balloon endometrial ablation in dysfunctional uterine bleeding: impact on patients' health‐related quality of life. Fertility and Sterility2005;83(3):724‐34. BongersMY , BourdrezP , MolBWJ , HeintzAPM , BrolmannHAM . Randomised controlled trial of bipolar radio‐frequency endometrial ablation and balloon endometrial ablation. British Journal of Obstetrics and Gynaecology2004;111:1095‐102. HermanM , PenninxM , MolB , BongersM . Ten‐year follow‐up of a randomised controlled trial comparing bipolar endometrial ablation with balloon ablation for heavy menstrual bleeding. British Journal Obstetrics and Gynaecology2013;120:966‐970. [DOI: 10.1111/1471‐0528.12213] KleijnJH , EngelsR , BourdrezP , MolBWJ , BongersMY . Five‐year follow up of a randomised controlled trial comparing NovaSure and ThermaChoice endometrial ablation. British Journal of Obstetrics and Gynaecology2008;115:193‐8. ">Bongers 2004</a>; <a href="./references#CD001501-bbs2-0005" title="BoujidaVH , PhilipsenT , PelleJ , JoergensenJC . Five‐year follow‐up of endometrial ablation: endometrial coagulation versus endometrial resection. Obstetrics and Gynecology2002;99:988‐92. FurstSN , PhilipsenT , JoergensenJC . Ten‐year follow‐up of endometrial ablation. Acta Obstetricia et Gynecologica2007;86:334‐8. ">Boujida 2002</a>; <a href="./references#CD001501-bbs2-0008" title="BainC , CooperKG , ParkinDE . Microwave endometrial ablation versus endometrial resection: a randomized controlled trial. Obstetrics and Gynecology2002;99:983‐7. CooperKG , BainC , LawrieL , ParkinDE . A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium: follow up at a minimum of five years. British Journal of Obstetrics and Gynaecology2005;112:470‐5. CooperKG , BainC , ParkinDE . Comparison of microwave endometrial ablation and transcervical resection of the endometrium for treatment of heavy menstrual loss: a randomised trial. Lancet1999;354:1859‐63. SambrookAM , BainC , ParkinDE , CooperKG . A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium: follow up at a minimum of 10 years. British Journal of Obstetrics and Gynaecology2009;116:1033‐7. ">Cooper 1999</a>). </p> <p>One trial did not follow up on women, and all outcomes were related to the procedure (<a href="./references#CD001501-bbs2-0027" title="vanZon‐RabelinkIAA , VleugelsMPH . Treating menorrhagia with endometrial ablation: rollerball electrocoagulation versus thermal ablation with the uterine balloon. Gynaecological Endoscopy Abstract from the 6th Annual Congress of the European Society for Gynaecological Endoscopy1997;6 Suppl 2:41. vanZon‐RabelinkIAA , VleugelsMPH , MerkusHMWM , deGraafR . Efficacy and satisfaction rate comparing endometrial ablation by rollerball electrocoagulation to uterine balloon thermal ablation in a randomised controlled trial. European Journal of Obstetrics, Gynecology, and Reproductive Biology2004;114(1):97‐103. vanZon‐RabelinkIAA , VleugelsMPH , MerkusHMWM , deGraafR . Endometrial ablation by rollerball electrocoagulation compared to uterine balloon thermal ablation. Technical and safety aspects. European Journal of Obstetrics, Gynecology, and Reproductive Biology2003;110:220‐3. ">van Zon‐Rabelink 2003</a>). </p> <p>Three trials described unclear follow‐up time (<a href="./references#CD001501-bbs2-0014" title="GhazizadehS , PanahiZ , GhanbariZ , Tarafdari MenshadiA , FarahmandianT , JavadianP . Comparative efficacy of NovaSure, the levonorgestrel‐releasing intrauterine system, and hysteroscopic endometrial resection in the treatment of menorrhagia: a randomized clinical trial. Journal of Gynecologic Surgery2014;30(4):215‐8. [DOI: 10.1089/gyn.2012.0041] ">Ghazizadeh 2014</a>; <a href="./references#CD001501-bbs2-0019" title="OnogluA , TaskinO , InalM , SadikS , SimsekM , AkarM , et al. Comparison of the long‐term histopathologic and morphologic changes after endometrial rollerball ablation and resection: a prospective randomized trial. Journal of Minimally Invasive Gynecology2007;14:39‐42. ">Onoglu 2007</a>; <a href="./references#CD001501-bbs2-0026" title="ThabetSMA . New attempt using ablative curettage technique for managing benign premenopausal uterine bleeding. Obstetrics and Gynaecology Research2010;36(4):803‐9. ">Thabet 2010</a>). </p> </section> <section id="CD001501-sec-0099"> <h5 class="title">Funding and conflicts of interest</h5> <p>In terms of funding, four trials reported institutional or government funding: from the Chief Scientist Office at the Scottish Department of Health (<a href="./references#CD001501-bbs2-0003" title="BhattacharyaS , CameronIM , ParkinDE , AbramovichDR , MollisonJ , PinionSB , et al. A pragmatic randomised comparison of transcervical resection of the endometrium with endometrial laser ablation for the treatment of menorrhagia. British Journal of Obstetrics and Gynaecology1997;104:601‐7. ">Bhattacharya 1997</a>), from the Research Foundation of the County of West Zealand (<a href="./references#CD001501-bbs2-0005" title="BoujidaVH , PhilipsenT , PelleJ , JoergensenJC . Five‐year follow‐up of endometrial ablation: endometrial coagulation versus endometrial resection. Obstetrics and Gynecology2002;99:988‐92. FurstSN , PhilipsenT , JoergensenJC . Ten‐year follow‐up of endometrial ablation. Acta Obstetricia et Gynecologica2007;86:334‐8. ">Boujida 2002</a>), from Akdeniz University (<a href="./references#CD001501-bbs2-0019" title="OnogluA , TaskinO , InalM , SadikS , SimsekM , AkarM , et al. Comparison of the long‐term histopathologic and morphologic changes after endometrial rollerball ablation and resection: a prospective randomized trial. Journal of Minimally Invasive Gynecology2007;14:39‐42. ">Onoglu 2007</a>), and from the Chief Scientist Office at the Scottish Government Health Directorates (<a href="./references#CD001501-bbs2-0025" title="SambrookA , EldersA , CooperK . Microwave endometrial ablation versus thermal balloon endometrial ablation (MEATBall): 5‐year follow up of a randomised controlled trial. British Journal of Obstetrics and Gynaecology2014;121:748‐54. [DOI: 10.1111/1471‐0528.12585] SambrookAM , CooperKG , CampbellMK , CookJA . Clinical outcomes from a randomised comparison of microwave endometrial ablation with thermal balloon endometrial ablation for the treatment of heavy menstrual bleeding. British Journal of Obstetrics and Gynaecology2009;116:1038‐45. ">Sambrook 2009</a>). </p> <p>Fourteen trials reported that funding was received from industry, that study authors were associated with industry, or that equipment was provided by industry (<a href="./references#CD001501-bbs2-0001" title="AbbottJ , HaweJ , HunterD , GarryR . A double‐blind randomized trial comparing the Cavaterm and the Novasure endometrial ablation systems for the treatment of dysfunctional uterine bleeding. Fertility and Sterility2003;80(1):203‐8. ">Abbott 2003</a>; <a href="./references#CD001501-bbs2-0004" title="BongersM , HermanM , JosienP , MolBW . Ten‐year follow‐up of a randomized controlled trial comparing NovaSure and Thermachoice in endometrial ablation for dysfunctional uterine bleeding. Journal of Minimally Invasive Gynecology2011;18(6 Suppl 1):S127. BongersMY , BourdrezP , HeintzPM , BrolmannHAM , MolBWJ . Bipolar radio frequency endometrial ablation compared with balloon endometrial ablation in dysfunctional uterine bleeding: impact on patients' health‐related quality of life. Fertility and Sterility2005;83(3):724‐34. BongersMY , BourdrezP , MolBWJ , HeintzAPM , BrolmannHAM . Randomised controlled trial of bipolar radio‐frequency endometrial ablation and balloon endometrial ablation. British Journal of Obstetrics and Gynaecology2004;111:1095‐102. HermanM , PenninxM , MolB , BongersM . Ten‐year follow‐up of a randomised controlled trial comparing bipolar endometrial ablation with balloon ablation for heavy menstrual bleeding. British Journal Obstetrics and Gynaecology2013;120:966‐970. [DOI: 10.1111/1471‐0528.12213] KleijnJH , EngelsR , BourdrezP , MolBWJ , BongersMY . Five‐year follow up of a randomised controlled trial comparing NovaSure and ThermaChoice endometrial ablation. British Journal of Obstetrics and Gynaecology2008;115:193‐8. ">Bongers 2004</a>; <a href="./references#CD001501-bbs2-0007" title="ClarkTJ , SamuelN , MalickS , MiddletonLJ , DanielsJ , GuptaJK . Bipolar radiofrequency compared with thermal balloon endometrial ablation in the office. Obstetrics and Gynecology2011;117:109‐18. ">Clark 2011</a>; <a href="./references#CD001501-bbs2-0008" title="BainC , CooperKG , ParkinDE . Microwave endometrial ablation versus endometrial resection: a randomized controlled trial. Obstetrics and Gynecology2002;99:983‐7. CooperKG , BainC , LawrieL , ParkinDE . A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium: follow up at a minimum of five years. British Journal of Obstetrics and Gynaecology2005;112:470‐5. CooperKG , BainC , ParkinDE . Comparison of microwave endometrial ablation and transcervical resection of the endometrium for treatment of heavy menstrual loss: a randomised trial. Lancet1999;354:1859‐63. SambrookAM , BainC , ParkinDE , CooperKG . A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium: follow up at a minimum of 10 years. British Journal of Obstetrics and Gynaecology2009;116:1033‐7. ">Cooper 1999</a>; <a href="./references#CD001501-bbs2-0009" title="CooperJ , GimpelsonR , LabergeP , GalenD , Garza‐LealJG , ScottJ , et al. A randomized, multicenter trial of safety and efficacy of the NovaSure system in the treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2002;9(4):418‐28. ">Cooper 2002</a>; <a href="./references#CD001501-bbs2-0010" title="CooperJM , AndersonTL , FortinCA , JackSA , PlentlMB . Microwave endometrial ablation vs rollerball electroablation for menorrhagia: a multicenter randomized trial. Journal of the American Association of Gynecologic Laparoscopists2004;11(3):394‐403. ">Cooper 2004</a>; <a href="./references#CD001501-bbs2-0011" title="CorsonSL , BrillAI , BrooksPG , CooperJM , IndmanPD , LiuJH , et al. Interim results of the American Vesta trial of endometrial ablation. Journal of the American Association of Gynecologic Laparoscopists1999;6(1):45‐9. CorsonSL , BrillAI , BrooksPG , CooperJM , IndmanPD , LiuJH , et al. One‐year results of the Vesta system for endometrial ablation. Journal of the American Association of Gynecologic Laparoscopists2000;7(4):489‐97. ">Corson 2000</a>; <a href="./references#CD001501-bbs2-0012" title="CorsonSL . A multicenter evaluation of endometrial ablation by hydrothermablator and rollerball for treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2001;8(3):359‐67. GoldrathMH . Evaluation of hydrothermablator and rollerball endometrial ablation for menorrhagia 3 years after treatment. Journal of the American Association of Gynecologic Laparoscopists2003;10(4):505‐11. LofferF . A clinical comparison of hydrothermablation (HTA) and rollerball for endometrial ablation to treat menorrhagia: a randomized multicenter clinical trial. XVI FIGO World Congress of Obstetrics &amp; Gynecology. 2000; Vol. Abstract Book 2:95. ">Corson 2001</a>; <a href="./references#CD001501-bbs2-0013" title="DulebaAJ , HeppardMC , SoderstromRM , TownsendDE . A randomized study comparing endometrial cryoablation and rollerball electroablation for treatment of dysfunctional uterine bleeding. Journal of the American Association of Gynecologic Laparoscopists2003;10(1):17‐26. TownsendDE , DulebaAJ , WilkesMM , et al. Durability of treatment effects after cryoablation versus rollerball electroablation for abnormal uterine bleeding: two‐year results of a multicenter randomized trial. American Journal of Obstetrics and Gynecology2003;188:699‐701. ">Duleba 2003</a>; <a href="./references#CD001501-bbs2-0015" title="HaweJ , AbbottJ , HunterD , PhillipsG , GarryR . A randomised controlled trial comparing the Cavaterm endometrial ablation system with the Nd:YAG laser for the treatment of dysfunctional uterine bleeding. British Journal of Obstetrics and Gynaecology2003;110:350‐7. ">Hawe 2003</a>; <a href="./references#CD001501-bbs2-0016" title="LabergeP , Garza‐LealJ , FortinC , BasinskiC , ThielJ , LeylandN , et al. A prospective, randomized, multi‐center, controlled, international clinical study of the safety and efficacy of the Minerva endometrial ablation system: 6 and 12‐month follow‐up results. Journal of Minimally Invasive Gynecology. 2014. LabergeP , Garza‐LealJ , FortinC , GraingerD , JohnsDA , AdkinsRT , et al. A randomized controlled multicenter US Food and Drug Administration trial of the safety and efficacy of the Minerva Endometrial Ablation System: one‐year follow‐up results. Journal of Minimally Invasive Gynecology2017;24(1):124‐32. [DOI: 10.1016/j.jmig.2016.09.009] LabergeP , Garza‐LealJ , FortinC , ThielJ , JohnsD , GraingerD , et al. A randomized, controlled, multi‐center trial of the safety and efficacy of the Minerva Endometrial Ablation System: one‐year follow‐up results. Journal of Minimally Invasive Gynecology. 2016; Vol. 23:S1‐S252. ">Laberge 2016</a>; <a href="./references#CD001501-bbs2-0018" title="GraingerDA , TjadenDO , RowlandC , MeyerWR . Thermal balloon and rollerball ablation to treat menorrhagia: two‐year results of a multicenter, prospective, randomized clinical trial. Journal of the American Association of Gynecologic Laparoscopists2000;7(2):175‐9. LofferFD . Five year post‐procedure follow‐up of patients participating in a randomised trial of uterine balloon therapy vs rollerball ablation for the treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopy2001;8(1):48‐54. LofferFD . Three‐year comparison of thermal balloon and rollerball ablation in treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2001;8(1):48‐54. MeyerWR , WalshBW , GraingerDA , PeacockLM , LofferFD , SteegeJF . Thermal balloon and rollerball ablation to treat menorrhagia: a multicenter comparison. Obstetrics and Gynecology1998;92:98‐103. ">Meyer 1998</a>; <a href="./references#CD001501-bbs2-0020" title="PellicanoM , GuidaM , AcunzoG , CirilloD , BifulcoG , NappiC . Hysteroscopic transcervical endometrial resection versus thermal destruction for menorrhagia: a prospective randomized trial on satisfaction rate. American Journal of Obstetrics and Gynecology2002;187:545‐50. ">Pellicano 2002</a>; <a href="./references#CD001501-bbs2-0028" title="VercelliniP , OldaniS , YaylayanL , ZainaB , DeGiorgiO , CrosignaniPG . Randomised comparison of vaporising electrode and cutting loop for endometrial ablation. Obstetrics and Gynecology1999;94:521‐7. ">Vercellini 1999</a>). One trial acknowledged a medical equipment company for technical assistance, but it is unknown whether or not the trial received funding (<a href="./references#CD001501-bbs2-0006" title="BrunJ‐L , RaynalJ , BurletG , GalandB , QuereuxC , BernardP . Cavaterm thermal balloon endometrial ablation versus hysteroscopic endometrial resection to treat menorrhagia: the French, multicenter, randomized study. Journal of Minimally Invasive Gynecology2006;13:424‐30. ">Brun 2006</a>). </p> <p>Two trials reported no external funding (<a href="./references#CD001501-bbs2-0014" title="GhazizadehS , PanahiZ , GhanbariZ , Tarafdari MenshadiA , FarahmandianT , JavadianP . Comparative efficacy of NovaSure, the levonorgestrel‐releasing intrauterine system, and hysteroscopic endometrial resection in the treatment of menorrhagia: a randomized clinical trial. Journal of Gynecologic Surgery2014;30(4):215‐8. [DOI: 10.1089/gyn.2012.0041] ">Ghazizadeh 2014</a>; <a href="./references#CD001501-bbs2-0022" title="PenninxJ , BongersM . Bipolar radiofrequency endometrial ablation versus thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. www.controlled‐trials.com/ISRCTN17974690. PenninxJ , HermanM , KruitwagenR , Ter HaarA , MolB , BongersM . Bipolar versus balloon endometrial ablation in the office: a randomized controlled trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;196:52‐6. [DOI: 10.1016/j.ejogrb.2015.10.010] PenninxJ , HermanM , MolB , KruitwagenR , BongersM . Bipolar radiofrequency endometrial ablation versus Thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. Journal of Minimally Invasive Gynecology2012;19(6):S21‐S22. [DOI: 10.1016/j.jmig.2012.08.076] PenninxJPM , HermanMC , MolBW , BongersMY . Bipolar radiofrequency endometrial ablation versus thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. Journal of Minimally Invasive Gynecology2012;19(6 Suppl 1):S21‐2. ">Penninx 2016</a>). </p> <p>Seven trials did not report details on the source of funding (<a href="./references#CD001501-bbs2-0002" title="AthanatosD , PadosG , VenetisC , StamatopoulosP , RoussoD , TsolakidisD , et al. Novasure impedance control system versus microwave endometrial ablation for the treatment of dysfunctional uterine bleeding: a double‐blind, randomized controlled trial. Clinical and Experimental Obstetrics &amp; Gynecology2015;42(3):347‐51. [PMID: 26152008] PadosG . Treatment of dysfunctional uterine bleeding with second generation ablation devices: microwaves (MEAA) vs Bipolar Impedance Control System (Novasure). http://clinicaltrials.gov/show/NCT01173965. ">Athanatos 2015</a>; <a href="./references#CD001501-bbs2-0017" title="McClureN , MarnersM , HealyDL , HillDJ , LawrenceAS , WingfieldM , et al. A quantitative assessment of endometrial electrocautery in the management of menorrhagia and a comparative report of argon laser endometrial ablation. Gynaecological Endoscopy1992;1:199‐202. ">McClure 1992</a>; <a href="./references#CD001501-bbs2-0021" title="BongersM , HermanM , PenninxJ , MolBW . Longterm follow‐up of a randomized controlled trial comparing NovaSure and hydrothermablation for dysfunctional uterine bleeding. Journal of Minimally Invasive Gynecology2011;18(6 Suppl 1):S34. PenninxJPM , HermanMC , MolBW , BongersMY . Five‐year follow‐up after comparing bipolar endometrial ablation with hydrothermablation for menorrhagia. Obstetrics and Gynecology2011;118:1287‐92. PenninxJPM , MolBW , EngelsR , vanRumsteMME , KleijnC , KoksCAM , et al. Bipolar radiofrequency endometrial ablation compared with hydrothermablation for dysfunctional uterine bleeding. Obstetrics and Gynecology2010;116:819‐26. ">Penninx 2010</a>; <a href="./references#CD001501-bbs2-0023" title="PerinoA , CastelliA , CucinellaG , BiondoA , PaneA , VeneziaR . A randomized comparison of endometrial laser intrauterine thermotherapy and hysteroscopic endometrial resection. Fertility and Sterility2004;82:731‐4. ">Perino 2004</a>; <a href="./references#CD001501-bbs2-0024" title="RomerT . The treatment of recurrent menorrhagias ‐ Cavaterm‐balloon‐coagulation versus Rollerball‐endometrial ablation ‐ a prospective randomized comparative study [Die therapie rezidivierender Menorrhagien ‐ Cavaterm‐Ballon‐Koagulatioon versus Roller‐Ball‐Endometriumkoagulation ‐ eine prospektive randomisierte Vergleichsstudie]. Zentralblatt fur Gynakologie1998;120(10):511‐4. ">Romer 1998</a>; <a href="./references#CD001501-bbs2-0026" title="ThabetSMA . New attempt using ablative curettage technique for managing benign premenopausal uterine bleeding. Obstetrics and Gynaecology Research2010;36(4):803‐9. ">Thabet 2010</a>; <a href="./references#CD001501-bbs2-0027" title="vanZon‐RabelinkIAA , VleugelsMPH . Treating menorrhagia with endometrial ablation: rollerball electrocoagulation versus thermal ablation with the uterine balloon. Gynaecological Endoscopy Abstract from the 6th Annual Congress of the European Society for Gynaecological Endoscopy1997;6 Suppl 2:41. vanZon‐RabelinkIAA , VleugelsMPH , MerkusHMWM , deGraafR . Efficacy and satisfaction rate comparing endometrial ablation by rollerball electrocoagulation to uterine balloon thermal ablation in a randomised controlled trial. European Journal of Obstetrics, Gynecology, and Reproductive Biology2004;114(1):97‐103. vanZon‐RabelinkIAA , VleugelsMPH , MerkusHMWM , deGraafR . Endometrial ablation by rollerball electrocoagulation compared to uterine balloon thermal ablation. Technical and safety aspects. European Journal of Obstetrics, Gynecology, and Reproductive Biology2003;110:220‐3. ">van Zon‐Rabelink 2003</a>). </p> <p>Four trials reported conflicts of interest.</p> <p> <ul id="CD001501-list-0027"> <li> <p><a href="./references#CD001501-bbs2-0008" title="BainC , CooperKG , ParkinDE . Microwave endometrial ablation versus endometrial resection: a randomized controlled trial. Obstetrics and Gynecology2002;99:983‐7. CooperKG , BainC , LawrieL , ParkinDE . A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium: follow up at a minimum of five years. British Journal of Obstetrics and Gynaecology2005;112:470‐5. CooperKG , BainC , ParkinDE . Comparison of microwave endometrial ablation and transcervical resection of the endometrium for treatment of heavy menstrual loss: a randomised trial. Lancet1999;354:1859‐63. SambrookAM , BainC , ParkinDE , CooperKG . A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium: follow up at a minimum of 10 years. British Journal of Obstetrics and Gynaecology2009;116:1033‐7. ">Cooper 1999</a>: one study author was funded in part by industry as a research fellow, other study authors had received travel and accommodation support from industry for attending conferences and training courses, and one study author is director and a stock shareholder and receives travel grants from industry. </p> </li> <li> <p><a href="./references#CD001501-bbs2-0013" title="DulebaAJ , HeppardMC , SoderstromRM , TownsendDE . A randomized study comparing endometrial cryoablation and rollerball electroablation for treatment of dysfunctional uterine bleeding. Journal of the American Association of Gynecologic Laparoscopists2003;10(1):17‐26. TownsendDE , DulebaAJ , WilkesMM , et al. Durability of treatment effects after cryoablation versus rollerball electroablation for abnormal uterine bleeding: two‐year results of a multicenter randomized trial. American Journal of Obstetrics and Gynecology2003;188:699‐701. ">Duleba 2003</a>: study authors are consultants for industry. </p> </li> <li> <p><a href="./references#CD001501-bbs2-0021" title="BongersM , HermanM , PenninxJ , MolBW . Longterm follow‐up of a randomized controlled trial comparing NovaSure and hydrothermablation for dysfunctional uterine bleeding. Journal of Minimally Invasive Gynecology2011;18(6 Suppl 1):S34. PenninxJPM , HermanMC , MolBW , BongersMY . Five‐year follow‐up after comparing bipolar endometrial ablation with hydrothermablation for menorrhagia. Obstetrics and Gynecology2011;118:1287‐92. PenninxJPM , MolBW , EngelsR , vanRumsteMME , KleijnC , KoksCAM , et al. Bipolar radiofrequency endometrial ablation compared with hydrothermablation for dysfunctional uterine bleeding. Obstetrics and Gynecology2010;116:819‐26. ">Penninx 2010</a>: one study author received an unconditional grant from industry for another research project. </p> </li> <li> <p><a href="./references#CD001501-bbs2-0025" title="SambrookA , EldersA , CooperK . Microwave endometrial ablation versus thermal balloon endometrial ablation (MEATBall): 5‐year follow up of a randomised controlled trial. British Journal of Obstetrics and Gynaecology2014;121:748‐54. [DOI: 10.1111/1471‐0528.12585] SambrookAM , CooperKG , CampbellMK , CookJA . Clinical outcomes from a randomised comparison of microwave endometrial ablation with thermal balloon endometrial ablation for the treatment of heavy menstrual bleeding. British Journal of Obstetrics and Gynaecology2009;116:1038‐45. ">Sambrook 2009</a>: two study authors received financial support from industry for travel and for attending meetings. </p> </li> </ul> </p> <p>Three studies declared that authors had no conflicts of interest (<a href="./references#CD001501-bbs2-0001" title="AbbottJ , HaweJ , HunterD , GarryR . A double‐blind randomized trial comparing the Cavaterm and the Novasure endometrial ablation systems for the treatment of dysfunctional uterine bleeding. Fertility and Sterility2003;80(1):203‐8. ">Abbott 2003</a>; <a href="./references#CD001501-bbs2-0016" title="LabergeP , Garza‐LealJ , FortinC , BasinskiC , ThielJ , LeylandN , et al. A prospective, randomized, multi‐center, controlled, international clinical study of the safety and efficacy of the Minerva endometrial ablation system: 6 and 12‐month follow‐up results. Journal of Minimally Invasive Gynecology. 2014. LabergeP , Garza‐LealJ , FortinC , GraingerD , JohnsDA , AdkinsRT , et al. A randomized controlled multicenter US Food and Drug Administration trial of the safety and efficacy of the Minerva Endometrial Ablation System: one‐year follow‐up results. Journal of Minimally Invasive Gynecology2017;24(1):124‐32. [DOI: 10.1016/j.jmig.2016.09.009] LabergeP , Garza‐LealJ , FortinC , ThielJ , JohnsD , GraingerD , et al. A randomized, controlled, multi‐center trial of the safety and efficacy of the Minerva Endometrial Ablation System: one‐year follow‐up results. Journal of Minimally Invasive Gynecology. 2016; Vol. 23:S1‐S252. ">Laberge 2016</a>; <a href="./references#CD001501-bbs2-0022" title="PenninxJ , BongersM . Bipolar radiofrequency endometrial ablation versus thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. www.controlled‐trials.com/ISRCTN17974690. PenninxJ , HermanM , KruitwagenR , Ter HaarA , MolB , BongersM . Bipolar versus balloon endometrial ablation in the office: a randomized controlled trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;196:52‐6. [DOI: 10.1016/j.ejogrb.2015.10.010] PenninxJ , HermanM , MolB , KruitwagenR , BongersM . Bipolar radiofrequency endometrial ablation versus Thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. Journal of Minimally Invasive Gynecology2012;19(6):S21‐S22. [DOI: 10.1016/j.jmig.2012.08.076] PenninxJPM , HermanMC , MolBW , BongersMY . Bipolar radiofrequency endometrial ablation versus thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. Journal of Minimally Invasive Gynecology2012;19(6 Suppl 1):S21‐2. ">Penninx 2016</a>). </p> <p>Twenty‐one trials provided no details on conflicts of interest (<a href="./references#CD001501-bbs2-0002" title="AthanatosD , PadosG , VenetisC , StamatopoulosP , RoussoD , TsolakidisD , et al. Novasure impedance control system versus microwave endometrial ablation for the treatment of dysfunctional uterine bleeding: a double‐blind, randomized controlled trial. Clinical and Experimental Obstetrics &amp; Gynecology2015;42(3):347‐51. [PMID: 26152008] PadosG . Treatment of dysfunctional uterine bleeding with second generation ablation devices: microwaves (MEAA) vs Bipolar Impedance Control System (Novasure). http://clinicaltrials.gov/show/NCT01173965. ">Athanatos 2015</a>; <a href="./references#CD001501-bbs2-0003" title="BhattacharyaS , CameronIM , ParkinDE , AbramovichDR , MollisonJ , PinionSB , et al. A pragmatic randomised comparison of transcervical resection of the endometrium with endometrial laser ablation for the treatment of menorrhagia. British Journal of Obstetrics and Gynaecology1997;104:601‐7. ">Bhattacharya 1997</a>; <a href="./references#CD001501-bbs2-0004" title="BongersM , HermanM , JosienP , MolBW . Ten‐year follow‐up of a randomized controlled trial comparing NovaSure and Thermachoice in endometrial ablation for dysfunctional uterine bleeding. Journal of Minimally Invasive Gynecology2011;18(6 Suppl 1):S127. BongersMY , BourdrezP , HeintzPM , BrolmannHAM , MolBWJ . Bipolar radio frequency endometrial ablation compared with balloon endometrial ablation in dysfunctional uterine bleeding: impact on patients' health‐related quality of life. Fertility and Sterility2005;83(3):724‐34. BongersMY , BourdrezP , MolBWJ , HeintzAPM , BrolmannHAM . Randomised controlled trial of bipolar radio‐frequency endometrial ablation and balloon endometrial ablation. British Journal of Obstetrics and Gynaecology2004;111:1095‐102. HermanM , PenninxM , MolB , BongersM . Ten‐year follow‐up of a randomised controlled trial comparing bipolar endometrial ablation with balloon ablation for heavy menstrual bleeding. British Journal Obstetrics and Gynaecology2013;120:966‐970. [DOI: 10.1111/1471‐0528.12213] KleijnJH , EngelsR , BourdrezP , MolBWJ , BongersMY . Five‐year follow up of a randomised controlled trial comparing NovaSure and ThermaChoice endometrial ablation. British Journal of Obstetrics and Gynaecology2008;115:193‐8. ">Bongers 2004</a>; <a href="./references#CD001501-bbs2-0005" title="BoujidaVH , PhilipsenT , PelleJ , JoergensenJC . Five‐year follow‐up of endometrial ablation: endometrial coagulation versus endometrial resection. Obstetrics and Gynecology2002;99:988‐92. FurstSN , PhilipsenT , JoergensenJC . Ten‐year follow‐up of endometrial ablation. Acta Obstetricia et Gynecologica2007;86:334‐8. ">Boujida 2002</a>; <a href="./references#CD001501-bbs2-0006" title="BrunJ‐L , RaynalJ , BurletG , GalandB , QuereuxC , BernardP . Cavaterm thermal balloon endometrial ablation versus hysteroscopic endometrial resection to treat menorrhagia: the French, multicenter, randomized study. Journal of Minimally Invasive Gynecology2006;13:424‐30. ">Brun 2006</a>; <a href="./references#CD001501-bbs2-0007" title="ClarkTJ , SamuelN , MalickS , MiddletonLJ , DanielsJ , GuptaJK . Bipolar radiofrequency compared with thermal balloon endometrial ablation in the office. Obstetrics and Gynecology2011;117:109‐18. ">Clark 2011</a>; <a href="./references#CD001501-bbs2-0009" title="CooperJ , GimpelsonR , LabergeP , GalenD , Garza‐LealJG , ScottJ , et al. A randomized, multicenter trial of safety and efficacy of the NovaSure system in the treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2002;9(4):418‐28. ">Cooper 2002</a>; <a href="./references#CD001501-bbs2-0010" title="CooperJM , AndersonTL , FortinCA , JackSA , PlentlMB . Microwave endometrial ablation vs rollerball electroablation for menorrhagia: a multicenter randomized trial. Journal of the American Association of Gynecologic Laparoscopists2004;11(3):394‐403. ">Cooper 2004</a>; <a href="./references#CD001501-bbs2-0011" title="CorsonSL , BrillAI , BrooksPG , CooperJM , IndmanPD , LiuJH , et al. Interim results of the American Vesta trial of endometrial ablation. Journal of the American Association of Gynecologic Laparoscopists1999;6(1):45‐9. CorsonSL , BrillAI , BrooksPG , CooperJM , IndmanPD , LiuJH , et al. One‐year results of the Vesta system for endometrial ablation. Journal of the American Association of Gynecologic Laparoscopists2000;7(4):489‐97. ">Corson 2000</a>; <a href="./references#CD001501-bbs2-0012" title="CorsonSL . A multicenter evaluation of endometrial ablation by hydrothermablator and rollerball for treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2001;8(3):359‐67. GoldrathMH . Evaluation of hydrothermablator and rollerball endometrial ablation for menorrhagia 3 years after treatment. Journal of the American Association of Gynecologic Laparoscopists2003;10(4):505‐11. LofferF . A clinical comparison of hydrothermablation (HTA) and rollerball for endometrial ablation to treat menorrhagia: a randomized multicenter clinical trial. XVI FIGO World Congress of Obstetrics &amp; Gynecology. 2000; Vol. Abstract Book 2:95. ">Corson 2001</a>; <a href="./references#CD001501-bbs2-0014" title="GhazizadehS , PanahiZ , GhanbariZ , Tarafdari MenshadiA , FarahmandianT , JavadianP . Comparative efficacy of NovaSure, the levonorgestrel‐releasing intrauterine system, and hysteroscopic endometrial resection in the treatment of menorrhagia: a randomized clinical trial. Journal of Gynecologic Surgery2014;30(4):215‐8. [DOI: 10.1089/gyn.2012.0041] ">Ghazizadeh 2014</a>; <a href="./references#CD001501-bbs2-0015" title="HaweJ , AbbottJ , HunterD , PhillipsG , GarryR . A randomised controlled trial comparing the Cavaterm endometrial ablation system with the Nd:YAG laser for the treatment of dysfunctional uterine bleeding. British Journal of Obstetrics and Gynaecology2003;110:350‐7. ">Hawe 2003</a>; <a href="./references#CD001501-bbs2-0017" title="McClureN , MarnersM , HealyDL , HillDJ , LawrenceAS , WingfieldM , et al. A quantitative assessment of endometrial electrocautery in the management of menorrhagia and a comparative report of argon laser endometrial ablation. Gynaecological Endoscopy1992;1:199‐202. ">McClure 1992</a>; <a href="./references#CD001501-bbs2-0018" title="GraingerDA , TjadenDO , RowlandC , MeyerWR . Thermal balloon and rollerball ablation to treat menorrhagia: two‐year results of a multicenter, prospective, randomized clinical trial. Journal of the American Association of Gynecologic Laparoscopists2000;7(2):175‐9. LofferFD . Five year post‐procedure follow‐up of patients participating in a randomised trial of uterine balloon therapy vs rollerball ablation for the treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopy2001;8(1):48‐54. LofferFD . Three‐year comparison of thermal balloon and rollerball ablation in treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2001;8(1):48‐54. MeyerWR , WalshBW , GraingerDA , PeacockLM , LofferFD , SteegeJF . Thermal balloon and rollerball ablation to treat menorrhagia: a multicenter comparison. Obstetrics and Gynecology1998;92:98‐103. ">Meyer 1998</a>; <a href="./references#CD001501-bbs2-0019" title="OnogluA , TaskinO , InalM , SadikS , SimsekM , AkarM , et al. Comparison of the long‐term histopathologic and morphologic changes after endometrial rollerball ablation and resection: a prospective randomized trial. Journal of Minimally Invasive Gynecology2007;14:39‐42. ">Onoglu 2007</a>; <a href="./references#CD001501-bbs2-0020" title="PellicanoM , GuidaM , AcunzoG , CirilloD , BifulcoG , NappiC . Hysteroscopic transcervical endometrial resection versus thermal destruction for menorrhagia: a prospective randomized trial on satisfaction rate. American Journal of Obstetrics and Gynecology2002;187:545‐50. ">Pellicano 2002</a>; <a href="./references#CD001501-bbs2-0023" title="PerinoA , CastelliA , CucinellaG , BiondoA , PaneA , VeneziaR . A randomized comparison of endometrial laser intrauterine thermotherapy and hysteroscopic endometrial resection. Fertility and Sterility2004;82:731‐4. ">Perino 2004</a>; <a href="./references#CD001501-bbs2-0024" title="RomerT . The treatment of recurrent menorrhagias ‐ Cavaterm‐balloon‐coagulation versus Rollerball‐endometrial ablation ‐ a prospective randomized comparative study [Die therapie rezidivierender Menorrhagien ‐ Cavaterm‐Ballon‐Koagulatioon versus Roller‐Ball‐Endometriumkoagulation ‐ eine prospektive randomisierte Vergleichsstudie]. Zentralblatt fur Gynakologie1998;120(10):511‐4. ">Romer 1998</a>; <a href="./references#CD001501-bbs2-0026" title="ThabetSMA . New attempt using ablative curettage technique for managing benign premenopausal uterine bleeding. Obstetrics and Gynaecology Research2010;36(4):803‐9. ">Thabet 2010</a>; <a href="./references#CD001501-bbs2-0027" title="vanZon‐RabelinkIAA , VleugelsMPH . Treating menorrhagia with endometrial ablation: rollerball electrocoagulation versus thermal ablation with the uterine balloon. Gynaecological Endoscopy Abstract from the 6th Annual Congress of the European Society for Gynaecological Endoscopy1997;6 Suppl 2:41. vanZon‐RabelinkIAA , VleugelsMPH , MerkusHMWM , deGraafR . Efficacy and satisfaction rate comparing endometrial ablation by rollerball electrocoagulation to uterine balloon thermal ablation in a randomised controlled trial. European Journal of Obstetrics, Gynecology, and Reproductive Biology2004;114(1):97‐103. vanZon‐RabelinkIAA , VleugelsMPH , MerkusHMWM , deGraafR . Endometrial ablation by rollerball electrocoagulation compared to uterine balloon thermal ablation. Technical and safety aspects. European Journal of Obstetrics, Gynecology, and Reproductive Biology2003;110:220‐3. ">van Zon‐Rabelink 2003</a>; <a href="./references#CD001501-bbs2-0028" title="VercelliniP , OldaniS , YaylayanL , ZainaB , DeGiorgiO , CrosignaniPG . Randomised comparison of vaporising electrode and cutting loop for endometrial ablation. Obstetrics and Gynecology1999;94:521‐7. ">Vercellini 1999</a>). </p> </section> </section> <section id="CD001501-sec-0100"> <h4 class="title">Excluded studies</h4> <p>We excluded six studies.</p> <p> <ul id="CD001501-list-0028"> <li> <p>One compared different waveforms for rollerball ablation (<a href="./references#CD001501-bbs2-0031" title="ChangP , VilosG , Abu‐RafeaB , Hollett‐CainesJ , AbyanehZ , EdrisF . Comparison of clinical outcomes with low‐voltage (cut) versus high‐voltage (coag) waveforms during hysteroscopic endometrial ablation with the rollerball: a pilot study. Journal of Minimally Invasive Gynecology2009;1:350‐4. ">Chang 2009</a>). </p> </li> <li> <p>One was not randomised (<a href="./references#CD001501-bbs2-0033" title="El‐NasharSA , HopkinsMR , CreedonDJ , ClibyWA , FamuyideAO . Efficacy of bipolar radiofrequency endometrial ablation vs thermal balloon ablation for management of menorrhagia: a population‐based cohort. Journal of Minimally Invasive Gynecology2009;16:692‐9. ">El‐Nashar 2009</a>). </p> </li> <li> <p>Two compared similar types of endometrial ablation with or without a co‐intervention (<a href="./references#CD001501-bbs2-0029" title="Abd Ek HammeedAA . Endometrial thermal balloon ablation by a simple technique using Foley’s catheter with or without pre ablation endometrial curettage to treat cases with intractable menorrhagia. Middle East Fertility Society Journal2012;17(2):116‐21. ">Abd Ek Hameed 2012</a>; <a href="./references#CD001501-bbs2-0030" title="CashC , Garza‐LealJ , DonovanA , GuidryC , RomanowskiC , PatelB . Clinical evaluation of long‐term safety and effectiveness of a third‐generation thermal uterine balloon therapy system for heavy menstrual bleeding. Journal of Minimally Invasive Gynecology2012;19(4):469‐76. ">Cash 2012</a>). </p> </li> <li> <p>One did not take place (<a href="./references#CD001501-bbs2-0032" title="CooperK . Blind versus visual endometrial ablation: a randomised controlled trial. http://www.controlled‐trials.com/mrct/trial/2292665/. [this trial did not take place due to lack of funding] ">Cooper 2012</a>). </p> </li> <li> <p>One included a population that does not meet review criteria (<a href="./references#CD001501-bbs2-0036" title="SoysalME , SoysalSK , VicdanK . Thermal balloon ablation in myoma‐induced menorrhagia under local anaesthesia. Gynecologic and Obstetric Investigation2001;51:128‐33. ">Soysal 2001</a>). </p> </li> </ul> </p> </section> </section> <section id="CD001501-sec-0101"> <h3 class="title">Risk of bias in included studies</h3> <p>We have provided information on risk of bias in the included studies in the <a href="./references#CD001501-sec-0344" title="">Characteristics of included studies</a> table, and we have summarised this information in <a href="#CD001501-fig-0002">Figure 2</a> and <a href="#CD001501-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD001501-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD001501-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> </div> <div class="figure" id="CD001501-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD001501-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD001501-sec-0102"> <h4 class="title">Allocation</h4> <section id="CD001501-sec-0103"> <h5 class="title">Randomisation method</h5> <p>Eighteen studies described adequate randomisation methods, and we judged them to be at low risk of selection bias. They used either computer‐generated numbers or lists of random numbers (<a href="./references#CD001501-bbs2-0001" title="AbbottJ , HaweJ , HunterD , GarryR . A double‐blind randomized trial comparing the Cavaterm and the Novasure endometrial ablation systems for the treatment of dysfunctional uterine bleeding. Fertility and Sterility2003;80(1):203‐8. ">Abbott 2003</a>; <a href="./references#CD001501-bbs2-0002" title="AthanatosD , PadosG , VenetisC , StamatopoulosP , RoussoD , TsolakidisD , et al. Novasure impedance control system versus microwave endometrial ablation for the treatment of dysfunctional uterine bleeding: a double‐blind, randomized controlled trial. Clinical and Experimental Obstetrics &amp; Gynecology2015;42(3):347‐51. [PMID: 26152008] PadosG . Treatment of dysfunctional uterine bleeding with second generation ablation devices: microwaves (MEAA) vs Bipolar Impedance Control System (Novasure). http://clinicaltrials.gov/show/NCT01173965. ">Athanatos 2015</a>; <a href="./references#CD001501-bbs2-0003" title="BhattacharyaS , CameronIM , ParkinDE , AbramovichDR , MollisonJ , PinionSB , et al. A pragmatic randomised comparison of transcervical resection of the endometrium with endometrial laser ablation for the treatment of menorrhagia. British Journal of Obstetrics and Gynaecology1997;104:601‐7. ">Bhattacharya 1997</a>; <a href="./references#CD001501-bbs2-0004" title="BongersM , HermanM , JosienP , MolBW . Ten‐year follow‐up of a randomized controlled trial comparing NovaSure and Thermachoice in endometrial ablation for dysfunctional uterine bleeding. Journal of Minimally Invasive Gynecology2011;18(6 Suppl 1):S127. BongersMY , BourdrezP , HeintzPM , BrolmannHAM , MolBWJ . Bipolar radio frequency endometrial ablation compared with balloon endometrial ablation in dysfunctional uterine bleeding: impact on patients' health‐related quality of life. Fertility and Sterility2005;83(3):724‐34. BongersMY , BourdrezP , MolBWJ , HeintzAPM , BrolmannHAM . Randomised controlled trial of bipolar radio‐frequency endometrial ablation and balloon endometrial ablation. British Journal of Obstetrics and Gynaecology2004;111:1095‐102. HermanM , PenninxM , MolB , BongersM . Ten‐year follow‐up of a randomised controlled trial comparing bipolar endometrial ablation with balloon ablation for heavy menstrual bleeding. British Journal Obstetrics and Gynaecology2013;120:966‐970. [DOI: 10.1111/1471‐0528.12213] KleijnJH , EngelsR , BourdrezP , MolBWJ , BongersMY . Five‐year follow up of a randomised controlled trial comparing NovaSure and ThermaChoice endometrial ablation. British Journal of Obstetrics and Gynaecology2008;115:193‐8. ">Bongers 2004</a>; <a href="./references#CD001501-bbs2-0006" title="BrunJ‐L , RaynalJ , BurletG , GalandB , QuereuxC , BernardP . Cavaterm thermal balloon endometrial ablation versus hysteroscopic endometrial resection to treat menorrhagia: the French, multicenter, randomized study. Journal of Minimally Invasive Gynecology2006;13:424‐30. ">Brun 2006</a>; <a href="./references#CD001501-bbs2-0007" title="ClarkTJ , SamuelN , MalickS , MiddletonLJ , DanielsJ , GuptaJK . Bipolar radiofrequency compared with thermal balloon endometrial ablation in the office. Obstetrics and Gynecology2011;117:109‐18. ">Clark 2011</a>; <a href="./references#CD001501-bbs2-0008" title="BainC , CooperKG , ParkinDE . Microwave endometrial ablation versus endometrial resection: a randomized controlled trial. Obstetrics and Gynecology2002;99:983‐7. CooperKG , BainC , LawrieL , ParkinDE . A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium: follow up at a minimum of five years. British Journal of Obstetrics and Gynaecology2005;112:470‐5. CooperKG , BainC , ParkinDE . Comparison of microwave endometrial ablation and transcervical resection of the endometrium for treatment of heavy menstrual loss: a randomised trial. Lancet1999;354:1859‐63. SambrookAM , BainC , ParkinDE , CooperKG . A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium: follow up at a minimum of 10 years. British Journal of Obstetrics and Gynaecology2009;116:1033‐7. ">Cooper 1999</a>; <a href="./references#CD001501-bbs2-0009" title="CooperJ , GimpelsonR , LabergeP , GalenD , Garza‐LealJG , ScottJ , et al. A randomized, multicenter trial of safety and efficacy of the NovaSure system in the treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2002;9(4):418‐28. ">Cooper 2002</a>; <a href="./references#CD001501-bbs2-0010" title="CooperJM , AndersonTL , FortinCA , JackSA , PlentlMB . Microwave endometrial ablation vs rollerball electroablation for menorrhagia: a multicenter randomized trial. Journal of the American Association of Gynecologic Laparoscopists2004;11(3):394‐403. ">Cooper 2004</a>; <a href="./references#CD001501-bbs2-0011" title="CorsonSL , BrillAI , BrooksPG , CooperJM , IndmanPD , LiuJH , et al. Interim results of the American Vesta trial of endometrial ablation. Journal of the American Association of Gynecologic Laparoscopists1999;6(1):45‐9. CorsonSL , BrillAI , BrooksPG , CooperJM , IndmanPD , LiuJH , et al. One‐year results of the Vesta system for endometrial ablation. Journal of the American Association of Gynecologic Laparoscopists2000;7(4):489‐97. ">Corson 2000</a>; <a href="./references#CD001501-bbs2-0012" title="CorsonSL . A multicenter evaluation of endometrial ablation by hydrothermablator and rollerball for treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2001;8(3):359‐67. GoldrathMH . Evaluation of hydrothermablator and rollerball endometrial ablation for menorrhagia 3 years after treatment. Journal of the American Association of Gynecologic Laparoscopists2003;10(4):505‐11. LofferF . A clinical comparison of hydrothermablation (HTA) and rollerball for endometrial ablation to treat menorrhagia: a randomized multicenter clinical trial. XVI FIGO World Congress of Obstetrics &amp; Gynecology. 2000; Vol. Abstract Book 2:95. ">Corson 2001</a>; <a href="./references#CD001501-bbs2-0015" title="HaweJ , AbbottJ , HunterD , PhillipsG , GarryR . A randomised controlled trial comparing the Cavaterm endometrial ablation system with the Nd:YAG laser for the treatment of dysfunctional uterine bleeding. British Journal of Obstetrics and Gynaecology2003;110:350‐7. ">Hawe 2003</a>; <a href="./references#CD001501-bbs2-0018" title="GraingerDA , TjadenDO , RowlandC , MeyerWR . Thermal balloon and rollerball ablation to treat menorrhagia: two‐year results of a multicenter, prospective, randomized clinical trial. Journal of the American Association of Gynecologic Laparoscopists2000;7(2):175‐9. LofferFD . Five year post‐procedure follow‐up of patients participating in a randomised trial of uterine balloon therapy vs rollerball ablation for the treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopy2001;8(1):48‐54. LofferFD . Three‐year comparison of thermal balloon and rollerball ablation in treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2001;8(1):48‐54. MeyerWR , WalshBW , GraingerDA , PeacockLM , LofferFD , SteegeJF . Thermal balloon and rollerball ablation to treat menorrhagia: a multicenter comparison. Obstetrics and Gynecology1998;92:98‐103. ">Meyer 1998</a>; <a href="./references#CD001501-bbs2-0020" title="PellicanoM , GuidaM , AcunzoG , CirilloD , BifulcoG , NappiC . Hysteroscopic transcervical endometrial resection versus thermal destruction for menorrhagia: a prospective randomized trial on satisfaction rate. American Journal of Obstetrics and Gynecology2002;187:545‐50. ">Pellicano 2002</a>; <a href="./references#CD001501-bbs2-0021" title="BongersM , HermanM , PenninxJ , MolBW . Longterm follow‐up of a randomized controlled trial comparing NovaSure and hydrothermablation for dysfunctional uterine bleeding. Journal of Minimally Invasive Gynecology2011;18(6 Suppl 1):S34. PenninxJPM , HermanMC , MolBW , BongersMY . Five‐year follow‐up after comparing bipolar endometrial ablation with hydrothermablation for menorrhagia. Obstetrics and Gynecology2011;118:1287‐92. PenninxJPM , MolBW , EngelsR , vanRumsteMME , KleijnC , KoksCAM , et al. Bipolar radiofrequency endometrial ablation compared with hydrothermablation for dysfunctional uterine bleeding. Obstetrics and Gynecology2010;116:819‐26. ">Penninx 2010</a>; <a href="./references#CD001501-bbs2-0023" title="PerinoA , CastelliA , CucinellaG , BiondoA , PaneA , VeneziaR . A randomized comparison of endometrial laser intrauterine thermotherapy and hysteroscopic endometrial resection. Fertility and Sterility2004;82:731‐4. ">Perino 2004</a>; <a href="./references#CD001501-bbs2-0025" title="SambrookA , EldersA , CooperK . Microwave endometrial ablation versus thermal balloon endometrial ablation (MEATBall): 5‐year follow up of a randomised controlled trial. British Journal of Obstetrics and Gynaecology2014;121:748‐54. [DOI: 10.1111/1471‐0528.12585] SambrookAM , CooperKG , CampbellMK , CookJA . Clinical outcomes from a randomised comparison of microwave endometrial ablation with thermal balloon endometrial ablation for the treatment of heavy menstrual bleeding. British Journal of Obstetrics and Gynaecology2009;116:1038‐45. ">Sambrook 2009</a>; <a href="./references#CD001501-bbs2-0028" title="VercelliniP , OldaniS , YaylayanL , ZainaB , DeGiorgiO , CrosignaniPG . Randomised comparison of vaporising electrode and cutting loop for endometrial ablation. Obstetrics and Gynecology1999;94:521‐7. ">Vercellini 1999</a>). We judged eight studies to be at unclear risk of selection bias; two reported unclear data about the random sequence generation (<a href="./references#CD001501-bbs2-0016" title="LabergeP , Garza‐LealJ , FortinC , BasinskiC , ThielJ , LeylandN , et al. A prospective, randomized, multi‐center, controlled, international clinical study of the safety and efficacy of the Minerva endometrial ablation system: 6 and 12‐month follow‐up results. Journal of Minimally Invasive Gynecology. 2014. LabergeP , Garza‐LealJ , FortinC , GraingerD , JohnsDA , AdkinsRT , et al. A randomized controlled multicenter US Food and Drug Administration trial of the safety and efficacy of the Minerva Endometrial Ablation System: one‐year follow‐up results. Journal of Minimally Invasive Gynecology2017;24(1):124‐32. [DOI: 10.1016/j.jmig.2016.09.009] LabergeP , Garza‐LealJ , FortinC , ThielJ , JohnsD , GraingerD , et al. A randomized, controlled, multi‐center trial of the safety and efficacy of the Minerva Endometrial Ablation System: one‐year follow‐up results. Journal of Minimally Invasive Gynecology. 2016; Vol. 23:S1‐S252. ">Laberge 2016</a>; <a href="./references#CD001501-bbs2-0026" title="ThabetSMA . New attempt using ablative curettage technique for managing benign premenopausal uterine bleeding. Obstetrics and Gynaecology Research2010;36(4):803‐9. ">Thabet 2010</a>), and six provided no details on the randomisation method (<a href="./references#CD001501-bbs2-0013" title="DulebaAJ , HeppardMC , SoderstromRM , TownsendDE . A randomized study comparing endometrial cryoablation and rollerball electroablation for treatment of dysfunctional uterine bleeding. Journal of the American Association of Gynecologic Laparoscopists2003;10(1):17‐26. TownsendDE , DulebaAJ , WilkesMM , et al. Durability of treatment effects after cryoablation versus rollerball electroablation for abnormal uterine bleeding: two‐year results of a multicenter randomized trial. American Journal of Obstetrics and Gynecology2003;188:699‐701. ">Duleba 2003</a>; <a href="./references#CD001501-bbs2-0014" title="GhazizadehS , PanahiZ , GhanbariZ , Tarafdari MenshadiA , FarahmandianT , JavadianP . Comparative efficacy of NovaSure, the levonorgestrel‐releasing intrauterine system, and hysteroscopic endometrial resection in the treatment of menorrhagia: a randomized clinical trial. Journal of Gynecologic Surgery2014;30(4):215‐8. [DOI: 10.1089/gyn.2012.0041] ">Ghazizadeh 2014</a>; <a href="./references#CD001501-bbs2-0017" title="McClureN , MarnersM , HealyDL , HillDJ , LawrenceAS , WingfieldM , et al. A quantitative assessment of endometrial electrocautery in the management of menorrhagia and a comparative report of argon laser endometrial ablation. Gynaecological Endoscopy1992;1:199‐202. ">McClure 1992</a>; <a href="./references#CD001501-bbs2-0022" title="PenninxJ , BongersM . Bipolar radiofrequency endometrial ablation versus thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. www.controlled‐trials.com/ISRCTN17974690. PenninxJ , HermanM , KruitwagenR , Ter HaarA , MolB , BongersM . Bipolar versus balloon endometrial ablation in the office: a randomized controlled trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;196:52‐6. [DOI: 10.1016/j.ejogrb.2015.10.010] PenninxJ , HermanM , MolB , KruitwagenR , BongersM . Bipolar radiofrequency endometrial ablation versus Thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. Journal of Minimally Invasive Gynecology2012;19(6):S21‐S22. [DOI: 10.1016/j.jmig.2012.08.076] PenninxJPM , HermanMC , MolBW , BongersMY . Bipolar radiofrequency endometrial ablation versus thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. Journal of Minimally Invasive Gynecology2012;19(6 Suppl 1):S21‐2. ">Penninx 2016</a>; <a href="./references#CD001501-bbs2-0024" title="RomerT . The treatment of recurrent menorrhagias ‐ Cavaterm‐balloon‐coagulation versus Rollerball‐endometrial ablation ‐ a prospective randomized comparative study [Die therapie rezidivierender Menorrhagien ‐ Cavaterm‐Ballon‐Koagulatioon versus Roller‐Ball‐Endometriumkoagulation ‐ eine prospektive randomisierte Vergleichsstudie]. Zentralblatt fur Gynakologie1998;120(10):511‐4. ">Romer 1998</a>; <a href="./references#CD001501-bbs2-0027" title="vanZon‐RabelinkIAA , VleugelsMPH . Treating menorrhagia with endometrial ablation: rollerball electrocoagulation versus thermal ablation with the uterine balloon. Gynaecological Endoscopy Abstract from the 6th Annual Congress of the European Society for Gynaecological Endoscopy1997;6 Suppl 2:41. vanZon‐RabelinkIAA , VleugelsMPH , MerkusHMWM , deGraafR . Efficacy and satisfaction rate comparing endometrial ablation by rollerball electrocoagulation to uterine balloon thermal ablation in a randomised controlled trial. European Journal of Obstetrics, Gynecology, and Reproductive Biology2004;114(1):97‐103. vanZon‐RabelinkIAA , VleugelsMPH , MerkusHMWM , deGraafR . Endometrial ablation by rollerball electrocoagulation compared to uterine balloon thermal ablation. Technical and safety aspects. European Journal of Obstetrics, Gynecology, and Reproductive Biology2003;110:220‐3. ">van Zon‐Rabelink 2003</a>). Two studies provided details of an inadequate randomisation method (<a href="./references#CD001501-bbs2-0005" title="BoujidaVH , PhilipsenT , PelleJ , JoergensenJC . Five‐year follow‐up of endometrial ablation: endometrial coagulation versus endometrial resection. Obstetrics and Gynecology2002;99:988‐92. FurstSN , PhilipsenT , JoergensenJC . Ten‐year follow‐up of endometrial ablation. Acta Obstetricia et Gynecologica2007;86:334‐8. ">Boujida 2002</a>; <a href="./references#CD001501-bbs2-0019" title="OnogluA , TaskinO , InalM , SadikS , SimsekM , AkarM , et al. Comparison of the long‐term histopathologic and morphologic changes after endometrial rollerball ablation and resection: a prospective randomized trial. Journal of Minimally Invasive Gynecology2007;14:39‐42. ">Onoglu 2007</a>); <a href="./references#CD001501-bbs2-0019" title="OnogluA , TaskinO , InalM , SadikS , SimsekM , AkarM , et al. Comparison of the long‐term histopathologic and morphologic changes after endometrial rollerball ablation and resection: a prospective randomized trial. Journal of Minimally Invasive Gynecology2007;14:39‐42. ">Onoglu 2007</a> reported that researchers allocated participants to treatment in the order in which they came into the clinic. <a href="./references#CD001501-bbs2-0005" title="BoujidaVH , PhilipsenT , PelleJ , JoergensenJC . Five‐year follow‐up of endometrial ablation: endometrial coagulation versus endometrial resection. Obstetrics and Gynecology2002;99:988‐92. FurstSN , PhilipsenT , JoergensenJC . Ten‐year follow‐up of endometrial ablation. Acta Obstetricia et Gynecologica2007;86:334‐8. ">Boujida 2002</a> reported using odd and even numbers. We judged these studies to be at high risk of bias. </p> </section> <section id="CD001501-sec-0104"> <h5 class="title">Allocation concealment</h5> <p>Thirteen studies provided evidence of adequate allocation concealment, and we judged them to be at low risk of bias. These studies used either sequentially numbered opaque envelopes or a central method for allocation to groups (<a href="./references#CD001501-bbs2-0003" title="BhattacharyaS , CameronIM , ParkinDE , AbramovichDR , MollisonJ , PinionSB , et al. A pragmatic randomised comparison of transcervical resection of the endometrium with endometrial laser ablation for the treatment of menorrhagia. British Journal of Obstetrics and Gynaecology1997;104:601‐7. ">Bhattacharya 1997</a>; <a href="./references#CD001501-bbs2-0004" title="BongersM , HermanM , JosienP , MolBW . Ten‐year follow‐up of a randomized controlled trial comparing NovaSure and Thermachoice in endometrial ablation for dysfunctional uterine bleeding. Journal of Minimally Invasive Gynecology2011;18(6 Suppl 1):S127. BongersMY , BourdrezP , HeintzPM , BrolmannHAM , MolBWJ . Bipolar radio frequency endometrial ablation compared with balloon endometrial ablation in dysfunctional uterine bleeding: impact on patients' health‐related quality of life. Fertility and Sterility2005;83(3):724‐34. BongersMY , BourdrezP , MolBWJ , HeintzAPM , BrolmannHAM . Randomised controlled trial of bipolar radio‐frequency endometrial ablation and balloon endometrial ablation. British Journal of Obstetrics and Gynaecology2004;111:1095‐102. HermanM , PenninxM , MolB , BongersM . Ten‐year follow‐up of a randomised controlled trial comparing bipolar endometrial ablation with balloon ablation for heavy menstrual bleeding. British Journal Obstetrics and Gynaecology2013;120:966‐970. [DOI: 10.1111/1471‐0528.12213] KleijnJH , EngelsR , BourdrezP , MolBWJ , BongersMY . Five‐year follow up of a randomised controlled trial comparing NovaSure and ThermaChoice endometrial ablation. British Journal of Obstetrics and Gynaecology2008;115:193‐8. ">Bongers 2004</a>; <a href="./references#CD001501-bbs2-0005" title="BoujidaVH , PhilipsenT , PelleJ , JoergensenJC . Five‐year follow‐up of endometrial ablation: endometrial coagulation versus endometrial resection. Obstetrics and Gynecology2002;99:988‐92. FurstSN , PhilipsenT , JoergensenJC . Ten‐year follow‐up of endometrial ablation. Acta Obstetricia et Gynecologica2007;86:334‐8. ">Boujida 2002</a>; <a href="./references#CD001501-bbs2-0006" title="BrunJ‐L , RaynalJ , BurletG , GalandB , QuereuxC , BernardP . Cavaterm thermal balloon endometrial ablation versus hysteroscopic endometrial resection to treat menorrhagia: the French, multicenter, randomized study. Journal of Minimally Invasive Gynecology2006;13:424‐30. ">Brun 2006</a>; <a href="./references#CD001501-bbs2-0007" title="ClarkTJ , SamuelN , MalickS , MiddletonLJ , DanielsJ , GuptaJK . Bipolar radiofrequency compared with thermal balloon endometrial ablation in the office. Obstetrics and Gynecology2011;117:109‐18. ">Clark 2011</a>; <a href="./references#CD001501-bbs2-0008" title="BainC , CooperKG , ParkinDE . Microwave endometrial ablation versus endometrial resection: a randomized controlled trial. Obstetrics and Gynecology2002;99:983‐7. CooperKG , BainC , LawrieL , ParkinDE . A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium: follow up at a minimum of five years. British Journal of Obstetrics and Gynaecology2005;112:470‐5. CooperKG , BainC , ParkinDE . Comparison of microwave endometrial ablation and transcervical resection of the endometrium for treatment of heavy menstrual loss: a randomised trial. Lancet1999;354:1859‐63. SambrookAM , BainC , ParkinDE , CooperKG . A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium: follow up at a minimum of 10 years. British Journal of Obstetrics and Gynaecology2009;116:1033‐7. ">Cooper 1999</a>; <a href="./references#CD001501-bbs2-0010" title="CooperJM , AndersonTL , FortinCA , JackSA , PlentlMB . Microwave endometrial ablation vs rollerball electroablation for menorrhagia: a multicenter randomized trial. Journal of the American Association of Gynecologic Laparoscopists2004;11(3):394‐403. ">Cooper 2004</a>; <a href="./references#CD001501-bbs2-0011" title="CorsonSL , BrillAI , BrooksPG , CooperJM , IndmanPD , LiuJH , et al. Interim results of the American Vesta trial of endometrial ablation. Journal of the American Association of Gynecologic Laparoscopists1999;6(1):45‐9. CorsonSL , BrillAI , BrooksPG , CooperJM , IndmanPD , LiuJH , et al. One‐year results of the Vesta system for endometrial ablation. Journal of the American Association of Gynecologic Laparoscopists2000;7(4):489‐97. ">Corson 2000</a>; <a href="./references#CD001501-bbs2-0015" title="HaweJ , AbbottJ , HunterD , PhillipsG , GarryR . A randomised controlled trial comparing the Cavaterm endometrial ablation system with the Nd:YAG laser for the treatment of dysfunctional uterine bleeding. British Journal of Obstetrics and Gynaecology2003;110:350‐7. ">Hawe 2003</a>; <a href="./references#CD001501-bbs2-0021" title="BongersM , HermanM , PenninxJ , MolBW . Longterm follow‐up of a randomized controlled trial comparing NovaSure and hydrothermablation for dysfunctional uterine bleeding. Journal of Minimally Invasive Gynecology2011;18(6 Suppl 1):S34. PenninxJPM , HermanMC , MolBW , BongersMY . Five‐year follow‐up after comparing bipolar endometrial ablation with hydrothermablation for menorrhagia. Obstetrics and Gynecology2011;118:1287‐92. PenninxJPM , MolBW , EngelsR , vanRumsteMME , KleijnC , KoksCAM , et al. Bipolar radiofrequency endometrial ablation compared with hydrothermablation for dysfunctional uterine bleeding. Obstetrics and Gynecology2010;116:819‐26. ">Penninx 2010</a>; <a href="./references#CD001501-bbs2-0022" title="PenninxJ , BongersM . Bipolar radiofrequency endometrial ablation versus thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. www.controlled‐trials.com/ISRCTN17974690. PenninxJ , HermanM , KruitwagenR , Ter HaarA , MolB , BongersM . Bipolar versus balloon endometrial ablation in the office: a randomized controlled trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;196:52‐6. [DOI: 10.1016/j.ejogrb.2015.10.010] PenninxJ , HermanM , MolB , KruitwagenR , BongersM . Bipolar radiofrequency endometrial ablation versus Thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. Journal of Minimally Invasive Gynecology2012;19(6):S21‐S22. [DOI: 10.1016/j.jmig.2012.08.076] PenninxJPM , HermanMC , MolBW , BongersMY . Bipolar radiofrequency endometrial ablation versus thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. Journal of Minimally Invasive Gynecology2012;19(6 Suppl 1):S21‐2. ">Penninx 2016</a>; <a href="./references#CD001501-bbs2-0025" title="SambrookA , EldersA , CooperK . Microwave endometrial ablation versus thermal balloon endometrial ablation (MEATBall): 5‐year follow up of a randomised controlled trial. British Journal of Obstetrics and Gynaecology2014;121:748‐54. [DOI: 10.1111/1471‐0528.12585] SambrookAM , CooperKG , CampbellMK , CookJA . Clinical outcomes from a randomised comparison of microwave endometrial ablation with thermal balloon endometrial ablation for the treatment of heavy menstrual bleeding. British Journal of Obstetrics and Gynaecology2009;116:1038‐45. ">Sambrook 2009</a>; <a href="./references#CD001501-bbs2-0028" title="VercelliniP , OldaniS , YaylayanL , ZainaB , DeGiorgiO , CrosignaniPG . Randomised comparison of vaporising electrode and cutting loop for endometrial ablation. Obstetrics and Gynecology1999;94:521‐7. ">Vercellini 1999</a>). </p> <p>We judged that 14 studies were at unclear risk of bias because they did not provide details as to whether allocation was concealed (<a href="./references#CD001501-bbs2-0001" title="AbbottJ , HaweJ , HunterD , GarryR . A double‐blind randomized trial comparing the Cavaterm and the Novasure endometrial ablation systems for the treatment of dysfunctional uterine bleeding. Fertility and Sterility2003;80(1):203‐8. ">Abbott 2003</a>; <a href="./references#CD001501-bbs2-0002" title="AthanatosD , PadosG , VenetisC , StamatopoulosP , RoussoD , TsolakidisD , et al. Novasure impedance control system versus microwave endometrial ablation for the treatment of dysfunctional uterine bleeding: a double‐blind, randomized controlled trial. Clinical and Experimental Obstetrics &amp; Gynecology2015;42(3):347‐51. [PMID: 26152008] PadosG . Treatment of dysfunctional uterine bleeding with second generation ablation devices: microwaves (MEAA) vs Bipolar Impedance Control System (Novasure). http://clinicaltrials.gov/show/NCT01173965. ">Athanatos 2015</a>; <a href="./references#CD001501-bbs2-0009" title="CooperJ , GimpelsonR , LabergeP , GalenD , Garza‐LealJG , ScottJ , et al. A randomized, multicenter trial of safety and efficacy of the NovaSure system in the treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2002;9(4):418‐28. ">Cooper 2002</a>; <a href="./references#CD001501-bbs2-0012" title="CorsonSL . A multicenter evaluation of endometrial ablation by hydrothermablator and rollerball for treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2001;8(3):359‐67. GoldrathMH . Evaluation of hydrothermablator and rollerball endometrial ablation for menorrhagia 3 years after treatment. Journal of the American Association of Gynecologic Laparoscopists2003;10(4):505‐11. LofferF . A clinical comparison of hydrothermablation (HTA) and rollerball for endometrial ablation to treat menorrhagia: a randomized multicenter clinical trial. XVI FIGO World Congress of Obstetrics &amp; Gynecology. 2000; Vol. Abstract Book 2:95. ">Corson 2001</a>; <a href="./references#CD001501-bbs2-0013" title="DulebaAJ , HeppardMC , SoderstromRM , TownsendDE . A randomized study comparing endometrial cryoablation and rollerball electroablation for treatment of dysfunctional uterine bleeding. Journal of the American Association of Gynecologic Laparoscopists2003;10(1):17‐26. TownsendDE , DulebaAJ , WilkesMM , et al. Durability of treatment effects after cryoablation versus rollerball electroablation for abnormal uterine bleeding: two‐year results of a multicenter randomized trial. American Journal of Obstetrics and Gynecology2003;188:699‐701. ">Duleba 2003</a>; <a href="./references#CD001501-bbs2-0014" title="GhazizadehS , PanahiZ , GhanbariZ , Tarafdari MenshadiA , FarahmandianT , JavadianP . Comparative efficacy of NovaSure, the levonorgestrel‐releasing intrauterine system, and hysteroscopic endometrial resection in the treatment of menorrhagia: a randomized clinical trial. Journal of Gynecologic Surgery2014;30(4):215‐8. [DOI: 10.1089/gyn.2012.0041] ">Ghazizadeh 2014</a>; <a href="./references#CD001501-bbs2-0016" title="LabergeP , Garza‐LealJ , FortinC , BasinskiC , ThielJ , LeylandN , et al. A prospective, randomized, multi‐center, controlled, international clinical study of the safety and efficacy of the Minerva endometrial ablation system: 6 and 12‐month follow‐up results. Journal of Minimally Invasive Gynecology. 2014. LabergeP , Garza‐LealJ , FortinC , GraingerD , JohnsDA , AdkinsRT , et al. A randomized controlled multicenter US Food and Drug Administration trial of the safety and efficacy of the Minerva Endometrial Ablation System: one‐year follow‐up results. Journal of Minimally Invasive Gynecology2017;24(1):124‐32. [DOI: 10.1016/j.jmig.2016.09.009] LabergeP , Garza‐LealJ , FortinC , ThielJ , JohnsD , GraingerD , et al. A randomized, controlled, multi‐center trial of the safety and efficacy of the Minerva Endometrial Ablation System: one‐year follow‐up results. Journal of Minimally Invasive Gynecology. 2016; Vol. 23:S1‐S252. ">Laberge 2016</a>; <a href="./references#CD001501-bbs2-0017" title="McClureN , MarnersM , HealyDL , HillDJ , LawrenceAS , WingfieldM , et al. A quantitative assessment of endometrial electrocautery in the management of menorrhagia and a comparative report of argon laser endometrial ablation. Gynaecological Endoscopy1992;1:199‐202. ">McClure 1992</a>; <a href="./references#CD001501-bbs2-0018" title="GraingerDA , TjadenDO , RowlandC , MeyerWR . Thermal balloon and rollerball ablation to treat menorrhagia: two‐year results of a multicenter, prospective, randomized clinical trial. Journal of the American Association of Gynecologic Laparoscopists2000;7(2):175‐9. LofferFD . Five year post‐procedure follow‐up of patients participating in a randomised trial of uterine balloon therapy vs rollerball ablation for the treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopy2001;8(1):48‐54. LofferFD . Three‐year comparison of thermal balloon and rollerball ablation in treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2001;8(1):48‐54. MeyerWR , WalshBW , GraingerDA , PeacockLM , LofferFD , SteegeJF . Thermal balloon and rollerball ablation to treat menorrhagia: a multicenter comparison. Obstetrics and Gynecology1998;92:98‐103. ">Meyer 1998</a>; <a href="./references#CD001501-bbs2-0020" title="PellicanoM , GuidaM , AcunzoG , CirilloD , BifulcoG , NappiC . Hysteroscopic transcervical endometrial resection versus thermal destruction for menorrhagia: a prospective randomized trial on satisfaction rate. American Journal of Obstetrics and Gynecology2002;187:545‐50. ">Pellicano 2002</a>; <a href="./references#CD001501-bbs2-0023" title="PerinoA , CastelliA , CucinellaG , BiondoA , PaneA , VeneziaR . A randomized comparison of endometrial laser intrauterine thermotherapy and hysteroscopic endometrial resection. Fertility and Sterility2004;82:731‐4. ">Perino 2004</a>; <a href="./references#CD001501-bbs2-0024" title="RomerT . The treatment of recurrent menorrhagias ‐ Cavaterm‐balloon‐coagulation versus Rollerball‐endometrial ablation ‐ a prospective randomized comparative study [Die therapie rezidivierender Menorrhagien ‐ Cavaterm‐Ballon‐Koagulatioon versus Roller‐Ball‐Endometriumkoagulation ‐ eine prospektive randomisierte Vergleichsstudie]. Zentralblatt fur Gynakologie1998;120(10):511‐4. ">Romer 1998</a>; <a href="./references#CD001501-bbs2-0026" title="ThabetSMA . New attempt using ablative curettage technique for managing benign premenopausal uterine bleeding. Obstetrics and Gynaecology Research2010;36(4):803‐9. ">Thabet 2010</a>; <a href="./references#CD001501-bbs2-0027" title="vanZon‐RabelinkIAA , VleugelsMPH . Treating menorrhagia with endometrial ablation: rollerball electrocoagulation versus thermal ablation with the uterine balloon. Gynaecological Endoscopy Abstract from the 6th Annual Congress of the European Society for Gynaecological Endoscopy1997;6 Suppl 2:41. vanZon‐RabelinkIAA , VleugelsMPH , MerkusHMWM , deGraafR . Efficacy and satisfaction rate comparing endometrial ablation by rollerball electrocoagulation to uterine balloon thermal ablation in a randomised controlled trial. European Journal of Obstetrics, Gynecology, and Reproductive Biology2004;114(1):97‐103. vanZon‐RabelinkIAA , VleugelsMPH , MerkusHMWM , deGraafR . Endometrial ablation by rollerball electrocoagulation compared to uterine balloon thermal ablation. Technical and safety aspects. European Journal of Obstetrics, Gynecology, and Reproductive Biology2003;110:220‐3. ">van Zon‐Rabelink 2003</a>). We scored the remaining study as having no concealment and judged it to be at high risk of bias (<a href="./references#CD001501-bbs2-0019" title="OnogluA , TaskinO , InalM , SadikS , SimsekM , AkarM , et al. Comparison of the long‐term histopathologic and morphologic changes after endometrial rollerball ablation and resection: a prospective randomized trial. Journal of Minimally Invasive Gynecology2007;14:39‐42. ">Onoglu 2007</a>). </p> </section> </section> <section id="CD001501-sec-0105"> <h4 class="title">Blinding</h4> <section id="CD001501-sec-0106"> <h5 class="title">Performance bias</h5> <p>Most of the studies did not specifically undertake or report blinding; for all these studies, blinding was unlikely due to the nature of the interventions. Three studies that compared second‐generation techniques (bipolar radiofrequency vs balloon) (<a href="./references#CD001501-bbs2-0001" title="AbbottJ , HaweJ , HunterD , GarryR . A double‐blind randomized trial comparing the Cavaterm and the Novasure endometrial ablation systems for the treatment of dysfunctional uterine bleeding. Fertility and Sterility2003;80(1):203‐8. ">Abbott 2003</a>; <a href="./references#CD001501-bbs2-0004" title="BongersM , HermanM , JosienP , MolBW . Ten‐year follow‐up of a randomized controlled trial comparing NovaSure and Thermachoice in endometrial ablation for dysfunctional uterine bleeding. Journal of Minimally Invasive Gynecology2011;18(6 Suppl 1):S127. BongersMY , BourdrezP , HeintzPM , BrolmannHAM , MolBWJ . Bipolar radio frequency endometrial ablation compared with balloon endometrial ablation in dysfunctional uterine bleeding: impact on patients' health‐related quality of life. Fertility and Sterility2005;83(3):724‐34. BongersMY , BourdrezP , MolBWJ , HeintzAPM , BrolmannHAM . Randomised controlled trial of bipolar radio‐frequency endometrial ablation and balloon endometrial ablation. British Journal of Obstetrics and Gynaecology2004;111:1095‐102. HermanM , PenninxM , MolB , BongersM . Ten‐year follow‐up of a randomised controlled trial comparing bipolar endometrial ablation with balloon ablation for heavy menstrual bleeding. British Journal Obstetrics and Gynaecology2013;120:966‐970. [DOI: 10.1111/1471‐0528.12213] KleijnJH , EngelsR , BourdrezP , MolBWJ , BongersMY . Five‐year follow up of a randomised controlled trial comparing NovaSure and ThermaChoice endometrial ablation. British Journal of Obstetrics and Gynaecology2008;115:193‐8. ">Bongers 2004</a>; <a href="./references#CD001501-bbs2-0022" title="PenninxJ , BongersM . Bipolar radiofrequency endometrial ablation versus thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. www.controlled‐trials.com/ISRCTN17974690. PenninxJ , HermanM , KruitwagenR , Ter HaarA , MolB , BongersM . Bipolar versus balloon endometrial ablation in the office: a randomized controlled trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;196:52‐6. [DOI: 10.1016/j.ejogrb.2015.10.010] PenninxJ , HermanM , MolB , KruitwagenR , BongersM . Bipolar radiofrequency endometrial ablation versus Thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. Journal of Minimally Invasive Gynecology2012;19(6):S21‐S22. [DOI: 10.1016/j.jmig.2012.08.076] PenninxJPM , HermanMC , MolBW , BongersMY . Bipolar radiofrequency endometrial ablation versus thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. Journal of Minimally Invasive Gynecology2012;19(6 Suppl 1):S21‐2. ">Penninx 2016</a>), along with another comparing balloon versus laser (<a href="./references#CD001501-bbs2-0015" title="HaweJ , AbbottJ , HunterD , PhillipsG , GarryR . A randomised controlled trial comparing the Cavaterm endometrial ablation system with the Nd:YAG laser for the treatment of dysfunctional uterine bleeding. British Journal of Obstetrics and Gynaecology2003;110:350‐7. ">Hawe 2003</a>), described triple blinding (patients, investigators, and assessors), and two studies on second‐generation approaches reported double blinding (patients and assessors) (<a href="./references#CD001501-bbs2-0002" title="AthanatosD , PadosG , VenetisC , StamatopoulosP , RoussoD , TsolakidisD , et al. Novasure impedance control system versus microwave endometrial ablation for the treatment of dysfunctional uterine bleeding: a double‐blind, randomized controlled trial. Clinical and Experimental Obstetrics &amp; Gynecology2015;42(3):347‐51. [PMID: 26152008] PadosG . Treatment of dysfunctional uterine bleeding with second generation ablation devices: microwaves (MEAA) vs Bipolar Impedance Control System (Novasure). http://clinicaltrials.gov/show/NCT01173965. ">Athanatos 2015</a>; <a href="./references#CD001501-bbs2-0022" title="PenninxJ , BongersM . Bipolar radiofrequency endometrial ablation versus thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. www.controlled‐trials.com/ISRCTN17974690. PenninxJ , HermanM , KruitwagenR , Ter HaarA , MolB , BongersM . Bipolar versus balloon endometrial ablation in the office: a randomized controlled trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;196:52‐6. [DOI: 10.1016/j.ejogrb.2015.10.010] PenninxJ , HermanM , MolB , KruitwagenR , BongersM . Bipolar radiofrequency endometrial ablation versus Thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. Journal of Minimally Invasive Gynecology2012;19(6):S21‐S22. [DOI: 10.1016/j.jmig.2012.08.076] PenninxJPM , HermanMC , MolBW , BongersMY . Bipolar radiofrequency endometrial ablation versus thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. Journal of Minimally Invasive Gynecology2012;19(6 Suppl 1):S21‐2. ">Penninx 2016</a>). Women were blinded to allocation in <a href="./references#CD001501-bbs2-0007" title="ClarkTJ , SamuelN , MalickS , MiddletonLJ , DanielsJ , GuptaJK . Bipolar radiofrequency compared with thermal balloon endometrial ablation in the office. Obstetrics and Gynecology2011;117:109‐18. ">Clark 2011</a>, although they were likely to have guessed allocation; we judged this study to be at unclear risk of bias. Two other studies blinded women but not investigators (<a href="./references#CD001501-bbs2-0021" title="BongersM , HermanM , PenninxJ , MolBW . Longterm follow‐up of a randomized controlled trial comparing NovaSure and hydrothermablation for dysfunctional uterine bleeding. Journal of Minimally Invasive Gynecology2011;18(6 Suppl 1):S34. PenninxJPM , HermanMC , MolBW , BongersMY . Five‐year follow‐up after comparing bipolar endometrial ablation with hydrothermablation for menorrhagia. Obstetrics and Gynecology2011;118:1287‐92. PenninxJPM , MolBW , EngelsR , vanRumsteMME , KleijnC , KoksCAM , et al. Bipolar radiofrequency endometrial ablation compared with hydrothermablation for dysfunctional uterine bleeding. Obstetrics and Gynecology2010;116:819‐26. ">Penninx 2010</a>; <a href="./references#CD001501-bbs2-0025" title="SambrookA , EldersA , CooperK . Microwave endometrial ablation versus thermal balloon endometrial ablation (MEATBall): 5‐year follow up of a randomised controlled trial. British Journal of Obstetrics and Gynaecology2014;121:748‐54. [DOI: 10.1111/1471‐0528.12585] SambrookAM , CooperKG , CampbellMK , CookJA . Clinical outcomes from a randomised comparison of microwave endometrial ablation with thermal balloon endometrial ablation for the treatment of heavy menstrual bleeding. British Journal of Obstetrics and Gynaecology2009;116:1038‐45. ">Sambrook 2009</a>). </p> </section> <section id="CD001501-sec-0107"> <h5 class="title">Detection bias</h5> <p>We judged seven studies to be at low risk of detection bias (<a href="./references#CD001501-bbs2-0001" title="AbbottJ , HaweJ , HunterD , GarryR . A double‐blind randomized trial comparing the Cavaterm and the Novasure endometrial ablation systems for the treatment of dysfunctional uterine bleeding. Fertility and Sterility2003;80(1):203‐8. ">Abbott 2003</a>; <a href="./references#CD001501-bbs2-0002" title="AthanatosD , PadosG , VenetisC , StamatopoulosP , RoussoD , TsolakidisD , et al. Novasure impedance control system versus microwave endometrial ablation for the treatment of dysfunctional uterine bleeding: a double‐blind, randomized controlled trial. Clinical and Experimental Obstetrics &amp; Gynecology2015;42(3):347‐51. [PMID: 26152008] PadosG . Treatment of dysfunctional uterine bleeding with second generation ablation devices: microwaves (MEAA) vs Bipolar Impedance Control System (Novasure). http://clinicaltrials.gov/show/NCT01173965. ">Athanatos 2015</a>; <a href="./references#CD001501-bbs2-0004" title="BongersM , HermanM , JosienP , MolBW . Ten‐year follow‐up of a randomized controlled trial comparing NovaSure and Thermachoice in endometrial ablation for dysfunctional uterine bleeding. Journal of Minimally Invasive Gynecology2011;18(6 Suppl 1):S127. BongersMY , BourdrezP , HeintzPM , BrolmannHAM , MolBWJ . Bipolar radio frequency endometrial ablation compared with balloon endometrial ablation in dysfunctional uterine bleeding: impact on patients' health‐related quality of life. Fertility and Sterility2005;83(3):724‐34. BongersMY , BourdrezP , MolBWJ , HeintzAPM , BrolmannHAM . Randomised controlled trial of bipolar radio‐frequency endometrial ablation and balloon endometrial ablation. British Journal of Obstetrics and Gynaecology2004;111:1095‐102. HermanM , PenninxM , MolB , BongersM . Ten‐year follow‐up of a randomised controlled trial comparing bipolar endometrial ablation with balloon ablation for heavy menstrual bleeding. British Journal Obstetrics and Gynaecology2013;120:966‐970. [DOI: 10.1111/1471‐0528.12213] KleijnJH , EngelsR , BourdrezP , MolBWJ , BongersMY . Five‐year follow up of a randomised controlled trial comparing NovaSure and ThermaChoice endometrial ablation. British Journal of Obstetrics and Gynaecology2008;115:193‐8. ">Bongers 2004</a>; <a href="./references#CD001501-bbs2-0015" title="HaweJ , AbbottJ , HunterD , PhillipsG , GarryR . A randomised controlled trial comparing the Cavaterm endometrial ablation system with the Nd:YAG laser for the treatment of dysfunctional uterine bleeding. British Journal of Obstetrics and Gynaecology2003;110:350‐7. ">Hawe 2003</a>; <a href="./references#CD001501-bbs2-0021" title="BongersM , HermanM , PenninxJ , MolBW . Longterm follow‐up of a randomized controlled trial comparing NovaSure and hydrothermablation for dysfunctional uterine bleeding. Journal of Minimally Invasive Gynecology2011;18(6 Suppl 1):S34. PenninxJPM , HermanMC , MolBW , BongersMY . Five‐year follow‐up after comparing bipolar endometrial ablation with hydrothermablation for menorrhagia. Obstetrics and Gynecology2011;118:1287‐92. PenninxJPM , MolBW , EngelsR , vanRumsteMME , KleijnC , KoksCAM , et al. Bipolar radiofrequency endometrial ablation compared with hydrothermablation for dysfunctional uterine bleeding. Obstetrics and Gynecology2010;116:819‐26. ">Penninx 2010</a>; <a href="./references#CD001501-bbs2-0022" title="PenninxJ , BongersM . Bipolar radiofrequency endometrial ablation versus thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. www.controlled‐trials.com/ISRCTN17974690. PenninxJ , HermanM , KruitwagenR , Ter HaarA , MolB , BongersM . Bipolar versus balloon endometrial ablation in the office: a randomized controlled trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;196:52‐6. [DOI: 10.1016/j.ejogrb.2015.10.010] PenninxJ , HermanM , MolB , KruitwagenR , BongersM . Bipolar radiofrequency endometrial ablation versus Thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. Journal of Minimally Invasive Gynecology2012;19(6):S21‐S22. [DOI: 10.1016/j.jmig.2012.08.076] PenninxJPM , HermanMC , MolBW , BongersMY . Bipolar radiofrequency endometrial ablation versus thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. Journal of Minimally Invasive Gynecology2012;19(6 Suppl 1):S21‐2. ">Penninx 2016</a>; <a href="./references#CD001501-bbs2-0025" title="SambrookA , EldersA , CooperK . Microwave endometrial ablation versus thermal balloon endometrial ablation (MEATBall): 5‐year follow up of a randomised controlled trial. British Journal of Obstetrics and Gynaecology2014;121:748‐54. [DOI: 10.1111/1471‐0528.12585] SambrookAM , CooperKG , CampbellMK , CookJA . Clinical outcomes from a randomised comparison of microwave endometrial ablation with thermal balloon endometrial ablation for the treatment of heavy menstrual bleeding. British Journal of Obstetrics and Gynaecology2009;116:1038‐45. ">Sambrook 2009</a>). We judged three studies to be at unclear risk of detection bias because they provided insufficient details (<a href="./references#CD001501-bbs2-0007" title="ClarkTJ , SamuelN , MalickS , MiddletonLJ , DanielsJ , GuptaJK . Bipolar radiofrequency compared with thermal balloon endometrial ablation in the office. Obstetrics and Gynecology2011;117:109‐18. ">Clark 2011</a>; <a href="./references#CD001501-bbs2-0014" title="GhazizadehS , PanahiZ , GhanbariZ , Tarafdari MenshadiA , FarahmandianT , JavadianP . Comparative efficacy of NovaSure, the levonorgestrel‐releasing intrauterine system, and hysteroscopic endometrial resection in the treatment of menorrhagia: a randomized clinical trial. Journal of Gynecologic Surgery2014;30(4):215‐8. [DOI: 10.1089/gyn.2012.0041] ">Ghazizadeh 2014</a>; <a href="./references#CD001501-bbs2-0016" title="LabergeP , Garza‐LealJ , FortinC , BasinskiC , ThielJ , LeylandN , et al. A prospective, randomized, multi‐center, controlled, international clinical study of the safety and efficacy of the Minerva endometrial ablation system: 6 and 12‐month follow‐up results. Journal of Minimally Invasive Gynecology. 2014. LabergeP , Garza‐LealJ , FortinC , GraingerD , JohnsDA , AdkinsRT , et al. A randomized controlled multicenter US Food and Drug Administration trial of the safety and efficacy of the Minerva Endometrial Ablation System: one‐year follow‐up results. Journal of Minimally Invasive Gynecology2017;24(1):124‐32. [DOI: 10.1016/j.jmig.2016.09.009] LabergeP , Garza‐LealJ , FortinC , ThielJ , JohnsD , GraingerD , et al. A randomized, controlled, multi‐center trial of the safety and efficacy of the Minerva Endometrial Ablation System: one‐year follow‐up results. Journal of Minimally Invasive Gynecology. 2016; Vol. 23:S1‐S252. ">Laberge 2016</a>). For the remaining trials, we considered risk of detection bias to be high. </p> </section> </section> <section id="CD001501-sec-0108"> <h4 class="title">Incomplete outcome data</h4> <p>For assessments regarding incomplete outcome data, we scored 17 studies as having adequately addressed their missing data (if any) because they reported no dropouts, missing data were balanced between groups, or they had minimal loss to follow‐up that was unlikely to affect the calculation of estimates (<a href="./references#CD001501-bbs2-0001" title="AbbottJ , HaweJ , HunterD , GarryR . A double‐blind randomized trial comparing the Cavaterm and the Novasure endometrial ablation systems for the treatment of dysfunctional uterine bleeding. Fertility and Sterility2003;80(1):203‐8. ">Abbott 2003</a>; <a href="./references#CD001501-bbs2-0002" title="AthanatosD , PadosG , VenetisC , StamatopoulosP , RoussoD , TsolakidisD , et al. Novasure impedance control system versus microwave endometrial ablation for the treatment of dysfunctional uterine bleeding: a double‐blind, randomized controlled trial. Clinical and Experimental Obstetrics &amp; Gynecology2015;42(3):347‐51. [PMID: 26152008] PadosG . Treatment of dysfunctional uterine bleeding with second generation ablation devices: microwaves (MEAA) vs Bipolar Impedance Control System (Novasure). http://clinicaltrials.gov/show/NCT01173965. ">Athanatos 2015</a>; <a href="./references#CD001501-bbs2-0004" title="BongersM , HermanM , JosienP , MolBW . Ten‐year follow‐up of a randomized controlled trial comparing NovaSure and Thermachoice in endometrial ablation for dysfunctional uterine bleeding. Journal of Minimally Invasive Gynecology2011;18(6 Suppl 1):S127. BongersMY , BourdrezP , HeintzPM , BrolmannHAM , MolBWJ . Bipolar radio frequency endometrial ablation compared with balloon endometrial ablation in dysfunctional uterine bleeding: impact on patients' health‐related quality of life. Fertility and Sterility2005;83(3):724‐34. BongersMY , BourdrezP , MolBWJ , HeintzAPM , BrolmannHAM . Randomised controlled trial of bipolar radio‐frequency endometrial ablation and balloon endometrial ablation. British Journal of Obstetrics and Gynaecology2004;111:1095‐102. HermanM , PenninxM , MolB , BongersM . Ten‐year follow‐up of a randomised controlled trial comparing bipolar endometrial ablation with balloon ablation for heavy menstrual bleeding. British Journal Obstetrics and Gynaecology2013;120:966‐970. [DOI: 10.1111/1471‐0528.12213] KleijnJH , EngelsR , BourdrezP , MolBWJ , BongersMY . Five‐year follow up of a randomised controlled trial comparing NovaSure and ThermaChoice endometrial ablation. British Journal of Obstetrics and Gynaecology2008;115:193‐8. ">Bongers 2004</a>; <a href="./references#CD001501-bbs2-0005" title="BoujidaVH , PhilipsenT , PelleJ , JoergensenJC . Five‐year follow‐up of endometrial ablation: endometrial coagulation versus endometrial resection. Obstetrics and Gynecology2002;99:988‐92. FurstSN , PhilipsenT , JoergensenJC . Ten‐year follow‐up of endometrial ablation. Acta Obstetricia et Gynecologica2007;86:334‐8. ">Boujida 2002</a>; <a href="./references#CD001501-bbs2-0008" title="BainC , CooperKG , ParkinDE . Microwave endometrial ablation versus endometrial resection: a randomized controlled trial. Obstetrics and Gynecology2002;99:983‐7. CooperKG , BainC , LawrieL , ParkinDE . A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium: follow up at a minimum of five years. British Journal of Obstetrics and Gynaecology2005;112:470‐5. CooperKG , BainC , ParkinDE . Comparison of microwave endometrial ablation and transcervical resection of the endometrium for treatment of heavy menstrual loss: a randomised trial. Lancet1999;354:1859‐63. SambrookAM , BainC , ParkinDE , CooperKG . A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium: follow up at a minimum of 10 years. British Journal of Obstetrics and Gynaecology2009;116:1033‐7. ">Cooper 1999</a>; <a href="./references#CD001501-bbs2-0010" title="CooperJM , AndersonTL , FortinCA , JackSA , PlentlMB . Microwave endometrial ablation vs rollerball electroablation for menorrhagia: a multicenter randomized trial. Journal of the American Association of Gynecologic Laparoscopists2004;11(3):394‐403. ">Cooper 2004</a>; <a href="./references#CD001501-bbs2-0015" title="HaweJ , AbbottJ , HunterD , PhillipsG , GarryR . A randomised controlled trial comparing the Cavaterm endometrial ablation system with the Nd:YAG laser for the treatment of dysfunctional uterine bleeding. British Journal of Obstetrics and Gynaecology2003;110:350‐7. ">Hawe 2003</a>; <a href="./references#CD001501-bbs2-0016" title="LabergeP , Garza‐LealJ , FortinC , BasinskiC , ThielJ , LeylandN , et al. A prospective, randomized, multi‐center, controlled, international clinical study of the safety and efficacy of the Minerva endometrial ablation system: 6 and 12‐month follow‐up results. Journal of Minimally Invasive Gynecology. 2014. LabergeP , Garza‐LealJ , FortinC , GraingerD , JohnsDA , AdkinsRT , et al. A randomized controlled multicenter US Food and Drug Administration trial of the safety and efficacy of the Minerva Endometrial Ablation System: one‐year follow‐up results. Journal of Minimally Invasive Gynecology2017;24(1):124‐32. [DOI: 10.1016/j.jmig.2016.09.009] LabergeP , Garza‐LealJ , FortinC , ThielJ , JohnsD , GraingerD , et al. A randomized, controlled, multi‐center trial of the safety and efficacy of the Minerva Endometrial Ablation System: one‐year follow‐up results. Journal of Minimally Invasive Gynecology. 2016; Vol. 23:S1‐S252. ">Laberge 2016</a>; <a href="./references#CD001501-bbs2-0017" title="McClureN , MarnersM , HealyDL , HillDJ , LawrenceAS , WingfieldM , et al. A quantitative assessment of endometrial electrocautery in the management of menorrhagia and a comparative report of argon laser endometrial ablation. Gynaecological Endoscopy1992;1:199‐202. ">McClure 1992</a>; <a href="./references#CD001501-bbs2-0018" title="GraingerDA , TjadenDO , RowlandC , MeyerWR . Thermal balloon and rollerball ablation to treat menorrhagia: two‐year results of a multicenter, prospective, randomized clinical trial. Journal of the American Association of Gynecologic Laparoscopists2000;7(2):175‐9. LofferFD . Five year post‐procedure follow‐up of patients participating in a randomised trial of uterine balloon therapy vs rollerball ablation for the treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopy2001;8(1):48‐54. LofferFD . Three‐year comparison of thermal balloon and rollerball ablation in treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2001;8(1):48‐54. MeyerWR , WalshBW , GraingerDA , PeacockLM , LofferFD , SteegeJF . Thermal balloon and rollerball ablation to treat menorrhagia: a multicenter comparison. Obstetrics and Gynecology1998;92:98‐103. ">Meyer 1998</a>; <a href="./references#CD001501-bbs2-0019" title="OnogluA , TaskinO , InalM , SadikS , SimsekM , AkarM , et al. Comparison of the long‐term histopathologic and morphologic changes after endometrial rollerball ablation and resection: a prospective randomized trial. Journal of Minimally Invasive Gynecology2007;14:39‐42. ">Onoglu 2007</a>; <a href="./references#CD001501-bbs2-0021" title="BongersM , HermanM , PenninxJ , MolBW . Longterm follow‐up of a randomized controlled trial comparing NovaSure and hydrothermablation for dysfunctional uterine bleeding. Journal of Minimally Invasive Gynecology2011;18(6 Suppl 1):S34. PenninxJPM , HermanMC , MolBW , BongersMY . Five‐year follow‐up after comparing bipolar endometrial ablation with hydrothermablation for menorrhagia. Obstetrics and Gynecology2011;118:1287‐92. PenninxJPM , MolBW , EngelsR , vanRumsteMME , KleijnC , KoksCAM , et al. Bipolar radiofrequency endometrial ablation compared with hydrothermablation for dysfunctional uterine bleeding. Obstetrics and Gynecology2010;116:819‐26. ">Penninx 2010</a>; <a href="./references#CD001501-bbs2-0023" title="PerinoA , CastelliA , CucinellaG , BiondoA , PaneA , VeneziaR . A randomized comparison of endometrial laser intrauterine thermotherapy and hysteroscopic endometrial resection. Fertility and Sterility2004;82:731‐4. ">Perino 2004</a>; <a href="./references#CD001501-bbs2-0024" title="RomerT . The treatment of recurrent menorrhagias ‐ Cavaterm‐balloon‐coagulation versus Rollerball‐endometrial ablation ‐ a prospective randomized comparative study [Die therapie rezidivierender Menorrhagien ‐ Cavaterm‐Ballon‐Koagulatioon versus Roller‐Ball‐Endometriumkoagulation ‐ eine prospektive randomisierte Vergleichsstudie]. Zentralblatt fur Gynakologie1998;120(10):511‐4. ">Romer 1998</a>; <a href="./references#CD001501-bbs2-0025" title="SambrookA , EldersA , CooperK . Microwave endometrial ablation versus thermal balloon endometrial ablation (MEATBall): 5‐year follow up of a randomised controlled trial. British Journal of Obstetrics and Gynaecology2014;121:748‐54. [DOI: 10.1111/1471‐0528.12585] SambrookAM , CooperKG , CampbellMK , CookJA . Clinical outcomes from a randomised comparison of microwave endometrial ablation with thermal balloon endometrial ablation for the treatment of heavy menstrual bleeding. British Journal of Obstetrics and Gynaecology2009;116:1038‐45. ">Sambrook 2009</a>;; <a href="./references#CD001501-bbs2-0027" title="vanZon‐RabelinkIAA , VleugelsMPH . Treating menorrhagia with endometrial ablation: rollerball electrocoagulation versus thermal ablation with the uterine balloon. Gynaecological Endoscopy Abstract from the 6th Annual Congress of the European Society for Gynaecological Endoscopy1997;6 Suppl 2:41. vanZon‐RabelinkIAA , VleugelsMPH , MerkusHMWM , deGraafR . Efficacy and satisfaction rate comparing endometrial ablation by rollerball electrocoagulation to uterine balloon thermal ablation in a randomised controlled trial. European Journal of Obstetrics, Gynecology, and Reproductive Biology2004;114(1):97‐103. vanZon‐RabelinkIAA , VleugelsMPH , MerkusHMWM , deGraafR . Endometrial ablation by rollerball electrocoagulation compared to uterine balloon thermal ablation. Technical and safety aspects. European Journal of Obstetrics, Gynecology, and Reproductive Biology2003;110:220‐3. ">van Zon‐Rabelink 2003</a>; <a href="./references#CD001501-bbs2-0028" title="VercelliniP , OldaniS , YaylayanL , ZainaB , DeGiorgiO , CrosignaniPG . Randomised comparison of vaporising electrode and cutting loop for endometrial ablation. Obstetrics and Gynecology1999;94:521‐7. ">Vercellini 1999</a>); we judged these studies to be at low risk of attrition bias. For seven studies, it was unclear whether their missing data could cause bias (<a href="./references#CD001501-bbs2-0009" title="CooperJ , GimpelsonR , LabergeP , GalenD , Garza‐LealJG , ScottJ , et al. A randomized, multicenter trial of safety and efficacy of the NovaSure system in the treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2002;9(4):418‐28. ">Cooper 2002</a>; <a href="./references#CD001501-bbs2-0011" title="CorsonSL , BrillAI , BrooksPG , CooperJM , IndmanPD , LiuJH , et al. Interim results of the American Vesta trial of endometrial ablation. Journal of the American Association of Gynecologic Laparoscopists1999;6(1):45‐9. CorsonSL , BrillAI , BrooksPG , CooperJM , IndmanPD , LiuJH , et al. One‐year results of the Vesta system for endometrial ablation. Journal of the American Association of Gynecologic Laparoscopists2000;7(4):489‐97. ">Corson 2000</a>; <a href="./references#CD001501-bbs2-0012" title="CorsonSL . A multicenter evaluation of endometrial ablation by hydrothermablator and rollerball for treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2001;8(3):359‐67. GoldrathMH . Evaluation of hydrothermablator and rollerball endometrial ablation for menorrhagia 3 years after treatment. Journal of the American Association of Gynecologic Laparoscopists2003;10(4):505‐11. LofferF . A clinical comparison of hydrothermablation (HTA) and rollerball for endometrial ablation to treat menorrhagia: a randomized multicenter clinical trial. XVI FIGO World Congress of Obstetrics &amp; Gynecology. 2000; Vol. Abstract Book 2:95. ">Corson 2001</a>; <a href="./references#CD001501-bbs2-0013" title="DulebaAJ , HeppardMC , SoderstromRM , TownsendDE . A randomized study comparing endometrial cryoablation and rollerball electroablation for treatment of dysfunctional uterine bleeding. Journal of the American Association of Gynecologic Laparoscopists2003;10(1):17‐26. TownsendDE , DulebaAJ , WilkesMM , et al. Durability of treatment effects after cryoablation versus rollerball electroablation for abnormal uterine bleeding: two‐year results of a multicenter randomized trial. American Journal of Obstetrics and Gynecology2003;188:699‐701. ">Duleba 2003</a>; <a href="./references#CD001501-bbs2-0014" title="GhazizadehS , PanahiZ , GhanbariZ , Tarafdari MenshadiA , FarahmandianT , JavadianP . Comparative efficacy of NovaSure, the levonorgestrel‐releasing intrauterine system, and hysteroscopic endometrial resection in the treatment of menorrhagia: a randomized clinical trial. Journal of Gynecologic Surgery2014;30(4):215‐8. [DOI: 10.1089/gyn.2012.0041] ">Ghazizadeh 2014</a>; <a href="./references#CD001501-bbs2-0020" title="PellicanoM , GuidaM , AcunzoG , CirilloD , BifulcoG , NappiC . Hysteroscopic transcervical endometrial resection versus thermal destruction for menorrhagia: a prospective randomized trial on satisfaction rate. American Journal of Obstetrics and Gynecology2002;187:545‐50. ">Pellicano 2002</a>; <a href="./references#CD001501-bbs2-0022" title="PenninxJ , BongersM . Bipolar radiofrequency endometrial ablation versus thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. www.controlled‐trials.com/ISRCTN17974690. PenninxJ , HermanM , KruitwagenR , Ter HaarA , MolB , BongersM . Bipolar versus balloon endometrial ablation in the office: a randomized controlled trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;196:52‐6. [DOI: 10.1016/j.ejogrb.2015.10.010] PenninxJ , HermanM , MolB , KruitwagenR , BongersM . Bipolar radiofrequency endometrial ablation versus Thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. Journal of Minimally Invasive Gynecology2012;19(6):S21‐S22. [DOI: 10.1016/j.jmig.2012.08.076] PenninxJPM , HermanMC , MolBW , BongersMY . Bipolar radiofrequency endometrial ablation versus thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. Journal of Minimally Invasive Gynecology2012;19(6 Suppl 1):S21‐2. ">Penninx 2016</a>), and we judged them to be at unclear risk of bias. Most of them reported dropouts without reasons or details on the distribution per group. Four studies had high risk of attrition bias: one for differences in the number of participants providing data for different outcomes (<a href="./references#CD001501-bbs2-0003" title="BhattacharyaS , CameronIM , ParkinDE , AbramovichDR , MollisonJ , PinionSB , et al. A pragmatic randomised comparison of transcervical resection of the endometrium with endometrial laser ablation for the treatment of menorrhagia. British Journal of Obstetrics and Gynaecology1997;104:601‐7. ">Bhattacharya 1997</a>), one for differences in the number lost at assessment at 12 months for different outcomes (<a href="./references#CD001501-bbs2-0007" title="ClarkTJ , SamuelN , MalickS , MiddletonLJ , DanielsJ , GuptaJK . Bipolar radiofrequency compared with thermal balloon endometrial ablation in the office. Obstetrics and Gynecology2011;117:109‐18. ">Clark 2011</a>), one because withdrawals were unbalanced between groups (<a href="./references#CD001501-bbs2-0006" title="BrunJ‐L , RaynalJ , BurletG , GalandB , QuereuxC , BernardP . Cavaterm thermal balloon endometrial ablation versus hysteroscopic endometrial resection to treat menorrhagia: the French, multicenter, randomized study. Journal of Minimally Invasive Gynecology2006;13:424‐30. ">Brun 2006</a>), and another because dropouts were replaced by other cases, which is likely to cause major bias (<a href="./references#CD001501-bbs2-0026" title="ThabetSMA . New attempt using ablative curettage technique for managing benign premenopausal uterine bleeding. Obstetrics and Gynaecology Research2010;36(4):803‐9. ">Thabet 2010</a>). </p> </section> <section id="CD001501-sec-0109"> <h4 class="title">Selective reporting</h4> <p>We judged 23 out of 28 studies to have low risk of reporting bias; study authors reported all prespecified outcomes in the results sections (<a href="./references#CD001501-bbs2-0001" title="AbbottJ , HaweJ , HunterD , GarryR . A double‐blind randomized trial comparing the Cavaterm and the Novasure endometrial ablation systems for the treatment of dysfunctional uterine bleeding. Fertility and Sterility2003;80(1):203‐8. ">Abbott 2003</a>; <a href="./references#CD001501-bbs2-0002" title="AthanatosD , PadosG , VenetisC , StamatopoulosP , RoussoD , TsolakidisD , et al. Novasure impedance control system versus microwave endometrial ablation for the treatment of dysfunctional uterine bleeding: a double‐blind, randomized controlled trial. Clinical and Experimental Obstetrics &amp; Gynecology2015;42(3):347‐51. [PMID: 26152008] PadosG . Treatment of dysfunctional uterine bleeding with second generation ablation devices: microwaves (MEAA) vs Bipolar Impedance Control System (Novasure). http://clinicaltrials.gov/show/NCT01173965. ">Athanatos 2015</a>; <a href="./references#CD001501-bbs2-0003" title="BhattacharyaS , CameronIM , ParkinDE , AbramovichDR , MollisonJ , PinionSB , et al. A pragmatic randomised comparison of transcervical resection of the endometrium with endometrial laser ablation for the treatment of menorrhagia. British Journal of Obstetrics and Gynaecology1997;104:601‐7. ">Bhattacharya 1997</a>; <a href="./references#CD001501-bbs2-0005" title="BoujidaVH , PhilipsenT , PelleJ , JoergensenJC . Five‐year follow‐up of endometrial ablation: endometrial coagulation versus endometrial resection. Obstetrics and Gynecology2002;99:988‐92. FurstSN , PhilipsenT , JoergensenJC . Ten‐year follow‐up of endometrial ablation. Acta Obstetricia et Gynecologica2007;86:334‐8. ">Boujida 2002</a>; <a href="./references#CD001501-bbs2-0006" title="BrunJ‐L , RaynalJ , BurletG , GalandB , QuereuxC , BernardP . Cavaterm thermal balloon endometrial ablation versus hysteroscopic endometrial resection to treat menorrhagia: the French, multicenter, randomized study. Journal of Minimally Invasive Gynecology2006;13:424‐30. ">Brun 2006</a>; <a href="./references#CD001501-bbs2-0007" title="ClarkTJ , SamuelN , MalickS , MiddletonLJ , DanielsJ , GuptaJK . Bipolar radiofrequency compared with thermal balloon endometrial ablation in the office. Obstetrics and Gynecology2011;117:109‐18. ">Clark 2011</a>; <a href="./references#CD001501-bbs2-0008" title="BainC , CooperKG , ParkinDE . Microwave endometrial ablation versus endometrial resection: a randomized controlled trial. Obstetrics and Gynecology2002;99:983‐7. CooperKG , BainC , LawrieL , ParkinDE . A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium: follow up at a minimum of five years. British Journal of Obstetrics and Gynaecology2005;112:470‐5. CooperKG , BainC , ParkinDE . Comparison of microwave endometrial ablation and transcervical resection of the endometrium for treatment of heavy menstrual loss: a randomised trial. Lancet1999;354:1859‐63. SambrookAM , BainC , ParkinDE , CooperKG . A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium: follow up at a minimum of 10 years. British Journal of Obstetrics and Gynaecology2009;116:1033‐7. ">Cooper 1999</a>; <a href="./references#CD001501-bbs2-0009" title="CooperJ , GimpelsonR , LabergeP , GalenD , Garza‐LealJG , ScottJ , et al. A randomized, multicenter trial of safety and efficacy of the NovaSure system in the treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2002;9(4):418‐28. ">Cooper 2002</a>; <a href="./references#CD001501-bbs2-0010" title="CooperJM , AndersonTL , FortinCA , JackSA , PlentlMB . Microwave endometrial ablation vs rollerball electroablation for menorrhagia: a multicenter randomized trial. Journal of the American Association of Gynecologic Laparoscopists2004;11(3):394‐403. ">Cooper 2004</a>; <a href="./references#CD001501-bbs2-0011" title="CorsonSL , BrillAI , BrooksPG , CooperJM , IndmanPD , LiuJH , et al. Interim results of the American Vesta trial of endometrial ablation. Journal of the American Association of Gynecologic Laparoscopists1999;6(1):45‐9. CorsonSL , BrillAI , BrooksPG , CooperJM , IndmanPD , LiuJH , et al. One‐year results of the Vesta system for endometrial ablation. Journal of the American Association of Gynecologic Laparoscopists2000;7(4):489‐97. ">Corson 2000</a>; <a href="./references#CD001501-bbs2-0012" title="CorsonSL . A multicenter evaluation of endometrial ablation by hydrothermablator and rollerball for treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2001;8(3):359‐67. GoldrathMH . Evaluation of hydrothermablator and rollerball endometrial ablation for menorrhagia 3 years after treatment. Journal of the American Association of Gynecologic Laparoscopists2003;10(4):505‐11. LofferF . A clinical comparison of hydrothermablation (HTA) and rollerball for endometrial ablation to treat menorrhagia: a randomized multicenter clinical trial. XVI FIGO World Congress of Obstetrics &amp; Gynecology. 2000; Vol. Abstract Book 2:95. ">Corson 2001</a>; <a href="./references#CD001501-bbs2-0013" title="DulebaAJ , HeppardMC , SoderstromRM , TownsendDE . A randomized study comparing endometrial cryoablation and rollerball electroablation for treatment of dysfunctional uterine bleeding. Journal of the American Association of Gynecologic Laparoscopists2003;10(1):17‐26. TownsendDE , DulebaAJ , WilkesMM , et al. Durability of treatment effects after cryoablation versus rollerball electroablation for abnormal uterine bleeding: two‐year results of a multicenter randomized trial. American Journal of Obstetrics and Gynecology2003;188:699‐701. ">Duleba 2003</a>; <a href="./references#CD001501-bbs2-0015" title="HaweJ , AbbottJ , HunterD , PhillipsG , GarryR . A randomised controlled trial comparing the Cavaterm endometrial ablation system with the Nd:YAG laser for the treatment of dysfunctional uterine bleeding. British Journal of Obstetrics and Gynaecology2003;110:350‐7. ">Hawe 2003</a>; <a href="./references#CD001501-bbs2-0016" title="LabergeP , Garza‐LealJ , FortinC , BasinskiC , ThielJ , LeylandN , et al. A prospective, randomized, multi‐center, controlled, international clinical study of the safety and efficacy of the Minerva endometrial ablation system: 6 and 12‐month follow‐up results. Journal of Minimally Invasive Gynecology. 2014. LabergeP , Garza‐LealJ , FortinC , GraingerD , JohnsDA , AdkinsRT , et al. A randomized controlled multicenter US Food and Drug Administration trial of the safety and efficacy of the Minerva Endometrial Ablation System: one‐year follow‐up results. Journal of Minimally Invasive Gynecology2017;24(1):124‐32. [DOI: 10.1016/j.jmig.2016.09.009] LabergeP , Garza‐LealJ , FortinC , ThielJ , JohnsD , GraingerD , et al. A randomized, controlled, multi‐center trial of the safety and efficacy of the Minerva Endometrial Ablation System: one‐year follow‐up results. Journal of Minimally Invasive Gynecology. 2016; Vol. 23:S1‐S252. ">Laberge 2016</a>; <a href="./references#CD001501-bbs2-0017" title="McClureN , MarnersM , HealyDL , HillDJ , LawrenceAS , WingfieldM , et al. A quantitative assessment of endometrial electrocautery in the management of menorrhagia and a comparative report of argon laser endometrial ablation. Gynaecological Endoscopy1992;1:199‐202. ">McClure 1992</a>; <a href="./references#CD001501-bbs2-0018" title="GraingerDA , TjadenDO , RowlandC , MeyerWR . Thermal balloon and rollerball ablation to treat menorrhagia: two‐year results of a multicenter, prospective, randomized clinical trial. Journal of the American Association of Gynecologic Laparoscopists2000;7(2):175‐9. LofferFD . Five year post‐procedure follow‐up of patients participating in a randomised trial of uterine balloon therapy vs rollerball ablation for the treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopy2001;8(1):48‐54. LofferFD . Three‐year comparison of thermal balloon and rollerball ablation in treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2001;8(1):48‐54. MeyerWR , WalshBW , GraingerDA , PeacockLM , LofferFD , SteegeJF . Thermal balloon and rollerball ablation to treat menorrhagia: a multicenter comparison. Obstetrics and Gynecology1998;92:98‐103. ">Meyer 1998</a>; <a href="./references#CD001501-bbs2-0020" title="PellicanoM , GuidaM , AcunzoG , CirilloD , BifulcoG , NappiC . Hysteroscopic transcervical endometrial resection versus thermal destruction for menorrhagia: a prospective randomized trial on satisfaction rate. American Journal of Obstetrics and Gynecology2002;187:545‐50. ">Pellicano 2002</a>; <a href="./references#CD001501-bbs2-0022" title="PenninxJ , BongersM . Bipolar radiofrequency endometrial ablation versus thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. www.controlled‐trials.com/ISRCTN17974690. PenninxJ , HermanM , KruitwagenR , Ter HaarA , MolB , BongersM . Bipolar versus balloon endometrial ablation in the office: a randomized controlled trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;196:52‐6. [DOI: 10.1016/j.ejogrb.2015.10.010] PenninxJ , HermanM , MolB , KruitwagenR , BongersM . Bipolar radiofrequency endometrial ablation versus Thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. Journal of Minimally Invasive Gynecology2012;19(6):S21‐S22. [DOI: 10.1016/j.jmig.2012.08.076] PenninxJPM , HermanMC , MolBW , BongersMY . Bipolar radiofrequency endometrial ablation versus thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. Journal of Minimally Invasive Gynecology2012;19(6 Suppl 1):S21‐2. ">Penninx 2016</a>; <a href="./references#CD001501-bbs2-0023" title="PerinoA , CastelliA , CucinellaG , BiondoA , PaneA , VeneziaR . A randomized comparison of endometrial laser intrauterine thermotherapy and hysteroscopic endometrial resection. Fertility and Sterility2004;82:731‐4. ">Perino 2004</a>; <a href="./references#CD001501-bbs2-0025" title="SambrookA , EldersA , CooperK . Microwave endometrial ablation versus thermal balloon endometrial ablation (MEATBall): 5‐year follow up of a randomised controlled trial. British Journal of Obstetrics and Gynaecology2014;121:748‐54. [DOI: 10.1111/1471‐0528.12585] SambrookAM , CooperKG , CampbellMK , CookJA . Clinical outcomes from a randomised comparison of microwave endometrial ablation with thermal balloon endometrial ablation for the treatment of heavy menstrual bleeding. British Journal of Obstetrics and Gynaecology2009;116:1038‐45. ">Sambrook 2009</a>; <a href="./references#CD001501-bbs2-0026" title="ThabetSMA . New attempt using ablative curettage technique for managing benign premenopausal uterine bleeding. Obstetrics and Gynaecology Research2010;36(4):803‐9. ">Thabet 2010</a>; <a href="./references#CD001501-bbs2-0027" title="vanZon‐RabelinkIAA , VleugelsMPH . Treating menorrhagia with endometrial ablation: rollerball electrocoagulation versus thermal ablation with the uterine balloon. Gynaecological Endoscopy Abstract from the 6th Annual Congress of the European Society for Gynaecological Endoscopy1997;6 Suppl 2:41. vanZon‐RabelinkIAA , VleugelsMPH , MerkusHMWM , deGraafR . Efficacy and satisfaction rate comparing endometrial ablation by rollerball electrocoagulation to uterine balloon thermal ablation in a randomised controlled trial. European Journal of Obstetrics, Gynecology, and Reproductive Biology2004;114(1):97‐103. vanZon‐RabelinkIAA , VleugelsMPH , MerkusHMWM , deGraafR . Endometrial ablation by rollerball electrocoagulation compared to uterine balloon thermal ablation. Technical and safety aspects. European Journal of Obstetrics, Gynecology, and Reproductive Biology2003;110:220‐3. ">van Zon‐Rabelink 2003</a>; <a href="./references#CD001501-bbs2-0028" title="VercelliniP , OldaniS , YaylayanL , ZainaB , DeGiorgiO , CrosignaniPG . Randomised comparison of vaporising electrode and cutting loop for endometrial ablation. Obstetrics and Gynecology1999;94:521‐7. ">Vercellini 1999</a>). </p> <p>Three studies had unclear risk of selective reporting ‐ two because they did not report complications (<a href="./references#CD001501-bbs2-0021" title="BongersM , HermanM , PenninxJ , MolBW . Longterm follow‐up of a randomized controlled trial comparing NovaSure and hydrothermablation for dysfunctional uterine bleeding. Journal of Minimally Invasive Gynecology2011;18(6 Suppl 1):S34. PenninxJPM , HermanMC , MolBW , BongersMY . Five‐year follow‐up after comparing bipolar endometrial ablation with hydrothermablation for menorrhagia. Obstetrics and Gynecology2011;118:1287‐92. PenninxJPM , MolBW , EngelsR , vanRumsteMME , KleijnC , KoksCAM , et al. Bipolar radiofrequency endometrial ablation compared with hydrothermablation for dysfunctional uterine bleeding. Obstetrics and Gynecology2010;116:819‐26. ">Penninx 2010</a>; <a href="./references#CD001501-bbs2-0024" title="RomerT . The treatment of recurrent menorrhagias ‐ Cavaterm‐balloon‐coagulation versus Rollerball‐endometrial ablation ‐ a prospective randomized comparative study [Die therapie rezidivierender Menorrhagien ‐ Cavaterm‐Ballon‐Koagulatioon versus Roller‐Ball‐Endometriumkoagulation ‐ eine prospektive randomisierte Vergleichsstudie]. Zentralblatt fur Gynakologie1998;120(10):511‐4. ">Romer 1998</a>), and one because study authors did not report or prespecify adverse effects (<a href="./references#CD001501-bbs2-0004" title="BongersM , HermanM , JosienP , MolBW . Ten‐year follow‐up of a randomized controlled trial comparing NovaSure and Thermachoice in endometrial ablation for dysfunctional uterine bleeding. Journal of Minimally Invasive Gynecology2011;18(6 Suppl 1):S127. BongersMY , BourdrezP , HeintzPM , BrolmannHAM , MolBWJ . Bipolar radio frequency endometrial ablation compared with balloon endometrial ablation in dysfunctional uterine bleeding: impact on patients' health‐related quality of life. Fertility and Sterility2005;83(3):724‐34. BongersMY , BourdrezP , MolBWJ , HeintzAPM , BrolmannHAM . Randomised controlled trial of bipolar radio‐frequency endometrial ablation and balloon endometrial ablation. British Journal of Obstetrics and Gynaecology2004;111:1095‐102. HermanM , PenninxM , MolB , BongersM . Ten‐year follow‐up of a randomised controlled trial comparing bipolar endometrial ablation with balloon ablation for heavy menstrual bleeding. British Journal Obstetrics and Gynaecology2013;120:966‐970. [DOI: 10.1111/1471‐0528.12213] KleijnJH , EngelsR , BourdrezP , MolBWJ , BongersMY . Five‐year follow up of a randomised controlled trial comparing NovaSure and ThermaChoice endometrial ablation. British Journal of Obstetrics and Gynaecology2008;115:193‐8. ">Bongers 2004</a>). </p> <p>We judged only two studies as having high risk of selective reporting ‐ one because it reported no quantification of bleeding (<a href="./references#CD001501-bbs2-0014" title="GhazizadehS , PanahiZ , GhanbariZ , Tarafdari MenshadiA , FarahmandianT , JavadianP . Comparative efficacy of NovaSure, the levonorgestrel‐releasing intrauterine system, and hysteroscopic endometrial resection in the treatment of menorrhagia: a randomized clinical trial. Journal of Gynecologic Surgery2014;30(4):215‐8. [DOI: 10.1089/gyn.2012.0041] ">Ghazizadeh 2014</a>), and the other because study authors described prespecified bleeding patterns but did not report the data (<a href="./references#CD001501-bbs2-0019" title="OnogluA , TaskinO , InalM , SadikS , SimsekM , AkarM , et al. Comparison of the long‐term histopathologic and morphologic changes after endometrial rollerball ablation and resection: a prospective randomized trial. Journal of Minimally Invasive Gynecology2007;14:39‐42. ">Onoglu 2007</a>). </p> </section> <section id="CD001501-sec-0110"> <h4 class="title">Other potential sources of bias</h4> <p>Four studies had other potential sources of bias: one recruited participants over two different time periods and comparison of the two groups indicated substantial differences (<a href="./references#CD001501-bbs2-0003" title="BhattacharyaS , CameronIM , ParkinDE , AbramovichDR , MollisonJ , PinionSB , et al. A pragmatic randomised comparison of transcervical resection of the endometrium with endometrial laser ablation for the treatment of menorrhagia. British Journal of Obstetrics and Gynaecology1997;104:601‐7. ">Bhattacharya 1997</a>); in another, numbers in the two randomised groups differed substantially with no explanation given (<a href="./references#CD001501-bbs2-0027" title="vanZon‐RabelinkIAA , VleugelsMPH . Treating menorrhagia with endometrial ablation: rollerball electrocoagulation versus thermal ablation with the uterine balloon. Gynaecological Endoscopy Abstract from the 6th Annual Congress of the European Society for Gynaecological Endoscopy1997;6 Suppl 2:41. vanZon‐RabelinkIAA , VleugelsMPH , MerkusHMWM , deGraafR . Efficacy and satisfaction rate comparing endometrial ablation by rollerball electrocoagulation to uterine balloon thermal ablation in a randomised controlled trial. European Journal of Obstetrics, Gynecology, and Reproductive Biology2004;114(1):97‐103. vanZon‐RabelinkIAA , VleugelsMPH , MerkusHMWM , deGraafR . Endometrial ablation by rollerball electrocoagulation compared to uterine balloon thermal ablation. Technical and safety aspects. European Journal of Obstetrics, Gynecology, and Reproductive Biology2003;110:220‐3. ">van Zon‐Rabelink 2003</a>); in another, past medical history was significantly different between groups (<a href="./references#CD001501-bbs2-0014" title="GhazizadehS , PanahiZ , GhanbariZ , Tarafdari MenshadiA , FarahmandianT , JavadianP . Comparative efficacy of NovaSure, the levonorgestrel‐releasing intrauterine system, and hysteroscopic endometrial resection in the treatment of menorrhagia: a randomized clinical trial. Journal of Gynecologic Surgery2014;30(4):215‐8. [DOI: 10.1089/gyn.2012.0041] ">Ghazizadeh 2014</a>); and in another, one woman receiving cryoablation had higher PBAC scores than the others (<a href="./references#CD001501-bbs2-0013" title="DulebaAJ , HeppardMC , SoderstromRM , TownsendDE . A randomized study comparing endometrial cryoablation and rollerball electroablation for treatment of dysfunctional uterine bleeding. Journal of the American Association of Gynecologic Laparoscopists2003;10(1):17‐26. TownsendDE , DulebaAJ , WilkesMM , et al. Durability of treatment effects after cryoablation versus rollerball electroablation for abnormal uterine bleeding: two‐year results of a multicenter randomized trial. American Journal of Obstetrics and Gynecology2003;188:699‐701. ">Duleba 2003</a>). </p> </section> </section> <section id="CD001501-sec-0111"> <h3 class="title" id="CD001501-sec-0111">Effects of interventions</h3> <p>See: <a href="./full#CD001501-tbl-0001"><b>Summary of findings for the main comparison</b> Overall analyses: second‐generation endometrial ablation compared to first‐generation endometrial ablation for heavy menstrual bleeding</a> </p> <section id="CD001501-sec-0112"> <h4 class="title">First‐generation technique comparisons</h4> <section id="CD001501-sec-0113"> <h5 class="title">1. Laser ablation versus transcervical resection of the endometrium (TCRE) (Comparison 1) </h5> <p>Two studies with a total of 176 women reported laser versus transcervical resection of the endometrium (<a href="./references#CD001501-bbs2-0003" title="BhattacharyaS , CameronIM , ParkinDE , AbramovichDR , MollisonJ , PinionSB , et al. A pragmatic randomised comparison of transcervical resection of the endometrium with endometrial laser ablation for the treatment of menorrhagia. British Journal of Obstetrics and Gynaecology1997;104:601‐7. ">Bhattacharya 1997</a>; <a href="./references#CD001501-bbs2-0017" title="McClureN , MarnersM , HealyDL , HillDJ , LawrenceAS , WingfieldM , et al. A quantitative assessment of endometrial electrocautery in the management of menorrhagia and a comparative report of argon laser endometrial ablation. Gynaecological Endoscopy1992;1:199‐202. ">McClure 1992</a>) . </p> <section id="CD001501-sec-0114"> <h6 class="title">Primary outcomes</h6> <section id="CD001501-sec-0115"> <p><b>1.1 and 1.2 Bleeding</b></p> <p>No clear evidence showed any differences between laser ablation and TCRE groups in the rate of amenorrhoea at 6 months (risk ratio (RR) 0.97, 95% confidence interval (CI) 0.66 to 1.45; 348 women; 2 studies; I² = 28%), the combined rate of amenorrhoea and hypomenorrhoea at 6 months (RR 0.97, 95% CI 0.89 to 1.05; 326 women; 1 study) or at 12 months (RR 1.06, 95% CI 0.92 to 1.22; 306 women; 1 study), or mean blood loss at 6 months (mean difference (MD) 23.60 mL, 95% CI ‐8.32 to 55.52; 22 women; 1 study). See <a href="./references#CD001501-fig-0007" title="">Analysis 1.2</a> and <a href="./references#CD001501-fig-0006" title="">Analysis 1.1</a>. </p> </section> <section id="CD001501-sec-0116"> <p><b>1.3 Rate of satisfaction</b></p> <p>One trial provided no clear evidence of a difference between laser ablation and TCRE groups in the rate of satisfaction at 12 months (RR 0.99, 95% CI 0.92 to 1.06; 321 women; 1 study). See <a href="./references#CD001501-fig-0008" title="">Analysis 1.3</a>. </p> </section> </section> <section id="CD001501-sec-0117"> <h6 class="title">Secondary outcomes</h6> <section id="CD001501-sec-0118"> <p><b>1.4 Duration of surgery</b></p> <p>Duration of laser ablation surgery was on average 9 minutes longer than for TCRE (MD 9.15 minutes, 95% CI 7.2 to 11.1; 386 women; 2 studies; I² = 74%). See <a href="./references#CD001501-fig-0009" title="">Analysis 1.4</a>. </p> </section> <section id="CD001501-sec-0119"> <p><b>1.5 Operative difficulties</b></p> <p>Risks of equipment failure were greater among women who had laser ablation than among those with TCRE (RR 5.54, 95% CI 1.65 to 18.60; 366 women; 1 study). Trials found no clear evidence of differences between groups for abandonment of procedure (RR 1.47, 95% CI 0.61 to 3.51; 366 women; 1 study), instrument failure (RR 0.20, 95% CI 0.01 to 4.05; 366 women; 1 study), or need for immediate hysterectomy (RR 0.33, 95% CI 0.01 to 7.95; 366 women; 1 study). See <a href="./references#CD001501-fig-0010" title="">Analysis 1.5</a>. </p> </section> <section id="CD001501-sec-0120"> <p><b>1.6 Women's perceived change in quality of life</b></p> <p>Researchers found no clear evidence of a difference between laser ablation and TRCE at 12 months for the proportion of women reporting good general health (RR 1.03, 95% CI 0.95 to 1.12; 321 women). See <a href="./references#CD001501-fig-0011" title="">Analysis 1.6</a>. </p> </section> <section id="CD001501-sec-0121"> <p><b>1.7 Improvement in other menstrual symptoms</b></p> <p>We found no clear evidence of differences between laser ablation and TRCE for improvement in general symptoms (RR 1.03, 95% CI 0.87 to 1.21; 321 women; 1 study) or for improvement in dysmenorrhoea at 6 months' (RR 1.17, 95% CI 1.00 to 1.38; 253 women; 1 study) or 12 months' follow‐up (RR 1.00, 95% CI 0.87 to 1.15; 218 women; 1 study). See <a href="./references#CD001501-fig-0012" title="">Analysis 1.7</a>. </p> </section> <section id="CD001501-sec-0122"> <p><b>1.8 Complication rate: major complications</b></p> <p>No clear evidence showed a difference between laser ablation and TRCE in major complication rates including the following (see <a href="./references#CD001501-fig-0013" title="">Analysis 1.8</a>). </p> <p> <ul id="CD001501-list-0029"> <li> <p>Perforation (RR 0.14, 95% CI 0.01 to 2.69; 366 women; 1 study).</p> </li> <li> <p>Bowel obstruction (RR 2.94, 95% CI 0.12 to 71.59; 366 women; 1 study).</p> </li> <li> <p>Pelvic sepsis (RR 0.82, 95% CI 0.25 to 2.62; 366 women; 1 study).</p> </li> <li> <p>Haematometra (RR 0.20, 95% CI 0.01 to 4.05; 366 women; 1 study).</p> </li> <li> <p>Glycine toxicity (RR 4.23, 95% CI 0.23 to 79.10 ; 22 women; 1 study).</p> </li> <li> <p>Fluid overload &gt;1.5 L (RR 4.89, 95% CI 1.44 to 16.61; 366 women; 1 study).</p> </li> <li> <p>Uterine tamponade (RR 1.14, 95% CI 0.39 to 3.33; 366 women; 1 study).</p> </li> </ul> </p> </section> <section id="CD001501-sec-0123"> <p><b>1.9 Complication rate: minor complications</b></p> <p>No clear evidence showed a difference between laser ablation and TRCE in minor complication rates including the following (see <a href="./references#CD001501-fig-0014" title="">Analysis 1.9</a>). </p> <p> <ul id="CD001501-list-0030"> <li> <p>Burns (RR 4.89, 95% CI 0.24 to 101.21; 366 women; 1 study).</p> </li> <li> <p>Urinary tract infection (RR 1.96, 95% CI 0.36 to 10.55; 366 women; 1 study).</p> </li> </ul> </p> </section> <section id="CD001501-sec-0124"> <p><b>1.10 Requirement for further surgery</b></p> <p>Trials have provided no clear evidence of a difference between laser ablation and TRCE in the requirement of further surgery up to 12 months' follow‐up (RR 0.84, 95% CI 0.55 to 1.29; 388 women; 2 studies; I² = 0%). See <a href="./references#CD001501-fig-0015" title="">Analysis 1.10</a>. </p> <p>Researchers have provided no data on the proportion of women given local rather than general anaesthesia, length of hospital stay, and time or ability to return to normal activities or work. </p> </section> </section> </section> <section id="CD001501-sec-0125"> <h5 class="title">2. Vaporising electrode ablation versus TCRE (Comparison 2)</h5> <p>One study with 91 women reported on vaporising electrode ablation versus TCRE (<a href="./references#CD001501-bbs2-0028" title="VercelliniP , OldaniS , YaylayanL , ZainaB , DeGiorgiO , CrosignaniPG . Randomised comparison of vaporising electrode and cutting loop for endometrial ablation. Obstetrics and Gynecology1999;94:521‐7. ">Vercellini 1999</a>). </p> <section id="CD001501-sec-0126"> <h6 class="title">Primary outcomes</h6> <section id="CD001501-sec-0127"> <p><b>2.1 and 2.2 Bleeding</b></p> <p>Studies have provided no clear evidence of a difference between vaporising electrode ablation and TCRE for bleeding as measured by amenorrhoea (RR 0.90, 95% CI 0.73 to 1.12; 182 women; 1 study), hypomenorrhoea (scanty menstruation) rate (RR 0.99, 95% CI 0.80 to 1.22; 91 women; 1 study), or pictorial chart method (PBAC) score at 12 months (MD ‐5.00 units, 95% CI ‐19.18 to 9.18; 91 women; 1 study). See <a href="./references#CD001501-fig-0016" title="">Analysis 2.1</a> and <a href="./references#CD001501-fig-0017" title="">Analysis 2.2</a>. </p> </section> <section id="CD001501-sec-0128"> <p><b>2.3 Rate of satisfaction</b></p> <p>We found no clear evidence of a difference between vaporising electrode ablation and TCRE in the rate of satisfaction (very/moderately) with treatment at 12 months (RR 1.03, 95% CI 0.93 to 1.14; 91 women; 1 study). See <a href="./references#CD001501-fig-0018" title="">Analysis 2.3</a>. </p> </section> </section> <section id="CD001501-sec-0129"> <h6 class="title">Secondary outcomes</h6> <section id="CD001501-sec-0130"> <p><b>2.4 Duration of operation</b></p> <p>The duration of the operation/procedure was shorter with vaporising electrode ablation than with TRCE (MD ‐1.50 minutes, 95% CI ‐2.65 to ‐0.35; 91 women; 1 study). See <a href="./references#CD001501-fig-0019" title="">Analysis 2.4</a>. </p> </section> <section id="CD001501-sec-0131"> <p><b>2.5 Operative difficulties</b></p> <p>Vaporising electrode ablation was associated with a reduction in difficulty with surgery, reported as moderate or severe, compared with TCRE (RR 0.29, 95% CI 0.10 to 0.82; 91 women; 1 study). See <a href="./references#CD001501-fig-0020" title="">Analysis 2.5</a>. </p> </section> <section id="CD001501-sec-0132"> <p><b>2.6 Complication rate: major complications</b></p> <p>The extent of fluid deficit was greater in the TCRE group than in the vaporising electrode ablation group (MD ‐258.00, 95% CI ‐342.05 to ‐173.95; 91 women; 1 study). See <a href="./references#CD001501-fig-0021" title="">Analysis 2.6</a>. </p> <p>Researchers have provided no data on the proportion of women given local rather than general anaesthesia, length of hospital stay, time or ability to return to normal activities or work, women's perceived change in quality of life, improvement in menstrual symptoms, complication rates, requirement for further surgery, or mortality as a direct result of surgery. </p> </section> </section> </section> <section id="CD001501-sec-0133"> <h5 class="title">3. Rollerball versus TCRE (Comparison 3)</h5> <p>Two trials with a total of 165 women reported on rollerball versus TCRE (<a href="./references#CD001501-bbs2-0005" title="BoujidaVH , PhilipsenT , PelleJ , JoergensenJC . Five‐year follow‐up of endometrial ablation: endometrial coagulation versus endometrial resection. Obstetrics and Gynecology2002;99:988‐92. FurstSN , PhilipsenT , JoergensenJC . Ten‐year follow‐up of endometrial ablation. Acta Obstetricia et Gynecologica2007;86:334‐8. ">Boujida 2002</a>; <a href="./references#CD001501-bbs2-0019" title="OnogluA , TaskinO , InalM , SadikS , SimsekM , AkarM , et al. Comparison of the long‐term histopathologic and morphologic changes after endometrial rollerball ablation and resection: a prospective randomized trial. Journal of Minimally Invasive Gynecology2007;14:39‐42. ">Onoglu 2007</a>). </p> <section id="CD001501-sec-0134"> <h6 class="title">Primary outcomes</h6> <p>Researchers have provided no data on bleeding or satisfaction rates.</p> </section> <section id="CD001501-sec-0135"> <h6 class="title">Secondary outcomes</h6> <section id="CD001501-sec-0136"> <p><b>3.1 Duration of surgery</b></p> <p>No clear evidence showed a difference between rollerball and TCRE for duration of surgery (MD ‐1.10 minutes, 95% CI ‐2.92 to 0.72; 45 women; 1 study). <a href="./references#CD001501-bbs2-0005" title="BoujidaVH , PhilipsenT , PelleJ , JoergensenJC . Five‐year follow‐up of endometrial ablation: endometrial coagulation versus endometrial resection. Obstetrics and Gynecology2002;99:988‐92. FurstSN , PhilipsenT , JoergensenJC . Ten‐year follow‐up of endometrial ablation. Acta Obstetricia et Gynecologica2007;86:334‐8. ">Boujida 2002</a> provided data as median (range) values that we did not include in the meta‐analysis. These data suggest that the duration of surgery was shorter with rollerball than with TCRE, median 13 minutes with rollerball (range 6 to 105 minutes) in 61 women versus 20 minutes (range 4 to 45 minutes) with TCRE in 59 women. See <a href="./references#CD001501-fig-0022" title="">Analysis 3.1</a>. </p> </section> <section id="CD001501-sec-0137"> <p><b>3.2 Complication rate</b></p> <p>No clear evidence showed a difference in major complication rates between rollerball and TCRE such as the following (see <a href="./references#CD001501-fig-0023" title="">Analysis 3.2</a>). </p> <p> <ul id="CD001501-list-0031"> <li> <p>Fluid deficit (RR 0.32, 95% CI 0.01 to 7.76; 120 women; 1 study).</p> </li> <li> <p>Perforation (RR 0.32, 95% CI 0.01 to 7.76; 120 women; 1 study).</p> </li> </ul> </p> </section> <section id="CD001501-sec-0138"> <p><b>3.3 Requirement for further surgery</b></p> <p>Trials have provided no evidence of any differences between rollerball and TCRE in the number of women requiring either hysterectomy or any surgical intervention up to 10 years' follow‐up, including the following (see <a href="./references#CD001501-fig-0024" title="">Analysis 3.3</a>). </p> <p> <ul id="CD001501-list-0032"> <li> <p>2 years' follow‐up (hysterectomy and ablation) (RR 1.04, 95% CI 0.55 to 1.95; 120 women; 1 study). </p> </li> <li> <p>2 years' follow‐up (hysterectomy only) (RR 1.45, 95% CI 0.43 to 4.88; 120 women; 1 study). </p> </li> <li> <p>2 to 5 years' follow‐up (hysterectomy and ablation) (RR 1.21, 95% CI 0.70 to 2.10; 120 women; 1 study). </p> </li> <li> <p>2 to 5 years' follow‐up (hysterectomy only) (RR 1.21, 95% CI 0.51 to 2.85; 120 women; 1 study). </p> </li> <li> <p>More than 5 years' follow‐up (hysterectomy and ablation) (RR 1.39, 95% CI 0.82 to 2.36; 120 women; 1 study). </p> </li> <li> <p>More than 5 years' follow‐up (hysterectomy only) (RR 1.32, 95% CI 0.66 to 2.63; 120 women; 1 study). </p> </li> </ul> </p> <p>Researchers have provided no data for operative difficulties, the proportion of women given local rather than general anaesthesia, length of hospital stay, time or ability to return to normal activities or work, women's perceived change in quality of life, improvement in menstrual symptoms, complication rates, or mortality as a direct result of surgery. </p> </section> </section> </section> </section> <section id="CD001501-sec-0139"> <h4 class="title">Second‐generation versus first‐generation technique comparisons</h4> <section id="CD001501-sec-0140"> <h5 class="title">4. Thermal laser versus TCRE (Comparison 4)</h5> <p>One study with 111 women reported on thermal laser versus TCRE (<a href="./references#CD001501-bbs2-0023" title="PerinoA , CastelliA , CucinellaG , BiondoA , PaneA , VeneziaR . A randomized comparison of endometrial laser intrauterine thermotherapy and hysteroscopic endometrial resection. Fertility and Sterility2004;82:731‐4. ">Perino 2004</a>). </p> <section id="CD001501-sec-0141"> <h6 class="title">Primary outcomes</h6> <section id="CD001501-sec-0142"> <p><b>4.1 Bleeding</b></p> <p>Rates of amenorrhoea at 1 and 3 years after surgery were greater for women in the thermal laser group than in the TCRE group (RR 2.46, 95% CI 1.50 to 4.03; 111 women; 1 study; RR 2.49, 95% CI 1.48 to 4.21; 111 women; 1 study, respectively). See <a href="./references#CD001501-fig-0025" title="">Analysis 4.1</a>. </p> </section> <section id="CD001501-sec-0143"> <p><b>4.2 Rate of satisfaction</b></p> <p>Trials showed no clear evidence of a difference in satisfaction rates between thermal laser and TCRE at 1 year (RR 1.04, 95% CI 0.94 to 1.16; 111 women; 1 study) and 5 years' (RR 1.02, 95% CI 0.91 to 1.14; 111 women; 1 study) follow‐up. See <a href="./references#CD001501-fig-0026" title="">Analysis 4.2</a>. </p> </section> </section> <section id="CD001501-sec-0144"> <h6 class="title">Secondary outcomes</h6> <section id="CD001501-sec-0145"> <p><b>4.3 Duration of operation</b></p> <p>Mean length of surgery was shorter for women in the thermal laser group than in the TCRE group (MD ‐9.30, 95% CI ‐11.36 to ‐7.24; 111 women; 1 study). See <a href="./references#CD001501-fig-0027" title="">Analysis 4.3</a>. </p> </section> <section id="CD001501-sec-0146"> <p><b>4.4 Complication rate: major complications</b></p> <p>Researchers have provided no evidence of differences in the major complication rate between thermal laser and TCRE such as perforation (no events in either group). See <a href="./references#CD001501-fig-0028" title="">Analysis 4.4</a>. </p> </section> <section id="CD001501-sec-0147"> <p><b>4.5 Complication rate: minor complications</b></p> <p>Studies have reported no evidence of differences in the minor complication rate between thermal laser and TCRE such as urinary tract infection (RR 0.49, 95% CI 0.05 to 5.26; 111 women; 1 study). See <a href="./references#CD001501-fig-0029" title="">Analysis 4.5</a>. </p> </section> <section id="CD001501-sec-0148"> <p><b>4.6 Requirement for further surgery</b></p> <p>No clear evidence showed a difference in the requirement for hysterectomy at 2 to 5 years' follow‐up between thermal laser and TCRE groups (RR 0.59, 95% CI 0.15 to 2.35; 111 women; 1 study). See <a href="./references#CD001501-fig-0030" title="">Analysis 4.6</a>. </p> <p>Trials have provided no data for operative difficulties, the proportion of women given local rather than general anaesthesia, length of hospital stay, time or ability to return to normal activities or work, women's perceived change in quality of life, improvement in menstrual symptoms, or mortality as a direct result of surgery. </p> </section> </section> </section> <section id="CD001501-sec-0149"> <h5 class="title">5. Hydro ThermAblator (HTA) versus rollerball (Comparison 5)</h5> <p>One study with 276 women compared Hydro ThermAblator (HTA) versus rollerball (<a href="./references#CD001501-bbs2-0012" title="CorsonSL . A multicenter evaluation of endometrial ablation by hydrothermablator and rollerball for treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2001;8(3):359‐67. GoldrathMH . Evaluation of hydrothermablator and rollerball endometrial ablation for menorrhagia 3 years after treatment. Journal of the American Association of Gynecologic Laparoscopists2003;10(4):505‐11. LofferF . A clinical comparison of hydrothermablation (HTA) and rollerball for endometrial ablation to treat menorrhagia: a randomized multicenter clinical trial. XVI FIGO World Congress of Obstetrics &amp; Gynecology. 2000; Vol. Abstract Book 2:95. ">Corson 2001</a>). </p> <section id="CD001501-sec-0150"> <h6 class="title">Primary outcomes</h6> <section id="CD001501-sec-0151"> <p><b>5.1 Bleeding</b></p> <p>We assessed bleeding at 1 year, 2 years', and up to 5 years' follow‐up in three different ways: PBAC score up to and including 75; or PBAC score up to and including 100; or by reporting of amenorrhoea. Trials provided no clear evidence of a difference between HTA and rollerball, as shown by the following (see <a href="./references#CD001501-fig-0031" title="">Analysis 5.1</a>). </p> <p> <ul id="CD001501-list-0033"> <li> <p>PBAC ≤ 75 at 1 year follow‐up (RR 0.94, 95% CI 0.82 to 1.07; 250 women; 1 study).</p> </li> <li> <p>PBAC ≤ 100 at 1 year follow‐up (RR 0.96, 95% CI 0.86 to 1.07; 250 women; 1 study).</p> </li> <li> <p>PBAC ≤ 100 at 2 years' follow‐up (RR 1.00, 95% CI 0.92 to 1.09; 225 women; 1 study).</p> </li> <li> <p>PBAC ≤ 100 at 2 to 5 years' follow‐up (RR 1.03, 95% CI 0.95 to 1.12; 203 women; 1 study). </p> </li> <li> <p>Amenorrhoea at 1 year follow‐up (RR 0.79, 95% CI 0.60 to 1.05; 250 women; 1 study).</p> </li> <li> <p>Amenorrhoea at 2 years' follow‐up (RR 1.01, 95% CI 0.75 to 1.36; 225 women; 1 study).</p> </li> <li> <p>Amenorrhoea at 2 to 5 years' follow‐up (RR 1.17, 95% CI 0.86 to 1.59; 203 women; 1 study). </p> </li> </ul> </p> </section> <section id="CD001501-sec-0152"> <p><b>5.2 Rate of satisfaction</b></p> <p>We noted no clear evidence of a difference in the rate of satisfaction with treatment at 2 to 5 years' follow‐up between HTA and rollerball groups (RR 1.01, 95% CI 0.96 to 1.06; 203 women; 1 study). See <a href="./references#CD001501-fig-0032" title="">Analysis 5.2</a>. </p> </section> </section> <section id="CD001501-sec-0153"> <h6 class="title">Secondary outcomes</h6> <section id="CD001501-sec-0154"> <p><b>5.3 Proportion given local rather than general anaesthesia</b></p> <p>Women undergoing HTA ablation were almost twice as likely as those with TRCE to require only a local anaesthetic (RR 2.02, 95% CI 1.32 to 3.09; 269 women; 1 study). See <a href="./references#CD001501-fig-0033" title="">Analysis 5.3</a>. </p> </section> <section id="CD001501-sec-0155"> <p><b>5.4 Complication rate: major complications</b></p> <p>Women in the HTA group were less likely to experience the adverse event of haematometra (haemorrhage in the uterus) from surgery (RR 0.18, 95% CI 0.04 to 0.93). See <a href="./references#CD001501-fig-0034" title="">Analysis 5.4.</a> However, results showed no clear differences in other major complications such as the following. </p> <p> <ul id="CD001501-list-0034"> <li> <p>Cervical lacerations (RR 0.09, 95% CI 0.00 to 1.92; 269 women; 1 study).</p> </li> <li> <p>Endometritis (RR 0.92, 95% CI 0.08 to 10.05; 269 women; 1 study).</p> </li> </ul> </p> </section> <section id="CD001501-sec-0156"> <p><b>5.5 Complication rate: minor complications</b></p> <p>Women with HTA were more likely to experience abdominal pain (RR 1.40, 95% CI 1.03 to 1.90; 269 women; 1 study) and nausea and vomiting after surgery (RR 3.08, 95% CI 1.36 to 6.98; 269 women; 1 study). See <a href="./references#CD001501-fig-0035" title="">Analysis 5.5.</a> Study results showed no clear evidence of differences in other minor complications such as the following. </p> <p> <ul id="CD001501-list-0035"> <li> <p>Uterine cramping (RR 1.12, 95% CI 0.72 to 1.74; 269 women; 1 study).</p> </li> <li> <p>Urinary tract infection (RR 1.15, 95% CI 0.23 to 5.83; 269 women; 1 study).</p> </li> <li> <p>First‐degree burn (RR 2.32, 95% CI 0.11 to 47.89; 269 women; 1 study).</p> </li> </ul> </p> </section> <section id="CD001501-sec-0157"> <p><b>5.6 Requirement for further surgery</b></p> <p>We found no clear evidence of differences between groups in the requirement for further surgery, including any surgery at 1 year follow‐up (RR 2.32, 95% CI 0.11 to 47.89; 269 women; 1 study); any surgery at 2 to 5 years' follow‐up (RR 1.26, 95% CI 0.58 to 2.73; 269 women; 1 study); or hysterectomy at 5 years' follow‐up (RR 1.54, 95% CI 0.58 to 4.06; 269 women; 1 study). See <a href="./references#CD001501-fig-0036" title="">Analysis 5.6</a>. </p> <p>Researchers provided no data for duration of surgery, operative difficulties, length of hospital stay, time or ability to return to normal activities or work, women's perceived change in quality of life, improvement in menstrual symptoms, or mortality as a direct result of surgery. </p> </section> </section> </section> <section id="CD001501-sec-0158"> <h5 class="title">6. Cryoablation versus rollerball (Comparison 6)</h5> <p>One study with 279 women compared cryoablation and rollerball (<a href="./references#CD001501-bbs2-0013" title="DulebaAJ , HeppardMC , SoderstromRM , TownsendDE . A randomized study comparing endometrial cryoablation and rollerball electroablation for treatment of dysfunctional uterine bleeding. Journal of the American Association of Gynecologic Laparoscopists2003;10(1):17‐26. TownsendDE , DulebaAJ , WilkesMM , et al. Durability of treatment effects after cryoablation versus rollerball electroablation for abnormal uterine bleeding: two‐year results of a multicenter randomized trial. American Journal of Obstetrics and Gynecology2003;188:699‐701. ">Duleba 2003</a>). </p> <section id="CD001501-sec-0159"> <h6 class="title">Primary outcomes</h6> <section id="CD001501-sec-0160"> <p><b>6.1 Bleeding</b></p> <p>Women undergoing cryoablation were less likely to have amenorrhoea 1 year after surgery than women receiving rollerball treatment (odds ratio (OR) 0.5, 95% CI 0.36 to 0.69; 279 women; 1 study). See <a href="./references#CD001501-fig-0037" title="">Analysis 6.1</a>. </p> </section> <section id="CD001501-sec-0161"> <p><b>6.2 Rate of satisfaction</b></p> <p>We found no evidence of clear differences between groups for satisfaction with treatment at 1 year (RR 1.06, 95% CI 0.96 to 1.17; 279 women; 1 study) or 2 years' follow‐up (RR 1.04, 95% CI 0.91 to 1.17; 279 women; 1 study). See <a href="./references#CD001501-fig-0038" title="">Analysis 6.2</a>. </p> </section> </section> <section id="CD001501-sec-0162"> <h6 class="title">Secondary outcomes</h6> <p>Operative outcomes </p> <section id="CD001501-sec-0163"> <p><b>6.3 Proportion given local anaesthesia</b></p> <p>Women undergoing cryoablation were more likely to receive local rather than general anaesthesia than women undergoing rollerball ablation (RR 6.6, 95% CI 3.2 to 13.6; 279 women; 1 study). See <a href="./references#CD001501-fig-0039" title="">Analysis 6.3.</a> </p> </section> <section id="CD001501-sec-0164"> <p><b>6.4 Complication rate: major complications</b></p> <p>No evidence showed clear differences between groups for major complications such as the following (see <a href="./references#CD001501-fig-0040" title="">Analysis 6.4</a>). </p> <p> <ul id="CD001501-list-0036"> <li> <p>Perforation (RR 0.15, 95% CI 0.01 to 3.63; 279 women; 1 study).</p> </li> </ul> </p> </section> <section id="CD001501-sec-0165"> <p><b>6.5 Complication rate: minor complications</b></p> <p>No evidence showed clear differences between groups for minor complications such as the following (See <a href="./references#CD001501-fig-0041" title="">Analysis 6.5</a>) </p> <p> <ul id="CD001501-list-0037"> <li> <p>Vaginal bleeding (RR 1.35, 95% CI 0.06 to 32.70; 279 women; 1 study).</p> </li> <li> <p>Abdominal cramping (RR 2.24, 95% CI 0.11 to 46.21; 279 women; 1 study).</p> </li> <li> <p>Urinary tract infection (RR 0.15, 95% CI 0.01 to 3.63; 279 women; 1 study).</p> </li> <li> <p>Severe pelvic pain (RR 0.15, 95% CI 0.01 to 3.63; 279 women; 1 study).</p> </li> </ul> </p> </section> <section id="CD001501-sec-0166"> <p><b>6.6 Requirement for further surgery</b></p> <p>Researchers showed no clear evidence of differences between groups in the requirement for further surgery at 2 years after ablation treatment for any surgery (RR 1.00, 95% CI 0.45 to 2.22; 279 women; 1 study) or for hysterectomy only (RR 0.83, 95% CI 0.34 to 2.00; 279 women; 1 study). See <a href="./references#CD001501-fig-0042" title="">Analysis 6.6</a>. </p> <p>Researchers provided no data for duration of surgery, operative difficulties, length of hospital stay, time or ability to return to normal activities or work, women's perceived change in quality of life, improvement in menstrual symptoms, or mortality as a direct result of surgery. </p> </section> </section> </section> <section id="CD001501-sec-0167"> <h5 class="title">7. Electrode ablation (balloon or mesh) versus TCRE (Comparison 7)</h5> <p>Two studies with a total of 541 women compared electrode ablation (balloon or mesh) versus TCRE. <a href="./references#CD001501-bbs2-0011" title="CorsonSL , BrillAI , BrooksPG , CooperJM , IndmanPD , LiuJH , et al. Interim results of the American Vesta trial of endometrial ablation. Journal of the American Association of Gynecologic Laparoscopists1999;6(1):45‐9. CorsonSL , BrillAI , BrooksPG , CooperJM , IndmanPD , LiuJH , et al. One‐year results of the Vesta system for endometrial ablation. Journal of the American Association of Gynecologic Laparoscopists2000;7(4):489‐97. ">Corson 2000</a> compared electrode ablation with a balloon system, and <a href="./references#CD001501-bbs2-0009" title="CooperJ , GimpelsonR , LabergeP , GalenD , Garza‐LealJG , ScottJ , et al. A randomized, multicenter trial of safety and efficacy of the NovaSure system in the treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2002;9(4):418‐28. ">Cooper 2002</a> compared an electrode balloon system versus mesh. </p> <section id="CD001501-sec-0168"> <h6 class="title">Primary outcomes</h6> <section id="CD001501-sec-0169"> <p><b>7.1 , 7.2, and 7.3 Bleeding</b></p> <p>Trial results showed no clear evidence of differences between groups for bleeding.</p> <p> <ul id="CD001501-list-0038"> <li> <p>Amenorrhoea rate with the balloon system (RR 0.89, 95% CI 0.62 to 1.29; 234 women; 1 study) versus the mesh system (RR 1.16, 95% CI 0.82 to 1.64; 236 women; 1 study). See <a href="./references#CD001501-fig-0043" title="">Analysis 7.1</a>. </p> </li> <li> <p>PBAC score &lt; 75 with the balloon system (RR 1.05, 95% CI 0.94 to 1.17; 234 women; 1 study) versus the mesh system (RR 1.08, 95% CI 0.96 to 1.22; 236 women; 1 study). See <a href="./references#CD001501-fig-0044" title="">Analysis 7.2</a>. </p> </li> <li> <p>PBAC score at 12 months' follow‐up. See <a href="./references#CD001501-fig-0045" title="">Analysis 7.3</a>. </p> </li> </ul> </p> </section> <section id="CD001501-sec-0170"> <p><b>7.4 Rate of satisfaction</b></p> <p>Upon assessing rate of satisfaction with treatment after 1 year, study authors did not report clear differences between groups comparing the mesh system to TCRE (RR 0.99, 95% CI 0.92 to 1.06; 236 women; 1 study). See <a href="./references#CD001501-fig-0046" title="">Analysis 7.4</a>. </p> </section> </section> <section id="CD001501-sec-0171"> <h6 class="title">Secondary outcomes</h6> <p>Operative outcomes </p> <section id="CD001501-sec-0172"> <p><b>7.5 Duration of surgery</b></p> <p>The duration of the procedure was significantly longer for women undergoing TCRE compared with ablation (MD 18.7 minutes, 95% CI 16.8 to 20.7; 520 women; 2 studies; I² = 69%). See <a href="./references#CD001501-fig-0047" title="">Analysis 7.5</a>. </p> </section> <section id="CD001501-sec-0173"> <p><b>7.6 Procedure abandonment</b></p> <p>We found no evidence of a clear difference between groups for abandonment of the procedure (RR 2.57, 95% CI 0.11 to 62.41; 267 women; 1 study). See <a href="./references#CD001501-fig-0048" title="">Analysis 7.6</a>. </p> </section> <section id="CD001501-sec-0174"> <p><b>7.7 Proportion given general versus local anaesthesia</b></p> <p>Women undergoing electrode ablation were more likely to receive local rather than general anaesthesia compared with women having TCRE (RR 3.9, 95% CI 2.9 to 5.0; 520 women; 2 studies; I² = 0%). See <a href="./references#CD001501-fig-0049" title="">Analysis 7.7</a>. </p> </section> <section id="CD001501-sec-0175"> <p><b>7.8 Complication rate: major complications</b></p> <p>Clear evidence showed differences in major complications such as perforation and cervical tears or lacerations between groups. Perforation (RR 0.13, 95% CI 0.02 to 1.01; 532 women; 2 studies; I² = 0%) and cervical tears or lacerations (RR 0.11, 95% CI 0.01 to 0.87; 532 women; 2 studies; I² = 0%) were less likely with electrode ablation than with TCRE. See <a href="./references#CD001501-fig-0050" title="">Analysis 7.8</a>. </p> <p>We found no report of clear evidence of differences in other major complications such as the following. </p> <p> <ul id="CD001501-list-0039"> <li> <p>Pelvic abscess (RR 0.17, 95% CI 0.01 to 4.19; 267 women; 1 study).</p> </li> <li> <p>Haematometra (RR 0.43, 95% CI 0.08 to 2.23; 267 women; 1 study).</p> </li> <li> <p>Fluid overload (RR 0.29, 95% CI 0.01 to 6.93; 267 women; 1 study).</p> </li> <li> <p>Myometritis (RR 0.29, 95% CI 0.01 to 6.93; 267 women; 1 study).</p> </li> <li> <p>Urinary incontinence (RR 0.29, 95% CI 0.01 to 6.93; 267 women; 1 study).</p> </li> <li> <p>Pelvic inflammatory disease (RR 1.03, 95% CI 0.09 to 11.19; 267 women; 1 study).</p> </li> <li> <p>Endometritis (RR 0.34, 95% CI 0.06 to 2.01; 267 women; 1 study).</p> </li> </ul> </p> </section> <section id="CD001501-sec-0176"> <p><b>7.9 Complication rate: minor complications</b></p> <p>The minor complication rate did not show clear evidence of differences between groups for minor complications such as the following (see <a href="./references#CD001501-fig-0051" title="">Analysis 7.9</a>). </p> <p> <ul id="CD001501-list-0040"> <li> <p>Nausea/vomiting or severe pelvic pain (RR 1.10, 95% CI 0.37 to 3.27; 267 women; 1 study). </p> </li> <li> <p>Urinary tract infection (RR 1.05, 95% CI 0.39 to 2.84; 267 women; 1 study).</p> </li> <li> <p>Fever (RR 0.85, 95% CI 0.05 to 13.51; 267 women; 1 study).</p> </li> <li> <p>Haemorrhage (RR 0.51, 95% CI 0.03 to 8.13; 267 women; 1 study).</p> </li> <li> <p>Bradycardia (RR 1.55, 95% CI 0.06 to 37.70; 267 women; 1 study).</p> </li> </ul> </p> </section> <section id="CD001501-sec-0177"> <p><b>7.10 Requirement for further surgery</b></p> <p>At two years' follow‐up, comparison of the balloon system versus TCRE + roller ball provided no clear evidence of differences between groups for hysterectomy rate (RR 0.52, 95% CI 0.18 to 1.50; 255 women; 1 study). See <a href="./references#CD001501-fig-0052" title="">Analysis 7.10</a>. </p> <p>Researchers provided no data for operative difficulties, length of hospital stay, time or ability to return to normal activities or work, women's perceived change in quality of life, improvement in menstrual symptoms, or mortality as a direct result of surgery. </p> </section> </section> </section> <section id="CD001501-sec-0178"> <h5 class="title">8. Microwave versus TCRE plus rollerball (Comparison 8)</h5> <p>Two studies with a total of 585 women compared microwave versus TCRE plus rollerball (<a href="./references#CD001501-bbs2-0008" title="BainC , CooperKG , ParkinDE . Microwave endometrial ablation versus endometrial resection: a randomized controlled trial. Obstetrics and Gynecology2002;99:983‐7. CooperKG , BainC , LawrieL , ParkinDE . A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium: follow up at a minimum of five years. British Journal of Obstetrics and Gynaecology2005;112:470‐5. CooperKG , BainC , ParkinDE . Comparison of microwave endometrial ablation and transcervical resection of the endometrium for treatment of heavy menstrual loss: a randomised trial. Lancet1999;354:1859‐63. SambrookAM , BainC , ParkinDE , CooperKG . A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium: follow up at a minimum of 10 years. British Journal of Obstetrics and Gynaecology2009;116:1033‐7. ">Cooper 1999</a>; <a href="./references#CD001501-bbs2-0010" title="CooperJM , AndersonTL , FortinCA , JackSA , PlentlMB . Microwave endometrial ablation vs rollerball electroablation for menorrhagia: a multicenter randomized trial. Journal of the American Association of Gynecologic Laparoscopists2004;11(3):394‐403. ">Cooper 2004</a>). </p> <section id="CD001501-sec-0179"> <h6 class="title">Primary outcomes</h6> <section id="CD001501-sec-0180"> <p><b>8.1 Bleeding</b></p> <p>No evidence showed differences between groups in primary outcomes measuring menstrual blood loss (see <a href="./references#CD001501-fig-0053" title="">Analysis 8.1</a>). Bleeding was measured by: </p> <p> <ul id="CD001501-list-0041"> <li> <p>PBAC &lt; 75 or acceptable improvement at 1 year follow‐up (RR 1.04, 95% CI 0.96 to 1.13; 562 women; 2 studies; I² = 0%); </p> </li> <li> <p>PBAC &lt; 75 or acceptable improvement at 2 to 5 years' follow‐up (RR 1.12, 95% CI 0.97 to 1.28; 236 women; 1 study); </p> </li> <li> <p>PBAC &lt; 75 or acceptable improvement at &gt; 5 years' follow‐up (RR 1.08, 95% CI 0.87 to 1.34; 263 women; 1 study); </p> </li> <li> <p>Amenorrhoea at 1 year follow‐up (RR 1.12, 95% CI 0.93 to 1.36; 562 women; 2 studies; I² = 0%); </p> </li> <li> <p>Amenorrhoea at 2 years' follow‐up (RR 1.16, 95% CI 0.87 to 1.53; 249 women; 1 study);</p> </li> <li> <p>Amenorrhoea at 2 to 5 years' follow‐up (RR 0.93, 95% CI 0.78 to 1.12; 236 women; 1 study); and </p> </li> <li> <p>Amenorrhoea at &gt; 5 years' follow‐up (RR 0.94, 95% CI 0.83 to 1.05; 189 women; 1 study).</p> </li> </ul> </p> </section> <section id="CD001501-sec-0181"> <p><b>8.2 Rate of satisfaction</b></p> <p>Results of the comparison vary over time. At 2 years' follow‐up, results showed benefit for microwave ablation in terms of satisfaction with treatment when compared with TCRE (RR 1.01, 95% CI 0.95 to 1.07; 533 women; 2 studies; I² = 0%), and this benefit was maintained at 5 years' (RR 1.19, 95% CI 1.02 to 1.38; 249 women; 1 study) but not at 10 years' follow‐up in the same study (RR 1.14, 95% CI 0.92 to 1.42; participants = 263; studies = 1). See <a href="./references#CD001501-fig-0054" title="">Analysis 8.2</a>. </p> </section> </section> <section id="CD001501-sec-0182"> <h6 class="title">Secondary outcomes</h6> <p>Operative outcomes </p> <section id="CD001501-sec-0183"> <p><b>8.3 Duration of surgery</b></p> <p>In one study, the duration of the procedure was significantly shorter with microwave than with TCRE (MD 3.6, 95% CI ‐5.7 to ‐1.4; P = 0.001). See <a href="./references#CD001501-fig-0055" title="">Analysis 8.3</a>. </p> </section> <section id="CD001501-sec-0184"> <p><b>8.4 Surgery difficulties</b></p> <p>In one study, risk of equipment failure was higher in the microwave group than in the TCRE group (RR 3.81, 95% CI 1.09 to 13.34; 263 women; 1 study), and results did not show clear evidence of differences between groups in abandoning the procedure (RR 1.04, 95% CI 0.31 to 3.50; 263 women; 1 study). See <a href="./references#CD001501-fig-0056" title="">Analysis 8.4</a>. </p> </section> <section id="CD001501-sec-0185"> <p><b>8.5 Proportion given general versus local anaesthesia</b></p> <p>Participants undergoing microwave ablation were more likely to receive local anaesthesia than those undergoing TCRE (RR 2.54, 95% CI 1.73 to 3.72; 315 women; 1 study). See <a href="./references#CD001501-fig-0057" title="">Analysis 8.5</a>. </p> </section> <section id="CD001501-sec-0186"> <p><b>8.6 Duration of hospital stay</b></p> <p>We found no clear evidence of a difference between groups in terms of hours spent in the hospital (no differences; P = 0.17). See <a href="./references#CD001501-fig-0058" title="">Analysis 8.6</a>. </p> </section> <section id="CD001501-sec-0187"> <p><b>8.7 Inability to work</b></p> <p>Researchers provided no clear evidence of differences between groups in the proportion of women with inability to work at 12 months' (RR 0.53, 95% CI 0.17 to 1.73; 240 women; 1 study) and 5 years' follow‐up (RR 1.52, 95% CI 0.26 to 8.87; 189 women; 1 study). See <a href="./references#CD001501-fig-0059" title="">Analysis 8.7</a>. </p> </section> <section id="CD001501-sec-0188"> <p><b>8.8 Quality of life</b></p> <p>We found no clear evidence of differences between groups on Short Form‐36 (SF‐36) after treatment at 12 months, and at 2, 5, and 10 years. See <a href="./references#CD001501-fig-0060" title="">Analysis 8.8</a>. </p> </section> <section id="CD001501-sec-0189"> <p><b>8.9 Improvement in other menstrual symptoms: PMS</b></p> <p>We found no clear evidence of differences in PMS improvement between groups at 1 year follow‐up (RR 0.98, 95% CI 0.89 to 1.09; 533 women; 2 studies; I² = 0%) or at 2 years' follow‐up (RR 1.05, 95% CI 0.93 to 1.19; 249 women; 1 study). See <a href="./references#CD001501-fig-0061" title="">Analysis 8.9</a>. </p> </section> <section id="CD001501-sec-0190"> <p><b>8.10 and 8.11 Improvement in other menstrual symptoms: dysmenorrhoea</b></p> <p>Trial results showed no clear evidence of differences in improvement in the rate of dysmenorrhoea between groups at 1 year follow‐up (RR 0.98, 95% CI 0.89 to 1.09; 533 women; 2 studies; I² = 0%) nor at 2 years' follow‐up (RR 1.05, 95% CI 0.93 to 1.19; 249 women; 1 study). See <a href="./references#CD001501-fig-0062" title="">Analysis 8.10</a>. They also provided no clear evidence of differences in reduction in pain score at 5 years' follow‐up (MD ‐0.80, 95% CI ‐4.32 to 2.72; 189 women; 1 study). See <a href="./references#CD001501-fig-0063" title="">Analysis 8.11.</a> </p> </section> <section id="CD001501-sec-0191"> <p><b>8.12 Postoperative analgesia rate</b></p> <p>Researchers provided no clear evidence of differences between groups (RR 0.94, 95% CI 0.81 to 1.10; 263 women; 1 study). See <a href="./references#CD001501-fig-0064" title="">Analysis 8.12</a>. </p> </section> <section id="CD001501-sec-0192"> <p><b>8.13 Complication rate: major complications</b></p> <p>We found no clear evidence of differences between groups in the incidence of major complications such as haemorrhage (RR 0.09, 95% CI 0.01 to 1.69; 263 women; 1 study). See <a href="./references#CD001501-fig-0065" title="">Analysis 8.13</a>. </p> <p> <ul id="CD001501-list-0042"> <li> <p>Perforation (RR 1.63, 95% CI 0.22 to 12.12; 585 women; 2 studies; I² = 0%).</p> </li> <li> <p>Cervical laceration (RR 0.50, 95% CI 0.07 to 3.48; 322 women; 1 study).</p> </li> <li> <p>Cervical stenosis (RR 1.50, 95% CI 0.06 to 36.52; 322 women; 1 study).</p> </li> <li> <p>Endometritis (RR 6.50, 95% CI 0.37 to 114.31; 322 women; 1 study).</p> </li> </ul> </p> </section> <section id="CD001501-sec-0193"> <p><b>8.14 Complication rate: minor complications</b></p> <p>We found no clear evidence of differences between groups in the incidence of minor complications such as the following (see <a href="./references#CD001501-fig-0066" title="">Analysis 8.14</a>). </p> <p> <ul id="CD001501-list-0043"> <li> <p>Chills (RR 1.35, 95% CI 0.59 to 3.11; 322 women; 1 study).</p> </li> <li> <p>Bloating (RR 0.83, 95% CI 0.38 to 1.83; 322 women; 1 study).</p> </li> <li> <p>Dysuria (RR 0.77, 95% CI 0.37 to 1.58; 322 women; 1 study).</p> </li> <li> <p>Fever (RR 2.50, 95% CI 0.12 to 51.62; 322 women; 1 study).</p> </li> <li> <p>Headache (RR 0.75, 95% CI 0.22 to 2.59; 322 women; 1 study).</p> </li> <li> <p>Nausea (RR 1.35, 95% CI 0.83 to 2.21; 322 women; 1 study).</p> </li> <li> <p>Vomiting (RR 3.61, 95% CI 1.30 to 10.00; 322 women; 1 study).</p> </li> <li> <p>Urinary tract infection (RR 0.50, 95% CI 0.03 to 7.88; 322 women; 1 study).</p> </li> <li> <p>Vaginal infection (RR 1.50, 95% CI 0.06 to 36.52; 322 women; 1 study).</p> </li> <li> <p>Uterine cramping (RR 1.21, 95% CI 1.01 to 1.44; 322 women; 1 study).</p> </li> <li> <p>Abdominal tenderness (RR 0.61, 95% CI 0.26 to 1.42; 322 women; 1 study).</p> </li> </ul> </p> </section> <section id="CD001501-sec-0194"> <p><b>8.15 Requirement for further surgery</b></p> <p>At 10 years' follow‐up, risk of hysterectomy was reduced with microwave ablation compared with TCRE plus rollerball (RR 0.60, 95% CI 0.38 to 0.96; n = 263; 1 study). See <a href="./references#CD001501-fig-0067" title="">Analysis 8.15</a>. Caution is advised when these results are interpreted, as evidence is based on a single study that reported loss to follow‐up greater than 25%. </p> <p>Investigators reported no data for operative difficulties nor for mortality as a direct result of surgery. </p> </section> </section> </section> <section id="CD001501-sec-0195"> <h5 class="title">9. Balloon versus rollerball (Comparison 9)</h5> <p>Three studies with a total of 414 women compared balloon versus rollerball (<a href="./references#CD001501-bbs2-0018" title="GraingerDA , TjadenDO , RowlandC , MeyerWR . Thermal balloon and rollerball ablation to treat menorrhagia: two‐year results of a multicenter, prospective, randomized clinical trial. Journal of the American Association of Gynecologic Laparoscopists2000;7(2):175‐9. LofferFD . Five year post‐procedure follow‐up of patients participating in a randomised trial of uterine balloon therapy vs rollerball ablation for the treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopy2001;8(1):48‐54. LofferFD . Three‐year comparison of thermal balloon and rollerball ablation in treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2001;8(1):48‐54. MeyerWR , WalshBW , GraingerDA , PeacockLM , LofferFD , SteegeJF . Thermal balloon and rollerball ablation to treat menorrhagia: a multicenter comparison. Obstetrics and Gynecology1998;92:98‐103. ">Meyer 1998</a>; <a href="./references#CD001501-bbs2-0024" title="RomerT . The treatment of recurrent menorrhagias ‐ Cavaterm‐balloon‐coagulation versus Rollerball‐endometrial ablation ‐ a prospective randomized comparative study [Die therapie rezidivierender Menorrhagien ‐ Cavaterm‐Ballon‐Koagulatioon versus Roller‐Ball‐Endometriumkoagulation ‐ eine prospektive randomisierte Vergleichsstudie]. Zentralblatt fur Gynakologie1998;120(10):511‐4. ">Romer 1998</a>; <a href="./references#CD001501-bbs2-0027" title="vanZon‐RabelinkIAA , VleugelsMPH . Treating menorrhagia with endometrial ablation: rollerball electrocoagulation versus thermal ablation with the uterine balloon. Gynaecological Endoscopy Abstract from the 6th Annual Congress of the European Society for Gynaecological Endoscopy1997;6 Suppl 2:41. vanZon‐RabelinkIAA , VleugelsMPH , MerkusHMWM , deGraafR . Efficacy and satisfaction rate comparing endometrial ablation by rollerball electrocoagulation to uterine balloon thermal ablation in a randomised controlled trial. European Journal of Obstetrics, Gynecology, and Reproductive Biology2004;114(1):97‐103. vanZon‐RabelinkIAA , VleugelsMPH , MerkusHMWM , deGraafR . Endometrial ablation by rollerball electrocoagulation compared to uterine balloon thermal ablation. Technical and safety aspects. European Journal of Obstetrics, Gynecology, and Reproductive Biology2003;110:220‐3. ">van Zon‐Rabelink 2003</a>). </p> <section id="CD001501-sec-0196"> <h6 class="title">Primary outcomes</h6> <section id="CD001501-sec-0197"> <p><b>9.1 to 9.4 Bleeding</b></p> <p><b>9.1</b> Amenorrhoea was less likely after balloon ablation than after rollerball ablation at 1 year follow‐up (RR 0.62, 95% CI 0.39 to 1.00; 259 women; 2 studies; I² = 41%), but results showed no significant differences between groups at 2 years (RR 0.60, 95% CI 0.33 to 1.07; 227 women; 1 study) and up to 5 years (RR 0.70, 95% CI 0.39 to 1.25; 122 women; 1 study) after treatment, although a strong trend favoured rollerball ablation. See <a href="./references#CD001501-fig-0068" title="">Analysis 9.1</a>. No evidence showed significant differences between groups for rate of amenorrhoea/eumenorrhoea at 1 year follow‐up (RR 0.95, 95% CI 0.86 to 1.06; 259 women; 2 studies; I² = 0%), at 2 years' follow‐up (RR 0.99, 95% CI 0.91 to 1.08; 227 women; 1 study), or at 2 to 5 years' follow‐up (RR 0.98, 95% CI 0.91 to 1.06; 122 women; 1 study). See <a href="./references#CD001501-fig-0068" title="">Analysis 9.1</a>. </p> <p><b>9.2</b> Results showed no clear differences in PBAC score at 1 year follow‐up, but one study (<a href="./references#CD001501-bbs2-0027" title="vanZon‐RabelinkIAA , VleugelsMPH . Treating menorrhagia with endometrial ablation: rollerball electrocoagulation versus thermal ablation with the uterine balloon. Gynaecological Endoscopy Abstract from the 6th Annual Congress of the European Society for Gynaecological Endoscopy1997;6 Suppl 2:41. vanZon‐RabelinkIAA , VleugelsMPH , MerkusHMWM , deGraafR . Efficacy and satisfaction rate comparing endometrial ablation by rollerball electrocoagulation to uterine balloon thermal ablation in a randomised controlled trial. European Journal of Obstetrics, Gynecology, and Reproductive Biology2004;114(1):97‐103. vanZon‐RabelinkIAA , VleugelsMPH , MerkusHMWM , deGraafR . Endometrial ablation by rollerball electrocoagulation compared to uterine balloon thermal ablation. Technical and safety aspects. European Journal of Obstetrics, Gynecology, and Reproductive Biology2003;110:220‐3. ">van Zon‐Rabelink 2003</a>) found a significantly lower PBAC at 2 years' follow‐up in women treated with balloon (median 33.5, SD 0.905; vs median 73, SD 0.585; P = 0.01; 111 women). See <a href="./references#CD001501-fig-0069" title="">Analysis 9.2.</a> </p> <p><b>9.3</b> Results showed no clear differences between groups in terms of success of treatment measured as lighter periods and no need for further surgery at 2 to 5 years' follow‐up (RR 0.98, 95% CI 0.80 to 1.20; 170 women; 1 study). See <a href="./references#CD001501-fig-0070" title="">Analysis 9.3</a>. </p> <p><b>9.4</b> Researchers reported no clear differences between groups in terms of success of treatment measured as menstrual score &lt; 185 at 1 year follow‐up (RR 1.00, 95% CI 0.83 to 1.20; 129 women; 1 study) nor at 2 years' follow‐up (RR 1.01, 95% CI 0.83 to 1.23; 121 women; 1 study). </p> </section> <section id="CD001501-sec-0198"> <p><b>9.5 Rate of satisfaction</b></p> <p>No evidence showed clear differences between groups in terms of satisfaction with treatment at 1 year follow‐up (RR 0.97, 95% CI 0.93 to 1.01; 259 women; 2 studies; I² = 0%), at 2 years' follow‐up (RR 1.02, 95% CI 0.93 to 1.12; 348 women; 2 studies; I² = 0%), or at 2 to 5 years' follow‐up (RR 0.93, 95% CI 0.87 to 1.01; 122 women; 1 study). See <a href="./references#CD001501-fig-0072" title="">Analysis 9.5.</a> </p> </section> </section> <section id="CD001501-sec-0199"> <h6 class="title">Secondary outcomes</h6> <p>Operative outcomes </p> <section id="CD001501-sec-0200"> <p><b>9.6 Duration of surgery</b></p> <p>The mean difference between duration of surgery for women in the balloon group and those in the rollerball group was 15 minutes (MD ‐14.58, 95% CI ‐17.00 to ‐12.17; participants = 378; 2 studies; I² = 74%). See <a href="./references#CD001501-fig-0073" title="">Analysis 9.6.</a> </p> </section> <section id="CD001501-sec-0201"> <p><b>9.7 Operative difficulties</b></p> <p>We found no evidence of significant differences between groups in terms of technical complication rates (RR 1.05, 95% CI 0.49 to 2.22; 139 women; 1 study). See <a href="./references#CD001501-fig-0074" title="">Analysis 9.7</a>. </p> </section> <section id="CD001501-sec-0202"> <p><b>9.8 Inability to work</b></p> <p>Trials did not present clear evidence of differences between groups for ability to work at 1 year follow‐up (RR 1.52, 95% CI 0.37 to 6.22; 239 women; 1 study), at 2 years' follow‐up (RR 0.29, 95% CI 0.03 to 2.72; 227 women; 1 study), or at 2 to 5 years' follow‐up (RR 0.87, 95% CI 0.26 to 2.93; 210 women; 1 study). See <a href="./references#CD001501-fig-0075" title="">Analysis 9.8</a>. </p> </section> <section id="CD001501-sec-0203"> <p><b>9.9 Improvement in other menstrual symptoms</b></p> <p>Trials did not present clear evidence of differences between groups in terms of improvement in other menstrual symptoms for dysmenorrhoea at 12 months (RR 0.93, 95% CI 0.80 to 1.09; 239 women; 1 study) and in premenstrual symptoms from moderate to severe at 1 year (RR 0.94, 95% CI 0.74 to 1.19; 185 women; 1 study), at 2 years' (RR 1.03, 95% CI 0.82 to 1.29; 177 women; 1 study), and at 2 to 5 years' follow‐up (RR 0.99, 95% CI 0.75 to 1.30; 166 women; 1 study). See <a href="./references#CD001501-fig-0076" title="">Analysis 9.9.</a> </p> </section> <section id="CD001501-sec-0204"> <p><b>9.10 Complication rate: major complications</b></p> <p>We found no clear evidence of differences between groups in major complications such as the following (see <a href="./references#CD001501-fig-0077" title="">Analysis 9.10</a>). </p> <p> <ul id="CD001501-list-0044"> <li> <p>Fluid overload (RR 0.18, 95% CI 0.01 to 3.76; 239 women; 1 study).</p> </li> <li> <p>Perforation (RR 0.17, 95% CI 0.02 to 1.42; 378 women; 2 studies; I² = 0%).</p> </li> <li> <p>Cervical lacerations (RR 0.17, 95% CI 0.02 to 1.42; 378 women; 2 studies; I² = 0%).</p> </li> <li> <p>Endometritis (RR 2.74, 95% CI 0.29 to 25.93; 239 women; 1 study).</p> </li> <li> <p>Haematometra (RR 0.30, 95% CI 0.01 to 7.39; 239 women; 1 study).</p> </li> </ul> </p> </section> <section id="CD001501-sec-0205"> <p><b>9.11 Complication rate: minor complications</b></p> <p>We found no clear evidence of differences between groups in minor complications such as the following (see <a href="./references#CD001501-fig-0078" title="">Analysis 9.11</a>). </p> <p> <ul id="CD001501-list-0045"> <li> <p>Urinary tract infection (RR 2.74, 95% CI 0.11 to 66.54; 239 women; 1 study).</p> </li> <li> <p>Hydrosalpinx (RR 0.30, 95% CI 0.01 to 7.39; 239 women; 1 study).</p> </li> <li> <p>Pain (RR 5.65, 95% CI 0.30 to 107.43; 139 women; 1 study).</p> </li> <li> <p>Nausea (RR 0.27, 95% CI 0.01 to 6.50; 139 women; 1 study).</p> </li> <li> <p>Infection (RR 0.27, 95% CI 0.01 to 6.50; 139 women; 1 study).</p> </li> </ul> </p> </section> <section id="CD001501-sec-0206"> <p><b>9.12 Requirement for further surgery</b></p> <p>Trials provided no evidence of clear differences between groups in the requirement for further surgery including the following (see <a href="./references#CD001501-fig-0079" title="">Analysis 9.12</a>). </p> <p> <ul id="CD001501-list-0046"> <li> <p>Any surgery at 1 year follow‐up (RR 0.61, 95% CI 0.10 to 3.57; 239 women; 1 study), at 2 years' follow‐up (RR 0.67, 95% CI 0.35 to 1.28; 392 women; 2 studies; I² = 61%), and at 2 to 5 years' follow‐up (RR 1.00, 95% CI 0.64 to 1.55; 122 women; 1 study). . </p> </li> <li> <p>Hysterectomy at 2 years' follow‐up (RR 1.04, 95% CI 0.38 to 2.83; 137 women; 1 study) or at 2 to 5 years' follow‐up (RR 1.00, 95% CI 0.61 to 1.63; 122 women; 1 study). </p> </li> </ul> </p> <p>Researchers provided no data for the proportion having general versus local anaesthesia, time or ability to return to normal activities or work, or mortality as a direct result of surgery. </p> </section> </section> </section> <section id="CD001501-sec-0207"> <h5 class="title">10. Balloon versus laser (Comparison 10)</h5> <p>One study with 70 women compared balloon versus laser (<a href="./references#CD001501-bbs2-0015" title="HaweJ , AbbottJ , HunterD , PhillipsG , GarryR . A randomised controlled trial comparing the Cavaterm endometrial ablation system with the Nd:YAG laser for the treatment of dysfunctional uterine bleeding. British Journal of Obstetrics and Gynaecology2003;110:350‐7. ">Hawe 2003</a>). </p> <section id="CD001501-sec-0208"> <h6 class="title">Primary outcomes</h6> <section id="CD001501-sec-0209"> <p><b>10.1 and 10.2 Bleeding</b></p> <p>Researchers measured bleeding as rate of amenorrhoea and PBAC score after treatment. Evidence showed no clear differences between groups, including the following (see <a href="./references#CD001501-fig-0080" title="">Analysis 10.1</a> and <a href="./references#CD001501-fig-0081" title="">Analysis 10.2</a>). </p> <p> <ul id="CD001501-list-0047"> <li> <p>Amenorrhoea at 6 months' follow‐up (RR 1.11, 95% CI 0.61 to 2.02; 70 women; 1 study).</p> </li> <li> <p>Amenorrhoea at 12 months' follow‐up (RR 0.75, 95% CI 0.38 to 1.46; 67 women; 1 study).</p> </li> <li> <p>PBAC score at 6 months' follow‐up (mean (SD), 28.8 (59.6)/27.4 (57.6)); study authors did not report significance. </p> </li> </ul> </p> </section> <section id="CD001501-sec-0210"> <p><b>10.3 Rate of satisfaction</b></p> <p>Trials provided no clear evidence of differences between groups in rate of satisfaction with treatment at 6 months' (RR 1.04, 95% CI 0.91 to 1.20; 69 women; 1 study) and at 12 months' follow‐up (RR 0.97, 95% CI 0.86 to 1.09; 57 women; 1 study). See <a href="./references#CD001501-fig-0082" title="">Analysis 10.3.</a> </p> </section> </section> <section id="CD001501-sec-0211"> <h6 class="title">Secondary outcomes</h6> <p>Operative outcomes </p> <section id="CD001501-sec-0212"> <p><b>10.4 Operative difficulties</b></p> <p>No evidence showed clear differences between groups in the rate of equipment failure (RR 4.47, 95% CI 0.22 to 89.94; 70 women; 1 study). See <a href="./references#CD001501-fig-0083" title="">Analysis 10.4</a>. </p> <p><i>10.5 Post‐procedure pain</i> </p> <p>Participants completed a visual analogue scale (VAS) 4 hours postoperatively and indicated that the laser was significantly less painful than the balloon (mean (SD), 63.6 (17.6) vs 30.9 (20.4); MD 32.7, 95% CI 14.0 to 51.4; P = 0.002). See <a href="./references#CD001501-fig-0084" title="">Analysis 10.5</a>. </p> </section> <section id="CD001501-sec-0213"> <p><b>10.5 Quality of life</b></p> <p>Women receiving balloon treatment had a significantly greater pain score than women receiving laser treatment (MD 32.7, 95% CI 23.7 to 41.7; 1 study). At 12 months after treatment, women in the balloon group had higher scores on the EuroQoL Group Quality of Life Questionnaire based on 5 dimensions (EQ‐5D) VAS than women in the laser group (MD 10.1, 95% CI 2.4 to 17.8; 1 study); this was not found at earlier follow‐up nor for other quality of life scores. See <a href="./references#CD001501-fig-0085" title="">Analysis 10.6</a>. </p> </section> <section id="CD001501-sec-0214"> <p><b>10.7 Improvement in other menstrual symptoms: PMS</b></p> <p>In one study with 70 women, researchers reported on improvement in PMS for the balloon group versus the laser group at 6 months (mean (SD), 24.6 (33) for balloon and 30.5 (36) for laser) and at 12 months (mean (SD), 21.9 (26.9) for balloon and 30.5 (34.7) for laser) but did not report on the significance of differences between groups in improvement in PMS. See <a href="./references#CD001501-fig-0086" title="">Analysis 10.7</a>. </p> </section> <section id="CD001501-sec-0215"> <p><b>10.8 Improvement in other menstrual symptoms: dysmenorrhoea</b></p> <p>One study with 70 women reported on improvement in dysmenorrhoea for the balloon versus the laser at 6 months (mean (SD), 24 (30.9) for the balloon vs 23 (33.9) for the laser) and at 12 months (mean (SD), 25.2 (31.5) for the balloon and 16.5 (22.3) for the laser) but did not report on the significance of differences between groups in improvement of dysmenorrhoea. See <a href="./references#CD001501-fig-0087" title="">Analysis 10.8</a>. </p> </section> <section id="CD001501-sec-0216"> <p><b>10.9 Requirement for further surgery</b></p> <p>One study with 67 women found no clear differences between groups in the requirement for further surgery up to 12 months' follow‐up (RR 0.78, 95% CI 0.23 to 2.64). See <a href="./references#CD001501-fig-0088" title="">Analysis 10.9</a>. </p> <p>Study authors provided no data for duration of surgery, proportion given general versus local anaesthesia, length of hospital stay, time or ability to return to normal activities or work, complication rates, or mortality as a direct result of surgery. </p> </section> </section> </section> <section id="CD001501-sec-0217"> <h5 class="title">11. Balloon versus TCRE (Comparison 11)</h5> <p>Two studies with a total of 133 women compared balloon and TCRE (<a href="./references#CD001501-bbs2-0006" title="BrunJ‐L , RaynalJ , BurletG , GalandB , QuereuxC , BernardP . Cavaterm thermal balloon endometrial ablation versus hysteroscopic endometrial resection to treat menorrhagia: the French, multicenter, randomized study. Journal of Minimally Invasive Gynecology2006;13:424‐30. ">Brun 2006</a>; <a href="./references#CD001501-bbs2-0020" title="PellicanoM , GuidaM , AcunzoG , CirilloD , BifulcoG , NappiC . Hysteroscopic transcervical endometrial resection versus thermal destruction for menorrhagia: a prospective randomized trial on satisfaction rate. American Journal of Obstetrics and Gynecology2002;187:545‐50. ">Pellicano 2002</a>). </p> <section id="CD001501-sec-0218"> <h6 class="title">Primary outcomes</h6> <section id="CD001501-sec-0219"> <p><b>11.1 Bleeding</b></p> <p>We found no evidence of a clear difference between groups in rates of amenorrhoea at 6 months' (RR 0.95, 95% CI 0.31 to 2.93; 49 women; 1 study) and 12 months' follow‐up after surgery (RR 1.21, 95% CI 0.50 to 2.95; 45 women; 1 study). See <a href="./references#CD001501-fig-0089" title="">Analysis 11.1</a>. </p> </section> <section id="CD001501-sec-0220"> <p><b>11.2 Rate of satisfaction</b></p> <p>Satisfaction with treatment was greater in the balloon group than in the TCRE group 2 years after surgery (RR 1.4, 95% CI 1.1 to 1.7; 69 women; 1 study), but this difference was not evident at 6 months (RR 1.06, 95% CI 0.93 to 1.20; 50 women; 1 study) or 1 year after surgery (RR 1.06, 95% CI 0.96 to 1.18; 122 women; 2 studies; I² = 0%). See <a href="./references#CD001501-fig-0090" title="">Analysis 11.2</a>. </p> </section> </section> <section id="CD001501-sec-0221"> <h6 class="title">Secondary outcomes</h6> <p>Operative outcomes </p> <section id="CD001501-sec-0222"> <p><b>11.3 and 11.4 Duration of surgery</b></p> <p>One trial with 82 women found that surgical time was significantly shorter (35%) with balloon than with TCRE treatment (MD ‐13.00, 95% CI ‐15.20 to ‐10.80) (see <a href="./references#CD001501-fig-0091" title="">Analysis 11.3</a>), but the second trial did not confirm this finding (mean (SD) 48 (24 to 150)/45 (23 to 105); no statistical test reported, but significant difference unlikely). See <a href="./references#CD001501-fig-0092" title="">Analysis 11.4</a>. </p> </section> <section id="CD001501-sec-0223"> <p><b>11.5 Operative difficulties</b></p> <p>Equipment failure was not clearly different between groups (RR 7.22, 95% CI 0.42 to 123.83; 51 women; 1 study). See <a href="./references#CD001501-fig-0093" title="">Analysis 11.5</a>. </p> </section> <section id="CD001501-sec-0224"> <p><b>11.6 and 11.7 Intraoperative complications</b></p> <p>Mean intraoperative blood loss (measured in millilitres) was significantly less for balloon treatment than for laser treatment in one small trial ((MD ‐81.80, 95% CI ‐93.33 to ‐70.27; 82 women; 1 study). See <a href="./references#CD001501-fig-0101" title="">Analysis 11.13</a>. Study authors reported that fluid overload (RR 0.10, 95% CI 0.01 to 1.67; 82 women; 1 study), cervical tear (RR 0.35, 95% CI 0.01 to 8.34; 82 women; 1 study), and rate of conversion to hysterectomy (RR 0.24, 95% CI 0.01 to 4.84; 88 women; 1 study) did not show clear differences between groups. See <a href="./references#CD001501-fig-0100" title="">Analysis 11.12</a>. </p> </section> <section id="CD001501-sec-0225"> <p><b>11.9 and 11.10 Postoperative pain</b></p> <p>Postoperative pain (as measured by a continuous VAS score) was significantly greater for women in the TCRE group than in the balloon group in both trials (MD ‐0.60, 95% CI ‐0.88 to ‐0.32; 82 women; 1 study; see <a href="./references#CD001501-fig-0094" title="">Analysis 11.6</a>; mean (SD), 45 (1 to 100)/10 (0 to 90); P = 0.012; see <a href="./references#CD001501-fig-0095" title="">Analysis 11.7</a>). </p> </section> <section id="CD001501-sec-0226"> <p><b>11.10 and 11.11 Recovery</b></p> <p>Length of the stay in hospital was shorter in the balloon group than in the TCRE group (MD ‐0.30 days, 95% CI ‐0.52 to ‐0.08; 82 women; 1 study). See <a href="./references#CD001501-fig-0096" title="">Analysis 11.8</a>. </p> <p>Time until return to normal activities was significantly shorter for the balloon group in one study (MD ‐2.10 days, 95% CI ‐3.38 to ‐0.82; 82 women; 1 study; see <a href="./references#CD001501-fig-0098" title="">Analysis 11.10</a>), but it was not clearly different in the second study (mean (SD) 4 days (1 to 20) and 2 days (1 to 30); 49 women;1 study; see <a href="./references#CD001501-fig-0099" title="">Analysis 11.11</a>). </p> </section> <section id="CD001501-sec-0227"> <p><b>11.12 Complication rate: major complications</b></p> <p>Trial results showed no evidence of clear differences between groups for major complications such as the following (<a href="./references#CD001501-fig-0100" title="">Analysis 11.12</a>). </p> <p> <ul id="CD001501-list-0048"> <li> <p>Fluid overload (RR 0.10, 95% CI 0.01 to 1.67; 82 women; 1 study).</p> </li> <li> <p>Cervical tear (RR 0.35, 95% CI 0.01 to 8.34; 82 women; 1 study).</p> </li> <li> <p>Conversion to hysterectomy (RR 0.24, 95% CI 0.01 to 4.84; 88 women; 1 study).</p> </li> <li> <p>Blood transfusion (RR 5.24, 95% CI 0.26 to 105.97; 82 women; 1 study).</p> </li> </ul> </p> </section> <section id="CD001501-sec-0228"> <p><b>11.13 and 11.14 Complication rate: minor complications</b></p> <p>Blood loss during the procedure was clearly less in the balloon group (MD ‐81.80 mL, 95% CI ‐93.33 to ‐70.27; 82 women; 1 study). See <a href="./references#CD001501-fig-0101" title="">Analysis 11.13</a>. </p> <p>We found no evidence of clear differences between groups for other minor complications such as the following (see <a href="./references#CD001501-fig-0102" title="">Analysis 11.14</a>). </p> <p> <ul id="CD001501-list-0049"> <li> <p>Fever (RR 0.53, 95% CI 0.05 to 5.57; 82 women; 1 study).</p> </li> <li> <p>Urinary tract infection or retention (RR 0.35, 95% CI 0.01 to 8.34; 82 women; 1 study).</p> </li> <li> <p>Haemorrhage (RR 1.31, 95% CI 0.38 to 4.54; 82 women; 1 study).</p> </li> </ul> </p> </section> <section id="CD001501-sec-0229"> <p><b>11.15 Requirement for further surgery</b></p> <p>No evidence showed any differences between groups at 12 months' follow‐up after any surgery (RR 0.51, 95% CI 0.10 to 2.64; 75 women; 1 study) or after hysterectomy (RR 0.12, 95% CI 0.01 to 2.44; 45 women; 1 study), nor at 2 years' follow‐up, for any surgery (RR 0.38, 95% CI 0.08 to 1.81; 68 women; 1 study). See <a href="./references#CD001501-fig-0103" title="">Analysis 11.15</a>. </p> <p>Researchers provided no data for proportion given general versus local anaesthesia, women's perceived change in quality of life, improvement in menstrual symptoms, or mortality as a direct result of surgery. </p> </section> </section> </section> </section> <section id="CD001501-sec-0230"> <h4 class="title">Second‐generation ablation comparisons</h4> <section id="CD001501-sec-0231"> <h5 class="title">12. Bipolar electrode ablation (second generation) versus balloon (second generation) (Comparison 12) </h5> <p>Four studies with a total of 366 women compared bipolar electrode ablation versus balloon (<a href="./references#CD001501-bbs2-0001" title="AbbottJ , HaweJ , HunterD , GarryR . A double‐blind randomized trial comparing the Cavaterm and the Novasure endometrial ablation systems for the treatment of dysfunctional uterine bleeding. Fertility and Sterility2003;80(1):203‐8. ">Abbott 2003</a>; <a href="./references#CD001501-bbs2-0004" title="BongersM , HermanM , JosienP , MolBW . Ten‐year follow‐up of a randomized controlled trial comparing NovaSure and Thermachoice in endometrial ablation for dysfunctional uterine bleeding. Journal of Minimally Invasive Gynecology2011;18(6 Suppl 1):S127. BongersMY , BourdrezP , HeintzPM , BrolmannHAM , MolBWJ . Bipolar radio frequency endometrial ablation compared with balloon endometrial ablation in dysfunctional uterine bleeding: impact on patients' health‐related quality of life. Fertility and Sterility2005;83(3):724‐34. BongersMY , BourdrezP , MolBWJ , HeintzAPM , BrolmannHAM . Randomised controlled trial of bipolar radio‐frequency endometrial ablation and balloon endometrial ablation. British Journal of Obstetrics and Gynaecology2004;111:1095‐102. HermanM , PenninxM , MolB , BongersM . Ten‐year follow‐up of a randomised controlled trial comparing bipolar endometrial ablation with balloon ablation for heavy menstrual bleeding. British Journal Obstetrics and Gynaecology2013;120:966‐970. [DOI: 10.1111/1471‐0528.12213] KleijnJH , EngelsR , BourdrezP , MolBWJ , BongersMY . Five‐year follow up of a randomised controlled trial comparing NovaSure and ThermaChoice endometrial ablation. British Journal of Obstetrics and Gynaecology2008;115:193‐8. ">Bongers 2004</a>; <a href="./references#CD001501-bbs2-0007" title="ClarkTJ , SamuelN , MalickS , MiddletonLJ , DanielsJ , GuptaJK . Bipolar radiofrequency compared with thermal balloon endometrial ablation in the office. Obstetrics and Gynecology2011;117:109‐18. ">Clark 2011</a>; <a href="./references#CD001501-bbs2-0022" title="PenninxJ , BongersM . Bipolar radiofrequency endometrial ablation versus thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. www.controlled‐trials.com/ISRCTN17974690. PenninxJ , HermanM , KruitwagenR , Ter HaarA , MolB , BongersM . Bipolar versus balloon endometrial ablation in the office: a randomized controlled trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;196:52‐6. [DOI: 10.1016/j.ejogrb.2015.10.010] PenninxJ , HermanM , MolB , KruitwagenR , BongersM . Bipolar radiofrequency endometrial ablation versus Thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. Journal of Minimally Invasive Gynecology2012;19(6):S21‐S22. [DOI: 10.1016/j.jmig.2012.08.076] PenninxJPM , HermanMC , MolBW , BongersMY . Bipolar radiofrequency endometrial ablation versus thermablate balloon ablation for dysfunctional bleeding in the outpatient clinic: a randomized controlled trial. Journal of Minimally Invasive Gynecology2012;19(6 Suppl 1):S21‐2. ">Penninx 2016</a>). </p> <section id="CD001501-sec-0232"> <h6 class="title">Primary outcomes</h6> <section id="CD001501-sec-0233"> <p><b>12.1 and 12.2 Bleeding</b></p> <p> <ul id="CD001501-list-0050"> <li> <p>Amenorrhoea was more likely for women in the electrode ablation group than in the balloon group, both at 6 months (RR 3.37, 95% CI 2.09 to 5.44; 283 women; 3 studies; I² = 0%) and at 12 months after treatment (RR 3.12, 95% CI 2.06 to 4.72; 335 women; 4 studies; I² = 0%). Trial results showed no clear differences between groups at longer follow‐up: at 2 to 5 years' (RR 1.56, 95% CI 0.93 to 2.64;120 women; 1 study) nor at 10 years' follow‐up (RR 1.10, 95% CI 0.83 to 1.46; 104 women; 1 study). See <a href="./references#CD001501-fig-0104" title="">Analysis 12.1</a>. </p> </li> <li> <p>In terms of PBAC, results differed between studies. One trial at 12 months' follow‐up did not find a difference between groups in PBAC scores after treatment (median (SD), 3(0.720)/21(0.157); 55 women; 1 study), but a second trial reported a clear difference favouring bipolar ablation in light of PBAC &lt; 100 at 12 months' follow‐up (RR 0.4, 95% CI 0.2 to 0.8; 104 women; 1 study). See <a href="./references#CD001501-fig-0105" title="">Analysis 12.2</a>. </p> </li> </ul> </p> </section> <section id="CD001501-sec-0234"> <p><b>12.3 Rate of satisfaction</b></p> <p>The rate of satisfaction was variable over time. We found no evidence of significant differences between groups in rates of satisfaction after treatment at 6 months' (RR 1.08, 95% CI 0.94 to 1.24; 181 women; 2 studies; I² = 90%) or at 10 years' follow‐up, but at 12 months' follow‐up, a clear difference favoured bipolar.ablation (RR 1.14, 95% CI 1.04 to 1.26; 334 women; 4 studies; I² = 0%). </p> </section> </section> <section id="CD001501-sec-0235"> <h6 class="title">Secondary outcomes</h6> <p>Operative outcomes </p> <section id="CD001501-sec-0236"> <p><b>12.4 Duration of surgery</b></p> <p>The duration of the procedure was 2 to 19 minutes shorter with bipolar ablation than with balloon ablation in four studies (two of which recorded significant differences). See <a href="./references#CD001501-fig-0107" title="">Analysis 12.4</a>. </p> </section> <section id="CD001501-sec-0237"> <p><b>12.5 Operative difficulties</b></p> <p>Only one trial reported these without significant differences (<a href="./references#CD001501-bbs2-0001" title="AbbottJ , HaweJ , HunterD , GarryR . A double‐blind randomized trial comparing the Cavaterm and the Novasure endometrial ablation systems for the treatment of dysfunctional uterine bleeding. Fertility and Sterility2003;80(1):203‐8. ">Abbott 2003</a>). </p> </section> <section id="CD001501-sec-0238"> <p><b>12.6 Completion of the procedure</b></p> <p>Only one trial reported on this without significant differences (<a href="./references#CD001501-bbs2-0007" title="ClarkTJ , SamuelN , MalickS , MiddletonLJ , DanielsJ , GuptaJK . Bipolar radiofrequency compared with thermal balloon endometrial ablation in the office. Obstetrics and Gynecology2011;117:109‐18. ">Clark 2011</a>). </p> </section> <section id="CD001501-sec-0239"> <p><b>12.7 Time taken off work and 12.8 Time to return to work</b></p> <p>One trial reported on this but did not provide data in a format that could be entered into meta‐analysis (see <a href="./references#CD001501-fig-0110" title="">Analysis 12.7</a> and <a href="./references#CD001501-fig-0111" title="">Analysis 12.8</a>) (<a href="./references#CD001501-bbs2-0007" title="ClarkTJ , SamuelN , MalickS , MiddletonLJ , DanielsJ , GuptaJK . Bipolar radiofrequency compared with thermal balloon endometrial ablation in the office. Obstetrics and Gynecology2011;117:109‐18. ">Clark 2011</a>). </p> </section> <section id="CD001501-sec-0240"> <p><b>12.9 Quality of life</b></p> <p>Most quality of life scores revealed no significant differences between groups. However, women undergoing balloon ablation had significantly higher scores on the SF‐36 emotional role domain than those having bipolar ablation 5 years after treatment (MD ‐9.0 points, 95% CI ‐3.6 to ‐14.5), but not at other follow‐up times. See <a href="./references#CD001501-fig-0112" title="">Analysis 12.9</a>. </p> </section> <section id="CD001501-sec-0241"> <p><b>12.10 Menorrhagia outcome questionnaire</b></p> <p>Trial results showed no evidence of a difference between groups (MD ‐0.60, 95% CI ‐3.87 to 2.67; 51 women; 1 study). </p> </section> <section id="CD001501-sec-0242"> <p><b>12.11 Dysmenorhoea rate (VAS score)</b></p> <p>One trial reported this but did not provide data in a format that could be entered into meta‐analysis (see <a href="./references#CD001501-fig-0114" title="">Analysis 12.11</a>) (<a href="./references#CD001501-bbs2-0001" title="AbbottJ , HaweJ , HunterD , GarryR . A double‐blind randomized trial comparing the Cavaterm and the Novasure endometrial ablation systems for the treatment of dysfunctional uterine bleeding. Fertility and Sterility2003;80(1):203‐8. ">Abbott 2003</a>). </p> </section> <section id="CD001501-sec-0243"> <p><b>12.12 Improvement in other menstrual symptoms</b></p> <p>Results were inconsistent for rates of dysmenorrhoea and PMS: two trials found no evidence of a difference in rates of dysmenorrhoea between groups, and one trial found no evidence of a difference in PMS symptoms. However, another trial found that bipolar ablation was associated with improved dysmenorrhoea and PMS symptoms (summary figures not provided). </p> </section> <section id="CD001501-sec-0244"> <p><b>12.14 Complication rate and 12.15 Requirement for further surgery</b></p> <p>One trial showed no evidence of significant differences between groups for complications or requirement for further surgery up to 10 years' follow‐up. </p> </section> </section> </section> <section id="CD001501-sec-0245"> <h5 class="title">13. Microwave ablation (MEA) (second generation) versus balloon ablation (second generation) (Comparison 13) </h5> <p>One trial with 320 women compared microwave ablation versus balloon ablation (<a href="./references#CD001501-bbs2-0025" title="SambrookA , EldersA , CooperK . Microwave endometrial ablation versus thermal balloon endometrial ablation (MEATBall): 5‐year follow up of a randomised controlled trial. British Journal of Obstetrics and Gynaecology2014;121:748‐54. [DOI: 10.1111/1471‐0528.12585] SambrookAM , CooperKG , CampbellMK , CookJA . Clinical outcomes from a randomised comparison of microwave endometrial ablation with thermal balloon endometrial ablation for the treatment of heavy menstrual bleeding. British Journal of Obstetrics and Gynaecology2009;116:1038‐45. ">Sambrook 2009</a>). </p> <section id="CD001501-sec-0246"> <h6 class="title">Primary outcomes</h6> <section id="CD001501-sec-0247"> <p><b>13.1 Bleeding</b></p> <p>Researchers reported bleeding as rates of amenorrhoea and PBAC scores. Microwave ablation was associated with higher rates of amenorrhoea than balloon ablation at 6 months' follow‐up (RR 1.50, 95% CI 1.07 to 2.12; 277 women; 1 study). Trial results showed no clear differences between groups at 12 months' follow‐up (RR 1.10, 95% CI 0.82 to 1.47; n = 282; trials = 1) nor at 5 years' follow‐up (RR 1.03, 95% CI 0.86 to 1.23; 217 women; 1 study). See <a href="./references#CD001501-fig-0119" title="">Analysis 13.1</a>. Study authors reported PBAC scores as means with an interquartile range. No clear difference between groups was evident. See <a href="./references#CD001501-fig-0120" title="">Analysis 13.2</a>. </p> </section> <section id="CD001501-sec-0248"> <p><b>13.3 Rate of satisfaction</b></p> <p>Satisfaction rates were not clearly different between groups at 12 months' (RR 1.00, 95% CI 0.88 to 1.14; 278 women; 1 study) nor at 5 years' follow‐up (RR 0.99, 95% CI 0.87 to 1.13; 217 women; 1 study). See <a href="./references#CD001501-fig-0121" title="">Analysis 13.3</a>. </p> </section> </section> <section id="CD001501-sec-0249"> <h6 class="title">Secondary outcome</h6> <section id="CD001501-sec-0250"> <p><b>13.4 Duration of surgery</b></p> <p>Microwave ablation led to reduced operation time by almost 7 minutes compared to balloon ablation (MD ‐6.6 minutes, 95% CI ‐5.8 to ‐7.4; 314 women; 1 study). See <a href="./references#CD001501-fig-0122" title="">Analysis 13.4</a>. </p> </section> <section id="CD001501-sec-0251"> <p><b>13.5 Surgery difficulties causing failure</b></p> <p>The microwave device was less likely to fail than the balloon (RR 0.09, 95% CI 0.01 to 0.70; 314 women; 1 study). Researchers did not report clear differences between difficulties causing failure such as unsuitable cavity (RR 0.75, 95% CI 0.17 to 3.30; 314 women; 1 study) or use of a non‐sterile device (RR 5.00, 95% CI 0.24 to 103.32; 314 women; 1 study). See <a href="./references#CD001501-fig-0123" title="">Analysis 13.5</a>. </p> </section> <section id="CD001501-sec-0252"> <p><b>13.6 Proportion given local anaesthesia</b></p> <p>We found no evidence of clear differences between groups in the proportion of women choosing local or general anaesthesia (RR 1.01, 95% CI 0.79 to 1.31; 314 women; 1 study). See <a href="./references#CD001501-fig-0124" title="">Analysis 13.6</a>. </p> </section> <section id="CD001501-sec-0253"> <p><b>13.7 Proportion requiring opiate analgesia</b></p> <p>No evidence showed clear differences between groups in the requirement for opiate analgesia (RR 0.92, 95% CI 0.83 to 1.01; 314 women; 1 study). See <a href="./references#CD001501-fig-0125" title="">Analysis 13.7</a>. </p> </section> <section id="CD001501-sec-0254"> <p><b>13.8 Recovery: proportion requiring overnight stay</b></p> <p>No evidence showed clear differences between groups in the requirement for overnight stay (RR 0.66, 95% CI 0.42 to 1.04; 314 women; 1 study). See <a href="./references#CD001501-fig-0126" title="">Analysis 13.8</a>. </p> </section> <section id="CD001501-sec-0255"> <p><b>13.9 Quality of life</b></p> <p>Researchers measured quality of life using EQ‐5D and SF‐12 physical and mental scores. Results provide no evidence of clear differences between groups at any time point. Test scales range from 0 to 100: results at 12 months are presented here for EQ‐5D (MD 0.02 points, 95% CI ‐0.04 to 0.08; 285 women; 1 study), SF‐12 physical (MD ‐0.70 points, 95% CI ‐2.64 to 1.24; 285 women; 1 study), and SF‐12 mental (MD ‐1.20 points, 95% CI ‐3.67 to 1.27; 285 women; 1 study); and at 5 years for EQ‐5D (MD 0.00 points, 95% CI ‐0.07 to 0.07; 217 women; 1 study), SF‐12 physical (MD ‐1.50 points, 95% CI ‐3.99 to 0.99; 217 women; 1 study), and SF‐12 mental (MD ‐0.30 points, 95% CI ‐2.90 to 2.30; 217 women; 1 study). See <a href="./references#CD001501-fig-0127" title="">Analysis 13.9</a>. </p> </section> <section id="CD001501-sec-0256"> <p><b>13.10 Requirement for further surgery</b></p> <p>We found no evidence of clear differences in the requirement for further hysterectomy between groups at 12 months' (RR 0.94, 95% CI 0.31 to 2.84; 285 women; 1 study) and up to 5 years' follow‐up (RR 1.29, 95% CI 0.51 to 3.27; 217 women; 1 study). See <a href="./references#CD001501-fig-0128" title="">Analysis 13.10</a>. </p> <p>Study authors provided no data for time or ability to return to normal activities or work, improvement in menstrual symptoms, complication rates, or mortality as a direct result of surgery. </p> </section> </section> </section> <section id="CD001501-sec-0257"> <h5 class="title">14. Bipolar electrode ablation (second generation) versus hydrothermal ablation (second generation) (Comparison 14) </h5> <p>One study with 160 women compared bipolar electrode ablation versus hydrothermal ablation (<a href="./references#CD001501-bbs2-0021" title="BongersM , HermanM , PenninxJ , MolBW . Longterm follow‐up of a randomized controlled trial comparing NovaSure and hydrothermablation for dysfunctional uterine bleeding. Journal of Minimally Invasive Gynecology2011;18(6 Suppl 1):S34. PenninxJPM , HermanMC , MolBW , BongersMY . Five‐year follow‐up after comparing bipolar endometrial ablation with hydrothermablation for menorrhagia. Obstetrics and Gynecology2011;118:1287‐92. PenninxJPM , MolBW , EngelsR , vanRumsteMME , KleijnC , KoksCAM , et al. Bipolar radiofrequency endometrial ablation compared with hydrothermablation for dysfunctional uterine bleeding. Obstetrics and Gynecology2010;116:819‐26. ">Penninx 2010</a>). </p> <section id="CD001501-sec-0258"> <h6 class="title">Primary outcomes</h6> <section id="CD001501-sec-0259"> <p><b>14.1 Bleeding</b></p> <p>Amenorrhoea rates were significantly increased with bipolar ablation when compared to hydrothermal ablation at all time points: at 6 months' (RR 2.27, 95% CI 1.25 to 4.12; 150 women; 1 study), 12 months' (RR 1.95, 95% CI 1.21 to 3.15; 146 women; 1 study), or up to 2 to 5 years' follow‐up (RR 1.57, 95% CI 1.06 to 2.31; 139 women; 1 study). See <a href="./references#CD001501-fig-0129" title="">Analysis 14.1</a>. </p> </section> <section id="CD001501-sec-0260"> <p><b>14.2 Rate of satisfaction</b></p> <p>Satisfaction rates were higher in the bipolar group than in the hydrothermal balloon group at 6 months' (RR 1.44, 95% CI 1.17 to 1.77; 150 women; 1 study), 12 months' (RR 1.11, 95% CI 1.02 to 1.21; 146 women; 1 study), and up to 2 to 5 years' follow‐up (RR 1.62, 95% CI 1.23 to 2.13; 139 women; 1 study). See <a href="./references#CD001501-fig-0130" title="">Analysis 14.2</a>. </p> </section> </section> <section id="CD001501-sec-0261"> <h6 class="title">Secondary outcomes</h6> <p>Operative outcomes </p> <section id="CD001501-sec-0262"> <p><b>14.3 Duration of surgery</b></p> <p>The duration of the procedure was significantly shorter with bipolar ablation (median (range), 11.8 minutes (5 to 40) with bipolar vs 27.8 (14 to 55) minutes with hydrothermal ablation; 156 women; 1 study). See <a href="./references#CD001501-fig-0131" title="">Analysis 14.3</a>. </p> </section> <section id="CD001501-sec-0263"> <p><b>14.4 Improvement in other menstrual symptoms: dysmenorrhoea</b></p> <p>The chance of eliminating dysmenorrhoea symptoms was greater with bipolar ablation than with hydrothermal ablation at 5 years' follow‐up (RR 1.32, 95% CI 1.00 to 1.74; 139 women; 1 study), but no clear difference was evident at 12 months' follow‐up (RR 0.92, 95% CI 0.79 to 1.06; 146 women; 1 study). See <a href="./references#CD001501-fig-0132" title="">Analysis 14.4</a>. </p> </section> <section id="CD001501-sec-0264"> <p><b>14.5 Surgical complications: major complications</b></p> <p>We found no evidence of clear differences between groups for major complications including the following (see <a href="./references#CD001501-fig-0132" title="">Analysis 14.4</a>). </p> <p> <ul id="CD001501-list-0051"> <li> <p>Uterine perforation (RR 2.71, 95% CI 0.11 to 65.54; 156 women; 1 study).</p> </li> <li> <p>Saline leakage (RR 0.13, 95% CI 0.01 to 2.46; 156 women; 1 study).</p> </li> </ul> </p> </section> <section id="CD001501-sec-0265"> <p><b>14.6 Requirement for further surgery</b></p> <p>Risk of requiring any surgery (ablation or hysterectomy) was reduced with bipolar ablation compared to hydrothermal ablation both at 12 months' (RR 0.28, 95% CI 0.11 to 0.72; 160 women; 1 study) and up to 5 years' follow‐up (RR 0.44, 95% CI 0.23 to 0.83; 136 women; 1 study). The difference is not clear when the risk of requiring a hysterectomy was compared at 12 months' (RR 0.42, 95% CI 0.14 to 1.32; 160 women; 1 study) and up to 2 to 5 years' follow‐up (RR 0.63, 95% CI 0.29 to 1.38; 136 women; 1 study). See <a href="./references#CD001501-fig-0134" title="">Analysis 14.6</a>. </p> <p>Researchers provided no data for operative difficulties, proportion given general versus local anaesthesia, length of hospital stay, time or ability to return to normal activities or work, women's perceived change in quality of life, or mortality as a direct result of surgery. </p> </section> </section> </section> <section id="CD001501-sec-0266"> <h5 class="title">15. Ablative curettage versus overcurettage (Comparison 15)</h5> <p>One study with 100 women compared ablative curettage versus overcurettage (<a href="./references#CD001501-bbs2-0026" title="ThabetSMA . New attempt using ablative curettage technique for managing benign premenopausal uterine bleeding. Obstetrics and Gynaecology Research2010;36(4):803‐9. ">Thabet 2010</a>). </p> <section id="CD001501-sec-0267"> <h6 class="title">Primary outcomes</h6> <section id="CD001501-sec-0268"> <p><b>15.1 Bleeding</b></p> <p>Researchers measured bleeding as amenorrhoea or eumenorrhoea at 3 years' follow‐up. Ablative curettage resulted in significantly higher rates of amenorrhoea compared with overcurettage (RR 4.50, 95% CI 2.33 to 8.69; 100 women; 1 study) and higher rates of amenorrhoea and normal menses combined (RR 1.9, 95% CI 1.3 to 2.7; 100 women; 1 study). See <a href="./references#CD001501-fig-0135" title="">Analysis 15.1</a>. </p> </section> </section> <section id="CD001501-sec-0269"> <h6 class="title">Secondary outcomes</h6> <p>Operative outcomes </p> <section id="CD001501-sec-0270"> <p><b>15.2 Surgery difficulties</b></p> <p>Failure of the procedure was less likely with ablative curettage than with overcurettage (RR 0.29, 95% CI 0.12 to 0.74; 100 women; 1 study). See <a href="./references#CD001501-fig-0136" title="">Analysis 15.2</a>. </p> </section> <section id="CD001501-sec-0271"> <p><b>15.3 Recovery hospital stay</b></p> <p>Overcurettage was associated with a significantly reduced hospital stay in comparison to ablative curettage (MD 1.6 days, 95% CI 1.2 to 2.0; 100 women; 1 study). See <a href="./references#CD001501-fig-0137" title="">Analysis 15.3</a>; </p> </section> <section id="CD001501-sec-0272"> <p><b>15.4 Complication rate: major complications</b></p> <p>Evidence showed no clear difference in the rate of perforation between groups (RR 0.14, 95% CI 0.01 to 2.70; 100 women; 1 study). </p> </section> <section id="CD001501-sec-0273"> <p><b>15.5 Complication rate: minor complications</b></p> <p>Bleeding complications were significantly less likely with ablative curettage than with overcurettage (RR 0.21, 95% CI 0.07 to 0.70; 100 women; 1 study); study authors provided no evidence of clear differences in the rate of infection or vaginal discharge (leucorrhoea) between groups (RR 0.80, 95% CI 0.23 to 2.81; 100 women; 1 study). See <a href="./references#CD001501-fig-0138" title="">Analysis 15.4</a>. </p> </section> <section id="CD001501-sec-0274"> <p><b>15.6 Requirement for further surgery</b></p> <p>Trial results showed no evidence of clear differences between groups in the requirement for hysterectomy up to 3 years' follow‐up (RR 0.42, 95% CI 0.16 to 1.10; 100 women; 1 study). See <a href="./references#CD001501-fig-0140" title="">Analysis 15.6</a>. </p> <p>Study authors provided no data on rate of satisfaction, duration of surgery, proportion given general versus local anaesthesia, time or ability to return to normal activities or work, women's perceived change in quality of life, improvement in menstrual symptoms, or mortality as a direct result of surgery. </p> </section> </section> </section> <section id="CD001501-sec-0275"> <h5 class="title">16. Microwave ablation (second generation) versus bipolar radiofrequency ablation (second generation) (Comparison 16) </h5> <p>One trial with a total of 66 women compared microwave ablation versus bipolar radiofrequency ablation (<a href="./references#CD001501-bbs2-0002" title="AthanatosD , PadosG , VenetisC , StamatopoulosP , RoussoD , TsolakidisD , et al. Novasure impedance control system versus microwave endometrial ablation for the treatment of dysfunctional uterine bleeding: a double‐blind, randomized controlled trial. Clinical and Experimental Obstetrics &amp; Gynecology2015;42(3):347‐51. [PMID: 26152008] PadosG . Treatment of dysfunctional uterine bleeding with second generation ablation devices: microwaves (MEAA) vs Bipolar Impedance Control System (Novasure). http://clinicaltrials.gov/show/NCT01173965. ">Athanatos 2015</a>). </p> <section id="CD001501-sec-0276"> <h6 class="title">Primary outcomes</h6> <section id="CD001501-sec-0277"> <p><b>16.1 and 16.2 Bleeding</b></p> <p>Amenorrhoea rates were increased in the microwave ablation group when compared to the bipolar radiofrequency ablation group at 3 months (RR 0.19, 95% CI 0.07 to 0.54; 66 women; 1 study) and at 12 months (RR 0.10, 95% CI 0.03 to 0.32; 66 women; 1 study). See <a href="./references#CD001501-fig-0141" title="">Analysis 16.1</a>. The PBAC at 12 months showed a clear difference favouring the bipolar group (RR ‐57.42, 95%CI ‐108.41 to ‐6.43; 66 women; 1 study). See <a href="./references#CD001501-fig-0142" title="">Analysis 16.2</a>. </p> </section> <section id="CD001501-sec-0278"> <p><b>16.3 Rate of satisfaction</b></p> <p>Researchers measured rate of satisfaction as satisfaction with treatment and as improvement in everyday life. No evidence showed a clear difference at 3 months (RR 0.97, 95% CI 0.89 to 1.05; 66 women; 1 study); results indicated that microwave ablation may decrease the rate of satisfaction compared with bipolar frequency ablation at 12 months (RR 0.85, 95% CI 0.73 to 0.99; 66 women; 1 study). See <a href="./references#CD001501-fig-0143" title="">Analysis 16.3</a>. For improvement in everyday life, study authors did not provide clear evidence of differences in both groups at 12 months' follow‐up (RR 0.91, 95% CI 0.81 to 1.03; 66 women; 1 study). </p> </section> </section> <section id="CD001501-sec-0279"> <h6 class="title">Secondary outcomes</h6> <p>Operative outcomes </p> <section id="CD001501-sec-0280"> <p><b>16.4 Duration of surgery</b></p> <p>Surgical duration was measured in seconds, so even though results show a clear difference (MD 9.80, 95% CI 2.63 to 16.97; 66 women; 1 study), both procedures took less than 2 minutes to perform. See <a href="./references#CD001501-fig-0144" title="">Analysis 16.4</a>. </p> </section> <section id="CD001501-sec-0281"> <p><b>16.5 Improvement in other menstrual symptoms: dysmenorrhoea</b></p> <p>The dysmenorrhoea rate did not show clear differences between groups at 3 months' (RR 2.00, 95% CI 0.39 to 10.18; 66 women; 1 study) nor at 12 months' (RR 4.00, 95% CI 0.92 to 17.44; 66 women; 1 study) follow‐up. See <a href="./references#CD001501-fig-0145" title="">Analysis 16.5</a>. </p> </section> <section id="CD001501-sec-0282"> <p><b>16.6 Complication rate: major and minor complications</b></p> <p>Researchers reported no complications in either group. See <a href="./references#CD001501-fig-0146" title="">Analysis 16.6</a>. </p> <p>The risk of requiring post‐procedure analgesia was significantly higher in the microwave endometrial ablation group (RR 25.98, 95% CI 1.44 to 468.00). See <a href="./references#CD001501-fig-0146" title="">Analysis 16.6</a>. </p> </section> <section id="CD001501-sec-0283"> <p><b>16.7 Requirement for further surgery</b></p> <p>Trial results did show a clear difference between groups in the requirement for hysterectomy at 12 months' follow‐up (RR 5.00, 95% CI 0.25 to 100.32; 66 women; 1 study). See <a href="./references#CD001501-fig-0147" title="">Analysis 16.7.</a> </p> <p>Study authors provided no data for operative difficulties, proportion given general versus local anaesthesia, length of hospital stay, time or ability to return to normal activities or work, women's perceived change in quality of life, or mortality as a direct result of surgery. </p> </section> </section> </section> <section id="CD001501-sec-0284"> <h5 class="title">17. Bipolar (Minerva) (second generation) versus rollerball ablation (first generation) (Comparison 17) </h5> <p>One study with 153 women compared bipolar an endometrial ablation system (Minerva) versus rollerball ablation (<a href="./references#CD001501-bbs2-0016" title="LabergeP , Garza‐LealJ , FortinC , BasinskiC , ThielJ , LeylandN , et al. A prospective, randomized, multi‐center, controlled, international clinical study of the safety and efficacy of the Minerva endometrial ablation system: 6 and 12‐month follow‐up results. Journal of Minimally Invasive Gynecology. 2014. LabergeP , Garza‐LealJ , FortinC , GraingerD , JohnsDA , AdkinsRT , et al. A randomized controlled multicenter US Food and Drug Administration trial of the safety and efficacy of the Minerva Endometrial Ablation System: one‐year follow‐up results. Journal of Minimally Invasive Gynecology2017;24(1):124‐32. [DOI: 10.1016/j.jmig.2016.09.009] LabergeP , Garza‐LealJ , FortinC , ThielJ , JohnsD , GraingerD , et al. A randomized, controlled, multi‐center trial of the safety and efficacy of the Minerva Endometrial Ablation System: one‐year follow‐up results. Journal of Minimally Invasive Gynecology. 2016; Vol. 23:S1‐S252. ">Laberge 2016</a>). </p> <section id="CD001501-sec-0285"> <h6 class="title">Primary outcome</h6> <section id="CD001501-sec-0286"> <p><b>17.1 Bleeding</b></p> <p>Researchers reported using haematin alkaline &lt; 80 mL/cycle at 12 months and rate of amenorrhoea at 12 months as dichotomous outcomes. Results for women having haematin alkaline less than 80 mL/cycle at 12 months did not show a clear difference between groups (RR 1.16, 95% CI 1.00 to 1.34), even though data showed a trend towards bipolar. The amenorrhoea rate at 12 months was clearly higher in the bipolar group (RR 1.46, 95% CI 1.08 to 1.98; 153 women; 1 study). See <a href="./references#CD001501-fig-0148" title="">Analysis 17.1</a>. </p> </section> <section id="CD001501-sec-0287"> <p><b>17.2 Rate of satisfaction</b></p> <p>The rate of satisfaction did not show clear differences between groups at 12 months' follow‐up. See <a href="./references#CD001501-fig-0149" title="">Analysis 17.2</a>. </p> </section> </section> <section id="CD001501-sec-0288"> <h6 class="title">Secondary outcomes</h6> <p>Operative outcomes </p> <section id="CD001501-sec-0289"> <p><b>17.3 Duration of surgery</b></p> <p>The duration of the procedure was significantly shorter in the bipolar group than in the rollerball group (MD ‐14.10 minutes, 95% CI ‐15.94 to ‐12.26; 153 women; 1 study). See <a href="./references#CD001501-fig-0150" title="">Analysis 17.3</a>. </p> </section> <section id="CD001501-sec-0290"> <p><b>17.4 Improvement in other menstrual symptoms: dysmenorrhoea</b></p> <p>The rate of improvement in dysmenorrhoea did not show clear differences between groups (RR 1.02, 95% CI 0.71 to 1.48; 153 women; 1 study). See <a href="./references#CD001501-fig-0151" title="">Analysis 17.4</a>. </p> </section> <section id="CD001501-sec-0291"> <p><b>17.5 Improvement in other menstrual symptoms: PMS</b></p> <p>The rate of improvement in PMS did not show clear differences between groups (RR 1.25, 95% CI 0.87 to 1.80; 153 women; 1 study). See <a href="./references#CD001501-fig-0152" title="">Analysis 17.5</a>. </p> </section> <section id="CD001501-sec-0292"> <p><b>17.6 Complication rate: major complications</b></p> <p>No evidence showed clear differences between groups in major complications such as the following (see <a href="./references#CD001501-fig-0153" title="">Analysis 17.6</a>). </p> <p> <ul id="CD001501-list-0052"> <li> <p>Endometritis or endomyometritis (RR 0.25, 95% CI 0.02 to 2.69; 153 women; 1 study).</p> </li> <li> <p>Pelvic inflammatory disease (RR 1.51, 95% CI 0.06 to 36.54; 153 women; 1 study).</p> </li> <li> <p>Haematometra (RR 1.51, 95% CI 0.06 to 36.54; 153 women; 1 study).</p> </li> </ul> </p> </section> <section id="CD001501-sec-0293"> <p><b>17.7 Complication rate: minor complications</b></p> <p>Studies have provided no evidence of clear differences between groups for minor complications such as the following (see <a href="./references#CD001501-fig-0154" title="">Analysis 17.7</a>). </p> <p> <ul id="CD001501-list-0053"> <li> <p>Intraoperative skin rash and/or itching or burning sensation (RR 1.51, 95% CI 0.06 to 36.54; 153 women; 1 study). </p> </li> <li> <p>Bleeding or spotting first 24 hours (RR 0.17, 95% CI 0.01 to 4.06; 153 women; 1 study).</p> </li> <li> <p>Nausea or vomiting first 24 hours (RR 0.17, 95% CI 0.01 to 4.06; 153 women; 1 study).</p> </li> <li> <p>Weakness, fatigue, sleepiness, lack of concentration, dizziness first 24 hours (RR 1.51, 95% CI 0.06 to 36.54; 153 women; 1 study). </p> </li> <li> <p>Backache first 24 hours (RR 1.51, 95% CI 0.06 to 36.54; 153 women; 1 study).</p> </li> <li> <p>Fever first 24 hours (RR 1.51, 95% CI 0.06 to 36.54; 153 women; 1 study).</p> </li> <li> <p>Abdominal pain or bloating up to 2 weeks (RR 1.50, 95% CI 0.16 to 14.06; 153 women; 1 study). </p> </li> <li> <p>Abdominal pain and/or bloating for more than 2 weeks (RR 0.17, 95% CI 0.01 to 4.06 ; 153 women; 1 study) </p> </li> <li> <p>Pelvic pain for up to 2 weeks (RR 1.51, 95% CI 0.06 to 36.54; 153 women; 1 study).</p> </li> <li> <p>Vaginal discharge and/or unpleasant vaginal smell or other abnormal sensation for up to 2 weeks (RR 1.51, 95% CI 0.06 to 36.54; 153 women; 1 study). </p> </li> <li> <p>Weakness, fatigue, sleepiness, lack of concentration, dizziness for up to 2 weeks (RR 0.50, 95% CI 0.03 to 7.83; 153 women; 1 study). </p> </li> <li> <p>Constipation for up to 2 weeks (RR 0.17, 95% CI 0.01 to 4.06; 153 women; 1 study).</p> </li> <li> <p>Skin rash and/or itching or burning sensation for up to 2 weeks (RR 0.50, 95% CI 0.03 to 7.83; 153 women; 1 study). </p> </li> <li> <p>Dysmenorrhea for up to 1 year (RR 0.17, 95% CI 0.01 to 4.06; 153 women; 1 study).</p> </li> </ul> </p> </section> <section id="CD001501-sec-0294"> <p><b>17.8 Requirement for further surgery</b></p> <p>Trial results showed no clear evidence of differences between groups in the rate of hysterectomy up to 1 year (RR 0.33, 95% CI 0.06 to 1.93; 153 women; 1 study). See <a href="./references#CD001501-fig-0155" title="">Analysis 17.8</a>. </p> <p>Study authors provided no data for duration of surgery, operative difficulties, proportion given general versus local anaesthesia, length of hospital stay, time or ability to return to normal activities or work, women's perceived change in quality of life, or mortality as a direct result of surgery. </p> </section> </section> </section> <section id="CD001501-sec-0295"> <h5 class="title">18 Second‐generation ablative techniques versus first‐generation ablation techniques (overall) </h5> <p>Thirteen studies with a total of 2368 women compared first‐ versus second‐generation ablation techniques (<a href="./references#CD001501-bbs2-0006" title="BrunJ‐L , RaynalJ , BurletG , GalandB , QuereuxC , BernardP . Cavaterm thermal balloon endometrial ablation versus hysteroscopic endometrial resection to treat menorrhagia: the French, multicenter, randomized study. Journal of Minimally Invasive Gynecology2006;13:424‐30. ">Brun 2006</a>; <a href="./references#CD001501-bbs2-0008" title="BainC , CooperKG , ParkinDE . Microwave endometrial ablation versus endometrial resection: a randomized controlled trial. Obstetrics and Gynecology2002;99:983‐7. CooperKG , BainC , LawrieL , ParkinDE . A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium: follow up at a minimum of five years. British Journal of Obstetrics and Gynaecology2005;112:470‐5. CooperKG , BainC , ParkinDE . Comparison of microwave endometrial ablation and transcervical resection of the endometrium for treatment of heavy menstrual loss: a randomised trial. Lancet1999;354:1859‐63. SambrookAM , BainC , ParkinDE , CooperKG . A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium: follow up at a minimum of 10 years. British Journal of Obstetrics and Gynaecology2009;116:1033‐7. ">Cooper 1999</a>; <a href="./references#CD001501-bbs2-0009" title="CooperJ , GimpelsonR , LabergeP , GalenD , Garza‐LealJG , ScottJ , et al. A randomized, multicenter trial of safety and efficacy of the NovaSure system in the treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2002;9(4):418‐28. ">Cooper 2002</a>; <a href="./references#CD001501-bbs2-0010" title="CooperJM , AndersonTL , FortinCA , JackSA , PlentlMB . Microwave endometrial ablation vs rollerball electroablation for menorrhagia: a multicenter randomized trial. Journal of the American Association of Gynecologic Laparoscopists2004;11(3):394‐403. ">Cooper 2004</a>; <a href="./references#CD001501-bbs2-0011" title="CorsonSL , BrillAI , BrooksPG , CooperJM , IndmanPD , LiuJH , et al. Interim results of the American Vesta trial of endometrial ablation. Journal of the American Association of Gynecologic Laparoscopists1999;6(1):45‐9. CorsonSL , BrillAI , BrooksPG , CooperJM , IndmanPD , LiuJH , et al. One‐year results of the Vesta system for endometrial ablation. Journal of the American Association of Gynecologic Laparoscopists2000;7(4):489‐97. ">Corson 2000</a>; <a href="./references#CD001501-bbs2-0012" title="CorsonSL . A multicenter evaluation of endometrial ablation by hydrothermablator and rollerball for treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2001;8(3):359‐67. GoldrathMH . Evaluation of hydrothermablator and rollerball endometrial ablation for menorrhagia 3 years after treatment. Journal of the American Association of Gynecologic Laparoscopists2003;10(4):505‐11. LofferF . A clinical comparison of hydrothermablation (HTA) and rollerball for endometrial ablation to treat menorrhagia: a randomized multicenter clinical trial. XVI FIGO World Congress of Obstetrics &amp; Gynecology. 2000; Vol. Abstract Book 2:95. ">Corson 2001</a>; <a href="./references#CD001501-bbs2-0013" title="DulebaAJ , HeppardMC , SoderstromRM , TownsendDE . A randomized study comparing endometrial cryoablation and rollerball electroablation for treatment of dysfunctional uterine bleeding. Journal of the American Association of Gynecologic Laparoscopists2003;10(1):17‐26. TownsendDE , DulebaAJ , WilkesMM , et al. Durability of treatment effects after cryoablation versus rollerball electroablation for abnormal uterine bleeding: two‐year results of a multicenter randomized trial. American Journal of Obstetrics and Gynecology2003;188:699‐701. ">Duleba 2003</a>; <a href="./references#CD001501-bbs2-0015" title="HaweJ , AbbottJ , HunterD , PhillipsG , GarryR . A randomised controlled trial comparing the Cavaterm endometrial ablation system with the Nd:YAG laser for the treatment of dysfunctional uterine bleeding. British Journal of Obstetrics and Gynaecology2003;110:350‐7. ">Hawe 2003</a>; <a href="./references#CD001501-bbs2-0016" title="LabergeP , Garza‐LealJ , FortinC , BasinskiC , ThielJ , LeylandN , et al. A prospective, randomized, multi‐center, controlled, international clinical study of the safety and efficacy of the Minerva endometrial ablation system: 6 and 12‐month follow‐up results. Journal of Minimally Invasive Gynecology. 2014. LabergeP , Garza‐LealJ , FortinC , GraingerD , JohnsDA , AdkinsRT , et al. A randomized controlled multicenter US Food and Drug Administration trial of the safety and efficacy of the Minerva Endometrial Ablation System: one‐year follow‐up results. Journal of Minimally Invasive Gynecology2017;24(1):124‐32. [DOI: 10.1016/j.jmig.2016.09.009] LabergeP , Garza‐LealJ , FortinC , ThielJ , JohnsD , GraingerD , et al. A randomized, controlled, multi‐center trial of the safety and efficacy of the Minerva Endometrial Ablation System: one‐year follow‐up results. Journal of Minimally Invasive Gynecology. 2016; Vol. 23:S1‐S252. ">Laberge 2016</a>; <a href="./references#CD001501-bbs2-0018" title="GraingerDA , TjadenDO , RowlandC , MeyerWR . Thermal balloon and rollerball ablation to treat menorrhagia: two‐year results of a multicenter, prospective, randomized clinical trial. Journal of the American Association of Gynecologic Laparoscopists2000;7(2):175‐9. LofferFD . Five year post‐procedure follow‐up of patients participating in a randomised trial of uterine balloon therapy vs rollerball ablation for the treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopy2001;8(1):48‐54. LofferFD . Three‐year comparison of thermal balloon and rollerball ablation in treatment of menorrhagia. Journal of the American Association of Gynecologic Laparoscopists2001;8(1):48‐54. MeyerWR , WalshBW , GraingerDA , PeacockLM , LofferFD , SteegeJF . Thermal balloon and rollerball ablation to treat menorrhagia: a multicenter comparison. Obstetrics and Gynecology1998;92:98‐103. ">Meyer 1998</a>; <a href="./references#CD001501-bbs2-0023" title="PerinoA , CastelliA , CucinellaG , BiondoA , PaneA , VeneziaR . A randomized comparison of endometrial laser intrauterine thermotherapy and hysteroscopic endometrial resection. Fertility and Sterility2004;82:731‐4. ">Perino 2004</a>; <a href="./references#CD001501-bbs2-0024" title="RomerT . The treatment of recurrent menorrhagias ‐ Cavaterm‐balloon‐coagulation versus Rollerball‐endometrial ablation ‐ a prospective randomized comparative study [Die therapie rezidivierender Menorrhagien ‐ Cavaterm‐Ballon‐Koagulatioon versus Roller‐Ball‐Endometriumkoagulation ‐ eine prospektive randomisierte Vergleichsstudie]. Zentralblatt fur Gynakologie1998;120(10):511‐4. ">Romer 1998</a>; <a href="./references#CD001501-bbs2-0027" title="vanZon‐RabelinkIAA , VleugelsMPH . Treating menorrhagia with endometrial ablation: rollerball electrocoagulation versus thermal ablation with the uterine balloon. Gynaecological Endoscopy Abstract from the 6th Annual Congress of the European Society for Gynaecological Endoscopy1997;6 Suppl 2:41. vanZon‐RabelinkIAA , VleugelsMPH , MerkusHMWM , deGraafR . Efficacy and satisfaction rate comparing endometrial ablation by rollerball electrocoagulation to uterine balloon thermal ablation in a randomised controlled trial. European Journal of Obstetrics, Gynecology, and Reproductive Biology2004;114(1):97‐103. vanZon‐RabelinkIAA , VleugelsMPH , MerkusHMWM , deGraafR . Endometrial ablation by rollerball electrocoagulation compared to uterine balloon thermal ablation. Technical and safety aspects. European Journal of Obstetrics, Gynecology, and Reproductive Biology2003;110:220‐3. ">van Zon‐Rabelink 2003</a>). </p> <section id="CD001501-sec-0296"> <h6 class="title">Primary outcomes</h6> <section id="CD001501-sec-0297"> <p><b>18.1 Bleeding</b></p> <p>We found no evidence of clear differences in bleeding parameters such as the following (see <a href="./references#CD001501-fig-0156" title="">Analysis 18.1</a>). </p> <p> <ul id="CD001501-list-0054"> <li> <p>Amenorrhoea at 6 months' follow‐up (RR 1.27, 95% CI 0.91 to 1.77; 49 women; 1 study).</p> </li> <li> <p>Amenorrhoea at 2 years' follow‐up (RR 0.97, 95% CI 0.72 to 1.30; 701 women; 3 studies; I² = 51%). </p> </li> <li> <p>Amenorrhoea at 2 to 5 years' follow‐up (RR 1.16, 95% CI 0.78 to 1.72; 672 women; 4 studies; I² = 80%). </p> </li> <li> <p>Amenorrhoea at up to 10 years' follow‐up (RR 0.94, 95% CI 0.83 to 1.05; 189 women; 1 study). </p> </li> <li> <p>PBAC &lt; 75 or acceptable improvement at 12 months' follow‐up (RR 1.03, 95% CI 0.98 to 1.09; 1282 women; 5 studies; I² = 0%). </p> </li> <li> <p>PBAC &lt; 75 or acceptable improvement at 2 to 5 years' follow‐up (RR 1.12, 95% CI 0.97 to 1.28; 236 women; 1 study). </p> </li> <li> <p>PBAC &lt; 75 or acceptable improvement at up to 10 years' follow‐up (RR 1.11, 95% CI 0.95 to 1.30; 189 women; 1 study). </p> </li> </ul> </p> </section> <section id="CD001501-sec-0298"> <p><b>18.2 Amenorrhoea at 1 year follow‐up</b></p> <p>Trials provided no evidence of clear differences in the rate of amenorrhoea between groups at 12 months' follow‐up (RR 0.99, 95% CI 0.78 to 1.27; 2145 women; 12 studies; I² = 77%). See <a href="./references#CD001501-fig-0157" title="">Analysis 18.2</a>. See the funnel plot for this comparison in <a href="#CD001501-fig-0004">Figure 4</a>. </p> <div class="figure" id="CD001501-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 18 Overall analyses: second‐generation endometrial ablation versus first‐generation endometrial ablation, outcome: 18.2 Bleeding ‐ amenorrhoea at 12 months (final plot)." data-id="CD001501-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 18 Overall analyses: second‐generation endometrial ablation versus first‐generation endometrial ablation, outcome: 18.2 Bleeding ‐ amenorrhoea at 12 months (final plot). </p> </div> </div> </div> </section> <section id="CD001501-sec-0299"> <p><b>18.3 Rate of satisfaction</b></p> <p>We found no evidence of clear differences in satisfaction rates up to 10 years' follow‐up, including the following (see <a href="./references#CD001501-fig-0158" title="">Analysis 18.3</a>). </p> <p> <ul id="CD001501-list-0055"> <li> <p>Satisfaction rate at 6 months' follow‐up (RR 1.06, 95% CI 0.93 to 1.20; 50 women; 1 study). </p> </li> </ul> <ul id="CD001501-list-0056"> <li> <p>Satisfaction rate at 2 years' follow‐up (RR 1.09, 95% CI 0.99 to 1.21; 802 women; 5 studies; I² = 52%). </p> </li> <li> <p>Satisfaction rate at 2 to 5 years' follow‐up (RR 1.02, 95% CI 0.93 to 1.13; 672 women; 4 studies; I² = 81%). </p> </li> <li> <p>Satisfaction rate at 10 years' follow‐up (RR 1.11, 95% CI 0.95 to 1.30; 189 women; 1 study). </p> </li> </ul> </p> </section> <section id="CD001501-sec-0300"> <p><b>18.4 Satisfaction rate at 12 months' follow‐up</b></p> <p>Study results showed no evidence of clear differences in rates of amenorrhoea between groups at 12 months' follow‐up (RR 1.01, 95% CI 0.98 to 1.04; 1750 women; 11 studies; I² = 36%). See <a href="./references#CD001501-fig-0159" title="">Analysis 18.4</a>. See the funnel plot for this comparison in <a href="#CD001501-fig-0005">Figure 5</a>. </p> <div class="figure" id="CD001501-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 18 Overall analyses: second‐generation endometrial ablation versus first‐generation endometrial ablation, outcome: 18.4 Satisfaction rate at 1 year follow‐up (final plot)." data-id="CD001501-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 18 Overall analyses: second‐generation endometrial ablation versus first‐generation endometrial ablation, outcome: 18.4 Satisfaction rate at 1 year follow‐up (final plot). </p> </div> </div> </div> </section> </section> <section id="CD001501-sec-0301"> <h6 class="title">Secondary outcomes</h6> <p>Operative outcomes </p> <section id="CD001501-sec-0302"> <p><b>18.5 Duration of surgery</b></p> <p>The mean difference in average surgical time between first‐ and second‐generation techniques was 13 minutes, ranging between 17 and 10 minutes. Heterogeneity was very high (94%), so we could not pool the analysis; we found that removing studies with high risk of allocation bias did not make any difference. See <a href="./references#CD001501-fig-0160" title="">Analysis 18.5</a>. </p> </section> <section id="CD001501-sec-0303"> <p><b>18.6 Operative difficulties</b></p> <p>Risk of equipment failure was greater with second‐generation devices (RR 4.26, 95% CI 1.46 to 12.43; 384 women; 3 studies; I² = 0%). See <a href="./references#CD001501-fig-0161" title="">Analysis 18.6</a>. It is important to mention here that only 3 of 10 studies comparing first‐ versus second‐generation ablation techniques reported equipment failure. Lack of reporting of treatment failure does not necessarily mean that it did not happen. The theory that treatment failure could be associated with the beginning of the technique does not explain it; only one of the remaining seven studies is newer than the ones reporting equipment failure. We found no evidence of clear differences between groups in terms of abandoning the procedure (RR 1.18, 95% CI 0.38 to 3.67; 629 women; 3 studies; I² = 0%). </p> </section> <section id="CD001501-sec-0304"> <p><b>18.7 Proportion given local anaesthesia</b></p> <p>The chance that local rather than general anaesthesia would be used was greater with second‐generation devices (RR 2.78, 95% CI 1.76 to 4.40; I² = 85%). This must be carefully interpreted because heterogeneity was high. See <a href="./references#CD001501-fig-0162" title="">Analysis 18.7</a>. </p> </section> <section id="CD001501-sec-0305"> <p><b>18.8 Inability to work</b></p> <p>We noted no evidence of a clear difference between groups in inability to work (RR 0.84, 95% CI 0.30 to 2.30; 279 women; 2 studies; I² = 20%). See <a href="./references#CD001501-fig-0163" title="">Analysis 18.8</a>. </p> </section> <section id="CD001501-sec-0306"> <p><b>18.9 Complication rate: major complications</b></p> <p>Regarding major complications, women undergoing second‐generation ablation procedures, when compared to the group having first‐generation procedures, were less likely to have the following major complications. </p> <p> <ul id="CD001501-list-0057"> <li> <p>Cervical lacerations (RR 0.21, 95% CI 0.07 to 0.61; 1583 women; 7 studies; I² = 0%).</p> </li> <li> <p>Haematometra (RR 0.34, 95% CI 0.12 to 0.95; 1193 women; 5 studies; I² = 0%).</p> </li> <li> <p>Fluid overload (RR 0.16, 95% CI 0.03 to 0.94; 588 women; 3 studies; I² = 0%).</p> </li> </ul> </p> <p>We found no clear evidence of differences between groups in other major complications such as the following (see <a href="./references#CD001501-fig-0164" title="">Analysis 18.9</a>). </p> <p> <ul id="CD001501-list-0058"> <li> <p>Perforation (RR 0.32, 95% CI 0.10 to 1.01; 1885 women; 8 studies; I² = 0%).</p> </li> <li> <p>Endometritis (RR 1.19, 95% CI 0.33 to 4.37; 1095 women; 4 studies; I² = 25%).</p> </li> <li> <p>Myometritis (RR 0.29, 95% CI 0.01 to 6.93; 267 women; 1 study).</p> </li> <li> <p>Cervical stenosis (RR 1.50, 95% CI 0.06 to 36.52; 322 women; 1 study).</p> </li> <li> <p>Pelvic abscess (RR 0.17, 95% CI 0.01 to 4.19; 265 women; 1 study).</p> </li> <li> <p>Pelvic inflammatory disease (RR 1.18, 95% CI 0.18 to 7.98; 418 women; 2 studies; I² = 0%). </p> </li> </ul> <ul id="CD001501-list-0059"> <li> <p>Blood transfusion (RR 5.24, 95% CI 0.26 to 105.97; 82 women; 1 study).</p> </li> </ul> </p> </section> <section id="CD001501-sec-0307"> <p><b>18.10 Complication rate: minor complications</b></p> <p>Regarding minor complications, women undergoing first‐generation ablation procedures, when compared to those having second‐generation procedures, were less likely to have the following minor complications. </p> <p> <ul id="CD001501-list-0060"> <li> <p>Nausea and vomiting (RR 2.01, 95% CI 1.40 to 2.88; 997 women; 4 studies; I² = 0%).</p> </li> <li> <p>Uterine cramping (RR 1.21, 95% CI 1.02 to 1.45; 601 women; 2 studies; I² = 0%).</p> </li> </ul> </p> <p>Trial results provided no clear evidence of differences between groups for other minor complications such as the following (see <a href="./references#CD001501-fig-0165" title="">Analysis 18.10</a>). </p> <p> <ul id="CD001501-list-0061"> <li> <p>Urinary tract infection (RR 0.88, 95% CI 0.45 to 1.73; 1834 women; 4 studies; I² = 0%). </p> </li> <li> <p>Fever (RR 0.98, 95% CI 0.22 to 4.26; 671 women; 3 studies; I² = 0%).</p> </li> <li> <p>Haemorrhage (RR 0.64, 95% CI 0.26 to 1.58; 889 women; 4 studies; I² = 4%).</p> </li> <li> <p>Muscle fasciculation (RR 2.57, 95% CI 0.11 to 62.41; 267 women; 1 study).</p> </li> <li> <p>External burns (first degree) (RR 2.32, 95% CI 0.11 to 47.89; 269 women; 1 study).</p> </li> <li> <p>Hydrosalpinx (RR 0.30, 95% CI 0.01 to 7.39; 239 women; 1 study).</p> </li> <li> <p>Severe pelvic pain (RR 0.95, 95% CI 0.36 to 2.48; OR 0.95, 95% CI 0.35 to 2.60; 683 women; 3 studies; I² = 30%). </p> </li> </ul> </p> </section> <section id="CD001501-sec-0308"> <p><b>18.11 Requirement for further surgery</b></p> <p>We found no evidence of significant differences in the requirement for any additional surgery (hysterectomy or ablation) or hysterectomy in both groups up to 5 years' follow‐up, including the following (see <a href="./references#CD001501-fig-0166" title="">Analysis 18.11</a>). </p> <p> <ul id="CD001501-list-0062"> <li> <p>Requirement for any additional surgery (hysterectomy or ablation) at 1 year follow‐up (RR 0.72, 95% CI 0.41 to 1.26; 935 women; 6 studies; I² = 0%). </p> </li> <li> <p>Requirement for any additional surgery (hysterectomy or ablation) at 2 years' follow‐up (RR 0.83, 95% CI 0.52 to 1.32; 988 women; 5 studies; I² = 13%). </p> </li> <li> <p>Requirement for any additional surgery (hysterectomy or ablation) at 2 to 5 years' follow‐up (RR 0.95, 95% CI 0.72 to 1.26; 647 women; 3 studies; I² = 0%). </p> </li> <li> <p>Requirement for hysterectomy at 1 year follow‐up (RR 0.66, 95% CI 0.35 to 1.21; (RR 0.66, 95% CI 0.35 to 1.21; 925 women ; 5 studies; I<sup>2</sup> = 0%). </p> </li> <li> <p>Requirement for hysterectomy at 2 years' follow‐up (RR 0.86, 95% CI 0.52 to 1.42; 920 women; 4 studies; I² = 0%). </p> </li> <li> <p>Requirement for hysterectomy at 2 to 5 years' follow‐up (RR 0.85, 95% CI 0.59 to 1.22; 758 women; 4 studies; I² = 14%). </p> </li> </ul> </p> <p>At 10 years' follow‐up, women undergoing second‐generation techniques have reduced possibilities of undergoing any further surgery (ablation or hysterectomy) (RR 0.57, 95% CI 0.37 to 0.87; 189 women; 1 study) or a subsequent hysterectomy (RR 0.60, 95% CI 0.38 to 0.96; 189 women; 1 study). These results must be interpreted cautiously; they reflect only one trial, in which more than 25% of participants were lost to follow‐up. Study authors also reported 9% requiring further hysteroscopies with the second‐generation technique but did not provide further details. </p> <p>The main outcomes for this overall comparison can be viewed in <a href="./full#CD001501-tbl-0001">summary of findings Table for the main comparison</a>. </p> </section> </section> </section> </section> <section id="CD001501-sec-0309"> <h4 class="title">Heterogeneity</h4> <section id="CD001501-sec-0310"> <h5 class="title">1. Specific types of endometrial resection or ablation</h5> <p>Most of the forest plots comparing specific types of endometrial ablation showed comparisons between groups in individual studies or pooled two or four studies at most, and they provided little evidence of statistical heterogeneity. However, we found substantial statistical heterogeneity (I² &gt; 50%) for the following forest plots. </p> <p>Comparison 1.4 (<a href="./references#CD001501-fig-0009" title="">Analysis 1.4</a>): duration of operation (laser vs TCRE). </p> <p>Comparison 7.5 (<a href="./references#CD001501-fig-0047" title="">Analysis 7.5</a>): duration of operation (electrode ablation vs TCRE + rollerball). </p> <p>Comparison 9.6 (<a href="./references#CD001501-fig-0073" title="">Analysis 9.6</a>): duration of operation (balloon vs rollerball). </p> <p>Comparison 9.12 (<a href="./references#CD001501-fig-0079" title="">Analysis 9.12</a>): requirement for further surgery (2 years' follow‐up) (balloon vs rollerball). </p> <p>Comparison 12.3 (<a href="./references#CD001501-fig-0106" title="">Analysis 12.3</a>): satisfaction rate (6 months' follow‐up) (bipolar radiofrequency ablation vs balloon). </p> <p>Comparison 12.15 (<a href="./references#CD001501-fig-0118" title="">Analysis 12.15</a>): requirement for further surgery (bipolar radiofrequency vs balloon). </p> <p>Duration of operation was affected by numerous confounding factors such as expertise of individual surgeons, hospital type and procedures, and differences between groups of women. For the comparison laser versus TCRE, the Bhattacharya study did not include total time spent in theatre, and the McClure study recorded induction and reversal of anaesthesia in the estimation of operation time, which resulted in much larger estimates. In this latter trial, temporary laser malfunction prolonged two laser cases to 240 minutes. For the comparison electrode ablation versus TCRE + rollerball, differences between studies were likely to be explained by the two different systems used: the Corson study used the Vesta balloon ablation, and the Cooper study used Novasure. In the comparison balloon versus rollerball, all three pooled studies used the Thermachoice balloon system. The operation time recorded for rollerball ablation was similar in the three trials, but times differed between studies for balloon ablation. The Meyer study provided no preoperative treatment to thin the endometrium, whereas the other two studies provided 2 months of gonadotropin‐releasing hormone (GnRH) agonist pretreatment. Other factors such as cavity length were correlated with operation time, and it is not clear whether these were similarly distributed between participants in the three trials. Another major confounding factor was the ability to use local rather than general anaesthesia, which was more likely in trials comparing second‐generation versus first‐generation ablation methods. </p> <p>Satisfaction is also likely to have varied because of different methods of measurement used. In the comparison bipolar radiofrequency ablation versus balloon, satisfaction rates at 6 months in the small Abbott trial may have been related to the technical failure rate for the Novasure procedure, but rates at 12 months' follow‐up were similar and were not significantly different. </p> <p>Significant heterogeneity was evident for the outcome requirement for further surgery in the comparisons of balloon versus rollerball and bipolar electrode ablation versus balloon. Different results in the two pooled trials for either comparison could not be explained by examining their characteristics. Neither trial reported a significant difference in outcomes by ablation technique. </p> </section> <section id="CD001501-sec-0311"> <h5 class="title">2. Overall analyses comparing first‐ and second‐generation techniques</h5> <p>Substantial heterogeneity was evident for many outcomes when researchers compared first‐generation procedures versus second‐generation procedures (Comparison 18), in particular, rate of amenorrhoea, duration of operation, and proportion given local as opposed to general anaesthesia. The I² value for the outcome amenorrhoea at 1 year after surgery was 77%, at 2 years 51%, and at 2 to 5 years 80%. Rates of amenorrhoea ranged widely in the included trials, and study authors reported no statistical differences between groups. When we compared estimates calculated with the fixed‐effect model versus estimates calculated with a random‐effects model, we found that estimates did not change markedly, but confidence intervals (CIs) were wider with the latter approach. Thus no evidence shows that amenorrhoea rates varied according to whether first‐ or second‐generation techniques were used to ablate the endometrium. </p> <p>Forest plots for the outcomes duration of surgery and local versus general anaesthesia also indicated substantial heterogeneity. Given that these two categories were very broad and included several different ablative techniques, we expected to find heterogeneity, and we used a random‐effects model to display results. As previously explained, apart from differences between techniques, duration of surgery was likely to be affected by extraneous factors such as skill and expertise of the surgeon, hospital policy, and the operating environment. However, each of the included trials reported separately that second‐generation techniques took significantly less time to perform than first‐generation techniques, regardless of the procedures compared. A random‐effects model approach indicated significantly less time required for second‐generation procedures; each of the trials individually showed a statistically significant difference. The other comparison ‐ proportion of women given local as opposed to general anaesthesia ‐ also showed highly significant heterogeneity. For all trials in the meta‐analysis, the proportions of women undergoing ablation with first‐generation techniques under local anaesthesia (either TCRE + rollerball or rollerball alone) ranged from 8% to 23%, and the proportion undergoing second‐generation ablation under local anaesthesia (Vesta, HTA, Novasure, cryoablation, or microwave) ranged from 45% to 86%. All trials separately reported large significant differences between first‐ and second‐generation techniques. A random‐effects model confirmed these differences in pooled results. </p> <p>To sum up, random‐effects model analyses confirmed the following.</p> <p> <ul id="CD001501-list-0063"> <li> <p>Evidence showing no difference in rates of amenorrhoea when first‐generation techniques were compared with second‐generation techniques. </p> </li> <li> <p>Evidence suggesting that duration of surgery with second‐generation techniques overall was less than with first‐generation techniques (average of 14 minutes less); however, due to high levels of heterogeneity, we were unable to pool the data for meta‐analysis. </p> </li> <li> <p>Women undergoing ablation with second‐generation techniques were more likely to be given local anaesthesia than those undergoing ablation with first‐generation techniques. </p> </li> </ul> </p> </section> </section> <section id="CD001501-sec-0312"> <h4 class="title">Sensitivity analyses</h4> <p>We performed sensitivity analyses only on comparisons for which five or more trials were pooled, specifically for the comparison of rates of satisfaction and amenorrhoea at 1 year follow‐up between first‐ and second‐generation ablation. We found no significant differences reported between randomised groups, and planned sensitivity analyses did not substantially change the results of included trials, although heterogeneity was reduced. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD001501-sec-0313" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD001501-sec-0313"></div> <section id="CD001501-sec-0314"> <h3 class="title" id="CD001501-sec-0314">Summary of main results</h3> <p>See <a href="./full#CD001501-tbl-0001">summary of findings Table for the main comparison</a>. </p> <p>This review has assessed a wide range of efficacy, satisfaction, and safety outcomes related to different techniques for ablation or resection of the endometrium for women with heavy menstrual bleeding. </p> <section id="CD001501-sec-0315"> <h4 class="title">Overall comparison of first‐generation versus second‐generation techniques</h4> <p>Some types of intraoperative and postoperative complications such as fluid overload, cervical lacerations, and haematometra were more common with first‐generation ablation; other types of complications, nausea and vomiting, and uterine cramping and pain were more common with second‐generation techniques. No clear evidence shows differences in perforation rates between first‐ and second‐generation techniques. Concerns about these 'blind' methods leading to bowel injuries from undetected uterine perforation did not seem to be confirmed in published studies. However, many anecdotal examples indicate that such events can occur, and great care must be taken to minimise the risk of such potentially serious complications. </p> <p>Trial results showed no differences in rates of re‐intervention ‐ either repeat ablation or hysterectomy or both ‐ between first‐ and second‐generation ablation up to 5 years' follow‐up. Only one small trial reported a clear difference at 10 years, but this should be interpreted cautiously because if repeated hysteroscopy is considered a surgical procedure, the difference is not significant, and no report provided the number of women transitioned through menopause. A recurrent comment about newer techniques that rely on 'devices' inserted into the uterine cavity to destroy the endometrium involved the incidence of equipment failure. This may represent expected 'teething problems' associated with new equipment. However, given that the older methods are extremely simple (a loop, laser, or diathermy to destroy the endometrium below it) and that newer techniques are potentially complex (microwaves, bags of fluid, etc.), the potential remains for mechanical breakdown to occur. In addition, considerable experience in intrauterine cavity assessment and manipulation is required for safe use any of these devices. </p> </section> <section id="CD001501-sec-0316"> <h4 class="title">Comparison of different types of first‐generation ablation techniques</h4> <p>First‐generation ablation techniques have been acknowledged traditionally as the 'gold standard' by which other, newer procedures were judged (<a href="./references#CD001501-bbs2-0082" title="PapadopoulosNP , MagosA . First‐generation endometrial ablation: rollerball vs loop vs laser. Best Practice and Research. Clinical Obstetrics and Gynaecology2007;21(6):915‐29. [DOI: 10.1016/j.bpobgyn.2007.03.014] ">Papadopoulos 2007</a>). Improvement in menstrual bleeding and satisfaction seems to be similar between first‐generation techniques. The complication profile between techniques is slightly different; for example, fluid overload was more likely with laser ablation than with transcervical resection of the endometrium (TCRE) and was more likely with TCRE than with vaporising electrode ablation. However, it is likely that operator safety is a much more important arbiter of patient safety than the instrument itself. Duration of surgery was longer with the laser than with TCRE and was longer with TCRE than with vaporising electrode ablation. Equipment failure was more likely with laser ablation than with TCRE, and the procedure was more difficult with TCRE than with vaporising electrode ablation. </p> </section> <section id="CD001501-sec-0317"> <h4 class="title">Comparison of different types of second‐generation ablation techniques</h4> <p>Bipolar radiofrequency ablation was associated with significantly higher rates of amenorrhoea than was balloon ablation up to 12 months' follow‐up, but researchers report no significant differences at 2, 5, and 10 years' follow‐up. In accordance with the amenorrhoea report, the satisfaction rate is higher at 12 months for bipolar radiofrequency ablation but trials show no significant differences at 6 months' or 10 years' follow‐up. Surgery was shorter with bipolar ablation, and premenstrual syndrome (PMS) scores were reduced. No evidence shows that bipolar radiofrequency ablation resulted in lower rates of further surgery for heavy menstrual bleeding when compared to balloon ablation. </p> <p>Bipolar ablation also increased rates of amenorrhoea and satisfaction when compared with hydrothermal ablation. Procedure time was shorter with bipolar ablation and women were less likely to require additional surgery at later follow‐up when compared to hydrothermal ablation. Amenorrhoea rates appeared to be increased with microwave when compared with balloon, but trials reported no differences in Pictorial Blood Assessment Chart (PBAC) scores or satisfaction. Operation time was also reduced with microwave ablation. </p> </section> <section id="CD001501-sec-0318"> <h4 class="title">Comparison of different types of first‐generation and second‐generation techniques</h4> <p>With reference to comparisons of different types of second‐generation techniques versus first‐generation techniques, thermal laser was more effective than TCRE in reducing blood loss (as measured by rates of amenorrhoea), but research shows no differences in patient satisfaction between approaches (using the same measurement tools). Although rollerball ablation was more likely to result in amenorrhoea when compared to cryoablation, trial results showed no difference in patient satisfaction between approaches. Patients appeared to be more satisfied with microwave than with TCRE at 2 and 5 years after surgery, but these findings were not significant at 1 and 10 years' follow‐up. With regards to secondary outcomes, duration of surgery was consistently shorter with second‐generation ablation, and procedures were more likely to be performed with the patient under local anaesthesia. Post‐surgical pain was also more likely with some types of second‐generation techniques such as thermal laser, balloon, and Hydro ThermAblator (HTA), but not all trials measured this outcome. Data show no significant differences between procedures in terms of improvement in dysmenorrhoea. </p> </section> </section> <section id="CD001501-sec-0319"> <h3 class="title" id="CD001501-sec-0319">Overall completeness and applicability of evidence</h3> <p>The diagnosis of HMB is based on subjective complaints and its impact on quality of life ‐ not on objective measures of blood loss (<a href="./references#CD001501-bbs2-0075" title="MunroeMG . Endometrial ablation: where have we been? Where are we going?. Clinical Obstetrics and Gynecology2006;49(4):736‐66. [DOI: 10.1097/01.grf.0000211947.28842.93] ">Munroe 2006</a>; <a href="./references#CD001501-bbs2-0079" title="National Institute of Health and Care Excellence (NICE). Heavy menstrual bleeding. National Institute for Health and Care Excellence (2018) Heavy menstrual bleeding (NICE Guideline 88). Available at: https://www.nice.org.uk/guidance/conditions‐and‐diseases/gynaecological‐conditions/heavy‐menstrual‐bleeding [Accessed 22 May 2018]. [https://www.nice.org.uk/guidance/conditions‐and‐diseases/gynaecological‐conditions/heavy‐menstrual‐bleeding] ">NICE 2018</a>). However, many women with heavy menstrual bleeding (HMB) referred from primary to tertiary care do not describe HMB when directly questioned, suggesting a tendency for broad description of menstrual characteristics to be reframed as excessive bleeding at referral and during management (<a href="./references#CD001501-bbs2-0092" title="WarnerP , CritchleyHO , LumsdenMA , Campbell‐BrownM , DouglasA , MurrayG . Referral for menstrual problems: cross sectional survey of symptoms, reasons for referral and management. British Medical Journal2001;323:2‐8. [DOI: 10.1136/bmj.323.7303.24] ">Warner 2001</a>). This is likely to result in women receiving inappropriate care and will influence the actual and perceived efficacy of treatment modalities for HMB. </p> <p>Published literature on endometrial destruction techniques for HMB covers a wide range of surgical methods and uses a variety of outcome measures to assess treatment success, making clear comparisons between studies difficult. Participant groups showed varied and often potentially important clinical factors such as the presence of uterine fibroids or a perimenopausal state, which were not mentioned in the inclusion or exclusion criteria. This is particularly important with longer follow‐up studies. Current clinical approaches to HMB advise that medical therapy should be offered in the first instance, and it would be unusual in normal practice to advise endometrial resection or ablation without trying any medical therapies. Indeed, medical treatment with the levonorgestrel‐releasing intrauterine system (Mirena, Schering) reduces menstrual blood loss (MBL) by 94% at 3 months (<a href="./references#CD001501-bbs2-0064" title="IrvineGA , Campbell‐BrownMB , LumsdenMA , HeikkilaA , WalkerJJ , CameronIT . Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for the treatment of idiopathic menorrhagia. British Journal of Obstetrics and Gynaecology1998;105:592‐8. [PMID: 9647148] ">Irvine 1998</a>), and it is equally effective as thermal balloon ablation (<a href="./references#CD001501-bbs2-0049" title="deSouzaS , S.CamargosA , deRezendeC , PereiraF , AraujoC , Silva FilhoA . A randomized prospective trial comparing the levonorgestrel‐releasing intrauterine system with thermal balloon ablation for the treatment of heavy menstrual bleeding. Contraception2010;81(3):226‐31. [DOI: 10.1016/j.contraception.2009.09.012] ">de Souza 2010</a>; <a href="./references#CD001501-bbs2-0089" title="ShawRW , SymondsIM , TamizianO , ChaplainJ , MukhopadhyayS . Randomised comparative trial of thermal balloon ablation and levonorgestrel intrauterine system in patients with idiopathic menorrhagia. Australia and New Zealand Journal of Obstetrics and Gynaecology2007;47(4):335‐40. [DOI: 10.1111/j.1479‐828X.2007.00747.x] ">Shaw 2007</a>), rollerball endometrial ablation (<a href="./references#CD001501-bbs2-0053" title="ErgunB , KuruO , SenS , KilicY , BastuE . Rollerball endometrial ablation versus levonorgestrel releasing intrauterine system in the management of abnormal uterine bleeding. Journal Romanian Society of Ultrasonography in Obstetrics and Gynecology2012;8(30):199‐201. [CRSREF 3289369] ">Ergun 2012</a>), and endometrial ablation. Surgical approaches to resect or ablate the endometrium are generally second‐line after medical therapies. Fourteen published studies focussed on women with failed medical management of HMB. </p> <p>Published studies show wide variation in the outcome criteria used to assess the efficacy of endometrial ablation and resection techniques. No studies have used women's perceptions of HMB as an inclusion criterion nor women's perception of improvement as an outcome, even though this is the main diagnostic criterion. Several studies used the PBAC (<a href="./references#CD001501-bbs2-0063" title="HighamJM , O'BrienPMS , ShawRW . Assessment of menstrual blood loss using a pictorial chart. British Journal of Obstetrics and Gynaecology1990;97:734‐9. [PMID: 2400752] ">Higham 1990</a>), but entry and success criteria for PBAC score varied widely between studies. It is important to identify core outcomes for future trials on treatments for HMB for better comparisons. The COMET initiative (Core Outcome Measures in Effectiveness Trials) is working towards this objective; it is hoped that this initiative will help to improve study outcomes for HMB (<a href="./references#CD001501-bbs2-0044" title="CooperN , KhanK . Defining core outcomes for clinical trials of heavy menstrual bleeding: a Core Outcome Sets for Gynaecological conditions (COGS) project. COMET Initiativeaccessed May 2018. [http://www.comet‐initiative.org/studies/details/789] ">COMET 2018</a>). </p> </section> <section id="CD001501-sec-0320"> <h3 class="title" id="CD001501-sec-0320">Quality of the evidence</h3> <p>The evidence base on which this review is based was of variable quality. In particular, few studies were blinded, and for most comparisons between individual techniques, a limited number of studies provided data. Lack of blinding is likely to influence more subjective outcomes such as satisfaction rates, so findings of these types of outcomes should be viewed with caution. </p> <p>We identified substantial heterogeneity in some outcomes in the overall comparison between first‐ and second‐generation techniques, and we have downgraded the quality of evidence to reflect the uncertainty around summary effect estimates. See <a href="./full#CD001501-tbl-0001">summary of findings Table for the main comparison</a>. </p> </section> <section id="CD001501-sec-0321"> <h3 class="title" id="CD001501-sec-0321">Potential biases in the review process</h3> <p>A comprehensive search for relevant studies, together with duplicate and independent study selection, data extraction, and quality assessment of studies, has minimised the chance of potential bias in the review process. </p> </section> <section id="CD001501-sec-0322"> <h3 class="title" id="CD001501-sec-0322">Agreements and disagreements with other studies or reviews</h3> <p>It is surprising that although numerous randomised controlled trials (RCTs) and observational studies have examined specific types of endometrial ablation techniques, few systematic reviews have made overall comparisons of specific endometrial ablation techniques for reduction of HMB. Numerous narrative reviews have been published, together with comprehensive audits for first‐generation techniques. Upon comparing first‐generation methods of endometrial ablation versus resection, the MISTLETOE study concluded that methods produced similar outcomes in terms of bleeding and participant satisfaction, but that resection methods are associated with significantly more complications, suggesting that ablation should be used for all women with a non‐fibroid uterus (<a href="./references#CD001501-bbs2-0081" title="OvertonC , HargreavesJ , MareshM . A national survey of the complications of endometrial destruction for menstrual disorders: the MISTLETOE study. British Journal of Obstetrics and Gynaecology1997;104(12):1351‐9. ">Overton 1997</a>). </p> <p>Systematic reviews ‐ one with individual participant data ‐ have not been able to determine major differences between first‐ and second‐generation techniques in terms of effectiveness or satisfaction with treatment (<a href="./references#CD001501-bbs2-0057" title="GarsideR , SteinK , WyattK , RoundA . Microwave and thermal balloon ablation for heavy menstrual bleeding: a systematic review. British Journal of Obstetrics and Gynaecology2005;112:12‐23. [PMID: 15663392] ">Garside 2005</a>; <a href="./references#CD001501-bbs2-0073" title="MiddletonLJ , ChampaneriaR , DanielsJP , BhattacharyaS , CooperKG , HilkenNH , et al. for the International Heavy Menstrual Bleeding Individual Patient Data Meta‐analysis Collaborative Group. Hysterectomy, endometrial destruction, and levonorgestrel releasing intrauterine system (Mirena) for heavy menstrual bleeding: systematic review and meta‐analysis of data from individual patients. British Medical Journal2010;341:c3929. [DOI: 10.1136/bmj.c3929] ">Middleton 2010</a>). However, Middleton has confirmed the findings of this review that second‐generation techniques are faster, local anaesthesia is more likely to be used, and some complications are less frequent. The suggestion in this review that additional surgery may be less likely with second‐generation techniques at longer follow‐up (10 years) is based on only one trial and needs confirmation from further research. On the other hand, at 2 to 5 years' follow‐up, researchers found no significant difference in the requirement for further surgery ‐ hysterectomy or ablation (risk ratio (RR) 0.95, 95% confidence interval (CI) 0.72 to 1.26; 647 women; 3 studies) or only hysterectomy (RR 0.85, 95% CI 0.59 to 1.22; 758 women; 4 studies). According to a Scottish review of 14,078 women with endometrial ablation having a subsequent hysterectomy, the median time interval between surgeries was 15 months (range 8 to 32 months) (<a href="./references#CD001501-bbs2-0045" title="CooperK , LeeAJ , ChienP , RajaEA , TimmarajuV , BhattacharyaS . Outcomes following hysterectomy or endometrial ablation for heavy menstrual bleeding: retrospective analysis of hospital episode statistics in Scotland. British Journal of Obstetrics and Gynaecology2011;118(10):1171‐9. [DOI: 10.1111/j.1471‐0528.2011.03011.x] ">Cooper 2011</a>). </p> <p>Among second‐generation techniques, the most studied have been Novasure, balloon, and microwave ablation (<a href="./references#CD001501-bbs2-0078" title="NHS Information Centre. Hospital episode statistics 2011. NHS2011. ">NHS 2011</a>). A recent network meta‐analysis reported that bipolar radiofrequency and microwave ablation resulted in higher rates of amenorrhoea than thermal balloon ablation at 12 months after treatment (<a href="./references#CD001501-bbs2-0048" title="DanielsJP , MiddletonLJ , ChampaneriaR , KhanKS , CooperK , MolBWJ , et al. on behalf of the International Heavy Menstrual Bleeding IPG Meta‐analysis Collaborative Group. Second generation endometrial ablation techniques for heavy menstrual bleeding: network meta‐analysis. British Medical Journal2012;344:e2564. [PMID: 22529302] ">Daniels 2012</a>), but no evidence shows a convincing difference between the three techniques in terms of satisfaction rates or the number of women still experiencing heavy bleeding. Researchers did not assess other outcomes. However, lack of a consistent measure of effectiveness has made it difficult to adequately compare techniques and reach conclusions on the technique of choice. Other study authors have suggested that there might be commercial resistance to comparing devices, given the likely effect on the market share for the inferior treatment (<a href="./references#CD001501-bbs2-0072" title="McGurganP , O'DonovanP . Second‐generation endometrial ablation ‐ an overview. Best Practice and Research. Clinical Obstetrics and Gynaecology2007;21(6):931‐45. [DOI: 10.1016/j.bpobgyn.2007.03.0151] ">McGurgan 2007</a>). It has also been suggested that a potential limitation of second‐generation devices involves restrictions on size and configuration of the endometrial cavity that may prevent general application of any device to the HMB population (<a href="./references#CD001501-bbs2-0075" title="MunroeMG . Endometrial ablation: where have we been? Where are we going?. Clinical Obstetrics and Gynecology2006;49(4):736‐66. [DOI: 10.1097/01.grf.0000211947.28842.93] ">Munroe 2006</a>). Many of the included studies that evaluated these devices in this review applied fairly strict inclusion criteria, limiting the applicability of results to women with large or distorted uteri. Thus, not all women with HMB may be candidates for second‐generation ablation, and it has been suggested that gynaecologists should retain their skills in hysteroscopic surgery for certain types of intrauterine pathology (<a href="./references#CD001501-bbs2-0082" title="PapadopoulosNP , MagosA . First‐generation endometrial ablation: rollerball vs loop vs laser. Best Practice and Research. Clinical Obstetrics and Gynaecology2007;21(6):915‐29. [DOI: 10.1016/j.bpobgyn.2007.03.014] ">Papadopoulos 2007</a>). </p> <p>An additional issue is the role of patient preferences in decision‐making regarding treatments for HBS. A recent review suggested that reaching a decision on a 'one size fits all' approach may be elusive, and that eliciting patient preferences, based on the evidence, is required to reach the decision on the 'best' approach (<a href="./references#CD001501-bbs2-0086" title="RobertsTE , TsourapasA , MiddletonLJ , ChampaneriaR , DanielsJP , CooperKG , et al. Hysterectomy, endometrial ablation, and levonorgestrel releasing intrauterine system (Mirena) for treatment of heavy menstrual bleeding: cost effectiveness analysis. British Medical Journal2011;342:d2202. [PMCID: PMC3082380] ">Roberts 2011</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD001501-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD001501-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/full#CD001501-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD001501-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/full#CD001501-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD001501-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/full#CD001501-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 18 Overall analyses: second‐generation endometrial ablation versus first‐generation endometrial ablation, outcome: 18.2 Bleeding ‐ amenorrhoea at 12 months (final plot)." data-id="CD001501-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of comparison: 18 Overall analyses: second‐generation endometrial ablation versus first‐generation endometrial ablation, outcome: 18.2 Bleeding ‐ amenorrhoea at 12 months (final plot). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/full#CD001501-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 18 Overall analyses: second‐generation endometrial ablation versus first‐generation endometrial ablation, outcome: 18.4 Satisfaction rate at 1 year follow‐up (final plot)." data-id="CD001501-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot of comparison: 18 Overall analyses: second‐generation endometrial ablation versus first‐generation endometrial ablation, outcome: 18.4 Satisfaction rate at 1 year follow‐up (final plot). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/full#CD001501-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Laser ablation (first generation) versus transcervical resection of the endometrium (TCRE) (first generation), Outcome 1 Bleeding ‐ blood loss (mL) at 6 months." data-id="CD001501-fig-0006" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Laser ablation (first generation) versus transcervical resection of the endometrium (TCRE) (first generation), Outcome 1 Bleeding ‐ blood loss (mL) at 6 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Laser ablation (first generation) versus transcervical resection of the endometrium (TCRE) (first generation), Outcome 2 Bleeding." data-id="CD001501-fig-0007" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Laser ablation (first generation) versus transcervical resection of the endometrium (TCRE) (first generation), Outcome 2 Bleeding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Laser ablation (first generation) versus transcervical resection of the endometrium (TCRE) (first generation), Outcome 3 Rate of satisfaction at 12 months (very/moderately)." data-id="CD001501-fig-0008" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Laser ablation (first generation) versus transcervical resection of the endometrium (TCRE) (first generation), Outcome 3 Rate of satisfaction at 12 months (very/moderately). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Laser ablation (first generation) versus transcervical resection of the endometrium (TCRE) (first generation), Outcome 4 Duration of operation (minutes)." data-id="CD001501-fig-0009" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Laser ablation (first generation) versus transcervical resection of the endometrium (TCRE) (first generation), Outcome 4 Duration of operation (minutes). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Laser ablation (first generation) versus transcervical resection of the endometrium (TCRE) (first generation), Outcome 5 Operative difficulties." data-id="CD001501-fig-0010" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Laser ablation (first generation) versus transcervical resection of the endometrium (TCRE) (first generation), Outcome 5 Operative difficulties. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Laser ablation (first generation) versus transcervical resection of the endometrium (TCRE) (first generation), Outcome 6 Good general health." data-id="CD001501-fig-0011" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Laser ablation (first generation) versus transcervical resection of the endometrium (TCRE) (first generation), Outcome 6 Good general health. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Laser ablation (first generation) versus transcervical resection of the endometrium (TCRE) (first generation), Outcome 7 Improvement in menstrual symptoms." data-id="CD001501-fig-0012" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Laser ablation (first generation) versus transcervical resection of the endometrium (TCRE) (first generation), Outcome 7 Improvement in menstrual symptoms. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Laser ablation (first generation) versus transcervical resection of the endometrium (TCRE) (first generation), Outcome 8 Complication rate: major complications." data-id="CD001501-fig-0013" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Laser ablation (first generation) versus transcervical resection of the endometrium (TCRE) (first generation), Outcome 8 Complication rate: major complications. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Laser ablation (first generation) versus transcervical resection of the endometrium (TCRE) (first generation), Outcome 9 Complication rate: minor complications." data-id="CD001501-fig-0014" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Laser ablation (first generation) versus transcervical resection of the endometrium (TCRE) (first generation), Outcome 9 Complication rate: minor complications. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Laser ablation (first generation) versus transcervical resection of the endometrium (TCRE) (first generation), Outcome 10 Requirement for further surgical treatment (within 12 months)." data-id="CD001501-fig-0015" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Laser ablation (first generation) versus transcervical resection of the endometrium (TCRE) (first generation), Outcome 10 Requirement for further surgical treatment (within 12 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vaporising electrode ablation (first generation) versus TCRE (first generation), Outcome 1 Bleeding ‐ amenorrhoea rate at 12 months' follow‐up." data-id="CD001501-fig-0016" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Vaporising electrode ablation (first generation) versus TCRE (first generation), Outcome 1 Bleeding ‐ amenorrhoea rate at 12 months' follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vaporising electrode ablation (first generation) versus TCRE (first generation), Outcome 2 Bleeding ‐ PBAC score at 12 months." data-id="CD001501-fig-0017" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Vaporising electrode ablation (first generation) versus TCRE (first generation), Outcome 2 Bleeding ‐ PBAC score at 12 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vaporising electrode ablation (first generation) versus TCRE (first generation), Outcome 3 Rate of satisfaction at 12 months (very/moderately)." data-id="CD001501-fig-0018" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Vaporising electrode ablation (first generation) versus TCRE (first generation), Outcome 3 Rate of satisfaction at 12 months (very/moderately). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vaporising electrode ablation (first generation) versus TCRE (first generation), Outcome 4 Duration of operation (minutes)." data-id="CD001501-fig-0019" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Vaporising electrode ablation (first generation) versus TCRE (first generation), Outcome 4 Duration of operation (minutes). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vaporising electrode ablation (first generation) versus TCRE (first generation), Outcome 5 Operative difficulties." data-id="CD001501-fig-0020" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Vaporising electrode ablation (first generation) versus TCRE (first generation), Outcome 5 Operative difficulties. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vaporising electrode ablation (first generation) versus TCRE (first generation), Outcome 6 Complication rate: major complications." data-id="CD001501-fig-0021" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Vaporising electrode ablation (first generation) versus TCRE (first generation), Outcome 6 Complication rate: major complications. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Rollerball (first generation) versus TCRE (first generation), Outcome 1 Duration of operation (minutes)." data-id="CD001501-fig-0022" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Rollerball (first generation) versus TCRE (first generation), Outcome 1 Duration of operation (minutes). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Rollerball (first generation) versus TCRE (first generation), Outcome 2 Complication rate: major complications." data-id="CD001501-fig-0023" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Rollerball (first generation) versus TCRE (first generation), Outcome 2 Complication rate: major complications. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Rollerball (first generation) versus TCRE (first generation), Outcome 3 Requirement for further surgery." data-id="CD001501-fig-0024" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Rollerball (first generation) versus TCRE (first generation), Outcome 3 Requirement for further surgery. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Thermal laser (second generation) versus TCRE (first generation), Outcome 1 Bleeding ‐ amenorrhoea rate." data-id="CD001501-fig-0025" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Thermal laser (second generation) versus TCRE (first generation), Outcome 1 Bleeding ‐ amenorrhoea rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Thermal laser (second generation) versus TCRE (first generation), Outcome 2 Rate of satisfaction." data-id="CD001501-fig-0026" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Thermal laser (second generation) versus TCRE (first generation), Outcome 2 Rate of satisfaction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Thermal laser (second generation) versus TCRE (first generation), Outcome 3 Duration of operation." data-id="CD001501-fig-0027" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Thermal laser (second generation) versus TCRE (first generation), Outcome 3 Duration of operation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Thermal laser (second generation) versus TCRE (first generation), Outcome 4 Complication rate: major complications." data-id="CD001501-fig-0028" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Thermal laser (second generation) versus TCRE (first generation), Outcome 4 Complication rate: major complications. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Thermal laser (second generation) versus TCRE (first generation), Outcome 5 Complication rate: minor complications." data-id="CD001501-fig-0029" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Thermal laser (second generation) versus TCRE (first generation), Outcome 5 Complication rate: minor complications. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Thermal laser (second generation) versus TCRE (first generation), Outcome 6 Requirement for further surgery rate (hysterectomy only)." data-id="CD001501-fig-0030" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Thermal laser (second generation) versus TCRE (first generation), Outcome 6 Requirement for further surgery rate (hysterectomy only). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Hydrothermal ablation (second generation) versus rollerball (first generation), Outcome 1 Bleeding." data-id="CD001501-fig-0031" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Hydrothermal ablation (second generation) versus rollerball (first generation), Outcome 1 Bleeding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Hydrothermal ablation (second generation) versus rollerball (first generation), Outcome 2 Rate of satisfaction." data-id="CD001501-fig-0032" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Hydrothermal ablation (second generation) versus rollerball (first generation), Outcome 2 Rate of satisfaction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Hydrothermal ablation (second generation) versus rollerball (first generation), Outcome 3 Proportion given local rather than general anaesthesia." data-id="CD001501-fig-0033" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Hydrothermal ablation (second generation) versus rollerball (first generation), Outcome 3 Proportion given local rather than general anaesthesia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Hydrothermal ablation (second generation) versus rollerball (first generation), Outcome 4 Complication rate: major complications." data-id="CD001501-fig-0034" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 Hydrothermal ablation (second generation) versus rollerball (first generation), Outcome 4 Complication rate: major complications. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-005-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-005-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Hydrothermal ablation (second generation) versus rollerball (first generation), Outcome 5 Complication rate: minor complications." data-id="CD001501-fig-0035" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-005-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5 Hydrothermal ablation (second generation) versus rollerball (first generation), Outcome 5 Complication rate: minor complications. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-005-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-005-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-005-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Hydrothermal ablation (second generation) versus rollerball (first generation), Outcome 6 Requirement for further surgery." data-id="CD001501-fig-0036" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-005-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5 Hydrothermal ablation (second generation) versus rollerball (first generation), Outcome 6 Requirement for further surgery. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-005-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Cryoablation (second generation) versus rollerball (first generation), Outcome 1 Bleeding." data-id="CD001501-fig-0037" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Cryoablation (second generation) versus rollerball (first generation), Outcome 1 Bleeding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Cryoablation (second generation) versus rollerball (first generation), Outcome 2 Rate of satisfaction." data-id="CD001501-fig-0038" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Cryoablation (second generation) versus rollerball (first generation), Outcome 2 Rate of satisfaction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Cryoablation (second generation) versus rollerball (first generation), Outcome 3 Proportion given local anaesthesia (%)." data-id="CD001501-fig-0039" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 Cryoablation (second generation) versus rollerball (first generation), Outcome 3 Proportion given local anaesthesia (%). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-006-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-006-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Cryoablation (second generation) versus rollerball (first generation), Outcome 4 Complication rate: major complications." data-id="CD001501-fig-0040" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-006-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 Cryoablation (second generation) versus rollerball (first generation), Outcome 4 Complication rate: major complications. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-006-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-006-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-006-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Cryoablation (second generation) versus rollerball (first generation), Outcome 5 Complication rate: minor complications." data-id="CD001501-fig-0041" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-006-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6 Cryoablation (second generation) versus rollerball (first generation), Outcome 5 Complication rate: minor complications. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-006-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-006-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-006-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Cryoablation (second generation) versus rollerball (first generation), Outcome 6 Requirement for further surgery." data-id="CD001501-fig-0042" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-006-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6 Cryoablation (second generation) versus rollerball (first generation), Outcome 6 Requirement for further surgery. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-006-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Electrode ablation (second generation) versus TCRE + rollerball (first generation), Outcome 1 Bleeding ‐ amenorrhoea rate at 1 year follow‐up." data-id="CD001501-fig-0043" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Electrode ablation (second generation) versus TCRE + rollerball (first generation), Outcome 1 Bleeding ‐ amenorrhoea rate at 1 year follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Electrode ablation (second generation) versus TCRE + rollerball (first generation), Outcome 2 Proportion with successful Rx (PBAC &lt; 75)." data-id="CD001501-fig-0044" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 Electrode ablation (second generation) versus TCRE + rollerball (first generation), Outcome 2 Proportion with successful Rx (PBAC &lt; 75). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0045"> <p> <div class="table" id="CD001501-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Electrode system</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>TCRE + RB</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Stat test for diff</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Balloon system</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Corson 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N=122<br/> Mean PBAC (SD): 18 (37) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N=112<br/> Mean PBAC (SD): 28 (70) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not significantly different</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Mesh system</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cooper 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N=154<br/> Mean PBAC (SD): 26.8 (57.4) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N=82<br/> Mean PBAC (SD): 36.4 (66.3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No reported difference</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7 Electrode ablation (second generation) versus TCRE + rollerball (first generation), Outcome 3 PBAC score 12 months after treatment. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0045">Navigate to figure in review</a></div> </div> <div class="figure" id="CD001501-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-007-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-007-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Electrode ablation (second generation) versus TCRE + rollerball (first generation), Outcome 4 Rate of satisfaction with treatment at 1 year." data-id="CD001501-fig-0046" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-007-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7 Electrode ablation (second generation) versus TCRE + rollerball (first generation), Outcome 4 Rate of satisfaction with treatment at 1 year. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-007-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-007-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-007-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Electrode ablation (second generation) versus TCRE + rollerball (first generation), Outcome 5 Duration of operation (minutes)." data-id="CD001501-fig-0047" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-007-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7 Electrode ablation (second generation) versus TCRE + rollerball (first generation), Outcome 5 Duration of operation (minutes). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-007-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-007-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-007-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Electrode ablation (second generation) versus TCRE + rollerball (first generation), Outcome 6 Procedure abandon." data-id="CD001501-fig-0048" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-007-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.6</div> <div class="figure-caption"> <p>Comparison 7 Electrode ablation (second generation) versus TCRE + rollerball (first generation), Outcome 6 Procedure abandon. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-007-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-007-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-007-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Electrode ablation (second generation) versus TCRE + rollerball (first generation), Outcome 7 Proportion given local anaesthesia (%)." data-id="CD001501-fig-0049" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-007-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.7</div> <div class="figure-caption"> <p>Comparison 7 Electrode ablation (second generation) versus TCRE + rollerball (first generation), Outcome 7 Proportion given local anaesthesia (%). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-007-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-007-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-007-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Electrode ablation (second generation) versus TCRE + rollerball (first generation), Outcome 8 Complication rate: major complications." data-id="CD001501-fig-0050" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-007-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.8</div> <div class="figure-caption"> <p>Comparison 7 Electrode ablation (second generation) versus TCRE + rollerball (first generation), Outcome 8 Complication rate: major complications. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-007-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-007-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-007-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Electrode ablation (second generation) versus TCRE + rollerball (first generation), Outcome 9 Complication rate: minor complications." data-id="CD001501-fig-0051" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-007-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.9</div> <div class="figure-caption"> <p>Comparison 7 Electrode ablation (second generation) versus TCRE + rollerball (first generation), Outcome 9 Complication rate: minor complications. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-007-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-007-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-007-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Electrode ablation (second generation) versus TCRE + rollerball (first generation), Outcome 10 Requirement for further surgery at 2 years (hysterectomy)." data-id="CD001501-fig-0052" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-007-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.10</div> <div class="figure-caption"> <p>Comparison 7 Electrode ablation (second generation) versus TCRE + rollerball (first generation), Outcome 10 Requirement for further surgery at 2 years (hysterectomy). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-007-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Microwave ablation (second generation) versus TCRE + rollerball (first generation), Outcome 1 Bleeding." data-id="CD001501-fig-0053" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 Microwave ablation (second generation) versus TCRE + rollerball (first generation), Outcome 1 Bleeding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-008-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-008-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Microwave ablation (second generation) versus TCRE + rollerball (first generation), Outcome 2 Rate of satisfaction." data-id="CD001501-fig-0054" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-008-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8 Microwave ablation (second generation) versus TCRE + rollerball (first generation), Outcome 2 Rate of satisfaction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-008-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0055"> <p> <div class="table" id="CD001501-tblf-0002"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Microwave</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>TCRE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Results</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cooper 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N=129<br/> Mean duration of procedure (SD):<br/> 11.4 (10.5) mins </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N=134<br/> Mean duration of procedure (SD):<br/> 15.0 (7.2) mins </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mann Whitney U test<br/> Mean difference:<br/> 3.6 (‐5.7, ‐1.4); P=0.001 </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8 Microwave ablation (second generation) versus TCRE + rollerball (first generation), Outcome 3 Duration of operation (minutes). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0055">Navigate to figure in review</a></div> </div> <div class="figure" id="CD001501-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-008-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-008-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Microwave ablation (second generation) versus TCRE + rollerball (first generation), Outcome 4 Operative difficulties." data-id="CD001501-fig-0056" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-008-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8 Microwave ablation (second generation) versus TCRE + rollerball (first generation), Outcome 4 Operative difficulties. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-008-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-008-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-008-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Microwave ablation (second generation) versus TCRE + rollerball (first generation), Outcome 5 Proportion given local anaesthesia." data-id="CD001501-fig-0057" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-008-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.5</div> <div class="figure-caption"> <p>Comparison 8 Microwave ablation (second generation) versus TCRE + rollerball (first generation), Outcome 5 Proportion given local anaesthesia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-008-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0058"> <p> <div class="table" id="CD001501-tblf-0003"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Microwave</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>TCRE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Results</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cooper 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N=129<br/> Mean duration of hospital stay (SD):<br/> 13.4 (17.6) hours </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N=134<br/> Mean duration of hospital stay (SD):<br/> 16.7 (21.2) hours </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mann Whitney U test<br/> No differences between groups; P=0.17 </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.6</div> <div class="figure-caption"> <p>Comparison 8 Microwave ablation (second generation) versus TCRE + rollerball (first generation), Outcome 6 Duration of hospital stay (hours). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0058">Navigate to figure in review</a></div> </div> <div class="figure" id="CD001501-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-008-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-008-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Microwave ablation (second generation) versus TCRE + rollerball (first generation), Outcome 7 Inability to work (proportion of women)." data-id="CD001501-fig-0059" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-008-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.7</div> <div class="figure-caption"> <p>Comparison 8 Microwave ablation (second generation) versus TCRE + rollerball (first generation), Outcome 7 Inability to work (proportion of women). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-008-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0060"> <p> <div class="table" id="CD001501-tblf-0004"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MEA</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>TCRE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Results</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Physical functioning</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cooper 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AT 1 YEAR:<br/> N=116<br/> Mean change (SD):<br/> 0.7 (18.9)<br/> <br/> AT 2 YEARS:<br/> N=120<br/> Mean change (SD):<br/> 2.3 (21.3)<br/> <br/> AT 5 YEARS:<br/> N=116<br/> Mean change (SD): 0.2 (24) </p> <p>At 10 YEARS:</p> <p>N=94</p> <p>Mean change (SD): ‐4.4 (27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AT 1 YEAR:<br/> N=124<br/> Mean change (SD):<br/> 2.4 (16.8)<br/> <br/> AT 2 YEARS:<br/> N=129<br/> Mean change (SD):<br/> 0.9 (20.4)<br/> <br/> AT 5 YEARS:<br/> N=120<br/> Mean change (SD): ‐1.2 (21) </p> <p>At 10 YEARS:</p> <p>N=95</p> <p>Mean change (SD): ‐3.0 (25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AT 1 YEAR:<br/> t test:<br/> CI (‐6.4, 2.9); P=0.45<br/> Ancova: P=0.58<br/> <br/> AT 2 YEARS:<br/> t test:<br/> P=0.28 (95% CI ‐3.8, 6.6)<br/> <br/> AT 5 YEARS:<br/> t test:<br/> NS (95% CI ‐4.5 to 7.3) </p> <p>At 10 YEARS:</p> <p>t test:</p> <p>NS (95% CI ‐8.9 to 6.1)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Social functioning</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cooper 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AT 1 YEAR:<br/> N=116<br/> Mean change (SD): 20.6 (26.5)<br/> <br/> AT 2 YEARS:<br/> N=120<br/> Mean change (SD): 10.1 (27.5)<br/> <br/> AT 5 YEARS:<br/> N=116<br/> Mean change (SD): 7.7 (30) </p> <p>At 10 YEARS:</p> <p>N=94</p> <p>Mean change (SD): 10.1 (30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At 1 YEAR:</p> <p>N=124<br/> Mean change (SD): 16.2 (24.4)<br/> <br/> AT 2 YEARS:<br/> N=129<br/> Mean change (SD): 6.2 (23.7)<br/> <br/> AT 5 YEARS:<br/> Mean change (SD):<br/> 9.7 (25) </p> <p>At 10 YEARS:</p> <p>N=95</p> <p>Mean change (SD): 9.9 (26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AT 1 YEAR:<br/> t test:<br/> CI (‐2.1, 10.90): P=0.18<br/> Ancova:<br/> P=0.12<br/> <br/> AT 2 YEARS:<br/> t test:<br/> P=0.33 (95% CI ‐2.5, 10.3)<br/> <br/> AT 5 YEARS:<br/> t test:<br/> NS (95% CI ‐9.0 to 5.0) </p> <p>At 10 YEARS:</p> <p>t test:</p> <p>NS (95% CI ‐7.9 to 8.3)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Physical role</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cooper 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AT 1 YEAR:<br/> N=116<br/> Mean change (SD): 23.9 (49.4)<br/> <br/> AT 2 YEARS:<br/> N=120<br/> Mean change (SD): 18.5 (53.7)<br/> <br/> AT 5 YEARS:<br/> N=116<br/> Mean change (SD): 17 (54) </p> <p>At 10 YEARS:</p> <p>N=94</p> <p>Mean change (SD): 15.0 (53)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AT 1 YEAR:<br/> N=124<br/> Mean change (SD): 11.3 (41.7)<br/> <br/> AT 2 YEARS:<br/> N=129<br/> Mean change (SD): 6.1 (43.8)<br/> <br/> AT 5 YEARS:<br/> N=120<br/> Mean change (SD): 11 (43) </p> <p>At 10 YEARS:</p> <p>N=95</p> <p>Mean change (SD): 10.9 (47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AT 1 YEAR:<br/> t test:<br/> CI (1.0 to 24.3);<br/> P=0.03<br/> Ancova:<br/> P=0.03<br/> <br/> AT 2 YEARS:<br/> t test:<br/> P=0.06 (95% CI ‐0.2, 24.6)<br/> <br/> AT 5 YEARS:<br/> t test:<br/> NS, 95% CI ‐5.8 to 19 </p> <p>At 10 YEARS:</p> <p>t test:</p> <p>NS, 95% CI ‐10.3 to 18.5</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Emotional role</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cooper 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AT ONE YEAR:<br/> N=116<br/> Mean change (SD): 17.0 (48.5)<br/> <br/> AT 2 YEARS:<br/> N=120<br/> Mean change (SD): 17.8 (47.5)<br/> <br/> AT 5 YEARS:<br/> N=116<br/> Mean change (SD): 19 (48) </p> <p>At 10 YEARS:</p> <p>N=94</p> <p>Mean change (SD): 21.1 (50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AT 1 YEAR:<br/> N=124<br/> Mean change (SD): 13.7 (47.9)<br/> <br/> AT 2 YEARS:<br/> N=129<br/> Mean change (SD): 4.2 (40.1)<br/> <br/> AT 5 YEARS: </p> <p>N=120<br/> Mean change (SD): 20 (41) </p> <p>At 10 YEARS:</p> <p>N=95</p> <p>Mean change (SD): 13.5 (47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AT 1 YEAR:<br/> t test:<br/> CI (‐9.1 to 15.6);<br/> P=0.59<br/> Ancova:<br/> P=0.38<br/> <br/> AT 2 YEARS:<br/> t test<br/> P=0.17 (95% CI ‐3.6, 23.5)<br/> <br/> AT 5 YEARS:<br/> t test:<br/> NS, 95% CI ‐13 to 10 </p> <p>At 10 YEARS:</p> <p>t test:</p> <p>NS, 95% CI 6.3 to 21.5</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Mental health</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cooper 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AT 1 YEAR:<br/> N=116<br/> Mean change (SD): 6.3 (19.5)<br/> <br/> AT 2 YEARS:<br/> N=120<br/> Mean change (SD): 6.0 (21.6)<br/> <br/> AT 5 YEARS:<br/> N=116<br/> Mean change (SD): 1.4 (21) </p> <p>At 10 YEARS:</p> <p>N=94</p> <p>Mean change (SD): 7.2 (21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AT 1 YEAR:<br/> N=124<br/> Mean change (SD): 6.0 (22.2)<br/> <br/> AT 2 YEARS:<br/> N=129<br/> Mean change (SD): 4.1 (19.8)<br/> <br/> AT 5 YEARS </p> <p>N=120<br/> Mean change (SD): 1.2 (21) </p> <p>At 10 YEARS:</p> <p>N=95</p> <p>Mean change (SD): 7.9 (25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AT 1 YEAR:<br/> t test:<br/> CI (‐4.9 to 5.7);<br/> P=0.89<br/> Ancova:<br/> P=0.83<br/> <br/> AT 2 YEARS:<br/> t test:<br/> P=0.44 (95% CI ‐3.3, 6.9)<br/> <br/> AT 5 YEARS:<br/> t test:<br/> NS, 95% CI ‐5.2 to 5.6 </p> <p>At 10 YEARS:</p> <p>t test:</p> <p>NS, 95% CI ‐7.3 to 5.9</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Energy/fatigue</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cooper 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AT 1 YEAR:<br/> N=116<br/> Mean change (SD): 12.8 (21.7)<br/> <br/> AT 2 YEARS:<br/> N=120<br/> Mean change (SD): 11.4 (25.1)<br/> <br/> AT 5 YEARS: </p> <p>N=116<br/> Mean change (SD): 9.3 (25) </p> <p>At 10 YEARS:</p> <p>N=94</p> <p>Mean change (SD): 12.9 (29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AT 1 YEAR:<br/> N=124<br/> Mean change (SD): 12.1 (23.0)<br/> <br/> AT 2 YEARS:<br/> N=129<br/> Mean change (SD): 11.8 (22.6)<br/> <br/> AT 5 YEARS: </p> <p>N=120<br/> Mean change (SD): 12 (26) </p> <p>At 10 YEARS:</p> <p>N=95</p> <p>Mean change (SD): 15.3 (27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AT 1 YEAR:<br/> t test:<br/> CI (‐4.9 to 6.5);<br/> p=0.80<br/> Ancova:<br/> p=0.58<br/> <br/> AT 2 YEARS:<br/> t test:<br/> P=0.90 (95% CI ‐6.4, 5.5)<br/> <br/> AT 5 YEARS:<br/> t test:<br/> NS, 95% CI ‐9.1 to 4.2 </p> <p>At 10 YEARS:</p> <p>t test:</p> <p>NS, 95% CI ‐10.4 to 5.6</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Pain</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cooper 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AT 1 YEAR:<br/> N=116<br/> Mean change (SD): 14.8 (31.0)<br/> <br/> AT 2 YEARS:<br/> N=120<br/> Mean change (SD): 13.5 (31.7)<br/> <br/> AT 5 YEARS: </p> <p>N=116<br/> Mean change (SD): 9.3 (35) </p> <p>At 10 YEARS:</p> <p>N=94</p> <p>Mean change (SD): 11.6 (37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AT 1 YEAR:<br/> N=124<br/> Mean change (SD): 7.2 (31.1)<br/> <br/> AT 2 YEARS:<br/> N=129<br/> Mean change (SD): 3.0 (29.8)<br/> <br/> AT 5 YEARS: </p> <p>N=120<br/> Mean change (SD): 6.4 (31) </p> <p>At 10 YEARS:</p> <p>N=95</p> <p>Mean change (SD): 12.3 (35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AT 1 YEAR:<br/> t test:<br/> CI (‐0.2 to 15.5);<br/> P=0.06<br/> Ancova:<br/> P=0.54<br/> <br/> AT 2 YEARS:<br/> t test:<br/> P=0.02 (95% CI 2.9, 18.2)<br/> <br/> AT 5 YEARS:<br/> t test:<br/> NS, 95% CI ‐5.7 to 12 </p> <p>At 10 YEARS:</p> <p>t test:</p> <p>NS, 95% CI ‐11.0 to 9.6</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>General health</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cooper 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AT 1 YEAR:<br/> N=116<br/> Mean change (SD): 2.4 (20.3)<br/> <br/> AT 2 YEARS:<br/> N=120<br/> Mean change (SD): 0.0 (24.4)<br/> <br/> AT 5 YEARS: </p> <p>N=116<br/> Mean change (SD): ‐3.3 (26) </p> <p>At 10 YEARS:</p> <p>N=94</p> <p>Mean change (SD): 0.94 (23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AT 1 YEAR:<br/> N=124<br/> Mean change (SD): ‐2.9 (20.0)<br/> <br/> AT 2 YEARS:<br/> N=129<br/> Mean change (SD): ‐2.9 (19.0)<br/> <br/> AT 5 YEARS: </p> <p>N=120<br/> Mean change (SD): ‐2.4 (19) </p> <p>At 10 YEARS:</p> <p>N=95</p> <p>Mean change (SD): 2.8 (22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AT 1 YEAR:<br/> t test:<br/> CI (0.2 to 10.5);<br/> P=0.04<br/> Ancova:<br/> P=0.06<br/> <br/> AT 2 YEARS:<br/> t test:<br/> P=0.29 (95% CI ‐2.5, 8.4)<br/> <br/> AT 5 YEARS:<br/> t test:<br/> NS, 95% CI ‐6.5 to 4.9 </p> <p>At 10 YEARS:</p> <p>t test:</p> <p>NS, 95% CI ‐8.3 to 4.6</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.8</div> <div class="figure-caption"> <p>Comparison 8 Microwave ablation (second generation) versus TCRE + rollerball (first generation), Outcome 8 Quality of life ‐ change in SF‐36 score after treatment. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0060">Navigate to figure in review</a></div> </div> <div class="figure" id="CD001501-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-008-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-008-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Microwave ablation (second generation) versus TCRE + rollerball (first generation), Outcome 9 Improvement in other menstrual symptoms: PMS." data-id="CD001501-fig-0061" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-008-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.9</div> <div class="figure-caption"> <p>Comparison 8 Microwave ablation (second generation) versus TCRE + rollerball (first generation), Outcome 9 Improvement in other menstrual symptoms: PMS. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-008-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-008-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-008-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Microwave ablation (second generation) versus TCRE + rollerball (first generation), Outcome 10 Improvement in other menstrual symptoms." data-id="CD001501-fig-0062" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-008-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.10</div> <div class="figure-caption"> <p>Comparison 8 Microwave ablation (second generation) versus TCRE + rollerball (first generation), Outcome 10 Improvement in other menstrual symptoms. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-008-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-008-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-008-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Microwave ablation (second generation) versus TCRE + rollerball (first generation), Outcome 11 Reduction in pain score (points)." data-id="CD001501-fig-0063" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-008-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.11</div> <div class="figure-caption"> <p>Comparison 8 Microwave ablation (second generation) versus TCRE + rollerball (first generation), Outcome 11 Reduction in pain score (points). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-008-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-008-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-008-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Microwave ablation (second generation) versus TCRE + rollerball (first generation), Outcome 12 Postoperative analgesia rate." data-id="CD001501-fig-0064" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-008-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.12</div> <div class="figure-caption"> <p>Comparison 8 Microwave ablation (second generation) versus TCRE + rollerball (first generation), Outcome 12 Postoperative analgesia rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-008-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-008-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-008-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Microwave ablation (second generation) versus TCRE + rollerball (first generation), Outcome 13 Complication rate: major complications." data-id="CD001501-fig-0065" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-008-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.13</div> <div class="figure-caption"> <p>Comparison 8 Microwave ablation (second generation) versus TCRE + rollerball (first generation), Outcome 13 Complication rate: major complications. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-008-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-008-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-008-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Microwave ablation (second generation) versus TCRE + rollerball (first generation), Outcome 14 Complication rate: minor complications." data-id="CD001501-fig-0066" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-008-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.14</div> <div class="figure-caption"> <p>Comparison 8 Microwave ablation (second generation) versus TCRE + rollerball (first generation), Outcome 14 Complication rate: minor complications. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-008-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-008-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-008-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Microwave ablation (second generation) versus TCRE + rollerball (first generation), Outcome 15 Requirement for further surgery." data-id="CD001501-fig-0067" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-008-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.15</div> <div class="figure-caption"> <p>Comparison 8 Microwave ablation (second generation) versus TCRE + rollerball (first generation), Outcome 15 Requirement for further surgery. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-008-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-009-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-009-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Balloon endometrial ablation (second generation) versus rollerball endometrial ablation (first generation), Outcome 1 Bleeding." data-id="CD001501-fig-0068" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-009-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9 Balloon endometrial ablation (second generation) versus rollerball endometrial ablation (first generation), Outcome 1 Bleeding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-009-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0069"> <p> <div class="table" id="CD001501-tblf-0005"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Balloon</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Rollerball</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Results</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>At 1 year follow‐up</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Meyer 1998</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N=125<br/> Mean PBAC (SD): 52.2 (85.2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N=114<br/> Mean PBAC (SD): 39.6 (86.4) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No statistical test performed of these outcomes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>van Zon‐Rabelink 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N=74<br/> Median PBAC (range): 70 (0, 2265) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N=55<br/> Median PBAC (range): 73 (0, 535) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wilcoxon test:<br/> P=0.90 </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>At 2 years' follow‐up</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>van Zon‐Rabelink 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N=66<br/> Median PBAC (range): 33.5 (0, 905) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N=55<br/> Median PBAC (range): 73 (0, 585) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wilcoxon test: P=0.01</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9 Balloon endometrial ablation (second generation) versus rollerball endometrial ablation (first generation), Outcome 2 PBAC score after treatment. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0069">Navigate to figure in review</a></div> </div> <div class="figure" id="CD001501-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-009-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-009-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Balloon endometrial ablation (second generation) versus rollerball endometrial ablation (first generation), Outcome 3 Success of treatment (lighter periods and no further surgery)." data-id="CD001501-fig-0070" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-009-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9 Balloon endometrial ablation (second generation) versus rollerball endometrial ablation (first generation), Outcome 3 Success of treatment (lighter periods and no further surgery). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-009-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-009-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-009-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Balloon endometrial ablation (second generation) versus rollerball endometrial ablation (first generation), Outcome 4 Success of treatment (menstrual score &lt; 185)." data-id="CD001501-fig-0071" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-009-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.4</div> <div class="figure-caption"> <p>Comparison 9 Balloon endometrial ablation (second generation) versus rollerball endometrial ablation (first generation), Outcome 4 Success of treatment (menstrual score &lt; 185). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-009-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-009-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-009-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Balloon endometrial ablation (second generation) versus rollerball endometrial ablation (first generation), Outcome 5 Rate of satisfaction." data-id="CD001501-fig-0072" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-009-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.5</div> <div class="figure-caption"> <p>Comparison 9 Balloon endometrial ablation (second generation) versus rollerball endometrial ablation (first generation), Outcome 5 Rate of satisfaction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-009-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-009-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-009-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Balloon endometrial ablation (second generation) versus rollerball endometrial ablation (first generation), Outcome 6 Duration of operation (minutes)." data-id="CD001501-fig-0073" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-009-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.6</div> <div class="figure-caption"> <p>Comparison 9 Balloon endometrial ablation (second generation) versus rollerball endometrial ablation (first generation), Outcome 6 Duration of operation (minutes). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-009-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-009-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-009-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Balloon endometrial ablation (second generation) versus rollerball endometrial ablation (first generation), Outcome 7 Operative difficulties." data-id="CD001501-fig-0074" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-009-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.7</div> <div class="figure-caption"> <p>Comparison 9 Balloon endometrial ablation (second generation) versus rollerball endometrial ablation (first generation), Outcome 7 Operative difficulties. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-009-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-009-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-009-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Balloon endometrial ablation (second generation) versus rollerball endometrial ablation (first generation), Outcome 8 Inability to work (proportion of women)." data-id="CD001501-fig-0075" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-009-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.8</div> <div class="figure-caption"> <p>Comparison 9 Balloon endometrial ablation (second generation) versus rollerball endometrial ablation (first generation), Outcome 8 Inability to work (proportion of women). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-009-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-009-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-009-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Balloon endometrial ablation (second generation) versus rollerball endometrial ablation (first generation), Outcome 9 Improvement in other menstrual symptoms." data-id="CD001501-fig-0076" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-009-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.9</div> <div class="figure-caption"> <p>Comparison 9 Balloon endometrial ablation (second generation) versus rollerball endometrial ablation (first generation), Outcome 9 Improvement in other menstrual symptoms. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-009-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-009-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-009-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Balloon endometrial ablation (second generation) versus rollerball endometrial ablation (first generation), Outcome 10 Complication rate: major complications." data-id="CD001501-fig-0077" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-009-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.10</div> <div class="figure-caption"> <p>Comparison 9 Balloon endometrial ablation (second generation) versus rollerball endometrial ablation (first generation), Outcome 10 Complication rate: major complications. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-009-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-009-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-009-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Balloon endometrial ablation (second generation) versus rollerball endometrial ablation (first generation), Outcome 11 Complication rate: minor complications." data-id="CD001501-fig-0078" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-009-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.11</div> <div class="figure-caption"> <p>Comparison 9 Balloon endometrial ablation (second generation) versus rollerball endometrial ablation (first generation), Outcome 11 Complication rate: minor complications. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-009-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-009-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-009-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Balloon endometrial ablation (second generation) versus rollerball endometrial ablation (first generation), Outcome 12 Requirement for further surgery." data-id="CD001501-fig-0079" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-009-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.12</div> <div class="figure-caption"> <p>Comparison 9 Balloon endometrial ablation (second generation) versus rollerball endometrial ablation (first generation), Outcome 12 Requirement for further surgery. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-009-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-010-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-010-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Balloon (second generation) versus laser (first generation), Outcome 1 Bleeding." data-id="CD001501-fig-0080" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-010-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10 Balloon (second generation) versus laser (first generation), Outcome 1 Bleeding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-010-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0081"> <p> <div class="table" id="CD001501-tblf-0006"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Balloon</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Laser</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Statistical test</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>At 6 months' follow‐up</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hawe 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N=37<br/> Mean PBAC (SD): 28.8 (59.6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N=33<br/> Mean PBAC (SD): 27.4 (57.6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Significance not reported</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10 Balloon (second generation) versus laser (first generation), Outcome 2 PBAC score after treatment. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0081">Navigate to figure in review</a></div> </div> <div class="figure" id="CD001501-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-010-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-010-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Balloon (second generation) versus laser (first generation), Outcome 3 Rate of satisfaction." data-id="CD001501-fig-0082" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-010-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10 Balloon (second generation) versus laser (first generation), Outcome 3 Rate of satisfaction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-010-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-010-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-010-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Balloon (second generation) versus laser (first generation), Outcome 4 Operative difficulties." data-id="CD001501-fig-0083" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-010-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.4</div> <div class="figure-caption"> <p>Comparison 10 Balloon (second generation) versus laser (first generation), Outcome 4 Operative difficulties. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-010-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-010-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-010-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Balloon (second generation) versus laser (first generation), Outcome 5 Pain score 4 hours post procedure." data-id="CD001501-fig-0084" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-010-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.5</div> <div class="figure-caption"> <p>Comparison 10 Balloon (second generation) versus laser (first generation), Outcome 5 Pain score 4 hours post procedure. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-010-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-010-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-010-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Balloon (second generation) versus laser (first generation), Outcome 6 Quality of life." data-id="CD001501-fig-0085" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-010-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.6</div> <div class="figure-caption"> <p>Comparison 10 Balloon (second generation) versus laser (first generation), Outcome 6 Quality of life. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-010-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0086"> <p> <div class="table" id="CD001501-tblf-0007"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Balloon</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Laser</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Statistical test</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>PMS at 6 months' follow‐up</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hawe 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N=37<br/> Mean score (SD): 24.6 (33) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N=33<br/> Mean score (SD): 34.8 (36) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>PMS at 12 months' follow‐up</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hawe 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N=34<br/> Mean score (SD): 21.9 (26.9) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N=33<br/> Mean score (SD): 30.5 (34.7) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.7</div> <div class="figure-caption"> <p>Comparison 10 Balloon (second generation) versus laser (first generation), Outcome 7 Improvement in other menstrual symptoms. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0086">Navigate to figure in review</a></div> </div> <div class="figure" id="CD001501-fig-0087"> <p> <div class="table" id="CD001501-tblf-0008"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Balloon</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Laser</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Statistical test</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Dysmenorrhoea at 6 months' follow‐up</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hawe 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N=37<br/> Mean score (SD): 24 (30.9) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N=33<br/> Mean score (SD): 23 (33.9) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Dysmenorrhoea at 12 months' follow‐up</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hawe 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N=34<br/> Mean score (SD): 25.2 (31.5) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N=33<br/> Mean score (SD): 16.5 (22.3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.8</div> <div class="figure-caption"> <p>Comparison 10 Balloon (second generation) versus laser (first generation), Outcome 8 Improvement in other menstrual symptoms: dysmenorrhoea (visual analogue). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0087">Navigate to figure in review</a></div> </div> <div class="figure" id="CD001501-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-010-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-010-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Balloon (second generation) versus laser (first generation), Outcome 9 Requirement for further surgery." data-id="CD001501-fig-0088" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-010-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.9</div> <div class="figure-caption"> <p>Comparison 10 Balloon (second generation) versus laser (first generation), Outcome 9 Requirement for further surgery. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-010-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0089"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-011-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-011-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Balloon (second generation) versus TCRE (first generation), Outcome 1 Bleeding." data-id="CD001501-fig-0089" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-011-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11 Balloon (second generation) versus TCRE (first generation), Outcome 1 Bleeding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0089">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-011-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0090"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-011-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-011-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Balloon (second generation) versus TCRE (first generation), Outcome 2 Rate of satisfaction." data-id="CD001501-fig-0090" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-011-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.2</div> <div class="figure-caption"> <p>Comparison 11 Balloon (second generation) versus TCRE (first generation), Outcome 2 Rate of satisfaction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0090">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-011-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0091"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-011-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-011-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Balloon (second generation) versus TCRE (first generation), Outcome 3 Duration of operation (minutes)." data-id="CD001501-fig-0091" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-011-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.3</div> <div class="figure-caption"> <p>Comparison 11 Balloon (second generation) versus TCRE (first generation), Outcome 3 Duration of operation (minutes). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0091">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-011-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0092"> <p> <div class="table" id="CD001501-tblf-0009"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cavaterm balloon</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>TCRE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comments</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Brun 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n=31</p> <p>Median (range): 48 (24‐150)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n=20</p> <p>Median (range): 45 (23‐105)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No statistical test reported ‐ unlikely to be a difference</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.4</div> <div class="figure-caption"> <p>Comparison 11 Balloon (second generation) versus TCRE (first generation), Outcome 4 Duration of operation (minutes). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0092">Navigate to figure in review</a></div> </div> <div class="figure" id="CD001501-fig-0093"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-011-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-011-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Balloon (second generation) versus TCRE (first generation), Outcome 5 Operative difficulties." data-id="CD001501-fig-0093" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-011-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.5</div> <div class="figure-caption"> <p>Comparison 11 Balloon (second generation) versus TCRE (first generation), Outcome 5 Operative difficulties. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0093">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-011-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0094"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-011-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-011-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Balloon (second generation) versus TCRE (first generation), Outcome 6 Postoperative pain (continuous data)." data-id="CD001501-fig-0094" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-011-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.6</div> <div class="figure-caption"> <p>Comparison 11 Balloon (second generation) versus TCRE (first generation), Outcome 6 Postoperative pain (continuous data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0094">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-011-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0095"> <p> <div class="table" id="CD001501-tblf-0010"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cavaterm balloon</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>TCRE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comments</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Brun 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n=31</p> <p>Pain score (VAS scale 0‐100): median (range): 45 (1‐100)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n=20</p> <p>Pain score (VAS scale 0‐100): median (range): 10 (0‐90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mann Whitney rank sum test:</p> <p>P=0.012</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.7</div> <div class="figure-caption"> <p>Comparison 11 Balloon (second generation) versus TCRE (first generation), Outcome 7 Postoperative pain (descriptive data). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0095">Navigate to figure in review</a></div> </div> <div class="figure" id="CD001501-fig-0096"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-011-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-011-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Balloon (second generation) versus TCRE (first generation), Outcome 8 Hospital stay (days)." data-id="CD001501-fig-0096" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-011-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.8</div> <div class="figure-caption"> <p>Comparison 11 Balloon (second generation) versus TCRE (first generation), Outcome 8 Hospital stay (days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0096">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-011-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0097"> <p> <div class="table" id="CD001501-tblf-0011"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cavaterm balloon</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>TCRE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comments</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Brun 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n=31</p> <p>Median (range): 21 (0‐36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n=20</p> <p>Median (range): 30 (6‐72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mann Whitney rank sum test</p> <p>P=0.012</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.9</div> <div class="figure-caption"> <p>Comparison 11 Balloon (second generation) versus TCRE (first generation), Outcome 9 Duration of hospital stay (hours). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0097">Navigate to figure in review</a></div> </div> <div class="figure" id="CD001501-fig-0098"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-011-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-011-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Balloon (second generation) versus TCRE (first generation), Outcome 10 Return to normal activities (days)." data-id="CD001501-fig-0098" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-011-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.10</div> <div class="figure-caption"> <p>Comparison 11 Balloon (second generation) versus TCRE (first generation), Outcome 10 Return to normal activities (days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0098">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-011-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0099"> <p> <div class="table" id="CD001501-tblf-0012"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cavaterm balloon</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>TCRE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comments</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Brun 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n=31</p> <p>Median (range): 4 (1‐20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n=20</p> <p>Median (range): 2 (1‐30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mann Whitney rank test ‐ not significantly different</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.11</div> <div class="figure-caption"> <p>Comparison 11 Balloon (second generation) versus TCRE (first generation), Outcome 11 Return to normal activities (days). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0099">Navigate to figure in review</a></div> </div> <div class="figure" id="CD001501-fig-0100"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-011-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-011-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Balloon (second generation) versus TCRE (first generation), Outcome 12 Complication rate: major complications." data-id="CD001501-fig-0100" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-011-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.12</div> <div class="figure-caption"> <p>Comparison 11 Balloon (second generation) versus TCRE (first generation), Outcome 12 Complication rate: major complications. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0100">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-011-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0101"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-011-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-011-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Balloon (second generation) versus TCRE (first generation), Outcome 13 Complication rate: minor complications." data-id="CD001501-fig-0101" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-011-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.13</div> <div class="figure-caption"> <p>Comparison 11 Balloon (second generation) versus TCRE (first generation), Outcome 13 Complication rate: minor complications. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0101">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-011-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0102"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-011-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-011-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Balloon (second generation) versus TCRE (first generation), Outcome 14 Complication rate: minor complications (dichotomous)." data-id="CD001501-fig-0102" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-011-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.14</div> <div class="figure-caption"> <p>Comparison 11 Balloon (second generation) versus TCRE (first generation), Outcome 14 Complication rate: minor complications (dichotomous). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0102">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-011-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0103"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-011-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-011-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Balloon (second generation) versus TCRE (first generation), Outcome 15 Requirement for further surgery." data-id="CD001501-fig-0103" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-011-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.15</div> <div class="figure-caption"> <p>Comparison 11 Balloon (second generation) versus TCRE (first generation), Outcome 15 Requirement for further surgery. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0103">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-011-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0104"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-012-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-012-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Bipolar radiofrequency (second generation) versus balloon ablation (second generation), Outcome 1 Bleeding." data-id="CD001501-fig-0104" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-012-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12 Bipolar radiofrequency (second generation) versus balloon ablation (second generation), Outcome 1 Bleeding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0104">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-012-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0105"> <p> <div class="table" id="CD001501-tblf-0013"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Electrode</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Balloon</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Statistical test</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>At 6 months' follow‐up</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Penninx 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>At 12 months' follow‐up</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abbott 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N=37<br/> Median PBAC (range): 3 (0, 720) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N=18<br/> Median PBAC (range): 21 (0, 157) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mann Whitney<br/> P=0.2 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Penninx 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N=52</p> <p>PBAC&lt;100 at 12 months: 44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N=52</p> <p>PBAC&lt;100 at 12 months: 31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR=0.4 95% CI=0.2‐0.8</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.2</div> <div class="figure-caption"> <p>Comparison 12 Bipolar radiofrequency (second generation) versus balloon ablation (second generation), Outcome 2 PBAC score after treatment. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0105">Navigate to figure in review</a></div> </div> <div class="figure" id="CD001501-fig-0106"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-012-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-012-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Bipolar radiofrequency (second generation) versus balloon ablation (second generation), Outcome 3 Rate of satisfaction." data-id="CD001501-fig-0106" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-012-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.3</div> <div class="figure-caption"> <p>Comparison 12 Bipolar radiofrequency (second generation) versus balloon ablation (second generation), Outcome 3 Rate of satisfaction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0106">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-012-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0107"> <p> <div class="table" id="CD001501-tblf-0014"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Electrode</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Balloon</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Statistical test</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abbott 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N=37<br/> Mean time in mins (range): 4 (2, 8) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N=18<br/> Mean time in mins (range): 23 (19, 29) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>t test<br/> P=0.0001 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bongers 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N=82<br/> Mean time in mins (range): 9 (5, 32) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N=43<br/> Mean time in mins (range): 14 (9, 40) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clark 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N=42</p> <p>Mean time in mins (SD): 5.7 (2.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N=39</p> <p>Mean time in mins (SD): 12.5 (2.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD=6.7 mins (95% CI 5.8 to 7.7); p&lt;0.001</p> <p>Note: this is an office procedure in both arms)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Penninx 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N=52 Mean time in mins (range)</p> <p>10.4 min (6‐30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N=52 Mean time in mins (range)</p> <p>12.1 (5‐45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>p=0.34</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.4</div> <div class="figure-caption"> <p>Comparison 12 Bipolar radiofrequency (second generation) versus balloon ablation (second generation), Outcome 4 Duration of operation. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0107">Navigate to figure in review</a></div> </div> <div class="figure" id="CD001501-fig-0108"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-012-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-012-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Bipolar radiofrequency (second generation) versus balloon ablation (second generation), Outcome 5 Operative difficulties." data-id="CD001501-fig-0108" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-012-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.5</div> <div class="figure-caption"> <p>Comparison 12 Bipolar radiofrequency (second generation) versus balloon ablation (second generation), Outcome 5 Operative difficulties. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0108">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-012-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0109"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-012-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-012-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Bipolar radiofrequency (second generation) versus balloon ablation (second generation), Outcome 6 Completion of procedure." data-id="CD001501-fig-0109" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-012-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.6</div> <div class="figure-caption"> <p>Comparison 12 Bipolar radiofrequency (second generation) versus balloon ablation (second generation), Outcome 6 Completion of procedure. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0109">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-012-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0110"> <p> <div class="table" id="CD001501-tblf-0015"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bipolar RF ablation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Thermal ablation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Results</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clark 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N=42</p> <p>Mean: 6.4 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N=39</p> <p>Mean: 6.6 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No significant difference between groups: 0.2 days difference (95% CI ‐5.9 to 6.2)</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.7</div> <div class="figure-caption"> <p>Comparison 12 Bipolar radiofrequency (second generation) versus balloon ablation (second generation), Outcome 7 Time taken off work (days). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0110">Navigate to figure in review</a></div> </div> <div class="figure" id="CD001501-fig-0111"> <p> <div class="table" id="CD001501-tblf-0016"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bipolar RF ablation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Balloon ablation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Results</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clark 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N=42</p> <p>Mean (days): 4.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N=39</p> <p>Mean (days): 8.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No significant difference between groups: 3.2 days difference (95% CI ‐1.6 to 8.1)</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.8</div> <div class="figure-caption"> <p>Comparison 12 Bipolar radiofrequency (second generation) versus balloon ablation (second generation), Outcome 8 Time to resume normal activities (days). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0111">Navigate to figure in review</a></div> </div> <div class="figure" id="CD001501-fig-0112"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-012-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-012-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Bipolar radiofrequency (second generation) versus balloon ablation (second generation), Outcome 9 Quality of life." data-id="CD001501-fig-0112" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-012-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.9</div> <div class="figure-caption"> <p>Comparison 12 Bipolar radiofrequency (second generation) versus balloon ablation (second generation), Outcome 9 Quality of life. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0112">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-012-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0113"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-012-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-012-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Bipolar radiofrequency (second generation) versus balloon ablation (second generation), Outcome 10 Menorrhagia Outcome Questionnaire." data-id="CD001501-fig-0113" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-012-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.10</div> <div class="figure-caption"> <p>Comparison 12 Bipolar radiofrequency (second generation) versus balloon ablation (second generation), Outcome 10 Menorrhagia Outcome Questionnaire. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0113">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-012-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0114"> <p> <div class="table" id="CD001501-tblf-0017"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Electrode</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Balloon</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Statistical test</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>At 12 months' follow‐up</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abbott 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N=37<br/> Median score (range): 0 (0, 96) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N=18<br/> Median score (range): 29 (0, 77) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mann Whitney<br/> P=0.008 </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.11</div> <div class="figure-caption"> <p>Comparison 12 Bipolar radiofrequency (second generation) versus balloon ablation (second generation), Outcome 11 Dysmenorrhoea rate (VAS score). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0114">Navigate to figure in review</a></div> </div> <div class="figure" id="CD001501-fig-0115"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-012-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-012-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Bipolar radiofrequency (second generation) versus balloon ablation (second generation), Outcome 12 Improvement in other menstrual symptoms." data-id="CD001501-fig-0115" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-012-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.12</div> <div class="figure-caption"> <p>Comparison 12 Bipolar radiofrequency (second generation) versus balloon ablation (second generation), Outcome 12 Improvement in other menstrual symptoms. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0115">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-012-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0116"> <p> <div class="table" id="CD001501-tblf-0018"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Electrode</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Balloon</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Statistical test</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>At 12 months' follow‐up</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abbott 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N=37<br/> Median score (range): 0 (0, 100) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N=18<br/> Median score (range): 32 (0, 100) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mann Whitney<br/> P=0.007 </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.13</div> <div class="figure-caption"> <p>Comparison 12 Bipolar radiofrequency (second generation) versus balloon ablation (second generation), Outcome 13 PMS rate (VAS score). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0116">Navigate to figure in review</a></div> </div> <div class="figure" id="CD001501-fig-0117"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-012-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-012-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Bipolar radiofrequency (second generation) versus balloon ablation (second generation), Outcome 14 Complication rate: major complications." data-id="CD001501-fig-0117" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-012-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.14</div> <div class="figure-caption"> <p>Comparison 12 Bipolar radiofrequency (second generation) versus balloon ablation (second generation), Outcome 14 Complication rate: major complications. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0117">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-012-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0118"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-012-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-012-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Bipolar radiofrequency (second generation) versus balloon ablation (second generation), Outcome 15 Requirement for further surgery." data-id="CD001501-fig-0118" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-012-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.15</div> <div class="figure-caption"> <p>Comparison 12 Bipolar radiofrequency (second generation) versus balloon ablation (second generation), Outcome 15 Requirement for further surgery. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0118">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-012-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0119"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-013-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-013-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Microwave ablation (second generation) versus balloon ablation (second generation), Outcome 1 Bleeding." data-id="CD001501-fig-0119" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-013-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.1</div> <div class="figure-caption"> <p>Comparison 13 Microwave ablation (second generation) versus balloon ablation (second generation), Outcome 1 Bleeding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0119">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-013-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0120"> <p> <div class="table" id="CD001501-tblf-0019"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Follow up</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Microwave ablation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Balloon ablation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Results</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sambrook 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N=143</p> <p>Mean PBAC score (interquartile range): 3.0 (0.0 to 14.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N=135</p> <p>Mean PBAC score (interquartile range): 4.0 (0.0 to 14.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence rate ratio (95% CI):</p> <p>0.91 (0.6 to 1.5)</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.2</div> <div class="figure-caption"> <p>Comparison 13 Microwave ablation (second generation) versus balloon ablation (second generation), Outcome 2 PBAC score at 12 months' follow‐up. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0120">Navigate to figure in review</a></div> </div> <div class="figure" id="CD001501-fig-0121"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-013-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-013-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Microwave ablation (second generation) versus balloon ablation (second generation), Outcome 3 Rate of satisfaction." data-id="CD001501-fig-0121" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-013-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.3</div> <div class="figure-caption"> <p>Comparison 13 Microwave ablation (second generation) versus balloon ablation (second generation), Outcome 3 Rate of satisfaction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0121">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-013-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0122"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-013-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-013-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Microwave ablation (second generation) versus balloon ablation (second generation), Outcome 4 Operation time (minutes)." data-id="CD001501-fig-0122" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-013-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.4</div> <div class="figure-caption"> <p>Comparison 13 Microwave ablation (second generation) versus balloon ablation (second generation), Outcome 4 Operation time (minutes). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0122">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-013-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0123"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-013-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-013-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Microwave ablation (second generation) versus balloon ablation (second generation), Outcome 5 Operative difficulties causing failure." data-id="CD001501-fig-0123" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-013-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.5</div> <div class="figure-caption"> <p>Comparison 13 Microwave ablation (second generation) versus balloon ablation (second generation), Outcome 5 Operative difficulties causing failure. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0123">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-013-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0124"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-013-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-013-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Microwave ablation (second generation) versus balloon ablation (second generation), Outcome 6 Proportion choosing local anaesthesia." data-id="CD001501-fig-0124" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-013-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.6</div> <div class="figure-caption"> <p>Comparison 13 Microwave ablation (second generation) versus balloon ablation (second generation), Outcome 6 Proportion choosing local anaesthesia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0124">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-013-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0125"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-013-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-013-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Microwave ablation (second generation) versus balloon ablation (second generation), Outcome 7 Proportion requiring opiate analgesia." data-id="CD001501-fig-0125" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-013-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.7</div> <div class="figure-caption"> <p>Comparison 13 Microwave ablation (second generation) versus balloon ablation (second generation), Outcome 7 Proportion requiring opiate analgesia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0125">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-013-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0126"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-013-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-013-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Microwave ablation (second generation) versus balloon ablation (second generation), Outcome 8 Recovery: proportion requiring overnight stay." data-id="CD001501-fig-0126" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-013-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.8</div> <div class="figure-caption"> <p>Comparison 13 Microwave ablation (second generation) versus balloon ablation (second generation), Outcome 8 Recovery: proportion requiring overnight stay. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0126">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-013-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0127"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-013-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-013-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Microwave ablation (second generation) versus balloon ablation (second generation), Outcome 9 Quality of life scores." data-id="CD001501-fig-0127" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-013-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.9</div> <div class="figure-caption"> <p>Comparison 13 Microwave ablation (second generation) versus balloon ablation (second generation), Outcome 9 Quality of life scores. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0127">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-013-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0128"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-013-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-013-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Microwave ablation (second generation) versus balloon ablation (second generation), Outcome 10 Requirement for further surgery (hysterectomy)." data-id="CD001501-fig-0128" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-013-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.10</div> <div class="figure-caption"> <p>Comparison 13 Microwave ablation (second generation) versus balloon ablation (second generation), Outcome 10 Requirement for further surgery (hysterectomy). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0128">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-013-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0129"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-014-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-014-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 Bipolar radiofrequency (second generation) versus hydrothermal ablation (second generation), Outcome 1 Bleeding." data-id="CD001501-fig-0129" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-014-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.1</div> <div class="figure-caption"> <p>Comparison 14 Bipolar radiofrequency (second generation) versus hydrothermal ablation (second generation), Outcome 1 Bleeding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0129">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-014-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0130"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-014-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-014-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 Bipolar radiofrequency (second generation) versus hydrothermal ablation (second generation), Outcome 2 Rate of satisfaction." data-id="CD001501-fig-0130" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-014-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.2</div> <div class="figure-caption"> <p>Comparison 14 Bipolar radiofrequency (second generation) versus hydrothermal ablation (second generation), Outcome 2 Rate of satisfaction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0130">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-014-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0131"> <p> <div class="table" id="CD001501-tblf-0020"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bipolar RF</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Hydrotherm ablation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Results</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Penninx 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N=82</p> <p>Median (range): 11.8 (5 to 40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N=74</p> <p>Median (range): 27.8 (14 to 55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Test used not stated</p> <p>p&lt;0.001</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.3</div> <div class="figure-caption"> <p>Comparison 14 Bipolar radiofrequency (second generation) versus hydrothermal ablation (second generation), Outcome 3 Duration of procedure (minutes). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0131">Navigate to figure in review</a></div> </div> <div class="figure" id="CD001501-fig-0132"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-014-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-014-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 Bipolar radiofrequency (second generation) versus hydrothermal ablation (second generation), Outcome 4 Improvement in other menstrual symptoms." data-id="CD001501-fig-0132" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-014-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.4</div> <div class="figure-caption"> <p>Comparison 14 Bipolar radiofrequency (second generation) versus hydrothermal ablation (second generation), Outcome 4 Improvement in other menstrual symptoms. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0132">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-014-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0133"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-014-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-014-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 Bipolar radiofrequency (second generation) versus hydrothermal ablation (second generation), Outcome 5 Complication rate: major complications." data-id="CD001501-fig-0133" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-014-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.5</div> <div class="figure-caption"> <p>Comparison 14 Bipolar radiofrequency (second generation) versus hydrothermal ablation (second generation), Outcome 5 Complication rate: major complications. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0133">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-014-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0134"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-014-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-014-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 Bipolar radiofrequency (second generation) versus hydrothermal ablation (second generation), Outcome 6 Requirement for further surgery." data-id="CD001501-fig-0134" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-014-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.6</div> <div class="figure-caption"> <p>Comparison 14 Bipolar radiofrequency (second generation) versus hydrothermal ablation (second generation), Outcome 6 Requirement for further surgery. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0134">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-014-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0135"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-015-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-015-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 Ablative curettage versus overcurettage, Outcome 1 Bleeding." data-id="CD001501-fig-0135" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-015-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.1</div> <div class="figure-caption"> <p>Comparison 15 Ablative curettage versus overcurettage, Outcome 1 Bleeding.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0135">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-015-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0136"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-015-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-015-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 Ablative curettage versus overcurettage, Outcome 2 Surgery difficulties: failure rate of procedure." data-id="CD001501-fig-0136" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-015-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.2</div> <div class="figure-caption"> <p>Comparison 15 Ablative curettage versus overcurettage, Outcome 2 Surgery difficulties: failure rate of procedure. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0136">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-015-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0137"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-015-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-015-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 Ablative curettage versus overcurettage, Outcome 3 Recovery: hospital stay (days)." data-id="CD001501-fig-0137" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-015-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.3</div> <div class="figure-caption"> <p>Comparison 15 Ablative curettage versus overcurettage, Outcome 3 Recovery: hospital stay (days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0137">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-015-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0138"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-015-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-015-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 Ablative curettage versus overcurettage, Outcome 4 Complication rate: major complications." data-id="CD001501-fig-0138" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-015-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.4</div> <div class="figure-caption"> <p>Comparison 15 Ablative curettage versus overcurettage, Outcome 4 Complication rate: major complications. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0138">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-015-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0139"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-015-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-015-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 Ablative curettage versus overcurettage, Outcome 5 Complication rate: minor complications." data-id="CD001501-fig-0139" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-015-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.5</div> <div class="figure-caption"> <p>Comparison 15 Ablative curettage versus overcurettage, Outcome 5 Complication rate: minor complications. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0139">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-015-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0140"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-015-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-015-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 Ablative curettage versus overcurettage, Outcome 6 Requirement for further surgery." data-id="CD001501-fig-0140" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-015-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.6</div> <div class="figure-caption"> <p>Comparison 15 Ablative curettage versus overcurettage, Outcome 6 Requirement for further surgery. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0140">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-015-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0141"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-016-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-016-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 Microwave ablation (second generation) versus bipolar radiofrequency (second generation), Outcome 1 Bleeding." data-id="CD001501-fig-0141" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-016-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.1</div> <div class="figure-caption"> <p>Comparison 16 Microwave ablation (second generation) versus bipolar radiofrequency (second generation), Outcome 1 Bleeding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0141">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-016-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0142"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-016-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-016-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 Microwave ablation (second generation) versus bipolar radiofrequency (second generation), Outcome 2 Bleeding PBAC at 12 months' follow‐up." data-id="CD001501-fig-0142" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-016-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.2</div> <div class="figure-caption"> <p>Comparison 16 Microwave ablation (second generation) versus bipolar radiofrequency (second generation), Outcome 2 Bleeding PBAC at 12 months' follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0142">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-016-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0143"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-016-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-016-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 Microwave ablation (second generation) versus bipolar radiofrequency (second generation), Outcome 3 Rate of satisfaction." data-id="CD001501-fig-0143" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-016-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.3</div> <div class="figure-caption"> <p>Comparison 16 Microwave ablation (second generation) versus bipolar radiofrequency (second generation), Outcome 3 Rate of satisfaction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0143">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-016-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0144"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-016-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-016-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 Microwave ablation (second generation) versus bipolar radiofrequency (second generation), Outcome 4 Duration of treatment (seconds)." data-id="CD001501-fig-0144" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-016-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.4</div> <div class="figure-caption"> <p>Comparison 16 Microwave ablation (second generation) versus bipolar radiofrequency (second generation), Outcome 4 Duration of treatment (seconds). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0144">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-016-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0145"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-016-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-016-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 Microwave ablation (second generation) versus bipolar radiofrequency (second generation), Outcome 5 Improvement in other menstrual symptoms: dysmenorrhoea." data-id="CD001501-fig-0145" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-016-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.5</div> <div class="figure-caption"> <p>Comparison 16 Microwave ablation (second generation) versus bipolar radiofrequency (second generation), Outcome 5 Improvement in other menstrual symptoms: dysmenorrhoea. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0145">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-016-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0146"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-016-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-016-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 Microwave ablation (second generation) versus bipolar radiofrequency (second generation), Outcome 6 Complication rate." data-id="CD001501-fig-0146" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-016-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.6</div> <div class="figure-caption"> <p>Comparison 16 Microwave ablation (second generation) versus bipolar radiofrequency (second generation), Outcome 6 Complication rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0146">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-016-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0147"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-016-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-016-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 Microwave ablation (second generation) versus bipolar radiofrequency (second generation), Outcome 7 Requirement for further surgery." data-id="CD001501-fig-0147" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-016-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.7</div> <div class="figure-caption"> <p>Comparison 16 Microwave ablation (second generation) versus bipolar radiofrequency (second generation), Outcome 7 Requirement for further surgery. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0147">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-016-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0148"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-017-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-017-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 Bipolar (Minerva) (second generation) versus rollerball ablation (first generation), Outcome 1 Bleeding." data-id="CD001501-fig-0148" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-017-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.1</div> <div class="figure-caption"> <p>Comparison 17 Bipolar (Minerva) (second generation) versus rollerball ablation (first generation), Outcome 1 Bleeding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0148">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-017-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0149"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-017-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-017-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 Bipolar (Minerva) (second generation) versus rollerball ablation (first generation), Outcome 2 Rate of satisfaction." data-id="CD001501-fig-0149" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-017-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.2</div> <div class="figure-caption"> <p>Comparison 17 Bipolar (Minerva) (second generation) versus rollerball ablation (first generation), Outcome 2 Rate of satisfaction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0149">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-017-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0150"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-017-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-017-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 Bipolar (Minerva) (second generation) versus rollerball ablation (first generation), Outcome 3 Duration of surgery." data-id="CD001501-fig-0150" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-017-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.3</div> <div class="figure-caption"> <p>Comparison 17 Bipolar (Minerva) (second generation) versus rollerball ablation (first generation), Outcome 3 Duration of surgery. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0150">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-017-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0151"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-017-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-017-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 Bipolar (Minerva) (second generation) versus rollerball ablation (first generation), Outcome 4 Improvement in other menstrual symptoms: dysmenorrhoea." data-id="CD001501-fig-0151" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-017-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.4</div> <div class="figure-caption"> <p>Comparison 17 Bipolar (Minerva) (second generation) versus rollerball ablation (first generation), Outcome 4 Improvement in other menstrual symptoms: dysmenorrhoea. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0151">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-017-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0152"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-017-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-017-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 Bipolar (Minerva) (second generation) versus rollerball ablation (first generation), Outcome 5 Improvement in other menstrual symptoms: PMS at 12 months' follow‐up." data-id="CD001501-fig-0152" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-017-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.5</div> <div class="figure-caption"> <p>Comparison 17 Bipolar (Minerva) (second generation) versus rollerball ablation (first generation), Outcome 5 Improvement in other menstrual symptoms: PMS at 12 months' follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0152">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-017-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0153"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-017-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-017-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 Bipolar (Minerva) (second generation) versus rollerball ablation (first generation), Outcome 6 Complication rate: major complications." data-id="CD001501-fig-0153" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-017-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.6</div> <div class="figure-caption"> <p>Comparison 17 Bipolar (Minerva) (second generation) versus rollerball ablation (first generation), Outcome 6 Complication rate: major complications. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0153">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-017-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0154"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-017-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-017-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 Bipolar (Minerva) (second generation) versus rollerball ablation (first generation), Outcome 7 Complication rate: minor complications." data-id="CD001501-fig-0154" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-017-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.7</div> <div class="figure-caption"> <p>Comparison 17 Bipolar (Minerva) (second generation) versus rollerball ablation (first generation), Outcome 7 Complication rate: minor complications. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0154">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-017-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0155"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-017-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-017-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 Bipolar (Minerva) (second generation) versus rollerball ablation (first generation), Outcome 8 Requirement for further surgery." data-id="CD001501-fig-0155" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-017-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.8</div> <div class="figure-caption"> <p>Comparison 17 Bipolar (Minerva) (second generation) versus rollerball ablation (first generation), Outcome 8 Requirement for further surgery. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0155">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-017-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0156"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-018-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-018-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 18 Overall analyses: second‐generation endometrial ablation versus first‐generation endometrial ablation, Outcome 1 Bleeding." data-id="CD001501-fig-0156" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-018-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.1</div> <div class="figure-caption"> <p>Comparison 18 Overall analyses: second‐generation endometrial ablation versus first‐generation endometrial ablation, Outcome 1 Bleeding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0156">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-018-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0157"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-018-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-018-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 18 Overall analyses: second‐generation endometrial ablation versus first‐generation endometrial ablation, Outcome 2 Bleeding ‐ amenorrhoea at 12 months' follow‐up (final plot)." data-id="CD001501-fig-0157" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-018-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.2</div> <div class="figure-caption"> <p>Comparison 18 Overall analyses: second‐generation endometrial ablation versus first‐generation endometrial ablation, Outcome 2 Bleeding ‐ amenorrhoea at 12 months' follow‐up (final plot). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0157">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-018-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0158"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-018-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-018-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 18 Overall analyses: second‐generation endometrial ablation versus first‐generation endometrial ablation, Outcome 3 Satisfaction rate." data-id="CD001501-fig-0158" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-018-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.3</div> <div class="figure-caption"> <p>Comparison 18 Overall analyses: second‐generation endometrial ablation versus first‐generation endometrial ablation, Outcome 3 Satisfaction rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0158">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-018-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0159"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-018-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-018-04.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 18 Overall analyses: second‐generation endometrial ablation versus first‐generation endometrial ablation, Outcome 4 Satisfaction rate at 1 year follow‐up (final plot)." data-id="CD001501-fig-0159" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-018-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.4</div> <div class="figure-caption"> <p>Comparison 18 Overall analyses: second‐generation endometrial ablation versus first‐generation endometrial ablation, Outcome 4 Satisfaction rate at 1 year follow‐up (final plot). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0159">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-018-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0160"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-018-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-018-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 18 Overall analyses: second‐generation endometrial ablation versus first‐generation endometrial ablation, Outcome 5 Duration of operation (minutes)." data-id="CD001501-fig-0160" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-018-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.5</div> <div class="figure-caption"> <p>Comparison 18 Overall analyses: second‐generation endometrial ablation versus first‐generation endometrial ablation, Outcome 5 Duration of operation (minutes). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0160">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-018-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0161"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-018-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-018-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 18 Overall analyses: second‐generation endometrial ablation versus first‐generation endometrial ablation, Outcome 6 Operative difficulties." data-id="CD001501-fig-0161" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-018-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.6</div> <div class="figure-caption"> <p>Comparison 18 Overall analyses: second‐generation endometrial ablation versus first‐generation endometrial ablation, Outcome 6 Operative difficulties. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0161">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-018-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0162"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-018-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-018-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 18 Overall analyses: second‐generation endometrial ablation versus first‐generation endometrial ablation, Outcome 7 Proportion given local anaesthesia (%)." data-id="CD001501-fig-0162" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-018-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.7</div> <div class="figure-caption"> <p>Comparison 18 Overall analyses: second‐generation endometrial ablation versus first‐generation endometrial ablation, Outcome 7 Proportion given local anaesthesia (%). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0162">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-018-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0163"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-018-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-018-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 18 Overall analyses: second‐generation endometrial ablation versus first‐generation endometrial ablation, Outcome 8 Inability to work." data-id="CD001501-fig-0163" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-018-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.8</div> <div class="figure-caption"> <p>Comparison 18 Overall analyses: second‐generation endometrial ablation versus first‐generation endometrial ablation, Outcome 8 Inability to work. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0163">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-018-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0164"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-018-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-018-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 18 Overall analyses: second‐generation endometrial ablation versus first‐generation endometrial ablation, Outcome 9 Complication rate: major complications." data-id="CD001501-fig-0164" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-018-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.9</div> <div class="figure-caption"> <p>Comparison 18 Overall analyses: second‐generation endometrial ablation versus first‐generation endometrial ablation, Outcome 9 Complication rate: major complications. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0164">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-018-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0165"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-018-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-018-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 18 Overall analyses: second‐generation endometrial ablation versus first‐generation endometrial ablation, Outcome 10 Complication rate: minor complications." data-id="CD001501-fig-0165" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-018-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.10</div> <div class="figure-caption"> <p>Comparison 18 Overall analyses: second‐generation endometrial ablation versus first‐generation endometrial ablation, Outcome 10 Complication rate: minor complications. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0165">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-018-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001501-fig-0166"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/urn:x-wiley:14651858:media:CD001501:CD001501-CMP-018-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_t/tCD001501-CMP-018-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 18 Overall analyses: second‐generation endometrial ablation versus first‐generation endometrial ablation, Outcome 11 Requirement for additional surgery." data-id="CD001501-fig-0166" src="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-018-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.11</div> <div class="figure-caption"> <p>Comparison 18 Overall analyses: second‐generation endometrial ablation versus first‐generation endometrial ablation, Outcome 11 Requirement for additional surgery. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-fig-0166">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/media/CDSR/CD001501/image_n/nCD001501-CMP-018-11.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD001501-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Overall analyses: second‐generation endometrial ablation compared to first‐generation endometrial ablation for heavy menstrual bleeding</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Overall analyses: second‐generation endometrial ablation compared to first‐generation endometrial ablation for heavy menstrual bleeding</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Patient or population:</b> heavy menstrual bleeding<br/> <b>Setting:</b> clinic<br/> <b>Intervention:</b> overall analyses: second‐generation endometrial ablation<br/> <b>Comparison:</b> first‐generation endometrial ablation </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="2" rowspan="2" valign=""> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with first‐generation endometrial ablation</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with overall analyses: second‐generation endometrial ablation</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Bleeding</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Amenorrhoea at 1 year follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>394 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>390 per 1000<br/> (307 to 501) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.99<br/> (0.78 to 1.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2145<br/> (12 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>PBAC &lt; 75 or acceptable improvement at 12 months' follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>809 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>833 per 1000<br/> (793 to 882) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.03<br/> (0.98 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1282<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>d,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Amenorrhoea at 2 to 5 years' follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>484 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>561 per 1000<br/> (377 to 832) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.16<br/> (0.78 to 1.72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>672<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>b,f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>PBAC &lt; 75 or acceptable improvement at 5 years' follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>537 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>580 per 1000<br/> (467 to 720) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.08<br/> (0.87 to 1.34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>263<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>e,g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Satisfaction rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>At 1 year follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>898 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>907 per 1000<br/> (880 to 933) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.01<br/> (0.98 to 1.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1750<br/> (11 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>f,h</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>At 2 to 5 years' follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>868 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>886 per 1000<br/> (808 to 981) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.02<br/> (0.93 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>672<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>b,e,i</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Duration of operation (minutes)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean duration of operation (minutes) was 27</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 13.52 lower<br/> (16.9 lower to 10.13 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1822<br/> (9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>b,d,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Proportion given local anaesthesia (%)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>208 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>578 per 1000<br/> (366 to 915) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.78<br/> (1.76 to 4.40) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1434<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>b,d,j</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Complication rate ‐ perforation</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 per 1000<br/> (1 to 13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.32<br/> (0.10 to 1.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1885<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>e,k</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Requirement for additional surgery</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>At 1 year follow‐up (ablation or hysterectomy)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>66 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47 per 1000<br/> (27 to 83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.72<br/> (0.41 to 1.26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>935<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>f,l</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>At 2 to 5 years' follow‐up (hysterectomy)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>191 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>162 per 1000<br/> (113 to 233) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.85<br/> (0.59 to 1.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>758<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> CI: confidence interval; MD: mean difference; PBAC: Pictorial Blood Assessment Chart; RCT: randomised controlled trial; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup>Eight studies provided insufficient details for a judgement about allocation concealment; downgraded one level. </p> <p><sup>b</sup>Heterogeneity was high at I² &gt; 75%; downgraded two levels. </p> <p><sup>c</sup>The funnel plot suggested asymmetry; downgraded one level. </p> <p><sup>d</sup>Only two studies provided sufficient details for a judgement about allocation concealment; no blinding of participants/researchers or outcome assessors; downgraded one level. </p> <p><sup>e</sup>No blinding of participants/researchers or outcome assessors; downgraded one level. </p> <p><sup>f</sup>Three studies provided insufficient details for a judgement about allocation concealment; only one study provided adequate data on blinding of participants/researchers and outcome assessors; downgraded two levels. </p> <p><sup>g</sup>Evidence of imprecision based on one study with n &lt; 300; downgraded one level. </p> <p><sup>h</sup>Only one study provided adequate data on blinding of participants/researchers and outcome assessors; downgraded one level. </p> <p><sup>i</sup>Only one study provided sufficient details for a judgement about allocation concealment; downgraded one level. </p> <p><sup>j</sup>The confidence interval has a very wide range (1.76 to 4.40); downgraded one level. </p> <p><sup>k</sup>The number of events is very low and the confidence interval is wide; downgraded one level. </p> <p><sup>l</sup>The number of events is very low; downgraded one level. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Overall analyses: second‐generation endometrial ablation compared to first‐generation endometrial ablation for heavy menstrual bleeding</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/full#CD001501-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001501-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Laser ablation (first generation) versus transcervical resection of the endometrium (TCRE) (first generation)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Bleeding ‐ blood loss (mL) at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>23.6 [‐8.32, 55.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Amenorrhoea rate at 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>348</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.66, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Amenorrhoea/hypomenorrhoea rate at 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>326</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.89, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Amenorrhoea/hypomenorrhoea rate at 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>306</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.92, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Rate of satisfaction at 12 months (very/moderately) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>321</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.92, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Duration of operation (minutes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>386</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.15 [7.21, 11.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Operative difficulties <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Procedure abandoned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [0.61, 3.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Failed instrumentation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.01, 4.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Equipment failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.54 [1.65, 18.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Immediate hysterectomy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Good general health <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>321</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.95, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Improvement in menstrual symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Improvement in symptoms (general)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>321</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.87, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Improvement in dysmenorrhoea at 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [1.00, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Improvement in dysmenorrhoea at 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>218</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.87, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Complication rate: major complications <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2218</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [0.83, 2.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Perforation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.01, 2.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Bowel obstruction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.94 [0.12, 71.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Pelvic sepsis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.25, 2.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 Haematometra</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.01, 4.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5 Glycine toxicity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.23 [0.23, 79.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.6 Fluid overload (&gt; 1.5 L)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.89 [1.44, 16.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.7 Uterine tamponade</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.39, 3.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Complication rate: minor complications <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Burns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.89 [0.24, 101.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Urinary tract infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.96 [0.36, 10.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Requirement for further surgical treatment (within 12 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>388</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.55, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Laser ablation (first generation) versus transcervical resection of the endometrium (TCRE) (first generation)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001501-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Vaporising electrode ablation (first generation) versus TCRE (first generation)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Bleeding ‐ amenorrhoea rate at 12 months' follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.73, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Amenorrhoea rate at 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.46, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Amenorrhea/hypomenorrhoea rate at 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.80, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Bleeding ‐ PBAC score at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.0 [‐19.18, 9.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Rate of satisfaction at 12 months (very/moderately) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.93, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Duration of operation (minutes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.50 [‐2.65, ‐0.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Operative difficulties <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Difficulty with surgery (moderate or severe)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.10, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Complication rate: major complications <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐258.0 [‐342.05, ‐173.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Degree of fluid deficit (mL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐258.0 [‐342.05, ‐173.95]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Vaporising electrode ablation (first generation) versus TCRE (first generation)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001501-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Rollerball (first generation) versus TCRE (first generation)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Duration of operation (minutes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.10 [‐2.92, 0.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Complication rate: major complications <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Fluid deficit</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.01, 7.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Perforation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.01, 7.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Requirement for further surgery <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 At 2 years' follow‐up hysterectomy or ablation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.55, 1.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 At 2 years' follow‐up (hysterectomy only)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.43, 4.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 At 2 to 5 years' follow‐up (hysterectomy or ablation)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.70, 2.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 At 2 to 5 years' follow‐up (hysterectomy only)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.51, 2.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 At more than 5 years' follow‐up (hysterectomy or ablation)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.82, 2.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6 At more than 5 years' follow‐up (hysterectomy only)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.66, 2.63]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Rollerball (first generation) versus TCRE (first generation)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001501-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Thermal laser (second generation) versus TCRE (first generation)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Bleeding ‐ amenorrhoea rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 At 1 year follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.46 [1.50, 4.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 At 2 to 5 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.49 [1.48, 4.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Rate of satisfaction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 At 1 year follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.94, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 At 2 to 5 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.91, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Duration of operation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.30 [‐11.36, ‐7.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Complication rate: major complications <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Perforation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Complication rate: minor complications <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.04, 5.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 UTI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.04, 5.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Requirement for further surgery rate (hysterectomy only) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.15, 2.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 At 2 to 5 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.15, 2.35]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Thermal laser (second generation) versus TCRE (first generation)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001501-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Hydrothermal ablation (second generation) versus rollerball (first generation)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 PBAC ≤ 75 at 1 year follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.82, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 PBAC ≤ 100 at 1 year follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.86, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 PBAC ≤ 100 at 2 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.92, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 PBAC ≤ 100 at 2 to 5 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>203</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.95, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Amenorrhoea at 1 year follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.60, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 Amenorrhoea at 2 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.75, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7 Amenorrhoea at 2 to 5 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>203</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.86, 1.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Rate of satisfaction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>203</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.96, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 At 2 to 5 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>203</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.96, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Proportion given local rather than general anaesthesia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>269</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.02 [1.32, 3.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Complication rate: major complications <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Cervical lacerations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>269</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.00, 1.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Haematometra</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>269</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.04, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Endometritis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>269</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.08, 10.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Complication rate: minor complications <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Abdominal pain (at 2 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>269</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [1.03, 1.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Nausea or vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>269</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.08 [1.36, 6.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Uterine cramping</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>269</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.72, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Urinary tract infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>269</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.23, 5.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5 First‐degree burn</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>269</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.32 [0.11, 47.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Requirement for further surgery <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 At 1 year follow‐up (any surgery)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>269</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.32 [0.11, 47.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 At 2 to 5 years' follow‐up (any surgery)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.58, 2.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 At 5 years' follow‐up (hysterectomy only)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [0.58, 4.06]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Hydrothermal ablation (second generation) versus rollerball (first generation)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001501-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Cryoablation (second generation) versus rollerball (first generation)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.36, 0.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Amenorrhoea at 1 year follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.36, 0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Rate of satisfaction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 At 1 year follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.96, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 At 2 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.91, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Proportion given local anaesthesia (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.62 [3.22, 13.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Complication rate: major complications <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Perforation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.01, 3.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Complication rate: minor complications <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.15, 2.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Vaginal bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.05, 33.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Abdominal cramping</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.26 [0.11, 47.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 UTI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.01, 3.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Severe pelvic pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.01, 3.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Requirement for further surgery <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 At 2 years' follow‐up (any surgery)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.45, 2.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 At 2 years' follow‐up (hysterectomy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.34, 2.00]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Cryoablation (second generation) versus rollerball (first generation)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001501-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Electrode ablation (second generation) versus TCRE + rollerball (first generation)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Bleeding ‐ amenorrhoea rate at 1 year follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>470</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.79, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Balloon system</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.62, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Mesh system</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>236</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.82, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Proportion with successful Rx (PBAC &lt; 75) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>470</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.98, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Balloon system</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.94, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Mesh system</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>236</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.96, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 PBAC score 12 months after treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Balloon system</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Mesh system</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Rate of satisfaction with treatment at 1 year <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>236</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.92, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Mesh system</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>236</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.92, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Duration of operation (minutes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐18.70 [‐20.66, ‐16.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Balloon system</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐16.20 [‐19.55, ‐12.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Mesh system</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐20.0 [‐22.41, ‐17.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Procedure abandon <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.58 [0.10, 63.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Proportion given local anaesthesia (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.85 [2.94, 5.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Balloon system</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.66 [2.65, 5.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Mesh system</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.11 [2.61, 6.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Complication rate: major complications <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Cervical tear/stenosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>532</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.01, 0.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Perforation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>532</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.02, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Pelvic abscess</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.01, 4.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 Haematometra</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>532</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.08, 2.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5 Fluid overload</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.01, 6.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.6 Myometritis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.01, 6.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.7 Urinary incontinence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.01, 6.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.8 PID</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.09, 11.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.9 Endometritis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.06, 2.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Complication rate: minor complications <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Nausea/vomiting or severe pelvic pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>532</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.37, 3.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 UTI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>532</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.39, 2.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 Fever</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.05, 13.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4 Haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.03, 8.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.5 Bradycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [0.06, 37.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Requirement for further surgery at 2 years (hysterectomy) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.18, 1.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Balloon system</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.18, 1.50]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Electrode ablation (second generation) versus TCRE + rollerball (first generation)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001501-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Microwave ablation (second generation) versus TCRE + rollerball (first generation)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 PBAC &lt; 75 or acceptable improvement at 1 year follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>562</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.96, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 PBAC &lt; 75 or acceptable improvement at 2 to 5 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>236</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.97, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 PBAC &lt; 75 or acceptable improvement at &gt; 5 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.87, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Amenorrhoea at 1 year follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>562</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.93, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Amenorrhoea at 2 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.87, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 Amenorrhoea at 2 to 5 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>236</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.78, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7 Amenorrhoea at &gt; 5 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.83, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Rate of satisfaction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 At 1 year follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>533</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.95, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 At 2 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [1.02, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 At 2 to 5 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>236</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [1.04, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 At 10 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.95, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Duration of operation (minutes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Operative difficulties <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Equipment failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.81 [1.09, 13.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Procedure abandoned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.31, 3.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Proportion given local anaesthesia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>315</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.54 [1.73, 3.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Duration of hospital stay (hours) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Inability to work (proportion of women) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 At 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.17, 1.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 At &gt; 5 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.52 [0.26, 8.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Quality of life ‐ change in SF‐36 score after treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Physical functioning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Social functioning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Physical role</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 Emotional role</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5 Mental health</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.6 Energy/fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.7 Pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.8 General health</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Improvement in other menstrual symptoms: PMS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 At 1 year follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.90, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 At 2 to 5 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>236</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.97, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Improvement in other menstrual symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Improvement in dysmenorrhoea at 1 year follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>533</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.89, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Improvement in dysmenorrhoea at 2 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.93, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Reduction in pain score (points) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.80 [‐4.32, 2.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 At &gt; 5 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.80 [‐4.32, 2.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Postoperative analgesia rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.81, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Complication rate: major complications <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Perforation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>585</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.63 [0.22, 12.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 Cervical laceration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>322</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.07, 3.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3 Cervical stenosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>322</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.5 [0.06, 36.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.4 Endometritis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>322</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.5 [0.37, 114.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Complication rate: minor complications <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Chills</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>322</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.59, 3.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 Bloating</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>322</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.38, 1.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3 Dysuria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>322</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.37, 1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.4 Fever</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>322</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.5 [0.12, 51.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.5 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>322</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.22, 2.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.6 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>322</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.83, 2.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.7 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>322</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.61 [1.30, 10.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.8 UTI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>322</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.03, 7.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.9 Vaginal infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>322</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.5 [0.06, 36.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.10 Uterine cramping</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>322</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [1.01, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.11 Abdominal tenderness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>322</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.26, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.12 Haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.01, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Requirement for further surgery <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 At 1 year follow‐up (any surgery)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.38, 1.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 At 1 year follow‐up (hysterectomy only)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>562</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.35, 1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3 At 2 years' follow‐up (any surgery)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.55, 1.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.4 At 2 years' follow‐up (hysterectomy only)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.50, 1.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.5 At 5 years' follow‐up (ablation or hysterectomy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.56, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.6 At 5 years' follow‐up (hysterectomy only)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.38, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.7 At 10 years' follow‐up (ablation or hysterectomy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.57, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.8 At 10 years' follow‐up (hysterectomy only)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.38, 0.96]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Microwave ablation (second generation) versus TCRE + rollerball (first generation)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001501-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Balloon endometrial ablation (second generation) versus rollerball endometrial ablation (first generation)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Amenorrhoea at 1 year follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.39, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Amenorrhoea at 2 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.33, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Amenorrhoea at 2 to 5 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.7 [0.39, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Amenorrhoea/eumenorrhoea rate at 1 year follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.86, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Amenorrhoea/eumenorrhoea rate at 2 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.91, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 Amenorrhoea/eumenorrhoea rate at 2 to 5 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.91, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 PBAC score after treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 At 1 year follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 At 2 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Success of treatment (lighter periods and no further surgery) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 At 2 to 5 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.80, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Success of treatment (menstrual score &lt; 185) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 At 1 year follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.83, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 At 2 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.83, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Rate of satisfaction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 At 1 year follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.93, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 At 2 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>348</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.93, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 At 2 to 5 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.87, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Duration of operation (minutes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>378</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐14.58 [‐15.00, ‐12.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Operative difficulties <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.49, 2.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Technical complication rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.49, 2.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Inability to work (proportion of women) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 At 1 year follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>239</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.52 [0.37, 6.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 At 2 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.03, 2.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 At 2 to 5 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.26, 2.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Improvement in other menstrual symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Improvement in dysmenorrhoea at 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>239</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.80, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Improvement in premenstrual symptoms (from moderate/severe) at 1 year follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>185</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.74, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 Improvement in premenstrual symptoms (from moderate/severe) at 2 years follow up </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>177</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.82, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4 Improvement in premenstrual symptoms (from moderate/severe) at 2 to 5 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.75, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Complication rate: major complications <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Fluid overload</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>239</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.01, 3.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Perforation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>378</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.02, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 Cervical lacerations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>378</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.02, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4 Endometritis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>239</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.74 [0.29, 25.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.5 Haematometra</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>239</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.01, 7.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Complication rate: minor complications <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>895</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.32, 3.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 UTI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>239</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.76 [0.11, 68.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Hydrosalpinx</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>239</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.01, 7.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 Pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.87 [0.30, 115.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.4 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.01, 6.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.5 Infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.01, 6.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Requirement for further surgery <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 At 1 year follow‐up (any surgery)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>239</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.10, 3.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 At 2 years' follow‐up (any surgery)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>392</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.35, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 At 2 to 5 years' follow‐up (any surgery)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.64, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4 At 2 years' follow‐up (hysterectomy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.38, 2.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.5 At 2 to 5 years' follow‐up (hysterectomy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.61, 1.63]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Balloon endometrial ablation (second generation) versus rollerball endometrial ablation (first generation)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001501-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Balloon (second generation) versus laser (first generation)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Amenorrhoea at 6 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.61, 2.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Amenorrhoea at 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.38, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 PBAC score after treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 At 6 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Rate of satisfaction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 At 6 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.91, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 At 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.86, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Operative difficulties <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.47 [0.22, 89.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Failure of equipment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.47 [0.22, 89.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Pain score 4 hours post procedure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>32.7 [23.72, 41.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 EQ‐5D at 6 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.11, 0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 EQ‐5D VAS at 6 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [‐5.95, 8.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 SF‐12 physical scale at 6 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [‐2.18, 5.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 SF‐12 mental scale at 6 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.40 [‐0.42, 7.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5 SAQ pleasure scale at 6 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.5 [‐1.30, 2.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6 SAQ habit scale at 6 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.16 [‐0.42, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.7 SAQ discomfort scale at 6 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.14 [‐0.98, 0.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.8 EQ‐5D at 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.13, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.9 EQ‐5D VAS at 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.10 [2.43, 17.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.10 SF‐12 physical scale at 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐3.89, 3.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.11 SF‐12 mental scale at 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.10 [‐2.04, 6.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.12 SAQ pleasure scale at 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.60 [‐2.68, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.13 SAQ habit scale at 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.09 [‐0.27, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.14 SAQ discomfort scale at 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.67, 0.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Improvement in other menstrual symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 PMS at 6 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 PMS at 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Improvement in other menstrual symptoms: dysmenorrhoea (visual analogue) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Dysmenorrhoea at 6 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Dysmenorrhoea at 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Requirement for further surgery <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 At 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.23, 2.64]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Balloon (second generation) versus laser (first generation)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001501-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Balloon (second generation) versus TCRE (first generation)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Amenorrhoea at 6 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.31, 2.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Amenorrhoea at 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.50, 2.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Rate of satisfaction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 At 6 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.93, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 At 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.96, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 At 2 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [1.06, 1.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Duration of operation (minutes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐13.0 [‐15.20, ‐10.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Duration of operation (minutes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Operative difficulties <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.22 [0.42, 123.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Equipment failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.22 [0.42, 123.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Postoperative pain (continuous data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.60 [‐0.88, ‐0.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Postoperative pain (descriptive data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Hospital stay (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐0.52, ‐0.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Duration of hospital stay (hours) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Return to normal activities (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.10 [‐3.38, ‐0.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Return to normal activities (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Complication rate: major complications <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Fluid overload</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [0.01, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Cervical tear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.01, 8.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 Conversion to hysterectomy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.01, 4.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4 Blood transfusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.24 [0.26, 105.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Complication rate: minor complications <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐81.8 [‐93.33, ‐70.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Blood loss</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐81.8 [‐93.33, ‐70.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Complication rate: minor complications (dichotomous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Fever</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.05, 5.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 Urinary infection or retention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.01, 8.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3 Haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.38, 4.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Requirement for further surgery <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 At 12 months' follow‐up (ablation and hysterectomy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.10, 2.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 At 2 years' follow‐up (ablation and hysterectomy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.08, 1.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3 At 12 months' follow‐up (hysterectomy only)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.01, 2.44]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Balloon (second generation) versus TCRE (first generation)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001501-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Bipolar radiofrequency (second generation) versus balloon ablation (second generation)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Amenorrhoea at 6 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>283</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.37 [2.09, 5.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Amenorrhoea at 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.12 [2.06, 4.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Amenorrhoea at 2 to 5 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [0.93, 2.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Amenorrhoea at 10 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.83, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 PBAC score after treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 At 6 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 At 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Rate of satisfaction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 At 6 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.94, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 At 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [1.04, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 At 10 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.85, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Duration of operation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Operative difficulties <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Technical complication rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.13, 3.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Completion of procedure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.97, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Time taken off work (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Time to resume normal activities (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.18, 0.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 SF‐12 physical scale score at 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.60 [‐4.27, 7.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 SF‐12 mental scale score at 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.5 [‐0.52, 15.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 SF‐36 physical function scale score at 6 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [‐6.55, 10.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4 SF‐36 physical function scale score at 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [‐6.44, 12.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.5 SF‐36 physical function scale score at 2 to 5 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [‐8.26, 12.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.6 SF‐36 role physical at 6 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.0 [‐7.67, 17.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.7 SF‐36 role physical at 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.0 [‐6.96, 16.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.8 SF‐36 role physical at 2 to 5 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.0 [‐2.66, 18.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.9 SF‐36 role emotional at 6 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.0 [‐18.64, 6.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.10 SF‐36 role emotional at 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.0 [‐1.92, 9.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.11 SF‐36 role emotional at 2 to 5 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.0 [‐14.45, ‐3.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.12 SF‐36 social functioning at 6 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.0 [‐9.98, 7.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.13 SF‐36 social functioning at 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [‐6.17, 12.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.14 SF‐36 social functioning at 2 to 5 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.0 [‐5.60, 13.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.15 SF‐36 mental health at 6 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.0 [‐10.84, 4.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.16 SF‐36 mental health at 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐8.03, 8.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.17 SF‐36 mental health at 2 to 5 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.0 [‐11.39, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.18 SF‐36 energy/vitality at 6 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.0 [‐13.54, 1.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.19 SF‐36 energy/vitality at 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.0 [‐0.44, 18.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.20 SF‐36 energy/vitality at 2 to 5 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.0 [‐10.39, 4.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.21 SF‐36 pain at 6 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [‐6.00, 12.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.22 SF‐36 pain at 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.0 [‐12.61, 10.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.23 SF‐36 pain at 2 to 5 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.0 [‐14.79, 4.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.24 SF‐36 general health at 6 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.0 [‐13.30, 3.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.25 SF‐36 general health at 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.0 [‐4.10, 16.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.26 SF‐36 general health at 2 to 5 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.0 [‐5.72, 17.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.27 RSCL physical symptoms at 6 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [‐3.94, 5.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.28 RSCL physical symptoms at 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.0 [‐8.56, 0.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.29 RSCL psychological distress at 6 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.0 [‐10.14, 8.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.30 RSCL psychological distress at 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.0 [‐7.92, 5.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.31 RSCL activity level at 6 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.0 [‐3.35, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.32 RSCL activity level at 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.0 [‐4.32, 0.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.33 RSCL overall quality of life at 6 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.0 [‐12.29, 8.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.34 RSCL overall quality of life at 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.0 [‐18.77, 0.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.35 SDS depression at 6 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [‐1.55, 5.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.36 SDS depression at 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.0 [‐5.24, 3.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.37 Multi‐attribute utility tool at 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.80 [‐6.08, 23.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.38 EQ‐5D utility at 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.16, 0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.39 EQ‐5D health thermometer at 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.8 [‐10.07, 19.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Menorrhagia Outcome Questionnaire <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.60 [‐3.87, 2.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 At 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.60 [‐3.87, 2.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Dysmenorrhoea rate (VAS score) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 At 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Improvement in other menstrual symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>465</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.70, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Improvement in dysmenorrhoea at 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [0.89, 2.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Improvement in PMS (emotional) at 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.8 [0.45, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 Improvement in PMS (physical) at 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.3 [0.72, 2.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4 Dysmenorrhoea rate at 6 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.26, 1.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.5 Dysmenorrhoea rate at 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.18, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.6 Dysmenorrhoea rate at 2 to 5 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.26, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 PMS rate (VAS score) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 At 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Complication rate: major complications <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Infection (endometritis)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.06, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Requirement for further surgery <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 At 6 months' follow‐up (ablation or hysterectomy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 At 12 months' follow‐up (ablation or hysterectomy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>239</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.49, 3.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3 At 12 months' follow‐up (hysterectomy only)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.28, 1.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.4 At 2 to 5 years' follow‐up (ablation or hysterectomy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.28, 1.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.5 At 2 to 5 years' follow‐up (hysterectomy only)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.27, 2.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.6 At 10 years' follow‐up (hysterectomy only)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.38, 2.74]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Bipolar radiofrequency (second generation) versus balloon ablation (second generation)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001501-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Microwave ablation (second generation) versus balloon ablation (second generation)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Amenorrhoea at 6 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [1.07, 2.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Amenorrhoea at 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>282</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.82, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Amenorrhoea at 5 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.86, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 PBAC score at 12 months' follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Rate of satisfaction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 At 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>278</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.88, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 At 5 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.87, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Operation time (minutes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>314</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.60 [‐7.36, ‐5.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Operative difficulties causing failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Failure of device</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>314</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.01, 0.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Unsuitable cavity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>314</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.17, 3.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Device not sterile</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>314</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.0 [0.24, 103.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Proportion choosing local anaesthesia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>314</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.79, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Proportion requiring opiate analgesia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>314</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.83, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Recovery: proportion requiring overnight stay <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>314</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.42, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Quality of life scores <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 EQ‐5D at 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.04, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 EQ‐5D at 5 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.07, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 SF‐12 physical scores at 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.70 [‐2.64, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4 SF‐12 physical scores at 5 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.5 [‐3.99, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.5 SF‐12 mental scores at 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.20 [‐3.67, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.6 SF‐12 mental scores at 5 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐2.90, 2.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Requirement for further surgery (hysterectomy) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 At 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.31, 2.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 At 5 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.51, 3.27]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Microwave ablation (second generation) versus balloon ablation (second generation)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001501-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Bipolar radiofrequency (second generation) versus hydrothermal ablation (second generation)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Amenorrhoea at 6 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.27 [1.25, 4.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Amenorrhoea at 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.95 [1.21, 3.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Amenorrhoea at 2 to 5 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.57 [1.06, 2.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Rate of satisfaction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 At 6 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.44 [1.17, 1.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 At 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [1.02, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 At 2 to 5 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.62 [1.23, 2.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Duration of procedure (minutes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Improvement in other menstrual symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Absence of dysmenorrhoea at 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.79, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Absence of dysmenorrhoea at 2 to 5 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [1.00, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Complication rate: major complications <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Uterine perforation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.71 [0.11, 65.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Saline leakage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.01, 2.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Requirement for further surgery <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 At 12 months' follow‐up (ablation or hysterectomy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.11, 0.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 At 12 months' follow‐up (hysterectomy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.14, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 At 2 to 5 years' follow‐up (ablation or hysterectomy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.23, 0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 At 2 to 5 years' follow‐up (hysterectomy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.29, 1.38]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Bipolar radiofrequency (second generation) versus hydrothermal ablation (second generation)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001501-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">Ablative curettage versus overcurettage</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.59 [1.87, 3.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Amenorrhoea at 3 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.5 [2.33, 8.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Amenorrhoea and eumenorrhoea at 3 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.86 [1.30, 2.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Surgery difficulties: failure rate of procedure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.12, 0.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Recovery: hospital stay (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.6 [1.18, 2.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Complication rate: major complications <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Uterine perforation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.01, 2.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Complication rate: minor complications <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.16, 0.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.07, 0.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Infection/leucorrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.8 [0.23, 2.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Requirement for further surgery <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.16, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Within 3 years (hysterectomy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.16, 1.10]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">Ablative curettage versus overcurettage</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001501-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">Microwave ablation (second generation) versus bipolar radiofrequency (second generation)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.07 [3.29, 15.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Amenorrhoea at 3 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.33 [1.86, 15.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Amenorrhoea at 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.77 [3.17, 30.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Bleeding PBAC at 12 months' follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Rate of satisfaction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Satisfaction ‐ with treatment at 3 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.89, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Satisfaction ‐ with treatment at 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.73, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Satisfaction ‐ improvement in everyday life at 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.81, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Duration of treatment (seconds) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.80 [2.63, 16.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Improvement in other menstrual symptoms: dysmenorrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Dysmenorrhoea at 3 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.39, 10.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Dysmenorrhoea at 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.0 [0.92, 17.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Complication rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>25.98 [1.44, 468.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Minor complications</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Major complications</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Requirement for post‐procedure analgesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>25.98 [1.44, 468.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Requirement for further surgery <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 At 12 months' follow‐up (hysterectomy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.0 [0.25, 100.32]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">Microwave ablation (second generation) versus bipolar radiofrequency (second generation)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001501-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">Bipolar (Minerva) (second generation) versus rollerball ablation (first generation)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Haematin alkaline &lt; 80 mL/cycle at 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [1.00, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Amenorrhoea at 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [1.08, 1.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Rate of satisfaction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 At 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.99, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Duration of surgery <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐14.1 [‐15.94, ‐12.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Improvement in other menstrual symptoms: dysmenorrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.71, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Improvement in other menstrual symptoms: PMS at 12 months' follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Complication rate: major complications <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Endometritis or endomyometritis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.02, 2.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Pelvic inflammatory disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [0.06, 36.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Haematometra</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [0.06, 36.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Complication rate: minor complications <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.30, 1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Intraoperative skin rash and/or itching or burning sensation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [0.06, 36.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Bleeding or spotting first 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.01, 4.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Nausea or vomiting first 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.01, 4.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 Weakness, fatigue, sleepiness, lack of concentration, dizziness first 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [0.06, 36.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5 Backache first 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [0.06, 36.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6 Fever first 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [0.06, 36.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.7 Abdominal pain or bloating (&gt; 24 hours to 2 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.5 [0.16, 14.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.8 Abdominal pain and/or bloating &gt; 2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.01, 4.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.9 Pelvic pain (&gt; 24 hours to 2 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [0.06, 36.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.10 Vaginal discharge and/or unpleasant vaginal smell or other abnormal sensation (&gt; 24 hours to 2 weeks) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [0.06, 36.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.11 Weakness, fatigue, sleepiness, lack of concentration, dizziness (&gt; 24 hours to 2 weeks) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.5 [0.03, 7.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.12 Constipation (&gt; 24 hours to 2 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.01, 4.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.13 Skin rash and/or itching or burning sensation (&gt; 24 hours to 2 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.5 [0.03, 7.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.14 Dysmenorrhoea (2 weeks to 1 year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.01, 4.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Requirement for further surgery <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.06, 1.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Hysterectomy at 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.06, 1.93]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">Bipolar (Minerva) (second generation) versus rollerball ablation (first generation)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001501-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 18.</span> <span class="table-title">Overall analyses: second‐generation endometrial ablation versus first‐generation endometrial ablation</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Amenorrhoea at 6 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.91, 1.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Amenorrhoea at 1 year follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.78, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Amenorrhoea at 2 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>701</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.72, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Amenorrhoea at 2 to 5 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.78, 1.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Amenorrhoea &gt; 5 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.83, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 PBAC &lt; 75 or acceptable improvement at 12 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1282</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.98, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7 PBAC &lt; 75 or acceptable improvement at 2 to 5 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>236</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.97, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8 PBAC &lt; 75 or acceptable improvement at &gt; 5 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.87, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Bleeding ‐ amenorrhoea at 12 months' follow‐up (final plot) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.78, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Satisfaction rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 At 6 months' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.93, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 At 1 year follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1750</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.98, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 At 2 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>802</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.99, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 At 2 to 5 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.93, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 At 10 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.95, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Satisfaction rate at 1 year follow‐up (final plot) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1750</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.99, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Duration of operation (minutes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Operative difficulties <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Equipment failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>384</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.26 [1.46, 12.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Procedure abandoned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>629</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.38, 3.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Proportion given local anaesthesia (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.78 [1.76, 4.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Inability to work <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>479</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.30, 2.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Complication rate: major complications <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Perforation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1885</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.10, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Endometritis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1095</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.33, 4.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 Myometritis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.01, 6.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4 Cervical lacerations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1583</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.07, 0.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.5 Cervical stenosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>322</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.5 [0.06, 36.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.6 Pelvic abscess</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.01, 4.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.7 Pelvic inflammatory disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>418</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.18, 7.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.8 Haematometra</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.12, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.9 Blood transfusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.24 [0.26, 105.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.10 Fluid overload</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>588</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.03, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Complication rate: minor complications <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6450</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [1.11, 1.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Nausea/vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.01 [1.40, 2.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Uterine cramping</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>601</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [1.02, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 Urinary tract infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1834</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.45, 1.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4 Fever</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>671</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.22, 4.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.5 Haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>889</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.26, 1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.6 Muscle fasciculation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.57 [0.11, 62.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.7 External burns (first degree)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>269</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.32 [0.11, 47.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.8 Hydrosalpinx</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>239</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.01, 7.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.9 Severe pelvic pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>683</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.36, 2.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Requirement for additional surgery <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 At 1 year follow‐up (ablation or hysterectomy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>935</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.41, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 At 1 year follow‐up (hysterectomy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>925</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.35, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 At 2 years' follow‐up (ablation or hysterectomy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>988</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.52, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.4 At 2 years' follow‐up (hysterectomy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>920</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.52, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.5 At 2 to 5 years' follow‐up (ablation or hysterectomy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>647</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.72, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.6 At 2 to 5 years' follow‐up (hysterectomy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>758</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.59, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.7 At 10 years' follow‐up (ablation or hysterectomy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.37, 0.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.8 At 10 years' follow‐up (hysterectomy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.38, 0.91]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 18.</span> <span class="table-title">Overall analyses: second‐generation endometrial ablation versus first‐generation endometrial ablation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001501.pub5/references#CD001501-tbl-0019">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD001501.pub5&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD001501-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD001501-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD001501-note-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD001501-note-0004">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD001501-note-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="th#CD001501-note-0003">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD001501-note-0002">繁體中文</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD001501-note-0013">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001501\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001501\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001501\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001501\x2epub5"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001501\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001501\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001501\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001501\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001501\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001501\x2epub5"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001501\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001501\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001501\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001501\x2epub5"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001501\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001501\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001501\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001501\x2epub5"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=mvgXlmVk&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001501.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001501.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD001501.pub5/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD001501.pub5/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001501.pub5%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740719672905"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001501.pub5/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740719672909"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001501.pub5/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dee78cb599371',t:'MTc0MDcxOTY3My4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 